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Abstract
The hyacinthacine C-type alkaloids are polyhydroxylated pyrrolizidine alkaloids that were
first isolated in 1999 from the fruits and stalks of Hyacinthoides non-scripta and later in
2007 from the bulbs of Scilla socialis. Today they comprise hyacinthacines C1, C2, C3, C4
and C5 and have attracted considerable attention within the large community of those
interested in iminosugars, since they exhibit inherent glycosidase inhibitory activities.
Their low to moderate IC50 values (13 – 100 µM) against various α-glucosidases makes the
hyacinthacine C-type alkaloids important scaffolds towards finding medicines that help
treat type-2 diabetes as well as the increasing obesity epidemic.
The hyacinthacine C-type alkaloids can contain up to seven possible stereogenic centres.
This means that there are 128 unique stereoisomers (64 diastereomers and their
enantiomers) containing a 3-hydroxymethyl-5-methylpyrrolizidine-1,2,6,7-tetraol core
that have potentially different glycosidase inhibitory activities. Their constitutional
complexity has resulted in structural insecurities in four of the five naturally occurring
hyacinthacines, namely hyacinthacines C1, C3, C4 and C5. Their configurational ambiguity
coupled with their relatively low glycosidase inhibitory activity presents an enticing
challenge for many chemists and so has led to an increasing number of publications that
detail synthetic work towards this class of compounds.
To shed light on the current inconsistencies in the literature, the work presented in this
Ph.D. describes the successful total synthesis and consequent correction of the structures
for hyacinthacines C1 (Chapter 5), and C5 (Chapter 4B). More specifically, it was found
that the true structure for hyacinthacine C1 is the C8 epimer of the purported structure.
Moreover, the true structure for hyacinthacine C5 has the opposite conﬁguration at the three
contiguous stereogenic centres, C5, C6, and C7, to that of the originally proposed structure.
The successful pathway that resulted in these compounds was designed around the Petasis
borono-Mannich acid reaction between 3,5-di-O-benzyl-α,β-L-xylofuranose, 3-amino-1butene·hydrochloride and (E)-β-styrenylboronic acid. This led to the synthesis of two key
amino-diol motifs that when strategically subjected to key steps such as ring-closing
metathesis, cis-dihydroxylation, cyclic sulfate synthesis, regioselective cyclic sulfate ringi

opening and Swern oxidation/stereoselective reduction, resulted in the synthesis of an
additional nine hyacinthacine C-type analogues.
The eleven hyacinthacine C-type analogues synthesized as a part of this study were then
evaluated as glycosidase inhibitors and compared against the structurally analogous
casuarine (one of the most powerful glucosidase inhibitors) and a useful SAR was
developed. With respect to casuarine, hyacinthacine C-type analogues (‒)-6-epihyacinthacine C5 156 and (+)-7-epi-hyacinthacine C5 155 displayed comparable inhibition
against the α-glucosidase of rat intestinal sucrase (IC50 values of 13 μM and 9.9 μM,
respectively) and are suitable scaffolds towards investigating potential drug candidates for
anti-diabetic and anti-obesity medications.
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Chapter 1 : History and development of the
hyacinthacine C-type Alkaloids
1.1. The importance of natural products
A natural product can be defined as a substance that is produced by life. Such compounds
are initially isolated from a natural source and if useful, they can be later prepared by
chemical synthesis in a scalable manner. Whether perceived as good or bad, natural
products are undeniably one of the most influential compound classes for living and are
undoubtedly fundamental to the lifestyles of all species.
Among humans, the impact of natural products can be seen through the example of a cup
of tea or coffee. These brewed solutions enjoyed by most are rich sources of alkaloids.
More specifically, theophylline and caffeine (Figure 1.1) are the natural products that most
would recognize as the active ingredients in both drinks, respectively.

Figure 2.1: Natural products theophylline and caffeine.

Another example of a natural product and its impact on lifestyle is nicotine: a component
of tobacco blends (Figure 1.2). Similarly, this natural product is generally accepted to be
the potent parasympathomimetic stimulant alkaloid responsible for inducing relaxation
after it is inhaled.
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Figure 2.2: Natural product nicotine.

Even with advancements in medical technology to allow the design of potent drugs for
medical use, natural products are still actively and widely used on large commercial scales.
An example of this are the recently introduced Coles™ brand of cold and flu, pain relief
and decongestant tablets, whereby they solely contain natural product extracts from
Andrographis paniculate (Green chirayta), Echinacea purpurea (Eastern purple
coneflower), Salix alba (white willow) and Sambucus nigra (Black elderberry) (Figure
1.3).

Figure 2.3: From left to right, Andrographis paniculate (Green chirayta)1, Echinacea
purpurea (Eastern purple coneflower)2, Salix alba (white willow)3 and Sambucus nigra
(Black elderberry).4

Regardless of lifestyle or medicinal use, these examples only scratch the surface of the
importance and wide spread abundance of natural products in modern lifestyles. For the
remainder of this Chapter however, the broader focus of this research will address modern
natural product-derived medicines.
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1.2. Drug discovery and development
New drug discovery has been largely influenced through the examination of natural
product medicines that have been used for centuries. Interest and investigation into
naturally occurring medicines excelled in the early 1980s, and by 2002, it was found that
75% of new drugs for infectious disease and 60% of new drugs for cancer, stemmed from
natural products.5 However, this statistic was short lived. More specifically, between 2001
and 2005, only 23 new drugs succeeded from natural product to market to be used as:
immunosuppressive agents, pain relief, anti-bacterial and anti-fungal agents, treating
infections, cancer, diabetes, dyslipidemia, atopic dermatitis, Alzheimer’s disease and other
genetic diseases (tyrosinemia and Gaucher’s disease).6 This 20-year low is perceived as
the reason for a large number of pharmaceutical companies having reduced or cancelled
funding towards natural product research programs.6 In addition to this, the late 1990s
brought a significant paradigm shift amongst pharmaceutical companies and their
approach to sourcing first-in-class drugs. Technologies such as combinatorial chemistry
and high-throughput screening (HTS) allowed for high speed assays of large synthetic
compound libraries, but could not effectively be applied to natural product screening on a
similar magnitude.6-9
Today, the research and drug discovery model includes modern molecular biological
methods (understanding disease mechanisms, biomarkers, surrogate endpoints), HTS,
structure-based drug design, combinatorial and parallel chemistry, and the sequencing of
the human genome. This latest research and development (R&D) model is largely
influenced by the result of six decades of inflation-adjusted costs. On average, introducing
a new drug to the market doubles in cost approximately every 9 years.10 Despite such
innovations, there are many doubts and raised concerns over the current R&D model
simply because the number of drug approvals by the US Food and Drug Administration
(FDA) are not increasing proportionally with the advancements of the aforementioned
technologies.11-12 Furthermore, with less emphasis on natural product research and more
interest in developing large compound libraries, it is unsurprising that a notable reduction
in the discovery of new chemical entities has also been observed.6
These alarming facts suggest that the current R&D model should be revised.10 This does
not necessarily need to become more advanced, rather pharmaceutical natural product
3

research programs should be reconsidered. During the 1980s, natural product research
rarely considered aqueous extracts. If aqueous extracts of natural products were
investigated for the following reasons, perhaps similar success observed in the ‘golden era’
of new drug discovery would be achieved.

1.3. Polyhydroxylated Alkaloids- Distribution in Nature:
Unlike traditional preparations, drug discovery programs largely extracted natural products
and promising medicinal agents with the aid of organic solvents such as methanol,
dichloromethane, chloroform and hexane.13 However, folkloric medicines are almost
exclusively brewed as water soluble extracts of natural products, and so any ascribed
therapeutic benefit is likely to be attributed to water soluble components, including
polyhydroxylated carbohydrate analogues. Of these, the polyhydroxylated alkaloids (PAs)
prove particularly interesting for organic and medicinal chemists.13 More specifically, they
display high stereoselectivity and activity for biological systems.13 In conjunction with a
low molecular weight (~250 Da), heterocyclic nature and large stereoconfiguration scope,
this class of compound make them an ideal synthetic target.
Polyhydroxylated alkaloids can also be referred to as iminosugars, azasugars or sugarshaped alkaloids, largely owing to their structural resemblance to monosaccharides. As
their name suggests, their chief difference is that they contain a ring nitrogen in place of
oxygen. After their initial finding in 1966 (norjirimycin), this class of alkaloid was thought
to be restricted in Nature,13 however, today they can be subdivided into six ring systems:
pyrrolines, pyrrolidines, piperidines, pyrrolizidines, indolizidines and nortropanes. These
can either be monocyclic or bicyclic structures (Selected examples of each are found in
Table 1.1).

4

Table 2.1: Selected examples of the six polyhydroxylated alkaloid classes, along with of
their distribution and biological activity.
Alkaloids

Source
The first PA and
iminopyranose to
be discovered as
an isolate from
Streptomyces
roseochromogenes
R-468 and
Streptomyces
nojiriensis SF-426
between 1966 1967.14-15
The first naturally
occurring
iminofuranose to
be discovered and
isolated from the
leaves of Derris
elliptica (legume)
in 1976.18
The first naturally
occurring
pyrroline to be
discovered and
isolated from the
fungus Nectria
lucida F-4490
(Asscomycetes) in
1988.26
One of the first
examples of a
naturally
occurring
polyhydroxylated
pyrrolizidine with
a hydroxymethyl
substituent at the
C3 postion.
Alexine was
isolated in 1988
from Alexa
leiopetala
(Leguminosae).28

Figure

Biological
activity

Inhibitor of α- and βglucosidases as well
as antibiotic action.17
Streptomyces sp.16

Derris elliptica19

Inhibitor of
glycoprotein
processing. Inhibits αand β-glucosidases,
human lysosomal βmannosidase, βgalactosidase and βxylosidase 20-25

Nectria lucida F-449026

An immunomodulator
and inhibitor of αglucosidases, α- and
β-mannosidases, βglucosidases, β-Nacetylglucosaminidase
and trimming
glucosidase I.27

Alexa leiopetala29

Inhibitor of
disaccharidase-typeα- glucosidase
(trehalase,
amyloglucosidase)
and βglalactosidase.28, 30
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One of the first
examples of an
isolated
polyhydroxylated
nortropane from
Calystegia sepium
in 1988.31-32
The first
polyhydroxylated
indolizidine
isolated from
Swainsona
canescens.35

Inhibitor of βglucosidases, α- and
β- galactosidases, and
trehalase.34
Calystegia sepium33

Inhibitor of αmannosidase.37
Swainsona canescens36

To date, hundreds of novel polyhydroxylated alkaloids have and continue to be isolated by
a simple means of reinvestigating the aqueous fractions of previously characterised natural
products.13 Their initially proposed distribution in Nature is misleading because of
inadequate extraction methods previously employed. This suggests a huge potential to find
new subclasses of polyhydroxylated alkaloids in plants, micro-organisms and taxa not
previously considered to be alkaloid producing.13 More importantly, their analogous
structure to glycosides -like glucose and mannose- mean that the polyhydroxylated
alkaloids can interact with enzymes known as glycosidases and might therefore have
important therapeutic potential towards treating diseases such as viral infections, cancer
and diabetes.

1.4. Polyhydroxylated alkaloids as glycosidase inhibitors
Essential for existence and found in all domains of life, glycosidases are enzymes that
catalyse the hydrolysis of carbohydrates and complex glycosides to release simpler
monosaccharides and oligosaccharides. This large and diverse group of enzymes has been
extensively studied since the early 1830s.38 Today, these enzymes are well characterised
and facilitate many functions which range from the digestion of large polysaccharides
through to developing cellular structural integrity.13, 20
To ensure a range of unique functions, individual glycosidases must display distinct
affinity for certain carbohydrate molecules and also for specific anomeric configurations
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of that sugar.13 It is therefore reasonable that through mimicry of pyranosyl or furanosyl
moieties, polyhydroxylated alkaloids display the potential to be highly potent and specific
inhibitors of glycosidases. Furthermore, the number, position and configuration of the
hydroxy groups of each alkaloid can influence the type of glycosidase inhibited.13
The above rationale certainly paved way for the development of the oral antidiabetic drug,
miglitol. This evolution of a naturally occurring polyhydroxylated alkaloid to its
marketable drug should certainly be explored. However, before this case study is
examined, we must first consider the mechanisms of enzymatic glycoside hydrolysis.

1.5. Glycosidase hydrolysis
Glycosidases are an extremely efficient class of enzymes. In 1998, Wolfenden et al. were
able to demonstrate this, where they found that glycosidases were able to enhance the rate
of catalysis 1017 fold faster than the uncatalyzed reaction (noting that efforts to preserve
paper (cellulose) books and other rare documents is somewhat futile).39 Additionally, this
figure correlates to an estimated dissociation constant for the transition state to be no more
than 10-22 M, which suggests that the substrate must have a very strong binding affinity for
the enzyme.39-40 Therefore, the ideal mechanism-based glycosidase inhibitor should mimic
the transition state formed during glycosidase hydrolysis such that it binds strongly and
also reversibly to the glycosidase active site.41
Glycosidases can be segregated into two main groups based on whether the stereochemical
outcome of the anomeric configuration of the hydrolysed monosaccharide is either retained
or inverted (Figure 1.4).41-44 For instance, if a carbohydrate enters the active site of a
retaining glycosidase (Figure 1.4A), the anomeric carbon of the terminal glucose unit
undergoes a ‘double inversion’ and retains the original stereochemistry. More specifically,
after an initial attack at the anomeric carbon by a carboxylate nucleophile, a neighbouring
carboxylic acid residue concurrently donates a proton to the leaving group oxygen. The
proton deficient carboxylate can then expedite a second nucleophilic attack of a water
molecule at the anomeric carbon which subsequently displaces the monomeric sugar unit,
but retains the original stereochemistry.45-46 Comparatively, inverting glycosidases react
through a single step (SN2) mechanism (Figure 1.4B). To facilitate this process, one
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carboxylate residue acts as an acid and protonates the glycosidic oxygen. The other
carboxylic acid residue acts as a base and can deprotonate a water molecule, resulting in a
nucleophilic attack towards the anomeric carbon.45-46 Common to both glycoside
hydrolysis pathways is the formation of an oxocarbenium-ion-like transition state which
proves to be an important characteristic when considering the design of specific
glycosidase inhibitors. Additionally, through the advancements of an increasing number
of structural and mechanistic studies, glycoside hydrolases have, and continue to be,
subcategorized based on their specific mechanism of action. Since the PAs resemble the
oxocarbenium-ion-like transition state at certain pH levels, scientists are able to exploit
these scaffolds and design extremely potent and specific inhibitors of glycosidases.41 To
gain insight into this process, we will investigate the development of the non-insulin
dependent diabetes mellitus (NIDDM) drug, miglitol.
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Figure 2.4: Mechanisms of A) retaining and B) inverting glycosidases.

1.6. Case study: Deoxynorjirimycin to antidiabetic drug miglitol
At a physiological pH, PAs become protonated at their nitrogen atom which leads to the
formation of a stable complex within the glycosidase active site.41, 47 As seen with the
9

iminosugar 1-deoxynojirimycin (DNJ) in Figure 1.5, its adoption of a comparable
oxocarbenium-ion-like shape causes the enzyme to have a high affinity for the inhibitor.
When inside the active site cleft of the enzyme, the iminosugar can form an ion pair with
the carboxylate moieties resulting in a physical blockage of disaccharides that would
otherwise be hydrolysed. This partial bond allows for reversibility, where the strength and
specific inhibition will be largely dependent on the shape, size and stereoconfiguration of
the iminosugar, as well as the target enzyme.

Figure 2.5: Comparison of DNJ (left) and the oxocarbenium-ion-like transition state of
glycoside hydrolysis (right).

The importance of PA isolation and research can be clearly seen through the development
of the pseudomonosaccharide α-glucosidase inhibitor miglitol. Although approved in 1996
as a NIDDM treatment, miglitol (marketed under the name Glyset™) can be traced back
to the 1970s through its naturally occurring parent analogue DNJ (Figure 1.6).48-49 Prior to
its isolation in 1976 from the roots of a Mulberry species (Moraceae), DNJ had already
been the product of two syntheses reported in 1967 and 1968 by Paulsen et al. and Inouye
et al. respectively.15, 49-50 Its synthetic attention at this time was largely due to the recent
isolation of the closely related natural isolate, nojirimycin, an inherent antibiotic.51 It was
found that relative to norjirimycin, the lack of an anomeric hydroxy group at C1 caused
DNJ to act as a potent inhibitor of yeast and pancreas glycosidases.52
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Although this was a noteworthy find, the impressive glycosidase inhibitory activity of DNJ
could be considered an unsurprising result. In addition to its original isolation, DNJ has
been well established as a dominant constituent of various Moraceae; a species with a rich
history in East Asian, folklore-based use and medicine.22, 49, 53-54 In fact, brewed extracts
of Mulberry leaves are considered a traditional remedy used to treat and prevent “Xiaoke” (diabetes), particularly in China.54-55
Its traditional use, in conjunction with inherent glycosidase inhibitory activity, convinced
scientists that DNJ would be a promising NIDDM therapeutic. However, this was soon
dismissed on the basis of in vivo experiments, where DNJ displayed only moderate effects
on small intestinal D-glucose uptake.56 In light of this result, N-alkyl derivatives of DNJ
were synthesized on the basis of improved in vivo activity, whereby the N-hydroxyethylDNJ analogue (miglitol) proved most effective for managing postprandial blood glucose
and was consequently sold on the market as medicine for type-2 diabetes.57

Figure 2.6: Development of the naturally derived58 DNJ and its analogous marketed
NIDDM derivative, miglitol.59

Although effective for managing type-2 diabetes, miglitols mechanism and localization
(small intestine) of glycosidase inhibition led to undesired side effects. As a result of
preventing the digestion of polysaccharides, flatulence and gastrointestinal discomfort
were notable in patients and are today the largest deterrents for using this medication.60
However, it has also been observed that abdominal discomfort is dose-related and can be
better tolerated with continued use.61-62
The development of miglitol from the naturally occurring DNJ is a convincing example of
just how important it is for the present R&D model to include the investigation of natural
11

products as a source for drug scaffolds. The polyhydroxylated nature of DNJ and miglitol
validate the investigation into unexplored water-soluble components of natural products.
Although all classes of PAs should be of interest, the polyhydroxylated pyrrolizidine
alkaloids have gained considerable attention in the literature for their noteworthy
glycosidase inhibitory activities. For this reason, this class of PA will be the broader focus
for the remainder of this Chapter.

1.7. Polyhydroxylated Pyrrolizidine Alkaloids
Prior to discussing the polyhydroxylated pyrrolizidine alkaloids, it is worth noting
pyrrolizidine alkaloids, particularly those that contain a hydroxymethyl substituent at C1,
as they have been of exponentially growing interest since the 1960s.63

Figure 2.7: General structure for pyrrolizidine alkaloids.

Their appreciation is largely a result of the increasing number of deaths to livestock that
have consumed plants rich in pyrrolizidine alkaloids.63 A memorable example occurred in
Australia in the late 1970s, whereby a large number of chicken poisonings were reported.64
On closer inspection, researchers found that the ill-thrift, ascites and degenerative lesions
on the chickens, were the result of a commercial poultry feed containing heliotrine and
lasiocarpine: pyrrolizidine alkaloids found in the seeds of Heliotropium stenophyllum
(Figure 1.8).64 It is more alarming however that many cases of liver disease and cancer in
humans have been the direct result of pyrrolizidine alkaloid consumption.65-68 This wide
spread occurrence is not surprising since there have been recorded findings of pyrrolizidine
alkaloids detected in wheat flour, honey and also cow’s milk.69-71 At least from an
economic point of view, it remains important that improved methods of detection,
chromatographic separation and chiefly, natural product characterization are continually
explored.
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Figure 2.8: Heliotropium stenophyllum72 along with pyrrolizidine alkaloids heliotrine and
lasiocarpine.

By the 1980s, pyrrolizidine alkaloids were deemed pernicious upon ingestion and were
consequently flagged as a world-wide health concern.63 Their toxicity is a result of the 1,2unsaturated bond, in combination with an ester at the C9 position (Figure 1.7).63 After
consumption, hepatic mixed function oxidases convert these pyrrolizidine alkaloids to
their counter pyrrole derivatives. These metabolic products are highly reactive and can scar
various organs in the body, particularly rich in thiol containing amino acids.73-74
During this time, only a few examples existed of pyrrolizidine alkaloids that displayed
anti-tumour activity75 and neuromuscular blocking activity76 and so this class of alkaloid
was generally thought to be toxic. However, by the late 1980s, this view drastically
changed after the discovery of the polyhydroxylated pyrrolizidine alkaloids containing a
hydroxymethyl substituent at the C3 position.28 The compound first discovered of this
nature was alexine and was appropriately named after its source, the legume Alexia
leiopetala (Figure 1.9).28 Its structure was unequivocally confirmed by X-ray
crystallography28 and just a few months later, its C7a epimer (also crystalline), australine,
was reported as a constituent of Castanospermum australe seeds (Figure 1.9).77 Following
these discoveries, a number of closely related epimers were also isolated from C.
australe.30,

78-80

Interestingly, alexine and australine along with their related epimers

displayed notable anti-viral properties as well as low IC50 values towards specific
glycosidases.28, 77 These findings attracted significant attention to the polyhydroxylated
pyrrolizidine alkaloids, because contrary to their non-hydroxylated analogues, they proved
to be medicinally useful.
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Figure 2.9: Castanospermum australe81 seeds and polyhydroxylated pyrrolizidine
alkaloid containing a hydroxymethyl substituent at C3: Australine.

Prior to the discovery of alexine and australine, it was perceived that the only glycosidase
inhibitors

were

restricted

to

polyhydroxylated

indolizidines

(swainsonine),

polyhydroxylated pyrrolidines (DMDP) and polyhydroxylated piperidines (nojirimycin).77
The polyhydroxylated pyrrolizidine alkaloids unique structure and hydroxy substitution
patterns gives rise to their reported antiviral properties and other medicinal applications.
For this reason, it has become apparent that related analogues of alexine and australine,
synthetic or naturally derived, are of considerable interest for medicinal chemists
globally.23, 82-84
It was therefore an exciting discovery when the first pentahydroxylated pyrrolizidine
alkaloid, casuarine, was isolated from the bark of Casuarina equisetifolia L (Figure 1.10)
reported by Nash et al. in 1994.85 Nash and colleagues were initially interested in the bark
of C. equisetifolia L because of its traditional use as a medicine to treat diarrhoea, dysentery
and colic.85-86 Perhaps a more convincing reason for Nash et al. to examine this natural
source, was due to previous reports of prescribed C. equisetifolia L bark extract for the
treatment of breast cancer in Western Samoa.85 Their investigation started with an GC-MS
analysis of the extract, where a pentahydroxy- nitrogen-containing species, later
established to be casuarine, was identified to be one of the major compounds present.
Moreover, it contained the highest oxidation level to be found in any related naturally
occurring iminosugar. Glycosidase inhibition studies of casuarine found it to be a highly
potent glycosidase inhibitor.85
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Figure 2.10: Leaves of Casuarina equisetifolia L87 and casuarine.

Casuarine has also been identified as a common constituent within the leaves and seeds of
Eugenia jambolana (Figure 1.11), a plant native to India known particularly for its various
medicinal uses including the management of diabetes and bacterial infections.88 In the
related species, Eugenia uniflora, isolates initially labelled as uniflorine A and B were
assigned structures containing an indolizidine core. However, by members from the Pyne
research group, it was later found that both uniflorine A and B were incorrectly assigned
and were in fact casuarine along with its C6 epimer, respectively (Figure 1.11). 89-95 The
only other naturally occurring casuarine epimer reported in the literature is the C3 epimer
which was isolated from Myrtus communis L. in 2006 by Fleet et al.96 Compared to
casuarine, its notably weaker inhibition of α-D glucoside is a result of its single
stereochemical difference.96
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Figure 2.11: Above: Eugenia jambolana97 (left), Eugenia uniflora98 (middle), Myrtus
communis L99 (right) Below: (left) 6-epi-casuarine and analogue (right) 3-epi-casuarine.

Since their discovery, casuarine, alexine, australine and related structures have been
largely sought after due to their inherently selective glycosidase inhibition and are
consequently perceived as ideal leads for drug candidature. Although no marketable drug
has yet resulted from this class of compound, scientists have deduced that the
polyhydroxylated pyrrolizidine alkaloids containing a C3 hydroxymethyl are medicinally
useful (unlike their unsaturated analogues). Moreover, the absolute configuration as well
as the degree of oxidation is crucial for selectivity and potency against specific glycosidase
inhibition.

1.8. The Hyacinthacine Alkaloids: Isolation and Biological activity
One recently discovered subclass of polyhydroxylated pyrrolizidine alkaloid that has
attracted considerable attention for their inherent glycosidase inhibitory activities are the
hyacinthacine alkaloids. Despite their analogous structure to casuarine, alexine and
australine, these alkaloids have been named after their original source, namely the
Hyacinthaceae subfamily within the Asparagaceae.100 Shown in Figure 1.12, the
hyacinthacine alkaloids can be divided into three classes: Hyacinthacine A, B and C;
16

whereby the letter assignment denotes whether 0, 1 or 2 hydroxy/hydroxymethyl
substituents are found on the B-ring of the alkaloid, respectively.

Figure 2.12: Hyacinthacines A1, B1, C1, containing 0, 1 and 2 hydroxy or hydroxymethyl
substituents on the B-ring of the pyrrolizidine (red), respectively.

The discovery of the hyacinthacine alkaloids can be traced back to the late 1960s and is
considered an unprecedented find, largely because Asparagaceae is unrelated to the
Leguminosae, Casuarinaceae and Mytaceae plant families.101 In 1967 a report from The
Veterinary Record written by Thursby-Pelham, detailed the toxicological effects on
livestock after consuming Hyacinthoides non-scripta (Figure 1.13).102 More specifically,
Thursby-Pelham found that ingestion led to abdominal pain and dysentery in horses and
lethargy and dullness in cows.102 The plants metabolites however remained a mystery until
1997, where, prompted by this report and perhaps also the availability of this material,
Fleet et al. identified the presence of five pyrrolidine alkaloids present in the ethanolic
fraction of the leaves.103 This was the first report of any such alkaloids from the
Hyacinthaceae species and although the plant was considered detrimental to livestock
health, Fleet et al. were able to demonstrate that the isolated pyrrolidine alkaloids were
potential therapeutic leads. Glycosidase inhibition studies of these isolates found that they
might serve as useful chemotherapeutic agents against cancers, viruses and also
diabetes.101
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Figure 2.13: Hyacinthoides non-scripta.104

Two years after this novel finding, several of the same authors led by Asano, reported their
investigation into the fruits and stalks of the H. non-scripta.105 To further explore the
natural abundance of similar compounds, their research also detailed the analysis of the
bulbs of a related species, Scilla campanulata (Figure 1.14).105

Figure 2.14: Scilla campanulata.106

In addition to the isolation of six pyrrolidine alkaloids, three novel polyhydroxylated
pyrrolizidine alkaloids labelled as hyacinthacine alkaloids were reported (See Table
1.2).105 More specifically, from the 50% ethanoic extracts of the H. scripta stalks,
hyacinthacine C1 was isolated, and from the 50% ethanoic extract of the S. campanulata
bulbs, hyacinthacine B2 was isolated.105 Hyacinthacine B1 was common in both plants and
thus found as a constituent in both extracts.105 Although not necessarily potent, these three
alkaloids gained considerable interest for their selective glycosidase inhibition.
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Hyacinthacine B1 and B2 both displayed weak inhibition of almond β-glucosidase (IC50
values of 320 µM and 100 µM, respectively) and bovine liver β-galactosidase (IC50 values
of 110 µM and 160 µM, respectively). Both alkaloids also showed selective inhibition for
rat intestinal lactase β-galactosidase, however hyacinthacine B2 proved far more active
(IC50 = 3.6 µM) than hyacinthacine B1 (IC50 = 270 µM). Interestingly, hyacinthacine C1
proved moderately active against the amyloglucosidase of Aspergillus niger (IC50 = 84
µM), whereas hyacinthacine B1 and B2 displayed no inhibition for these two glycosidases.
Given these noteworthy glycosidase inhibitory activities, the therapeutic potential
warranted further investigation of the hyacinthacine alkaloids. Since there had not yet been
a proven synthetic route to access these novel structures, natural product investigation was
the only viable option. To increase the chance of finding similar novel hyacinthacine
alkaloids, the same authors reported in 2000, their investigation into the bulbs of the related
Muscari armeniacum whereby they identified four novel hyacinthacine type alkaloids.107
More specifically, Asano and co-workers successfully isolated (from 60% ethanoic
extracts) hyacinthacine C1 as well as new Hyacinthacines A1, A2, A3 and B3 (See Table
1).107 When tested against a panel of glycosidases, hyacinthacines A1, A2, A3 and B3
displayed weak to moderate activity against rat intestinal lactase β-galactosidase (IC50
values of 4.4 µM, 73 µM, 160 µM and 18 µM, respectively) and also A. niger
amyloglucosidase (IC50 values of 25 µM, 8.6 µM, 17 µM and 51 µM, respectively).
Hyacinthacine A1 proved to be the only alkaloid active against rat epididymis α-Lfucosidase (IC50 = 46 µM) and rice α-glucosidase (IC50 = 240 µM). Hyacinthacines A1 and
A2 also displayed activity against almond β-glucosidase with IC50 values of 250 µM and
150 µM, respectively.107

Figure 2.15: Muscari armeniacum.108
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Despite what could be considered a small compound library, Asano and co-workers
remarked on the difficulty to predict the specificity and potency of glycosidase inhibition
based on absolute configuration and also the degree of substitution on the pyrrolizidine
ring.107 Concluding statements from this body of work highlighted the need for a variety
of highly oxygenated or substituted pyrrolizidine alkaloids to better understand the
structural requirements for glycosidase inhibtition.107 Concurrently, glycosidase inhibitors
were also receiving considerable attention as therapeutic agents. In addition to potential
treatment for NIDDM (type II diabetes), glycosidase inhibitors were also established as
possible treatments for tumour metastasis, viral infections, and various lysosomal storage
disorders.13, 29, 109-112 For these reasons, investigation into the hyacinthacine type alkaloids
also received increased attention and resulted in perhaps the most profitable recordings of
novel hyacinthacine alkaloids isolated from a single species to date by Asano et al. in
2002.113 Their report detailed the analysis of the bulbs of the related Scilla sibrica (Figure
1.16) that were originally purchased from a flower shop in 1999. Specifics of this report
include 9 kg of S. sibirica bulbs being homogenized in 60% aqueous ethanol, and further
extracted to give seven new hyacinthacine alkaloids appropriately named hyacinthacines
A4, A5, A6, A7, B4, B5 and B6 (See Table 1.2).113 Although the majority of these
hyacinthacine alkaloids proved relatively inactive towards the selected panel of
glycosidase enzymes, they still added to the understanding of the structure-activity
relationships of these and related compounds. In summary, the only active hyacinthacine
alkaloids were A5, B4, and B5, where they showed inhibitory activity towards the
amylglucosidase of Aspergillus niger with IC50 values of 110 µM, 89 µM and 110 µM,
respectively. In addition to this, hyacinthacine B4 displayed a moderate inhibition of
bovine epididymis α-L-fucodisase with an IC50 value of 23 µM.113
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Figure 2.16: Scilla sibrica.114

Two years later, Asano and co-workers reported findings of long side chain pyrrolidines
and pyrrolizidines in a closely related Asparagaceae, Scilla peruviana (Figure 1.17).115
Asano et al. isolated three novel hyacinthacine A1-type related alkaloids along with one
novel australine type related alkaloid.115 These long-chain hyacinthacine derivatives were
isolated from 5 kg of bulb plant material using 50% aqueous ethanoic extracts and were
accordingly

named

α-5-C-(3-hydroxybutyl)hyacinthacine

A 1,

α-5-C-(1,3-

dihydroxybutyl)hyacinthacine A1, α-5-C-(1,3,4-trihydroxybutyl)hyacinthacine A1 and α5-C-(3-hydroxybutyl)-7-epi-australine (See Table 1.2).115 When tested against a panel of
glycosidases, α-5-C-(1,3-dihydroxybutyl)hyacinthacine A1 and α-5-C-(3-hydroxybutyl)7-epi-australine displayed relatively good activity against yeast α-glucosidase (IC50 values
of 3.6 µM and 6.6 µM, respectively), however only the former alkaloid, along with α-5-C(1,3,4-trihydroxybutyl)hyacinthacine A1, proved relatively low inhibition against almond
β-glucosidase and C. saccharolyticum β-glucosidase with IC50 values of 9.5 µM, 25.4 µM
and 5.1 µM, 11.4 µM, respectively.115
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Figure 2.17: Scilla peruviana.116

The most recent addition to the naturally occurring hyacinthacine alkaloids is the 2007
reporting of six new isolates from Scilla socialis (Figure 1.18).117 Kato and co-workers
initially purchased S. socialis plants in 2003 and cultivated this species in a heated
greenhouse. Once grown, 2.3 kg of the plant bulbs were homogenized in a 50% ethanol
solution and further investigated whereby α-5-C-(3-hydroxybutyl)hyacinthacine A2,
hyacinthacine B7, C2, C3, C4 and C5 were isolated and tested against a panel of selected
glycosidases (See Table 1.2). Of these results, hyacinthacine C2, C3 and C5 displayed
noteworthy activity against C. saccharolyticum β-glucosidase with IC50 values of 13 µM,
25 µM and 48 µM, respectively. Hyacinthacine C4 proved to be the only active compound
against rice α-glucosidase (IC50 = 110 µM), but shared similar activities with hyacinthacine
C5 against rat α-glucosidase (IC50 = 45 µM and 77 µM, respectively) and the
amyloglucosidase of A. niger (IC50 = 57 µM for both C4 and C5). Hyacinthacine C3
displayed a unique inhibition of bovine liver β-galactosidase with an IC50 value of 52 µM,
whilst hyacinthacine C2 proved the only alkaloid capable of inhibiting human placenta αL-fucosidase with an IC50 value of 17 µM.117

Figure 2.18: Scilla Socialis.118
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Table 2.2: Concentration (µM) of the naturally isolated hyacinthacine alkaloids giving
50% inhibition of various glycosidases (IC50 values).

a

“-”: Not tested, bNI : No inhibition (less than 50 % inhibition at 1000 µM)
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1.9. Structural assignment issues with the Hyacinthacine alkaloids
Excluding the three long-chain hyacinthacine A-type analogues, 19 hyacinthacine type
alkaloids have been isolated and reported between 1999 and 2007. In most cases, 2D NMR
experiments (gCOSY, HSQC, HMBC) were the sole basis of structure elucidation.
Moreover, NOE correlations as well as 3JH,H coupling patterns and constants were used to
determine the relative configuration but were limited such that they were unable to identify
the absolute configuration of the isolated hyacinthacines. With no X-ray crystallographic
structures of these complex natural isolates, this has understandably led to inconsistencies
among the hyacinthacine structures and suggests that their assigned configurations are not
secure. An immediately obvious example of this can be seen in the proposed structures of
hyacinthacines C1 and C4. Although reported nearly eight years apart, both alkaloids were
assigned with identical structures despite their prominent differences in both 1H and 13C
NMR spectroscopic data and their specific rotations. Despite plausible NOE correlations
presented for both structures (Figure 1.19), the aforementioned differences between the
spectroscopic data suggests at least one of these structures to be incorrect.105, 117

Figure 2.19: The NOE correlations reported for hyacinthacine C1105 and C4.117

Therefore, to confirm their structures (as well as the proposed relative and absolute
configurations) the hyacinthacine alkaloids have been of recent interest for total synthesis.
Furthermore, total synthesis also allows access to the core structure of these complex
alkaloids and so presents a great significance to the large community interested in the
preparation of glycosidase inhibitors and consequent therapeutic iminosugars.
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To date, 14 of the natural hyacinthacines, A1, A2, A3, A6, A7, B1, B2, B3, B4, B5, B7, C2, C3
and C5 have been synthesized, along with their related epimers and enantiomers.119-132 At
this point, the author notes that an increasing number of reports suggest the confirmation
of hyacinthacine A5 through methods of total synthesis.129,

131, 133

To the best of our

knowledge, hyacinthacine A5 has not yet been synthesized and although epimers of the
structure have been reported,134 the absolute configuration of the natural isolate is still yet
to be confirmed. In addition to the aforementioned issues, recent synthetic studies have
also revealed that the original structures proposed for hyacinthacines B7, C3 and C5 are
incorrect.126-130 It therefore becomes apparent that structural revision of the original
isolates is necessary because as demonstrated in Table 1.2, hyacinthacine alkaloid epimers
determine the degree of specificity as well as the potency for the inhibition of various
glycosidases.

1.10. Total syntheses of the Hyacinthacine C-type analogues
Each subclass of the hyacinthacine alkaloids displays relatively low glycosidase inhibitory
activities and so merits their total synthesis. Relative to A-type hyacinthacines, both B and
C-type analogues have a greater constitutional complexity and as a result, have led to a
greater number of insecure structural assignments. Synthetic work towards hyacinthacine
A and B-type analogues has been included in a number of reviews,135-137 with a
comprehensive analysis completed in 2012 by Pyne et al.138 The hyacinthacine C-type
analogues on the other hand have attracted considerable interest and there has been a
number of publications towards their synthetic work that has not yet been summarised.
When considered from a structural point of view, the hyacinthacine C-type analogues are
the most diverse subclass of the hyacinthacines. They can contain up to seven possible
stereogenic centres which means that there are 128 unique possible diastereomers (together
with their enantiomers) containing a 3-hydroxymethyl-5-methylpyrrolizidine-1,2,6,7tetraol core that can be potentially synthesized. Their high degree of oxidation presents a
remarkably analogous structure to glucose and is therefore an enticing, but challenging
synthesis for chemists interested in accessing medicinally useful iminosugars. For these
reasons, the remainder of this Chapter will largely focus on the hyacinthacine C-type
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alkaloids and will aim to deliver a comprehensive and collective review of all the different
synthetic approaches towards this subclass of hyacinthacine.

1.10.1. Yoda et al. 2009
The first synthesis of hyacinthacine C-type analogues was the synthesis of hyacinthacine
C2 and C3 along with their C5-epimers reported by Yoda et al. in 2009.128 This synthesis
was an initial attempt to reveal information regarding structure-activity relationships
between the hyacinthacine C-type alkaloids and their inhibition against various
glycosidases. Their synthetic strategy (Scheme 1.1) starts with the preparation of the NBoc lactam 1 from commercially available (S)-(–)-2-pyrrolidone-5-carboxylic acid.
Lactam 1 was subject to a Grignard addition followed by a 1,2-reduction of the resulting
unsaturated ketone formed by pyrrolidione ring opening to give the corresponding allyl
alcohol. Subsequent mesylation-cyclization then afforded the N-Boc-2 product. Next, the
Boc protecting group was replaced with Cbz in a high yielding, three-step procedure to
give N-Cbz-3. The olefin moiety of N-Cbz-3 was then subject to oxidative cleavage with
OsO4 and NaIO4 to give aldehyde 4 as a single isomer. A Reformatsky-type allylation of
4 returned a 79:21 separable mixture of the alcohols 5a and 5b, respectively. To establish
the methodology, alcohol 5a then underwent TBS protection of the hydroxy group
followed by a non-selective dihydroxylation of the terminal olefin moiety. The inseparable
diol mixture was then subject to a selective TBS protection of the primary alcohol,
affording a high yield (92%) of a 1:1 mixture of separable diastereomers 6a and 6b. In
separate reactions, mesylation of the secondary alcohols of 6a and 6b followed by Cbz
deprotection resulted in concerted cyclization to give the pyrrolizidines 7a and 7b.
Individual global deprotection of both pyrrolizidines afforded hyacinthacine C2 along with
its epimer, 5-epi-hyacinthacine C2 10 in 72% and 71% yields, respectively. Having
established the synthetic pathway to hyacinthacine C2, Yoda and co-workers employed a
similar synthetic methodology to alcohol 5b where they also successfully synthesized
hyacinthacine C3 along with its epimer, 5-epi-hyacinthacine C3 11. When compared with
the spectroscopic data of the natural isolates,117 Yoda et al. confirmed only the structure
for natural hyacinthacine C2 was correct. They found that the characterization data of their
synthetic sample of hyacinthacine C3 was inconsistent with the corresponding natural
product.
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Scheme 2.1: The first total synthesis of hyacinthacine C2 and proposed structure of C3 and
their C5 epimers 10 and 11, respectively by Yoda et al.128
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1.10.2. Tamayo et al. 2009
At around the same time as Yoda et al., Tamayo and co-workers published their work
detailing the synthetic approach to making analogues of hyacinthacines C 2/C3 from the
arabinose derived nitrone 12 (Scheme 1.2).139 Their synthesis began with the 1,3-dipolar
cycloaddition of the chemoenzymatically prepared 3-buten-1,2-diol derivatives 13a or 13b
to nitrone 12 to afford cycloadducts 14 or 15, respectively. At this stage, methodological
probing was performed with the pyrroloisoxazolidine 14, which was subsequently
converted into the mesylate 16. Compound 16 underwent an N-O reduction with
Zn/AcOH, which after a basic work up, spontaneously cyclized to give the pyrrolizidine
18. Deacetylation to give 19, followed by a catalytic hydrogenolysis under acidic
conditions afforded the final product 20. After access to the pyrrolizidine core was
established, Tamayo and co-workers focused their attention on cycloadduct 15. More
specifically, deacetylation of 15, followed by a TBDPS protection of the primary alcohol
afforded 17 in near quantitative yields. Using similar methodology (mesylation, N-O
reduction, global deprotection), the 5-epimer 24 was obtained. Although they were not
assessed as potential glycosidase inhibitors, access to these highly oxygenated iminosugars
is still important for the broader community interested in synthesizing complex azasugars.
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Scheme 2.2: The total synthesis of unnatural hyacinthacine C2/C3 analogues 19 and 24 by
Tamayo et al.139

1.10.3. Tamayo et al. 2010
At this stage, hyacinthacines C1, C4 and C3 proved to be insecure in their structural
assignment. Their glycosidase inhibitory activities proved noteworthy, but difficult to
predict, especially due to these inconsistencies. For these reasons, Tamayo and co-workers
were compelled to investigate and report the synthesis of unnatural 7a-epi-hyacinthacine
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C1 36 and 5,7a-di-epi-hyacinthaicne C1 37 in 2010.140 From their previous work towards
the synthesis of hyacinthacine A-type analogues,141 Tamayo et al. recognized that using
the common precursor, the ,-unsaturated ketone 25, would afford access to both
hyacinthacine C-type analogues (Scheme 1.3). More specifically, 25 was subject to a
catalytic dihydroxylation using OsO4 and NMO to afford a single diol diastereomer 26 in
high yield. The high diastereoselectivity achieved is a result of the steric hindrance created
by both the Boc protecting group at the amino moiety as well as the benzyl groups at C3
and C4. Diol 26 was then acetylated in good yield to afford the di-O-acetylated 27, which
was subsequently reduced with NaBH4 to afford a separable mixture of alcohols 28 and 29
in a 1:1 ratio (isolated yields of 25% and 22%, respectively). To prepare the pyrrolizidine
core, alcohols 28 and 29 underwent separate mesylation reactions, followed by an acidcatalysed N-Boc deprotection to give the secondary amines 32 and 33, respectively. After
heating at reflux in THF under basic conditions, both amines cyclised to give their
respective pyrrolidine cores. To both pyrrolizidine mixtures was then added MeONa in
MeOH to facilitate a one-pot debenzoyl- and deacetylation to afford triols 34 and 35,
respectively. A final O-benzyl deprotection of 34 and 35 revealed the desired
hyacinthacine C-type analogues, 7a-epi-hyacinthacine C1 36 and 5,7a-di-epihyacinthaicne C1 37, respectively. Although neither of the synthesized hyacinthacine Ctype analogues were able to resolve the structural discrepancies in the literature, access to
stereogenic variations of the heavily hydroxylated pyrrolizidine core proves important.
Their therapeutic potential remains unclear as these compounds were not assessed for their
glycosidase inhibitory activities.
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Scheme 2.3: The synthesis of unnatural hyacinthacine C1 analogues, 7a-epi-hyacinthacine
C1 36 and 5,7a-di-epi-hyacinthaicne C1 37 by Tamayo et al.140

1.10.4. Yu et al. 2011
In the following year, Yu et al. published their findings regarding the synthesis of (–)hyacinthacine C5, 6-epi-(–)-hyacinthacine C5 and 7-epi-(–)-hyacinthacine C5 from the Larabinose derived cyclic nitrone 38 (Scheme 1.4).129 This not only expanded the number
of hyacinthacine C-type analogues synthesized, but it was also the first synthesis of the
enantiomer of natural isolate hyacinthacine C5. Their synthesis began with the addition of
the lithiated dithiane 39 to the cyclic nitrone 38 which returned the stereoselective
hydroxylamine intermediate 40. Compound 40 was then subject to Cope-House
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cyclization conditions which afforded the separable pyrrolizidine N-oxides 41 and 42 in a
1:1 ratio (55% combined yield). Pyrrolizidine N-oxides 41 and 42 were then separately
reduced using Zn-HOAc to afford the pyrrolizidines 43 and 44, respectively. Initially
focusing on the enantiomer of hyacinthacine C5, the dithioketal moiety of pyrrolizidine 43
was hydrolysed to its corresponding ketone, which was then selectively reduced to the
corresponding diol 45 in an overall 31% yield. Subsequent debenzylation revealed the final
product as (–)-hyacinthacine C5. Turning their attention to the related epimers, Yu and
colleagues initially protected the free hydroxy moiety in 43 using MOMCl, followed by
hydrolysis of the dithioketal to give the corresponding ketone in 61% yield. A
stereoselective reduction of the ketone with NaBH4 afforded two separable
diastereoisomers favouring the desired alcohol 47 in a 5:1 ratio with an overall high yield
(96%). Global deprotection of the MOM and the O-benzyl groups afforded (–)-7-epihyacinthacine C5 49. Having established the synthetic pathway, Yu and co-workers
successfully synthesized (–)-6-epi-hyacinthacine C5 52 by subjecting 44 to similar
methodology. With the three products in hand, Yu et al. reported that none of the 1H and
13

C NMR spectroscopic data matched with those reported for the natural isolate labelled

(+)-hyacinthacine C5.117 This led to the conclusion that natural (+)-hyacinthacine C5 was
in fact, a different isomer. Regardless, all synthetic isomers of this study were assayed as
potential glycosidase inhibitors and found that (–)-6-epi-hyacinthacine C5 52 is a weak
inhibitor against the α-glucosidases of rat intestinal maltase (IC50 = 58.5 µM) and rice (IC50
= 64.2 µM).
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Scheme 2.4: A total synthesis of the proposed structure of (–)-hyacinthacine C5, (–)-6-epihyacinthacine C5 52 and (–)-7-epi-hyacinthacine C5 49 by Yu et al.129
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1.10.5. Tamayo et al. 2011
At the same time as Yu et al. and for similar reasons, Tamayo and co-workers also
published related work detailing a synthetic approach towards (+)-hyacinthacine C5 along
with its C6, C7-diepimer.130 Their synthesis began with the N-Cbz protected pyrrolidine
53, a 2,5-dideoxy-2,5-imino-D-mannitol (DMDP) derivative (Scheme 1.5). In this
synthesis, the primary alcohol of 53 was initially oxidised its corresponding aldehyde 54,
which was further treated in situ with 1-triphenylphosphoranylidene-2-propanone to afford
the α,β-unsaturated ketone 55. A non-selective dihydroxylation of 55 with OsO4 and NMO
returned a 1.4:1 separable mixture of diols 56 and 57, respectively. Individually, both diols
56 and 57 were subject to reductive amination to form their respective iminium
intermediates 58 and 59. Prolonged exposure to catalytic hydrogenation conditions over
Pd/C resulted in a stereospecific hydrogenation occurring anti to the sterically
encumbering CH2OTBDPS group of both pyrrolizidines. More specifically, both
pyrrolizidines 60 and 61 were synthesized with the same C5-stereochemistry. Individual
global deprotections of pyrrolizidines 60 and 61, which included a desilylation and
hydrogenolysis of the benzyl protecting groups, revealed both (+)-hyacinthacine C5 and
(+)-6,7-di-epi-hyacinthacine C5 64, respectively. Arriving to a similar conclusion made by
Yu et al., Tamayo and colleagues also found that neither of their spectroscopic data for
hyacinthacine C5 and its C6, C7-diepimer 64 matched that of the natural isolate117 further
suggesting it to be a different isomer. The final products of this study were not assessed
for their glycosidase inhibitory activities.
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Scheme 2.5: The total synthesis of the proposed structure of (+)-hyacinthacine C5 and (+)6,7-di-epi-hyacinthacine C5 64 by Tamayo et al.130
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1.10.6. Fischer et al. 2014
By 2014, synthetic work towards the hyacinthacine C-type analogues had revealed several
structural inconsistencies among their natural isolates. For this reason, and to also expand
the scope of information pertaining to these compounds, Fischer and co-workers
investigated the usefulness of asymmetric 1,3-dipolar cycloadditions to prepare optically
active nitrone templates towards making various polyhydroxylated pyrrolizidine
analogues.142 One of the iminosugars prepared by Fisher and co-workers can be considered
an unnatural hyacinthacine C-type alkaloid shown in Scheme 1.6. To obtain this analogue,
Fischer et al. began their synthesis through the preparation of the mannose-derived nitrone
65 (Scheme 1.6). The cyclic nitrone 65 underwent a 1,3-dipolar cycloaddition with vinyl
acetate and afforded a 9:1 separable mixture of isoxazolidines, favouring the formation of
66 for steric reasons. The acetate moiety of 66 then underwent a SN1-like reaction with
silylketene acetal 67, which exclusively produced the 2,3a-trans-isoxazolidine 68 in a 69%
yield. In a two-step procedure, the methyl ester of isoxazolidine 68 was initially reduced
with LiAlH4, then subsequently protected with tert-butyl(diphenyl)silyl chloride to give
isoxazolidine 69 in good yield (84% over two steps). The dimethyoxy ketal moiety in
compound 69 was then hydrolysed to the ketone to give product 70, which was subject to
N-O bond reduction and then reductive amination by hydrogenation over Pd/C to afford
the pyrrolizidine 71 as a single isomer. A global deprotection including the removal of the
silyl and the isopropylidene moieties returned the hexahydroxylated pyrroizidine 73 in
76% yield over two steps.
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Scheme 2.6: A total synthesis of an unnatural hyacinthacine C2/3 analogue 73 by Fischer
et al.142

1.10.7. Vankar et al. 2014
In the same year, Vankar and co-workers reported their synthetic work towards the
synthesis of homoanolouges of hyacinthacine C5.143 Their 2014 report details starting from
the arabinose-based cyclic nitrone 74 which underwent a 1,3-dipolar cycloaddition
reaction with the D-mannitol-aldehyde derived dipolarphile 75 (Scheme 1.7). The desired
cycloadduct 76 was obtained in a 9:1 ratio in a combined yield of 88%. Compound 76 was
then subject to a Zn/HOAc mediated N-O cleavage which produced the cyclic amine 77
which then underwent selective benzylation at the secondary amine to give 78 in 85% over
two steps. The ester moiety of 78 was then reduced to its corresponding alcohol to afford
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diol 79. A non-selective O-benzylation of both hydroxy groups afforded 80, which upon
removal of the cyclohexylidene acetal, resulted in the formation of the diol 81. The diol
moiety of compound 81 was then oxidatively cleaved with sodium periodate to give
aldehyde 82 which was then treated with MeMgI, returning a selective 10:1.2 mixture of
diastereomers 83a and 83b. The diastereomeric mixture was then oxidised to the respective
ketone product 84, which after a reductive amination followed by a benzyl ether
deprotection, afforded the crude hyacinthacine C-type analogue 86. To purify 86, Vankar
et al. peracetylated the crude mixture, followed by its deprotection. After washing the
residue with chloroform, the purified 86 was obtained.
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Scheme 2.7: A total synthesis of the hyacinthacine C-type related analogue 86 by Vankar
et al.143

1.10.8. Vankar et al. 2016
In continuation with synthetic efforts towards synthesizing different unnatural analogues
of bicyclic iminosugars, Vankar et al. reported in 2016, a new strategy for accessing a large
number of complex hyacinthacine C2/C3 related products.144 Vankar and co-workers’
synthesis of the unnatural hyacinthacine C-type analogues can be summarised in Scheme
1.8. Their synthetic work began with the oxidation of pyrrolidine 87 to its corresponding
aldehyde using a CrO3-pyrridine-Ac2O reagent system. The aldehyde formed was then
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treated with allylzinc bromide to afford compound 88 which underwent O-benzylation to
the product 89. The olefin moiety of compound 89 was then subject to a nonselective
dihydroxylation with OsO4 and NMO which returned an inseparable mixture of diols. A
selective protection of the primary alcohol in each diol resulted in the corresponding silyl
ethers 90 and 91, which were readily separable. To establish the methodology, Vankar and
co-workers quantitatively mesylated the free hydroxy group in compound 90. Without
purification, the mesylated 90 then underwent a N-Boc deprotection which under basic
conditions furnished pyrrolizidine 92. A global deprotection, followed by peracetylation
as a means of purification afforded the pentaacetylate 94. After a comprehensive structural
analysis, the pentaacetylate 94 was deprotected using aqueous ammonia in methanol which
gave the final pentahydroxlyated hyacinthacine C2/C3-type analogue 96. Having
established this synthetic route, Vankar and co-workers then employed a similar reaction
pathway to diastereomer 91 which successfully converted into compound 97. Vankar et al.
also readily obtained two more epimers, 107 and 108, from subjecting pyrrolidine 98 to
the same sequence of reactions. The only notable difference is that the hydroxy group of
olefin 99 was protected as the acetate 100 instead of the benzyl ether. Of the four
hyacinthacine C2/3 products synthesized, none matched the putative structure for
hyacinthacine C3, but they certainly provided a better understanding towards the access to
these complex iminosugars. Additionally, the biological activities the final products were
evaluated as potential glycosidase inhibitors against a panel of eight commercially
available enzymes. The hyacinthacine analogues 96 and 107 displayed selective activity
against jack bean α-mannosidae (IC50 = 81.2 µM and IC50 = 95 µM, respectively) with
analogue 107 also displaying moderate activity against coffee bean α-galactosidase (IC50
= 120 µM). Final remarks from the authors suggested that given these activities,
hyacinthacine analogues 96 and 107 are potential anti-diabetic and anti-cancer leads,
respectively.
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Scheme 2.8: A stereodivergent synthesis of hyacinthacine C2/C3 related analogues 96, 107,
97 and 108 by Vankar et al.144
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1.10.9. Goti et al. 2017
A recent addition towards the synthesis of the hyacinthacine C-type analogues was
reported in 2017 by Goti and co-workers through their synthesis of the proposed structure
of (+)-hyacinthacine C5 and its C5 epimer 120.131 Their goal was to implement a
straightforward and convenient synthesis towards these complex iminosugar motifs. To
access both these structures, their convergent synthesis began with the preparation of both
the arabinose-derived cyclic nitrone 109 and the racemic 3-methyl-substituted
benzyloxyallene 110 (Scheme 1.9). The lithiated benzyloxyallene 110 was then added to
nitrone 109 to form intermediate 111, which upon standing at room temperature for 24 h,
cyclized to afford a 1:1 separable mixture of 1,2-oxazines 112 and 113. Both oxazines
were then individually subjected to hydroboration which delivered respective alcohols 114
and 115. Goti and co-workers were initially focused on establishing the synthetic pathway
towards the proposed structure of (+)-hyacinthacine C5 and so their attention turned to
alcohol 114 which was protected to give the penta-benzylated product 116. Next, a
reductive amination of 116 with samarium diiodide in THF cleaved the N-O bond to give
the amino-alcohol, which was subsequently converted to pyrrolizidine 118 via mesylation
of the primary hydroxy group, then spontaneous cyclization. Finally, all benzyl ether
groups were removed via hydrogenolysis to afford the purported (+)-hyacinthacine C5.
Using a similar method, 5-epi-hyacinthacine C5 120 was synthesized after alcohol 115
underwent a reductive amination followed by bis-mesylation of the hydroxy groups which
concurrently cyclized to give pyrrolizidine 119. After a LiAlH4 reduction of the sulfonyl
group on 119, the corresponding alcohol was subject to hydrogenolysis to give the globally
deprotected pyrrolizidine, 5-epi-hyacinthacine C5 120.
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Scheme 2.9: The total synthesis of the proposed structure of (+)-hyacinthacine C5 and 5epi-hyacinthacine C5 120 by Goti et al.131
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As per the previous reports by Yu et al.129 and Tamayo et al.,130 Goti and co-workers also
found that the configuration of the putative structure of hyacinthacine C5 was incorrect.
Neither structure synthesized in this report matched the spectroscopic data of the natural
isolate. Despite being unable to resolve the true structure of hyacinthacine C 5, Goti et al.
revised the originally reported NOE enhancements for the natural isolate and after finding
similar NOE correlations in their synthetic products, were able to suggest an alternative
configuration which could be appropriately labelled as 1-epi-hyacinthacine C4 (Figure
1.20).

Figure 2.20: The NOE signals reported for the putative hyacinthacine C5 (left) along with
the revised NOE signals proposed by Goti et al.117, 131

1.11. Project aims:
The history and synthetic development towards the hyacinthacine alkaloids is certainly
rich and exciting. They have been isolated from the under-explored aqueous fractions of
various plants and contain an inherent glycosidase activity, making this class of compound
a suitable lead for the treatment of diabetes, cancer and bacterial infection. Additionally,
these novel compound motifs are highly complex and in this present day would not be
conceivably produced by technologies such as combinatorial chemistry. Their
configurational differences prove vital for their selectivity and potency against inhibiting
various glycosidases, and so has led to many synthetic approaches towards accessing this
class of natural product. Structurally, the hyacinthacine C-type analogues can be
considered the most diverse group of hyacinthacine, as they contain at least six possible
stereogenic centres and are analogous to glucose. Owing to their complexity, mistakes
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have been made when assigning their structures as proved in some cases by total synthesis.
More recently, this class of compound has been the focus of an increasing number of
synthetic attempts in hope to elucidate the mistakes and correct the structures currently
labelled as hyacinthacine C1, C3, C4 and C5. In addition to this, synthetic access to this
class of compound allows researchers to probe the structure activity relationship for
glycosidase inhibition, and design related analogues that can be marketed as treatment for
the illnesses previously mentioned.
After reviewing the entirety of the synthetic approaches towards the hyacinthacine C-type
analogues several observations can be made.
1. All pathways begin with a cyclic pyrrolidine derivative. Of these, just over half
favour the use of a sugar derived cyclic nitrone.
2. Although some syntheses are divergent the pathways discussed generally allow no
more than four hyacinthacine C-type analogues to be synthesized.
3. All nine publications raise awareness of the hyacinthacine C-type analogues and
their inherent glycosidase inhibitory activity but only two have been able to assess
the final products as glycosidase inhibitors.
4. Natural hyacinthacines C1, C3, C4 and C5 have insecure structures and the true
structures have not yet been revealed.
Starting this Ph.D. work in 2015, the aims of this project were to:
1. Develop a novel synthetic strategy to prepare hyacinthacine C-type analogues in
an efficient and flexible manner
2. Elucidate and correct the structure for either hyacinthacine C1, C4 or C5
3. Generate a moderate number of hyacinthacine C-type configurational analogues
and use the data generated from glycosidase inhibition studies to determine a
general structure-activity relationship.
Overall, these goals were achieved and although they will be discussed in greater detail in
the remaining Chapters, this work can be briefly summarised in the following paragraph.
Eleven configurationally different hyacinthacine C-type analogues were successfully
synthesized using a common but unique pathway. All final products were individually
assessed as potential glycosidase inhibitors, providing an interesting structure-activity
relationship. The highlight of this body of work was the elucidation of the correct structure
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for both natural hyacinthacine C1 and C5, which had been effectively a mystery for the past
20 and 10 years, respectively. In light of this, all final hyacinthacine C-type analogues
synthesized in this work are named in accordance to the newly corrected structures for
hyacinthacine C1 and C5.
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Chapter 2 : Synthesis of unnatural (+)-7-epihyacinthacine C5 and (‒)-6-epi-hyacinthacine C5.
The crux of this Ph.D. study is the successful synthesis and correction of the structures for
the natural isolates labelled as hyacinthacine C1105 and C5117 and will be discussed later.
This Chapter describes the strategy employed towards the synthesis of unnatural (+)-7-epihyacinthacine C5 155 and (‒)-6-epi-hyacinthacine C5 156. Accessing both these structures
proved integral towards establishing the synthetic methodology and foundations that
would later result in the correction of the aforementioned natural products. Herein, both
successful and unsuccessful synthetic attempts towards the hyacinthacine C-type
analogues are presented and will allow the reader to understand the logic that governed the
methodology which resulted in accessing the remaining nine hyacinthacine C-type
analogues.

2.1. The Petasis borono-Mannich reaction
The chiral anti-1,2-amino alcohol moiety is a common structural feature of many bioactive
azasugars including the hyacinthacine alkaloids A2, A3, A5, B3, B4, C3 and C5, as
highlighted in Figure 2.1.

Figure 2.1: Selected natural hyacinthacine alkaloids containing an anti-amino diol motif
(blue).
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In recent years, the Pyne research group has demonstrated synthetic methods to prepare
chiral anti-1,2-amino alcohols include: aminolysis of chiral vinyl epoxides, the boronoMannich reaction (Petasis reaction) and the borono-Mannich reaction via cyclic Nacyliminium ions (Figure 2.2 adapted from Pyne et al. review145).

Figure 2.2: An adapted figure from the review of Pyne et al. displaying the three reaction
types studied often used to prepare the 1,2 anti-amino alcohols.145

Of these three synthetic routes, the Pyne research group has explored the efficiency of
synthesizing bicyclic polyhydroxylated iminosugars containing this motif from a suitably
prepared borono-Mannich (Petasis) product (Scheme 2.1).89, 92, 126-127, 145-146 The successful
application of the Petasis borono-Mannich acid reaction in natural product synthesis is
largely because the resultant anti-1,2-amino alcohol is often obtained in high yields and
almost exclusively as a single diastereomer and enantiomer.147 Another desirable facet of
this reaction is the simple experimental procedure that generally involves mixing an aryl
or vinyl boronic acid, a primary or secondary amine and a chiral α-hydroxy-aldehyde under
relatively mild conditions.147 Previous Pyne group members, Davis, Machan and
Ritthiwigrom, demonstrated that the anti-1,2-amino alcohol 121 was the product of the
multi-component Petasis borono-Mannich acid reaction between (E)-β-styrenylboronic
acid, allylamine and L-xylose. More importantly, this Petasis product was a viable
precursor for the synthesis of natural products: (‒)-uniflorine A, (+)-castanospermine, (+)casuarine and (+)-australine (Scheme 2.1A).89, 146, 148 Of particular interest to this body of
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work, both Au126 and Savaspun127 have shown that hyacinthacine B3 and B7 could be
synthesized from the appropriate anti-1,2-amino alcohol 124; also a product of a Petasis
borono-Mannich acid reaction between 122, 123 and (E)-β-styrenylboronic acid (Scheme
2.1B). From these examples, particularly the latter, it was therefore reasonable to propose
that the hyacinthacine alkaloids shown in Figure 2.1, could be synthesized in a similar
manner.

Scheme 2.1: Natural products resulting from the Petasis reaction in the Pyne research
group.89, 92, 126-127, 145-146

2.2. Rationale for synthesizing hyacinthacine C5-type analogues
Discussed earlier in Chapter 1, there is a correlation between the degree of oxidation in the
hyacinthacine alkaloids and the prevalence for misassigned structures. For example, all the
synthetic attempts towards the A-type hyacinthacine alkaloids have confirmed so far that
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the natural isolates are correct in their stereoconfigurational assignment.119-123 Synthetic
attempts towards the hyacinthacine B-type suggest that only one is incorrect:
hyacinthacine B7.126 The hyacinthacine C-type (containing the highest relative degree of
oxidation) have four insecure structures, where only hyacinthacine C2 has been confirmed
to be the correct stereoconfiguration.105,

117, 128-131

We felt particularly drawn to

synthesizing the hyacinthacine C-type analogues due to the higher number of relative
mistakes associated with their structures. Additionally, synthesizing analogues would help
increase our understanding of the SARs and inherent glycosidase inhibition that these
iminosugars possess.
For each of the naturally occurring hyacinthacine C-type alkaloids, it becomes apparent
that each isolate contains the same absolute configuration at stereocentres C2, C3 and C7a
(Figure 2.3). The logical outcome of this would be that these stereocentres are the result of
a similar biosynthetic pathway. If these stereocentres are the correct absolute
configuration, then the stereoconfiguration of C1 is less ambiguous since the orientation
can be spectroscopically cross-examined against both C7a and C2. At this point, it seemed
reasonable that the most likely mistake would occur at the assignment of stereocentres C5,
C6 or C7 (Figure 2.3). Concurrent to our investigation, synthetic work towards
hyacinthacine C5 and various analogues was gaining considerable attention. Since their
first synthetic attempt in 2009,128 there has been an additional eight total syntheses
detailing access to related pyrrolizidine structures.129-131, 139-140, 142-144 Of these, the putative
structure for hyacinthacine C5, along with various diastereomers were synthesized in
2011129-130 and were sought after due to their inherent biological activities against various
glycosidases. The syntheses of hyacinthacine C5 have shown that the initially proposed
structure was incorrect since the 1H and

13

C NMR spectroscopic data of the synthetic

structures did not match the natural isolate.117 Until recently, Goti and co-workers reinterpreted the originally reported NOE enhancements for the natural isolate and proposed
an alternative configuration based on this interpretation.131 More specifically, their
interpretations suggested that the true structure for hyacinthacine C5 is actually the
configuration for 1-epi-hyacinthacine C4 (Chapter 1, Figure 1.20).131 However, before this
revision, the only other measure for determining the correct configuration of hyacinthacine
C5 was to compare the 1H and

13

C NMR spectroscopic data of previously synthesized
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hyacinthacine C5 analogues with that of the natural isolates. After searching the literature,
it was evident that no one had yet synthesized the true structure for hyacinthacine C5.

Figure 2.3: General structure for hyacinthacine C-type analogues.

Prior to Goti et al.,131 there were no reported attempts to synthesize hyacinthacine C5
alkaloids containing both an (R)-C7a nitrogen bridgehead proton and a (R)-C5 methyl. For
this reason, we initially focused on installing this stereochemical relationship in our final
hyacinthacine C5 related products. In addition to this, we were particularly interested in
manipulating the stereocentres at the C6 and C7 whilst simultaneously retaining the
original stereochemistry proposed in hyacinthacine C5 for stereocentres C7a, C1, C2 and
C3. As discussed earlier, a close inspection of the putative structure for hyacinthacine C5
reveals an anti-configuration between the C7a-N and the C1 carbinol and so our synthetic
strategy was designed around the Petasis borono-Mannich acid reaction to implement this
key motif.
Shown in Scheme 2.2, our initial retrosynthetic analysis suggested manipulating the C6
and C7 hydroxy group stereochemistry at later stages in the synthesis. The final
hyacinthacine C5-type analogues would be the result obtained from syn-dihydroxylation
across the alkene in pyrrolizidine 125. The diastereofacial selectivity would be influenced
by the concave nature of the pyrrolizidine core, as well as possible steric hindrance by the
(R)-C5 methyl. However, a non-selective dihydroxylation might still afford two syn-diol
diastereomers which would lead to two possible hyacinthacine C5-type analogues.
Pyrrolizidine 125, would be obtained by subjecting pyrrolidine 126 to ring closing
metathesis (RCM) conditions using either Grubbs’ I- or II-generation catalysts. Pyrrolidine
126 would be synthesised by N-alkylation of the amino-diol 127 using a steric-directed,
regioselective O-mesylation, then spontaneous cyclisation through the nitrogen. These
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reactions ultimately rely on synthesizing the stereochemically pure anti-amino-diol 127;
this is a product derived from the Petasis borono-Mannich acid reaction between 3,5-diO-benzyl-α,β-L-xylofuranose,

3-(R)-amino-1-butene·hydrochloride

and

(E)-β-

styrenylboronic acid.

Scheme 2.2: Retrosynthetic analysis for the synthesis of hyacinthacine C5-type analogues.

2.3. Synthesis of 3,5-di-O-benzyl-α,β-L-xylofuranose
Within the Pyne research group, the anti-amino-diol 127 had been previously synthesized
but not reported in the literature.149 To synthesize this product, 3,5-di-O-benzyl-α,β-Lxylofuranose was required. This protected sugar can be readily obtained from the
commercially available L-(‒)-xylose by using a modified three-step procedure employed
by Terashima and Matsuda150 as well as Baker and Schaue.151 The inherent stereochemistry
of L-(‒)-xylose was envisioned to produce the stereochemical configuration on the A-ring
of the final hyacinthacine C-type products. More specifically the hydroxy groups at C3,
C4 and C6 (Scheme 2.3) should account for the stereochemistry at C1, C2 and C3 in the
final product, respectively. To prepare this sugar, step one of the synthesis involved
dissolving L-(‒)-xylose in acetone followed by the addition of two equivalents of
copper(II) sulphate and a catalytic amount of sulfuric acid. After stirring the reaction for
24 h, a TLC analysis showed a near quantitative conversion to the corresponding bis-
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acetonide 128. Stirring a solution of 128 in 0.25 M solution of hydrochloric acid for 45
min returned the mono-acetonide 129 in quantitative yield.
The second step involved the conversion of acetonide 129 to its respective bis-benzyl ether
130. This reaction involved dissolving compound 129 in THF, followed by heating at
reflux for 30 min after the addition NaH, BnBr and a catalytic amount of the transfer
catalyst, tetrabutylammonium iodide (TBAI). After working up the reaction, the crude
mixture was purified by column chromatography and product 130 was obtained in overall
good yield (88%).
The last step towards the preparation of 3,5-di-O-benzyl-α,β-L-xylofuranose involved an
acid hydrolysis of the isopropylidene ketal from bis-benzylether 130. This involved stirring
130 in a solution of acetic acid (30% v/v) followed by the addition of a few drops of 5 M
HCl. The reaction was heated at 45 oC for 3 h or until the TLC confirmed the full
consumption of the starting material. After work up, the crude mixture was purified by
column chromatography to return a waxy solid which by 1H NMR analysis was determined
to be a 3:1 mixture of anomers of 3,5-di-O-benzyl-α,β-L-xylofuranose.
Although the products at each step had been well documented, 1H and

13

C NMR

spectroscopic data was still obtained for each product which were consistent with those
reported in the literature.150

Scheme 2.3: Synthesis of 3,5-di-O-benzyl-α,β-L-xylofuranose.
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2.4. The synthesis of anti-amino-diol 127
During the final stages of his Ph.D. candidature, Kongdech Savaspun attempted to develop
a facile route towards the synthesis of hyacinthacine B4 from the anti-amino-diol 127.
Although unsuccessful, we hypothesized this intermediate to be more suited in our total
synthesis for accessing hyacinthacine C5-type analogues. The anti-amino-diol 127 proves
integral to our synthetic plan as it accounts for five of the seven stereocentres required for
the final hyacinthacine C5-type analogues. Moreover, it incorporates the nitrogen such that
it adopts the anti-configuration between the C7a-N and the C1 carbinol. Finally, this
product delivers two suitably placed alkenes for the desired RCM reaction highlighted in
our retrosynthetic analysis (Scheme 2.2). Fortunately, optimised Petasis reaction
conditions had been explored.149 Following the procedure described by Savaspun, the
multicomponent reaction between 3,5-di-O-benzyl-α,β-L-xylofuranose, 3-(R)-amino-1butene·hydrochloride and (E)-β-styrenylboronic acid in a solution of ethanol under basic
conditions, took place over 3 d. Scheme 2.4 shows the proposed mechanism for this
reaction where the resultant product is dependent on the equilibrium interconversion
between 3,5-di-O-benzyl-α,β-L-xylofuranose (preferred form) and the respective ringopened aldehyde. When the aldehyde is formed, the base (Et3N)-activated 3-(R)-amino-1butene can react with the aldehyde to form the iminium ion intermediate A. A key
component of this intermediate is the availability of an α-hydroxy group.147, 152-153 Provided
this is available, it is believed that the boron reagent can coordinate to this hydroxy group,
and subsequently deliver the desired reagent.147, 152-153 In this example, prior to delivery of
the (E)-β-styrenyl unit, the iminium ion boron-complex B adopts a conformation that
minimizes the 1,3-allylic strain between the substituents at the α-position and on the N
atom of the iminium ion. This involves the smallest α-substituent (proton) on the
stereogenic carbon being eclipsed with the NH of the iminium moiety. As drawn here, the
(E)-β-styrenyl group is then transferred to the bottom face of the iminium ion to give the
desired product 127. After 3 d and in comparable yield to Savaspun (~65%), the purified
product was subject to 1H and 13C NMR spectroscopic studies and was concluded to be the
anti-amino-diol 127 previously characterised by Savaspun.149 Although extensively
characterised, key 1H NMR resonances of 127 appeared at δH 6.48 (1H, d, J = 16.0 Hz)
6.10 (1H, dd, J = 16.0, 8.7 Hz), 5.72 (1H, ddd, J = 17.3, 10.2, 7.2 Hz) and 5.09 (1H, d, J =
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10.2 Hz) to 4.98 (1H, d, J = 16.8 Hz), and are representative of the olefinic moieties at H7,
H6, H2′ and H3′cis/trans, respectively (Figure 2.4A).

Scheme 2.4: The mechanism of the Petasis borono-Mannich reaction and synthesis of antiamino-diol 127.

It was also serendipitously found that the crystalline anti-amino-diol 127 HCl salt could
form after dissolving 127 in EtOAc and washing the organic layer with 1N HCl. An X-ray
crystallographic analysis returned the ORTEP plot displayed in Figure 2.4B, and
unambiguously confirmed the spectroscopically determined absolute configuration of the
anti-amino diol 127.
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A)
H3′
H7
H6 H2′

B)

Figure 2.4: A) 1H NMR spectrum (500 MHz, CDCl3) of 127 and B) The ORTEP plot of
the crystal structure of the C31H38NO4+ cation of 127 with labelling of selected atoms.
Anisotropic displacement ellipsoids display 30% probability levels. Hydrogen atoms are
drawn as circles with small radii, the chloride counter ion is not shown.

2.5. The synthesis of RCM product 132
Following similar methodology to Savaspun, the anti-amino-diol 127 was converted to the
pyrrolidine 131 using well established mesylation-cyclisation conditions.149 Details of this
synthesis involved treating the anti-amino-diol 127 with 1.05 equivalents of
methanesulfonyl chloride in CH2Cl2 at 0 oC for 1.5 h. A regioselective mesylation was
anticipated to occur at the C2 hydroxy group since this is less sterically hindered than the
alternative C4 hydroxy group (Scheme 2.5). Once mesylated, a base-induced cyclisation
occurred and presumably furnished the pyrrolidine 131 (and consequently formed the Aring of the desired product). The 1H and

13

C NMR spectroscopic data of 131 were

consistent with the same product made by Savaspun.149 Unfortunately, due to the overlap
of key proton resonances for H3, H4 and H5, the absolute configuration was unable to be
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confidently assigned for this compound. Regardless, Savaspun attempted to synthesize the
pyrrolizidine core 132 by employing RCM conditions.149 Savaspun’s approach involved
deactivating the tertiary amine of pyrrolidine 131 with titanium isopropoxide to form a TiN complex.154 This complex was then subject to several different RCM conditions
involving either Grubbs’ II or Hoveyda Grubbs’ II catalyst (Table 2.1, entries 1-3).149
Unfortunately, Savaspun abandoned this pathway after each attempt resulted in formation
of the undesired pyrrole 133. It was concluded that the RCM product 132 was initially
formed but was prone to aromatization resulting from elimination of H7a from the titanium
complex. To avoid this problem, we employed an unexplored set of reaction conditions
which instead of making the Lewis acid complex at N, involved generating the relatively
mild p-toluene sulfonic acid salt of the tertiary amine 131 (Table 2.1, entry 4).155-156 With
our weakly deactivated tertiary amine 131 in hand, the compound was heated at reflux in
CH2Cl2 under an argon atmosphere in the presence of a catalytic amount of Hoveyda
Grubbs’ II generation ruthenium catalyst over the course of 3 d. To avoid formation of the
pyrrole 133, careful preparation was required to ensure no water or oxygen entered the
reaction environment during this time. This stringent set of conditions afforded the desired
RCM product 132 in 65% yield (Scheme 2.5).

Scheme 2.5: Synthesis of RCM product 133.

62

Table 2.1: Results of Savaspuns trialled conditions for RCM of 131 (entries 1-3) and the
successful conditions (entry 4) employed to generate RCM 132 from this Ph.D. work.
Ref.

Entry

1
Savaspun
et al.149

This
work

2

Reagents used
10 mol% Grubbs’ II
cat., 0.2 eq. Ti(OiPr)4,
under N2
10 mol% Hoveyda
Grubbs’ II cat., 1.0 eq.
Ti(OiPr)4, under Ar

Time.

Yield of

Yield of

o

( C)

(h)

132

133

CH2Cl2

45

24

0%

43%

CH2Cl2

40

20

0%

10%

Solvent

Temp.

3

10 mol% Grubbs’ II
cat., 0.3 eq. Ti(OiPr)4,
under Ar

Toluene

60

20

0%

17%

4

20 mol% Hoveyda
Grubbs’ II cat., 1.0 eq.
pTsOH, under Ar

CH2Cl2

50

72

65%

Trace
amounts

In addition to the mass spectrometric data (a LRESIMS [M+Na]+ ion peak at m/z 388
[M+Na]+ for 132 and a LRESIMS [M+Na]+ ion peak at m/z 386 for 133), the RCM product
132 can be largely differentiated from the corresponding pyrrole 133 based on appearance
of the H1′′ resonance in the 1H NMR spectrum (Figure 2.5). When compared, the 1H NMR
resonance of the methyl protons, H1′′ in alkene 132, should appear as a doublet and would
be expected to resonate below δH 2.0. After analysing the spectra from the RCM product
132 generated by our conditions, the resonance labelled H1′′ appeared as a doublet (J = 5.3
Hz) at δH 1.26 (Figure 2.5A). In contrast, the 1H NMR resonance for H1′′ in the pyrrole
133 appeared as a singlet and resonated at δH 2.11 (Figure 2.5B). This implied the loss of
a proton H5 and consequently the destruction of this stereocentre. Although we
successfully obtained the desired RCM product 132, we were unable to obtain reliable
NOESY data that would confirm the relative stereochemistry of the A-ring of the final
product. The 1H NMR spectrum displayed in Figure 2.5A shows that the key proton
resonance peaks for H7a and H3 were overlapping with those of H5 and H1′, respectively,
and so would have proved redundant for a clear NOESY extrapolation. More importantly,
we also noted the products tendency to degrade to the previously reported pyrrole 133.
Upon standing at room temperature for 1 h (in an NMR tube) degradation was noted.
Figure 2.5A shows a zoomed in region of the 1H NMR spectrum between δH 6.50 – 5.50
and displays characteristic aromatic peaks of pyrrole 133. Due to the limited amount of
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product 132, in conjunction with its instability, the purified product was taken through to
the next step in our planned pathway.

A)
Pyrrole 133
H7 H6

H5/H7a

H3/H1′

H1′′

H7 H6

B)

H6 H7

H1′′

Figure 2.5: A) 1H NMR spectrum (500 MHz, CDCl3) of 132 and B) 1H NMR spectrum
(500 MHz, CDCl3) of 133.149

2.6. Attempted cis-dihydroxylation of 132
At this stage, the degradation of alkene 132 to the corresponding pyrrole 133 suggested
the product to be air sensitive and was suspected to have a low tolerance towards oxidative
reaction conditions. Since our aim was to install hydroxy groups at C6 and C7 using
Upjohn cis-dihydroxylation conditions,157 we anticipated difficulty in obtaining the desired
product. This dichotomy influenced the decision to try only pilot reactions with little
exploration into optimising reaction conditions. More specifically, alkene 132 was
dissolved in a 3:1 solution of acetone/water followed by the addition of 2 eq. of N64

methylmorpholine-N-oxide along with a catalytic amount of potassium osmate dihydrate
(Scheme 2.6). Unsurprisingly, these conditions only encouraged faster degradation of 132
to the corresponding pyrrole 133. This was determined by the substantial increase in Rf of
the new product spot after analysing the reaction mixture by TLC. This Rf was
characteristic of the pyrrole 133, and not evident of the diol, as this would be considerably
more polar than the starting alkene 132. Regardless, purification of the reaction was
achieved and resulted in obtaining the pyrrole 133 which matched the spectroscopic data
of the pyrrole reported by Savaspun (Figure 2.5B).149

Scheme 2.6: Attempted cis-dihydroxylation of 132.

Although two steps (dihydroxylation, then global deprotection) remained towards the final
product, it was evident that the spontaneous degradation of the RCM product 132 to the
pyrrole 133 would be difficult and inefficient to work with (even under inert conditions).
Although compound 132 was successfully synthesized, the strict reaction conditions were
not easily reproduced and often required lengthy preparation periods. Not many conditions
were trialled since initial evidence suggested that formation of pyrrole 133 would most
likely accelerate under oxidative conditions. For this reason, our retrosynthetic pathway
was revised and focused on forming the B-ring of the hyacinthacine C5-type analogues
first.

2.7. Revised retrosynthetic strategy towards hyacinthacine C5-type
analogues
The original retrosynthetic path was reviewed to consider implementing the syn-C6, C7diol on the B-ring of the pyrrolizidine before establishing the A-ring. This new
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retrosynthetic pathway can be summarised in Scheme 2.7. The furnished pyrrolizidine that
would lead to the hyacinthacine C5-type analogues would be synthesised by N-alkylation
of the amino-diol 134 implementing a similar procedure used to obtain pyrrolidine 131
(Scheme 2.5). Prior to this, the hydroxy groups at both C6 and C7 would be installed using
UpJohn cis-dihydroxylation conditions, and then suitably protected to give 134.157
Although unsuccessful in our earlier attempt, this was hypothesized to work on the basis
of similar substrates and reaction conditions employed within the Pyne group.89 The alkene
in compound 135 would be obtained using Grubbs’ I- or II-generation catalyst and RCM
conditions. For the RCM reaction to efficiently synthesize, the anti-amino-diol 127 would
require protection at the secondary amine to give substrate 136. To ensure selectivity and
efficiency in the proposed reaction scheme, suitable hydroxy or amine protecting groups
at various stages would also be considered.

Scheme 2.7: Revised retrosynthetic analysis for the synthesis of hyacinthacine C5-type
analogues.

2.8. N-Protection of anti-amino-diol 127
It has been well established that unprotected primary and secondary amines interfere with
Ru-catalysed olefin-metathesis reactions.158 More specifically, their catalyst deactivating
affect and thus induced impairment of the RCM reaction is caused by coordination and
thus stabilization of the Ru-catalyst. Towards the end of his Ph.D. candidature, Savaspun
66

briefly explored conditions to convert the anti-amino-diol 127 to its corresponding
oxazolidinone 137 (Scheme 2.8).149 We envisioned the usefulness of this derivative since
it simultaneously protected the nitrogen as well as the hydroxy group at C4 of 127.
Interestingly, the conditions he employed resulted in the formation two products, namely
the oxazolidine-2-one 137 and the oxazepin-2-one 138 (Scheme 2.8, Table 2.2). This result
was not necessarily detrimental to the overall synthetic plan since this protecting group
would be removed at a later stage in the synthesis. However, the main concern with this
outcome was the number of isomeric products that would result at each stage until
deprotection. Even if the isomers would separate effectively, characterising both
compounds at each stage seemed inefficient. Fortunately, a literature search found a report
by Yahara and colleagues which detailed a one-step conversion between a related 7membered oxazepinone to its 5-membered oxazolidinone analogue after simply stirring a
solution of the oxazepinone in MeOH for 24 h.159 In light of Savaspuns result, we
considered this might overcome selectivity issues if the procedure established by Yahara
and co-workers was applied to the mixture of the oxazolidinone and oxazepinone. The
anti-amino-diol 127 was therefore subject to standard oxazolidinone conditions (CH2Cl2,
triphosgene, Et3N, 1 h) which returned a mixture of the oxazolidin-2-one 137 and the
oxazepin-2-one 138 (37% yield, 1:2, respectively, Scheme 2.8, Table 2.2). The mixture of
was left in HPLC grade MeOH for 20 h, but no conversion of the oxazepin-2-one 138 to
its 5-membered counterpart 137 was observed. This was confirmed by 1H NMR and TLC
analysis. However, after piloting the catalytic (0.1 eq.) addition of the non-nucleophilic
base DBU, followed by 24 h stirring under N2 conditions, 1H NMR and TLC analysis
confirmed the complete conversion of 138 to 137 (Scheme 2.9).

Scheme 2.8: Synthesis of the oxazolidinone 137 and the oxazepinone 138.
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Table 2.2: Savaspun’s reaction conditions (entry 1-3) and our reaction attempt (entry 4)
towards synthesizing oxazolidione 137.
Ref.

Entry
1

Savaspun
et al.149

2

3
This
work

4

Reagents used
1.5 eq. 1,1′
carbonyldiimidazo
le
0.5 eq.
Triphosgene, 1.5
eq Et3N
0.33 eq.
Triphosgene, 2.0
eq Et3N
0.5 eq.
Triphosgene, 2.0
eq Et3N

Solvent

Temp.
(oC)

Time.
(h)

Yield
of 137

Yield
of 138

CH2Cl2

rt (19)

2.5

11%

-

CH2Cl2

rt (18)

1

10%

52%

THF

rt (18)

24

53%

19%

CH2Cl2

0- rt
(18)

1

12%

25%

Further investigations found a strong correlation between increasing the relative molar
amount of DBU to compound 138, and a faster facile migration of the carbonyl and
conversion to the desired product 137. Therefore, future attempts to synthesise the
oxazolidinone involved treatment of a mixture of 137 and 138 with 1.5 eq. DBU in MeOH
for 4 h so to afforded clean conversion to the desired 5-membered product 137 in an overall
yield of 37%. In addition to the identical match of the 1H NMR spectrum with Savaspuns
product, the observed 7.1 Hz vicinal coupling constant J4,5, in the 1H NMR spectrum of
137 was consistent with the 4,5-cis relative conﬁguration.160-162
Despite the clean conversion of oxazepinone 138 to oxazolidinone 137, a collective yield
similar to Savaspun’s finding was unable to be replicated. After a number of attempts, only
a maximum yield of 37% could be achieved for the synthesis of oxazolidinone 137 (Table
2.2, entry 4). In a bid to improve the yield, different nitrogen protecting groups were
considered. Initial trials explored synthesising the N-Fmoc derivative. To obtain this, the
anti-amino-diol 127 was dissolved in MeCN, followed by the addition of 2 eq. of Et3N and
2 eq. of Fmoc chloride and sonicated at 35 oC over 24 h.163 However, as confirmed by TLC
and 1H NMR analysis, only starting material was recovered. The Boc protecting group was
then next considered. N-Boc protection of the anti-amino-diol 127 was trialled by
dissolving 127, Boc anhydride and Et3N in MeCN.163 The mixture was stirred at room
temperature for 24 h but only the starting anti-amino-diol 127 was recovered. These results
suggested the secondary amine 127 to be a poor nucleophile, most likely due to the
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sterically hindered nature of the N atom. To overcome this issue, increasing the
susceptibility of the Boc anhydride carbonyl group was considered. A literature search
identified that using iron chloride as a Lewis acid could promote activation of the carbonyl
group of Boc anhydride. Shown in Figure 2.6, the oxygen of either carbonyl would
coordinate to the FeCl3 which would increase the susceptibility towards mild nucleophiles
such as the secondary amine in the anti-amino-diol 127.164

Figure 2.6: Lewis acid promoted Boc protection for mild nucleophiles.164

Therefore, after dissolving both Boc anhydride and FeCl3 in 1:1 MeCN/H2O, the antiamino-diol 127 was added to the reaction mixture and stirred at room temperature for 24
h.164 Unfortunately, these conditions did not work and only returned starting material 127.
To overcome the steric hinderance of the amino diol, increasing the temperature of the
reaction was explored. This involved dissolving the anti-amino-diol 127 in 1,2dichloroethane, along with the addition of 2 eq. of N,N-diisopropylethyl amine and 2 eq.
of di-tert-butyl-dicarbonate and the solution was heated at reflux for 2 d. Fortunately, the
N-Boc diol 139 was obtained in 62% yield with 23% recovered starting material 127
(Scheme 2.9).
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Scheme 2.9: Synthesis of compound 139.

With successful protection of the anti-amino-diol 127 as both the oxazolidine-2-one 137
and the N-Boc diol 139, both were considered for ring closing metathesis in the next step
of the synthesis.

2.9. The synthesis of RCM products 140 and 141
Choosing either Grubbs’ I or II catalyst is generally decided based on sensitivity of the
substrate and the catalyst.165 Both catalysts have been thoroughly documented and so
understanding their different kinetics can also influence which is used.166-171 Shown in
Figure 2.7, Grubbs’ I catalyst has been found to readily dissociate from its phosphine
ligand, PCy3.168 Upon dissociation, the Ru-species can interact with a number of dienes
before it is quenched again with the free PCy3 ligand. To stop intermolecular reactions and
ensure an efficient turnover, RCM reactions involving Grubbs’ I catalyst are often
performed using dilute conditions.89 In contrast, Grubbs’ II catalyst undergoes a relatively
inefficient dissociation from its PCy3 ligand (Figure 2.7).171 However, once dissociated,
the Ru-species can undergo a four orders-of-magnitude higher rate of reaction relative to
its counter catalyst because re-coordination of the PCy3 ligand is less favourable.168
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Figure 2.7: Grubbs’ I and Grubbs’ II cat. mechanism.

Considering that both catalysts were capable of returning the desired RCM products,
Grubbs’ II generation catalyst was ultimately chosen since Grubbs’ I catalyst is generally
more reactive, and so is prone to side reactions.165 With a suitable amount of the
oxazolidinone 137 and the N-Boc alcohol 139 in hand, separate Ru-catalysed RCM
reactions using 5 mol % Grubbs’ II generation catalyst were employed. The most common
conditions used in the Pyne research group for similar substrates was to heat the diene with
a 10% loading Grubbs’ I or II generation catalyst in CH2Cl2 at reflux until the full
consumption of the starting material.89, 127, 146 For this reason, similar conditions were used,
trialling first the oxazolidinone 137 (Scheme 2.10). After 4 h, a TLC analysis showed full
consumption of the starting material as well as only one new spot on TLC with a
significantly lower Rf. A 1H NMR analysis of the crude reaction product indicated a clean
conversion to what was later deduced to be the RCM product 140. Careful monitoring by
TLC analysis proved important as the alkene group in 140 was prone to migration under
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extended reaction times and would give an inseparable mixture of oleﬁn-containing
species as well as lower the yield of the desired product. Using similar conditions, the NBoc alcohol 139 also afforded the RCM derivative 141 in comparable yields (70%)
(Scheme 2.11).
Shown in Figure 2.8, The 1H NMR spectrum of 140 displayed two, nearly overlapping,
characteristic cis-alkene resonances for H6 and H7 at δH 5.79 (1H, d, J = 6.6 Hz) and 5.81
(1H, d, J = 6.6 Hz), respectively. In conjunction with this, the olefinic proton resonances
from the starting diene 137 had disappeared. To eliminate the possibility that the pyrrole
had formed, the characteristic H1՛՛ methyl group was examined and found to resonate as a
defined doublet at δH 1.39 (3H, J = 6.8 Hz). In addition to this, the 13C NMR spectrum of
140 only displayed two olefinic-like resonances at δC 137.4 (C7) and 123.8 (C6). These
alkene 1H and 13C NMR assignments were based upon gCOSY and gHSQC experiments.
The HRESIMS of 140 showed a characteristic [M+Na]+ ion peak at m/z 432.1787, which
also established that the desired product had been formed.

Scheme 2.10: Synthesis of RCM product 140.

H1′′
H7

H6
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Figure 2.8: 1H NMR spectrum (500 MHz, CDCl3) of 140.
Similar resonances were also observed for the N-Boc pyrrolidine 141. Unfortunately, the
1

H NMR analysis became difficult due to the presence of Boc-induced rotamers and

consequent broadening of peaks (Figure 2.9). To confirm that this was not the
corresponding pyrrole derivative, the most reliable evidence was obtained from a the
HRESIMS of 141 which showed a characteristic [M+Na]+ ion peak at m/z 506.2542.
Although high-temperature 1H NMR studies can be used to improve the definition of the
rotamer resonances,172-173 it was hopeful that subjecting the product to further chemical
manipulation might instead improve the resolution of the 1H NMR spectrum. For this
reason, the RCM N-Boc diol 141 was also continued through to the next step of the
synthetic pathway.

Scheme 2.11: Synthesis of RCM product 141.

H3/H4
H1′′

Figure 2.9: 1H NMR spectrum (500 MHz, CDCl3) of 141.
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2.10. Dihydroxylation of 140 and 141
Although the initial attempts towards synthesis of the syn-diol at C6 and C7 in 132 were
unsuccessful, this did not deter trying the same conditions on the newly formed RCM
substrates 140 and 141. In fact, we hypothesized that the reaction would work well for both
140 and 141 using standard Upjohn cis-dihydroxylation conditions.157 This rationale was
largely influenced from previous co-workers results within the Pyne group. More
specifically, implementing these conditions on similar substrates containing an N-carbonyl
seemed to return high-yielding, high diastereoselective syn-diol products.89, 146 Although
this is a non-selective dihydroxylation, the high diastereoselectivity of akin substrates
seems to be influenced by the size of the protecting group attached to the secondary
amine.174 Considering the mechanism shown in Figure 2.10, the first step in this cycle is
the sterically influenced cycloaddition between the osmium(VIII) tetroxide and the alkene
140 to form the osmate ester A. In the presence of water, the osmate ester is hydrolysed to
the corresponding diol 142. Since both oxygen atoms were added in a concerted manner,
their relative stereochemistry remains syn. Interestingly, without the addition of NMO, the
reaction would require a molar equivalent of the expensive, and toxic OsO4. Here, only a
catalytic amount is required because the relatively safe and inexpensive NMO can readily
oxidize the Os(VI) back to the reactive Os(VIII).

Figure 2.10: Upjohn cis-dihydroxylation mechanism.
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Therefore, the RCM product 140 was subject to Upjohn Os(VIII)-catalyzed cisdihydroxylation reaction conditions157 which resulted in two diastereomeric diols 142
(major product) and 143 (minor product) in 78% yield (dr = 3:1 from the crude reaction
mixture) (Scheme 2.12). Only small amounts of pure compounds 142 and 143 could be
separated by ﬂash column chromatography (FCC) and so were subject to 1H and 13C NMR
analysis and other spectroscopic studies for characterisation. Although 2D NMR
spectroscopic data was obtained for both products, evidence towards their absolute
configuration will be discussed in Section 2.11.

Scheme 2.12: Synthesis of compounds 142 and 143.

Interestingly, applying similar dihydroxylation conditions to the N-Boc alkene 141 only
returned a single diastereomer 144 in high yield (95%) (Scheme 2.13). Fortunately, the 1H
NMR spectrum of compound 144 displayed clear resonance peaks. The C3, C4
stereochemistry of compound 144 was determined to be 3S and 4R, respectively after a 2D
ROESY experiment displayed clear correlations between the (5R)-methyl with the protons
resonances labelled H3 and H4 (Figure 2.11). Although the dihydroxylation was successful
for 141, the pathway was discontinued on the basis that it would be difficult to selectively
protect the newly formed diol at C3, C4 in 144 without impacting on the hydroxy groups
at C1′ and C3′. Comparatively, compounds 142 and 143 proved superior as it was
envisioned that forming the acetonide at C6, C7 would not impact on C2′. If both the
hydroxy group in the alkyl chain were available, such as with the tetraol 144, the acetonide
would form at the C3, C4 hydroxy groups, as well as potentially form the 6-memberedC1′ and C3′ acetal 145. Although further investigation is required, these results
demonstrated how the N-protecting groups on 5-membered pyrrolidines can sterically
influence the selectivity of the Upjohn Os(VIII)-catalyzed cis-dihydroxylation reaction.
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Scheme 2.13: Synthesis of compound 144.

H3

H4

H1′′

(H1′′-H4)

3
4
1''

144

H4
H3

(H3-H4)

Figure 2.11: 2D ROESY NMR spectrum (500 MHz, CDCl3) with key observed
correlations projected onto a DFT minimized molecular model [B3LYP/6-31G(d)] of 144
(hydroxy and benzyl protons not shown).

At this point in the course of the project, a colleague within the Pyne research group found
that N-Boc products could be converted to the corresponding oxazolidinones provided
there is an α-hydroxy group present.175 This motif was recognized in our N-Boc substrate
139 and so following a similar procedure, a base-induced (1.5 eq. NaH, THF) conversion
of 139 to the oxazolidinone 137 was employed and proved successful (85%) with no
observable formation of the oxazepinone 139. A comparison of the 1H and

13

C NMR

spectroscopic data was consistent with our initial oxazolidione 137 product. After
comparing both pathways to access the oxazolidinone 137 (triphosgene vs Boc anhydride),
we concluded that first synthesizing the N-Boc derivative of amino-diol 127, followed by
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base mediate conversion to 137 proved the better yielding (55% over two steps, compared
to 37% after one step).

2.11. The synthesis of acetonides 146 and 147
Although syn-dihydroxylation of the RCM product 140 was not completely selective, the
inseparable mixture of diastereomers 142 and 143 still proved important as there was the
potential to synthesize two hyacinthacine C5-type analogues. With the inseparable mixture
of diols 142 and 143 in hand, it was decided that conversion to their respective C6, C7
acetonides would differentiate the characteristics of both diastereomers and allow for their
efficient separation by column chromatography. Having previous experience with the
formation of the acetonide 6 from L-xylose, the same reaction conditions were applied to
the mixture of diols 142 and 143 (Scheme 2.14). This resulted in a clean conversion to
acetonides 146 and 147, respectively and also accentuated the Rf difference between the
resultant diastereomers allowing for easier separation by column chromatography. The
major diastereomer 146 obtained was the result from syn-dihydroxylation to the alkene
face of 142 that was anti to the C5 methyl substituent due to steric directing effects. An
extensive ROESY NMR analysis of 146 found key correlations between H1՛՛‒H8a, H1՛՛‒
3a, H8a‒H3a, H8‒H3b and H3b‒H4 (Figure 2.12 and Figure 2.14) which were consistent
with the assigned configurations. In comparison, 1D NOE difference studies on 147
showed NOE enhancements between H8‒H8a, H8‒H3a, H8a‒H3a, H3a‒H3b and H3b‒
H4 (Figure 2.13 and Figure 2.14). These were consistent with the structure assigned to
147.

Scheme 2.14: Synthesis of the acetonides 146 and 147.
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H3a H3b, H8a, H2′

H1′′

H3′
H1′
H8

H4
H1′′

(H1′′-H3a)
(H1′′-H8a)

(H3a-H8a)
H8
H3′
H1′
H3b, H8a, H2′

(H8-H3b)

H3a
H4

(H3b-H4)

Figure 2.12: 2D ROESY NMR spectrum (500 MHz, CDCl3) of 146.

A)
H8

H3a

C2-CH3
H1՛՛

H3b

H8a

B)

C2-CH3

H8a
H2՛

H3b

H8

H3a

Figure 2.13: Selected 1D-NOE irradiation spectrums (500 MHz, CDCl3) of A) H8a and
B) H3a of 147.
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147

Figure 2.14: 2D ROESY and 1D NOE difference NMR spectrum key observed
correlations projected onto DFT minimized molecular models [B3LYP/6-31G(d)] of
acetonides 146 and 147, respectively (C4 alkyl chain not shown).

2.12. Attempts to hydrolyse and cyclize oxazolidinones 146 and 147
Before hydrolysing the oxazolidinone group in acetonides 146 and 147, individual samples
were subject to mesylation of the hydroxy group at C3′. It was anticipated that mesylation
of the only free hydroxy groups in these compounds would require less stringent molar
equivalents of methane sulfonyl chloride (often difficult to measure an exact equivalent on
smaller scales). In addition to this, mesylation of the only hydroxy group, followed by base
hydrolysis of the oxazolidinone, may result in a one pot deprotection and consequent
cyclization of intermediate 148 (Scheme 2.15). As anticipated, mesylation of both
acetonides 146 and 147 worked reasonably well and afforded near quantitative amounts of
the respective mesylates 148 and 150 (Scheme 2.15). Both compounds were then subject
to standard microwave base-induced hydrolysis conditions,127 which involved dissolving
the mesylate in ethanol, followed by the addition of a few drops of NaOH solution, then
microwave heating (200 W, 100 oC) for 1 h. After this time, no observable product was
obtained, rather, both reactions returned a complex mixture as indicated from the many
spots observed by TLC analysis as well as the indistinguishable 1H NMR spectra. Although
a theoretically good idea, the poor results from this approach influenced the decision to
first perform the microwave assisted base hydrolysis of the oxazolidinones 146 and 147,
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followed by mesylation-cyclisation on the respective amino diols 152 and 153. This
approach resulted in a good yield of both amino diols 152 and 153, respectively (Scheme
2.16). These were then individually subject to similar mesylation-cyclisation conditions
initially used to convert the anti-amino-diol 127 to the pyrrolidine 131.

Scheme 2.15: Unsuccessful pathway to access pyrrolizidine core A) 149 and B) 151.
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Scheme 2.16: Hydrolysis of oxazolidinones 146 and 147 to afford amino diols 152 and
153, respectively.

2.13. Synthesis of pyrrolizidines 149 and 151
To furnish the pyrrolizidine core found in the hyacinthacine C5-type analogues, precedent
work with similar amino alcohols have employed treatment with a stoichiometric amount
of MsCl under basic conditions (Et3N).127-128, 130-131, 144 Having already had experience with
this reaction to obtain pyrrolidine 131 from anti amino diol 127, this method was employed
for both amino diols 152 and 153 (Scheme 2.17). The mesylation-cyclization of 152
aﬀorded a 30% yield of pyrrolizidine 149 as well as a 32% yield of the N,O-dimesylated
adduct 154 (Scheme 2.17). In an attempt to improve the yield of the desired product, Appel
cyclization reaction conditions176 were used and fortunately returned the same
pyrrolizidine 149 with an improved yield of 87% (Scheme 2.17A). Interestingly, both 149
and 154 crystallized after puriﬁcation by column chromatography (Figure 2.15).
The large colourless crystals obtained for 149 were subject to single crystal X-ray
structural analysis which unambiguously confirmed the absolute configuration initially
proposed for 149 (Figure 2.16). In addition to this, the crystal structure established that
mesylation occurs preferably at the hydroxy group of C3′ as opposed to C1′, which would
otherwise could have returned the 4-membered bicyclic N-heterocycle (azetidine).
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Comparatively, mesylation, then heat-induced cyclization of the O-mesylate of 153 proved
extremely regioselective, returning product 151 in high yield (87%) (Scheme 2.17B). Since
no crystal structure was obtained for this product, the pyrrolizidine was subject to extensive
1D and 2D NMR spectroscopic experiments. More specifically, to confirm the newly
formed stereochemistry on the A-ring of the pyrrolizidine 151, 1D NOE difference studies
were run where NOE enhancements were observed between H8b‒H3a, H7‒H8a, H1՛՛‒H6,
H1՛‒H7, H8a‒H8b and H4‒H3a (Figure 2.16). These were consistent with the structure
assigned to 151.

Scheme 2.17: Synthesis of pyrrolizidines 149 and 151.
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Figure 2.15: (left) Crystals of 149 and the ORTEP plot of the crystal structure for a
C26H33NO5 molecule of 149 with labelling of selected atoms. Anisotropic displacement
ellipsoids display 30% probability levels. Hydrogen atoms are drawn as circles with small
radii. (Right) Crystals of 154 and the ORTEP plot of the crystal structure for a
C28H39NO10S2 molecule of 154 with labelling of selected atoms. Anisotropic displacement
ellipsoids display 30% probability levels. Hydrogen atoms are drawn as circles with small
radii.
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A)
H3a

C2-CH3

H8b

B)
H8b

H4
H8a

C)
H7
H8

H6

H1՛՛

Figure 2.16: Selected 1D-NOE irradiation spectrums (500 MHz, CDCl3) of A) H8b, B)
H8a and C) H1՛՛ of 151.

This contrast in the formation of both pyrrolizidine 149 and 151 was intriguing, and the
differing yields from each reaction pathway can be attributed to steric factors. More
specifically, mesylation, then cyclisation of the amino diol 152 returned nearly equal
amounts of the bis-mesylate 154 and the pyrrolizidine 149. Confirmed by the crystal
structure for the bis-mesylate 154, regioselectivity of the mesylation of the hydroxy group
at C3′ suggests that this hydroxy group is less sterically hindered than the hydroxy group
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at C1′. To form the pyrrolizidine 149, an intramolecular SN2 displacement (shown earlier
in Scheme 2.15) then takes place. When the 1H NMR spectrum for 154 was obtained, the
only certainty was that two mesylates resided in the compound; it was difficult to
determine the bis-mesylation regioisomer obtained. However, prior to obtaining a crystal
structure there were a few 1H NMR spectrum characteristics that were supportive of
mesylation at the nitrogen and the hydroxy group at C3′. Shown in Figure 2.17B, two
mesylate peaks with different 1H NMR chemical shifts were present. Although it was not
definitive, it was proposed that the mesylate shift at δH 2.98 was characteristic of Nmesylation177 and the other at δH 3.06 would more likely resonate with a de-shielding effect
induced if the mesylate group was attached to a hydroxy group. Comparison of the 1H
NMR spectra for both the parent amino-diol 152 (Figure 2.17A) and the bis-mesylate 154
(Figure 2.17B), we noted significant differences in chemical shifts for proton resonances
labelled H4 (δH 3.08 and 4.38, respectively), H6 (δH 3.05 and 3.95, respectively) and H1′′
(δH 1.05 and 1.36, respectively). This de-shielding effect was convincing enough to
hypothesize that the secondary amine of amino-diol 152 had undergone mesylation. After
a gCOSY analysis, we also identified that the H3′ resonance had shifted from δH 4.06 in
152, to δH 5.00 in 154. In a similar manner, the resonance identified as H1′ in both
structures 152 and 154, had changed chemical shift slightly from δH 3.74 to δH 3.90,
respectively. This comparison supported the claim that both the nitrogen and the hydroxy
group at H3′ had undergone mesylation.
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A)
H1′′
H1′
H3′

B)

H4 H6

H1′′

H3′

H4 H1′

H6

Figure 2.17: A) 1H NMR spectrum (500 MHz, CDCl3) of 152 and B) 1H NMR spectrum
(500 MHz, CDCl3) of 154.

Obtaining both the pyrrolizidine 149 and the bis-mesylate 154 led to the rationalization
that C3′ O-mesylation and N-mesylation occurs at comparable rates. If O-mesylation at
C3′ occurs first, then the molecule will undergo a spontaneous intramolecular cyclization
to give 149. If N-mesylation occurs, then cyclisation is prevented and will eventually result
in product 154 provided a second mesylation occurs. In contrast, reversing the orientation
of the acetonide at C6a and C3a, such as for compound 153, O-mesylation at C3′ is
preferred. However, heat was required to furnish pyrrolizidine 151. Since the only
difference between both amino diols 152 and 153 was the orientation of the acetonide, it
is proposed that this moiety sterically hinders the secondary amine in compound 153
whereas the secondary amine in compound 152 is more susceptible to mesylation.
Interestingly, employing Appel cyclisation conditions resulted in exclusive formation of
pyrrolizidine 149 (Scheme 2.18). Since no nitrogen bound triphenylphosphine was
observed, it is assumed that the in situ formed triphenyphosphine bromide is too sterically
encumbering to bind to the secondary amine and so instead binds selectively to the hydroxy
group at C3′. Although retention of stereochemistry can occur through C3′ inversion via a
86

bromide anion, our crystal structure and improved yield of 149 displays the preference for
intramolecular cyclization via the SN2 N-alkylation pathway (Scheme 2.18).

Scheme 2.18: Appel cyclization of 152 to give pyrrolizidine 149.

2.14. Global deprotection of pyrrolizidines 149 and 151
After successfully furnishing the pyrrolizidine core, individual samples of 149 and 151
were then globally deprotected under hydrogenolysis conditions over PdCl2 to return novel
hyacinthacine C5-type compounds (+)-7-epi-hyacinthacine C5 155 [[α]25
𝐷 +5.4 (c 1.00,
H2O)] and (‒)-6-epi-hyacinthacine C5 156 [[α]25
𝐷 -7.2 (c 1.00, H2O)] (Scheme 2.19) in good
to high yields (87% and 98%, respectively), following purification and neutralization by
basic ion-exchange chromatography.
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Scheme 2.19: Global deprotection of pyrrolizidines 149 and 151 to give (+)-7-epihyacinthacine C5 155 and (‒)-6-epi-hyacinthacine C5 156, respectively.

All spectroscopic experiments used to determine the final structures have been included in
the appendix. After confidently identifying and assigning each proton resonance through
a gCOSY analysis, the relative configurations of each compound was extensively studied.
For 155, an extensive ROESY NMR analysis found key correlations between H9‒H3, H9‒
H6, H9‒H7, H7‒H6, H7‒H1 and H2‒H8 (Figure 2.18) which were consistent with the
assigned configurations. Similarly, compound 156 was subject to extensive ROESY NMR
analysis, where key correlations between H9‒H3, H6‒H5, H6‒H7, and H7a‒H7 were
observed (Figure 2.19). The 1H and 13C NMR spectroscopic data of both synthetic 155 and
156 were also compared with the natural isolates labelled hyacinthacine C1, C4 and C5
(Table 2.3 and Table 2.4). When compared, both synthetic 155 and 156 did not
spectroscopically match with any of the questionable natural products. Additionally, a
Scifinder Scholar™ search could not identify these structures in the literature and so it was
concluded that (+)-7-epi-hyacinthacine C5 155 and (‒)-6-epi-hyacinthacine C5 156 are
novel, unnatural hyacinthacine C5-type analogues.
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Figure 2.18: 2D ROESY NMR spectrum (500 MHz, CDCl3) with key observed
correlations projected onto a DFT minimized molecular model [B3LYP/6-31G(d)] of (+)7-epi-hyacinthacine C5 155 (hydroxy protons not shown).
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Figure 2.19: 2D ROESY NMR spectrum (500 MHz, CDCl3) with key observed
correlations projected onto a DFT minimized molecular model [B3LYP/6-31G(d)] of (‒)6-epi-hyacinthacine C5 156 (hydroxy protons not shown).
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Table 2.3: Comparison of the literature 1H NMR spectroscopic data of natural (+)hyacinthacine C1105 ( z, D2O), natural (+)-hyacinthacine C4117 ( z, D2O) and
natural (+)-hyacinthacine C5117 ( z, D2O) with synthetic 155 and synthetic 156 (500
MHz, D2O).
H NMR ( J in Hz)

1

position

(+)-hyacinthacine
C1105

(+)-hyacinthacine
C4117

(+)-hyacinthacine
C5117

155

156

1

4.15, t (3.9)

4.18, t (4.0)

4.01, t (7.6)

3.90-3.78, m

4.39-4.28, m

2

4.00, dd (3.9, 9.0)

4.00, dd (4.0, 8.7)

3.80, t (7.6)

3.94, t (7.3)

3.91, t (8.3)

3

3.44, dt (4.4, 9.0)

3.38, dt (4.6, 8.7)

3.01, m

3.10, dt (5.0,
7.2)

3.38, p (4.8)

5

3.29, dt (3.9, 7.0)

2.96, dq (6.9, 9.2)

2.81, dq (6.9, 7.6)

3.21-3.13, m

6

3.89, dd (3.9, 4.6)

3.90, dd (8.2, 9.2)

3.60, t (7.6)

7

4.50, dd (4.6, 8.6)

4.15, t (8.2)

3.99, t (7.6)

3.90-3.78, m
4.15, dd (2.7,
5.0)

7a

3.66, dd (3.9, 8.6)

3.57, dd (3.7, 8.2)

3.24, t (7.6)

8

3.66, m

3.65, d (4.6)

9

1.27, d (7.0)

1.29, d (6.9)

3.55, dd (4.1, 12.0)
3.50, dd (5.3, 12.0)
1.13, d (6.9)

3.24, dt (5.4,
7.0)
4.03, t (4.5)
4.39-4.28, m

3.21-3.13, m

3.31, t (7.6)

3.71-3.59, m

3.67, d (4.8)

1.26, d (7.0)

1.25, d (7.1)

Table 2.4: Comparison of the literature 13C NMR spectroscopic data of natural (+)hyacinthacine C1105 ( z, D2O), natural (+)-hyacinthacine C4117 ( z, D2O) and
natural (+)-hyacinthacine C5117 ( z, D2O) with synthetic 155 and synthetic 156 (125
MHz, D2O).
C NMR ()

13

position

105

(+)-hyacinthacine C1

(+)-hyacinthacine C4117

(+)-hyacinthacine C5117

1

74.6

75.2

78.2

2
3
5

77.7
64.7
60.4

77.3
65.1
62.0

81.0
65.1
61.4

6

77.1

82.9

81.7

7
7a
8
9

75.7
68.3
65.9
12.8

80.0
67.3
66.4
16.0

77.8
69.2
65.7
15.7

155
78.5 or
75.9
77.9
62.2
58.8
78.5 or
75.9
73.6
72.6
62.9
13.2

156
74.4
78.5
62.2
57.2
74.8
70.8
67.5
63.1
10.9

2.15. Chapter 2: Final remarks
The synthetic strategy employed towards the synthesis of hyacinthacine C5-type analogues
in this Chapter has been described. If the successful pathway alone were presented, the
reader would question the number of seemingly “unnecessary” steps. Hopefully, the reader
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will agree that our pathway must first furnish the B-ring of the pyrrolizidine prior to the
A-ring to avoid formation of the pyrrole 133. Although not explored, the author notes that
it would be worth subjecting RCM intermediate 132 to hydrogenation conditions, as this
may provide a short facile route to a number of hyacinthacine A-type alkaloid analogues.
In conclusion, this was the first known synthesis of the unnatural (+)-7-epi-hyacinthacine
C5 155 and (‒)-6-epi-hyacinthacine C5 156. Establishing this pathway was important, and
the reader will see how it was the basis for accessing the remaining nine hyacinthacine C5type analogues. Although the hyacinthacine alkaloids synthesised in this Chapter did not
match with any of the ambiguous structures for hyacinthacine C1, C4 or C5, they were still
assessed as glycosidase inhibitors and their biological activities will be discussed in
Chapter 6.
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Chapter 3 : Synthesis of unnatural (‒)-5,6-di-epihyacinthacine C5
The methodology towards accessing hyacinthacine C5-type analogues was established
through the synthesis of unnatural (+)-7-epi-hyacinthacine C5 155 and (‒)-6-epihyacinthacine C5 156. As per the nature of total synthetic pathways, the reader can assume
that some of the foundational compounds (3,5-di-O-benzyl-α,β-L-xylofuranose, the anti1,2-amino diol 127 the RCM products and the C6, C7-diols) have been synthesized a large
number of times to accommodate divergent pathways throughout the course of this work.
Of these, the anti-1,2-amino diol 127 was synthesized many times. One of the reagents
required for this reaction is 3-amino-1-butene·hydrochloride, which at later stages in the
project became difficult to acquire. Herein, the reader will see how synthesizing this
starting amine resulted in the synthesis of the third unnatural hyacinthacine C5-type
analogue (‒)-5,6-di-epi-hyacinthacine C5.

3.1. The Gabriel synthesis of 3-amino-1-butene·hydrochloride
The 3-(R)-amino-1-butene·hydrochloride used in the Petasis borono-Mannich reaction was
originally purchased from a company called NetChemTM. Unfortunately, during the later
years of this work, NetChemTM became unresponsive and so we could not reliably
purchase this starting material as a pure enantiomer. Comparatively, other chemical
suppliers often listed small amounts of the amine at high costs. As an up-to-date example,
the US company, Enamine Building BlocksTM, retails 5 g of the enantiomerically pure 3(R)-amino-1-butene·hydrochloride for AUD $4914; this value far exceeded the original
purchase price of this product when the project first started. Even though we were
confident that this material would be profitable towards accessing additional hyacinthacine
C5-type analogues, the exponential price increase in combination with the need to find a
reliable chemical company, influenced the decision to consider synthesizing this starting
product from a cheaper derivative.
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After searching the literature, it became apparent that the desired primary amine could be
made from implementing a two-step Gabriel synthesis using a suitable alkyl halide.178 The
difficulty (and partially justified cost) is that the 3-(S)- and 3-(R)-amino-1butene·hydrochloride are hard to separate as pure enantiomers. Despite this predicament,
we ultimately could not justify the current expense of the stereochemically pure amine.
Therefore, the decision was made to synthesize racemic 3-amino-1-butene·hydrochloride
and at a later point, consider resolving its enantiomers.
Interestingly, synthesizing the racemic 3-amino-1-butene·hydrochloride is relatively
simple and reported as high yielding.179, 180 More specifically, based on the precedent
literature by Pallavicini et al. and Wang et al., the related alkyl halide chosen to undergo
this transformation was 3-chloro-1-butene, which could be readily purchased.179, 180
3-Chloro-1-butene could be obtained from Sigma Aldrich™ in two packing sizes of 5 mL
and 100 mL at $48.00 and $215.00 AUD, respectively. The latter of these was purchased
for economic value, especially considering that synthesizing the racemate would diminish
the yield of our desired 3-(R)-amino-1-butene·hydrochloride by at least half. Therefore,
starting with 5 g of 3-chloro-1-butene, Gabriel’s synthesis and methodology were
employed. Shown in Scheme 3.1A, this initially involved dissolving both 3-chloro-1butene and potassium phthalimide in a solution of DMF, followed by heating at reflux for
3 h. The general mechanistic consideration for this reaction occurs via displacement of the
halogen via an SN2 attack of the phthalide to give a racemic mixture of the N-substituted
phthalimide 157. When this reaction was performed, colourless needle-like crystals of the
N-substituted phthalimide 157 were obtained in high yield (80%). The phthalimide of
racemate 157 was then cleaved using hydrazine hydrate along with heating the mixture at
60 oC in ethanol for 3 h. After this time, the reaction mixture had formed a gelatinous white
semi-solid which was then subject to an excess amount of concentrated hydrochloric acid
to return the desired 3-amino-1-butene·hydrochloride. This product was purified by a
series of acid-base extractions, and the HCl salt of this amine was formed by the addition
of 4 N HCl/EtOH followed by concentration in vacuo. The 1H and 13C NMR spectroscopic
data of the phthalimide intermediate 157 as well as the 3-amino-1-butene·hydrochloride,
matched with those in the literature.179
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This method is known as the Ing-Manske procedure181 and can be described by the
mechanism shown in Scheme 3.1B. Hydrazinolysis occurs when a hydrazine unit attacks
one of the carbonyls of the phthalimide moiety of 157. This results in a cascade ring
opening (Scheme 3.1B, intermediates A and B) which then allows for an intramolecular
nucleophilic attack at the remaining carbonyl from the other half of the attached hydrazine
unit (Scheme 3.1B, intermediate C). This attack at the second carbonyl liberates the final
primary amine, as well as the phthalhydrazide by-product.178

Scheme 3.1: A) Garbiel synthesis of 3-amino-1-butene·hydrochloride from 3-chloro-1butene and B) Mechanism for hydrazinolysis via the Ing-Manske procedure.
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While methods have been published for the resolution of the 3-amino-1butene·hydrochloride,179, 180 the decision was made to subject the racemic amine to the
Petasis reaction which would afford a diastereomeric mixture of the anti-1,2-amino-diols
127 and 161 (Scheme 3.2). Considering the basis of diastereomeric resolution, it was
envisioned that the amine would be incorporated into a larger stereochemically defined
motif which would display different chemical properties that might result in efficient
separation of both (1′S) and (1′R)-anti-amino-diols 127 and 161, by column
chromatography. Additionally, the resultant (1′S)-diastereomer 161 was valued since it
would lead to potential hyacinthacine C5-type derivatives containing the (5S)-methyl and
would prove important for gaining insight towards the SARs of glycosidase inhibition. If
the envisioned diastereomers would not separate at any point during the synthetic pathway,
then other purification methods would be considered.179, 180

3.2. Synthesis of anti-amino diols 127 and 161
In a similar manner to the synthesis described in Chapter 2, but included for clarity, a
retrosynthetic analysis towards hyacinthacine C5-type analogues containing a (5S)-methyl
is shown in Scheme 3.2. The reader will find that this retrosynthetic analysis is quite
specific and has been generated based on the reasonable success we experienced with the
previously synthesized unnatural (+)-7-epi-hyacinthacine C5 155 and (‒)-6-epihyacinthacine C5 156. The intention of this pathway was to synthesize more of the (1′R)methyl anti-1,2-amino-diol 127 for later divergency as well as explore the possibility of
synthesizing (5S)-methyl hyacinthacine C5-type analogues. In hope that diastereomeric
resolution via synthesis of the anti-1,2-amino-diols 127 and 161 would allow separation
of the (1′S)- and (1′R)-methyl products, obtaining pure (5S)-methyl hyacinthacine C-type
analogues would demonstrate the flexibility and effectiveness of this synthetic pathway.
Additionally, this result would be an interesting contrast for resultant SAR studies, where
we could compare the impact of the stereochemistry of C5 in the final hyacinthacine Ctype analogues. The retrosynthetic plan shown in Scheme 3.2 details that the pyrrolizidine
core would be derived from acetonide 158. Similarly, cis-dihydroxylation would result
from UpJohn cis-dihydroxylation157 across the alkene of RCM adduct 159. The alkene of
159 would be obtained using Grubbs’ I- or II-generation catalyst under ring-closing
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metathesis conditions on the suitably prepared oxazolidinone 160. Oxazolidinone 160
would be formed by subjecting the anti-1,2-amino-diol 161 to either N-Boc formation then
treatment with sodium hydride or by triphosgene under basic conditions. The
diastereomeric mixture of anti-1,2-amino-diols, 127 and 161, would be derived from the
Petasis borono-Mannich reaction between 3,5-di-O-benzyl-α,β-L-xylofuranose, racemic 3amino-1-butene·hydrochloride and (E)-β-styrenylboronic acid.

Scheme 3.2: Retrosynthetic analysis for the synthesis of hyacinthacine C5-type analogues
containing a (5S)-methyl.

Following this procedure, racemic 3-amino-1-butene·hydrochloride was treated with 3,5di-O-benzyl-α,β-L-xylofuranose and (E)-β-styrenylboronic acid using the same conditions
we employed for the synthesis of anti-1,2-amino-diol 127 (Scheme 3.3). This afforded an
approximate 1:2.5 inseparable mixture of anti-1,2-amino-diol 127 and 161, respectively as
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determined by the relative resonance intensities in the 1H NMR spectrum (Figure 3.1).
Since this mixture could not be separated into pure diastereomers, the 1H NMR resonance
peaks for anti-1,2-amino-diol 161 were deciphered by the process of elimination through
comparison of the previously characterized anti-1,2-amino-diol 127. This result indicated
some degree of kinetic preference for the reaction of the iminium ion intermediate arising
from the (S)-enantiomer 161 of the amine component. Allowing the mixture a longer
reaction time in future might afford a 1:1 mixture of anti-1,2-amino-diols 127 and 161.

Scheme 3.3: Synthesis of anti-amino diols 127 and 161.

In hindsight, the poor separation of anti-1,2-amino-diols 127 and 161 was not a surprising
result. It is well established that compounds containing amines or quaternary ammonium
salts often exhibit sever peak tailing and broad overlapping bands on silica gel; they do not
follow a regular hydrophobic retention behaviour.182 This phenomenon was experienced
even with the pure (1′R)-anti-1,2-amino-diol 127 described in Chapter 2, as the product
contained poor TLC peak symmetry and eluted over an excessive number of otherwise
reasonably sized collecting tubes during its purification by column chromatography.
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161-H1′′
161-H7
161-H6
127-H1′′
127-H7

127-H6

161-H2′

127-H2′

Figure 3.1: 1H NMR spectrum (500 MHz, CDCl3) of the inseparable 1:2.5 mixture of 127
and 161.

3.3. N-protection of the anti-1,2-amino-diols 127 and 161
In Chapter 2, two different protecting groups of the anti-1,2-amino-diol 127 were trialled
and results were described. More specifically, this entailed the synthesis of N-Boc 139 and
the oxazolidinone 137. Due to the previously described selectivity issues, it was found that
oxazolidinone 137 was more amendable for our synthetic approach. Therefore, attempts to
subject the mixture of (1′R)- and (1′S)-anti-1,2-amino-diols 127 and 161, respectively to
similar conditions were employed. It was envisioned that synthesizing the oxazolidinone
of the mixture may lead to better separation of the diastereomers as a result of increasing
the molecules rigidity which would accentuate the subtle characteristic differences
between both compounds. Considering anti-1,2-amino-diol 127, we concluded that
synthesizing the N-Boc product 139, then base induced cyclization to the respective
oxazolidinone 137 returned an overall better yield than compared to when the starting anti1,2-amino-diol 127 was subject to triphosgene under basic conditions. In hope that this
would be similar for anti-1,2-amino-diol 161, a pilot reaction of the diastereomeric mixture
of anti-1,2-amino-diols 127 and 161 was subject to N-Boc protection using our established
conditions. Unfortunately, this seemed to only work moderately well for the minor anti1,2-amino-diol 127, whilst only returning predominantly starting material for the major
anti-1,2-amino-diol 161. Although this reaction was only tried once, these preliminary
results suggest it could potentially be used as a method of purification, as diastereomer 127
can be converted to its N-Boc derivative 139. The obvious inefficiency with this method
is that anti-1,2-amino-diol 127 does not undergo complete conversion. Attempting to N98

Boc the mixture of anti-1,2-amino-diols 127 and 161 would need to be performed and
purified several times before a majority of the minor anti-1,2-amino-diol 127 is removed
from the mixture as the N-Boc derivative 139. Our attention then focused on synthesizing
oxazolidinones 137 and 160 using triphosgene. Therefore, the diastereomeric mixture of
127 and 161 was subject to triphosgene/Et3N conditions, where unsurprisingly, an
inseparable mixture of two oxazolidinones 137 and 160 and two oxazepinones 138 and
162 were obtained in an overall yield of 43% (Scheme 3.4). Unfortunately, the ratio of
these four products was unable to be determined due to the complexity of the 1H NMR
spectrum even after column purification (Figure 3.2). The N-Boc pathway for the mixture
of anti-1,2-amino-diols 127 and 161 was never re-visited. This is acknowledged with the
explanation that enough product from the triphosgene protection of the mixture of anti1,2-amino-diols 127 and 161 was obtained and never needed to be synthesized for the
remainder of this project.

Scheme 3.4: Formation of the oxazolidinones 137 and 160 along with the oxazepinones
138 and 162.
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Figure 3.2: 1H NMR spectrum (500 MHz, CDCl3) of the inseparable mixture of 137, 160,
138 and 162.

3.4. Oxazepinones 138 and 162 conversion to oxazolidinones 137 and
160, respectively
The inseparable mixture of the four diastereomers 160, 137, 138 and 162 was then subject
to our established conditions that would induce a facile migration of the carbonyl group to
give exclusively the oxazolidinone products 160 and 137 (Scheme 3.5). This fortuitously
resulted in returning a clean conversion of both oxazepinones 138 and 162 to their
respective oxazolidinones 137 and 160 (1:2 mixture, Figure 3.3). The reaction mixture still
proved inseparable by TLC and column chromatography. Oxazolidinone 160 was
characterized by the process of elimination from comparison of the 1H and

13

C NMR

spectrum of the diastereomeric mixture with the same data used to characterise the pure
(S)-methyl diastereomer 137.
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Scheme 3.5: Facile carbonyl migration: conversion of oxazepinones 138 and 162 to
oxazolidinones 137 and 160.

137-H1′′
160-H1′′
137-H2′
160-H2′

Figure 3.3: 1H NMR spectrum (500 MHz, CDCl3) of the inseparable mixture of 137 and
160.

3.5. Synthesis of compounds 140 and 149
Having experienced reasonable success in our previous RCM reaction with the
oxazolidinone 137, it was thought that treating the resultant mixture of oxazolidinones 137
and 160 to similar conditions would return a high yield of both RCM products 140 and
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159, respectively. In addition to this, it was hypothesized that increasing the rigidity of the
structures via synthesis of the bicyclic core might accentuate the subtle chemical
differences between both diastereomers, enough for them to at least separate using standard
column chromatography methods. Applying these conditions, both RCM products 140 and
159

were

successfully

synthesized

and

fortuitously separated

after

column

chromatography in 27% and 53% yields, respectively (Scheme 3.6). The diastereoselective
resolution was therefore successful when the rigidity of the structure was increased.
Interestingly, column chromatography proved effective since there was a significant R f
difference (Figure 3.4, Rf = 0.20 for 140 and Rf = 0.45 for 159) between each RCM product
using 1:1 EtOAc/n-hexane as the solvent system. Spectroscopic data for the minor isomer
matched that of the previously synthesized 140.
To confirm that the major isomer 159 was the desired RCM product, the HRESIMS and
1

H NMR spectrum were examined. More specifically, the HRESIMS of 159 showed a

characteristic [M+Na]+ ion peak at m/z 432.1782. After examining the 1H NMR spectrum
(Figure 3.5), a proton resonance was found to reside at δH 4.86 (1H, dd, J = 8.5, 4.8 Hz)
and proved characteristic of H7a. In addition to this, the observed 8.5 Hz vicinal coupling
constant J1,7a between resonances labelled H1 and H7a were consistent with the 4,5-cis
relative conﬁguration in 159. To eliminate the possibility that the corresponding pyrrole
had formed, careful inspection of the resonance labelled H1′′ at δH 1.21 (3H, J = 6.8 Hz)
revealed that it appeared with the multiplicity of a doublet; this would otherwise appear as
a singlet if there was no proton at C5 and the pyrrole had formed.
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Scheme 3.6: Ring-closing metathesis of oxazolidinones 137 and 160 to give 140 and 159,
respectively.

Figure 3.4: The thin-layer-chromatography plate (solvent: 1:1 EtOAc/n-hexane) showing
the efficient separation of 140 and 159.
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H1′′
H1′′
H7a
H1

Figure 3.5: 1H NMR spectrum (500 MHz, CDCl3) of 159.

3.6. Synthesis of compound 163
Having successfully formed and separated the RCM product 159 from its (5R)- isomer
140, we next focused our attention on establishing the syn-diol at C6 and C7. To do this,
compound 159 was subject to UpJohn cis-dihydroxylation (Scheme 3.7).157 Interestingly,
applying these reaction conditions to compound 159 resulted in the formation of a single
diastereomer 163. An extensive ROESY NMR analysis shown in Figure 3.6, indicated that
the syn-diol at C6, C7 of 163 formed anti to the (5S)-methyl. Key correlations confirming
this stereoconfiguration were observed between the resonances labelled H1′′‒H6, H7‒H7a,
and H7a‒H1. The product was also crystalline (Figure 3.7) and so was examined by X-ray
crystallographic analysis. This unambiguously confirmed the absolute configuration
deduced by NMR spectroscopy for compound 163.

Scheme 3.7: UpJohn cis-dihydroxylation of 159 to give diol 163.
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(H1′′-H6)
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163

Figure 3.6: 2D ROESY NMR spectrum (500 MHz, CDCl3) with key observed correlations
projected onto a DFT minimized molecular model [B3LYP/6-31G(d)] of 163.

Figure 3.7: Crystals of 163 (left) and the ORTEP plot of the crystal structure for
C24H29NO7 molecule of 163 (right) with labelling of selected atoms. Anisotropic
displacement ellipsoids display 30% probability levels. Hydrogen atoms are drawn as
circles with small radii.
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3.7. Synthesis of acetonide 158
Having obtained the pure syn-diol 163, the next step in the synthetic pathway was to protect
the C6, C7 diol as the corresponding acetonide. In a similar manner described in Chapter
2, syn-diol 163 was dissolved in acetone followed by the addition of two equivalents of
copper(II) sulphate and a catalytic amount of sulfuric acid. After stirring the reaction for 1
h, a TLC analysis showed a near quantitative conversion to the respective acetonide 158
(Scheme 3.8). In addition to the HRESIMS of 158 which showed a characteristic [M+Na]+
ion peak at m/z 506.2182, both the 1H NMR and the

13

C NMR spectrum displayed key

resonances that correspond to the newly formed acetonide 158. More specifically, through
the comparison of the 13C NMR spectroscopic data between the parent syn-diol 163 and
the acetonide 158 (Figure 3.8). In this comparison, acetonide 158 displays three additional
carbon resonances at δC 112.7, 26.3 and 24.1 which coincide with C2 and both the methyl
carbons contingent at C2, respectively. Although subject to extensive 1D and 2D NMR
studies, the compound fortuitously crystalized (Figure 3.9) and so the relative
configuration was unequivocally confirmed by single-crystal X-ray studies.

Scheme 3.8: Synthesis of acetonide 158.
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A)

B)

Figure 3.8: A) 13C NMR spectrum (125 MHz, CDCl3) of 163 and B) 13C NMR spectrum
(125 MHz, CDCl3) of 158 with C2 and C2 contingent methyl resonances for 158
highlighted in red.

Figure 3.9: Crystals of 158 (left) and the ORTEP plot of the crystal structure for
C27H33NO7 molecule 158 (right) with labelling of selected atoms. Anisotropic
displacement ellipsoids display 30% probability levels. Hydrogen atoms are drawn as
circles with small radii.
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3.8. Synthesis of compound 166
With the acetonide 158 in hand, studies towards a one-pot oxazolidinone hydrolysis
followed by annulation to give 165 were explored. Despite our unsuccessful attempts
reported in Chapter 2, we recognized that acetonide 158 had exhibited differing properties
(i.e. formed crystals) compared to the related acetonide 147 (resultant oil). These notably
different properties were the result of a single stereocentre difference. Therefore, it was
optimistically envisioned that the (8S)-methyl acetonide would react differently relative to
the (8R)-methyl containing acetonide 147. More specifically, if 158 was subject to
mesylation at C2′, followed by base-induced microwave hydrolysis, then pyrrolizidine 165
might form. Consequently, acetonide 158 underwent mesylation at C2′ using an excess
amount of methanesulfonyl chloride and Et3N (Scheme 3.9A). This provided the
mesylated product 164 in near quantitative yields which after purification, was then subject
to base-induced microwave hydrolysis. Unfortunately, when subject to these conditions,
no observable product was formed, rather, a complex mixture of products was obtained.
Although unsuccessful, the curiosity towards the feasibility of this one-pot deprotection
and subsequent cyclisation was satisfied; our results suggest that the one-pot oxazolidinone
hydrolysis then cyclisation is inefficient for this synthetic pathway. Hydrolysis of the
oxazolidinone before mesylation was concluded to be the optimal approach towards
synthesizing the desired hyacinthacine C-type analogues. Therefore, subjecting the larger
bulk of the acetonide 158 to base-mediated microwave hydrolysis of the oxazolidinone
returned the desired amino diol 166 in high yield (84%) (Scheme 3.9B).
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Scheme 3.9: A) Unsuccessful annulation attempt of 158 and B) Synthesis of compound
166.

3.9. Synthesis of pyrrolizidine 165
To furnish the pyrrolizidine core, the amino-diol 166 was reacted with a stoichiometric
amount of methanesulfonyl chloride (Scheme 3.10) and returned two equally intense
product spots as determined by TLC analysis.

Scheme 3.10: Synthesis of pyrrolizidine 165.

Prior to purification by column chromatography, TLC analysis was undertaken again but
with two parallel areas marked with samples of the crude reaction mixture. Shown in
Figure 3.10, a similar process to that of preparative TLC was used in order to determine
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the products formed in this reaction. More specifically, only one half of the TLC was
stained and processed. It was assumed that the observed spot stains were mirrored on the
unprocessed half of the TLC plate and so the silica where it was assumed these spots
presided, was gently scrapped off and washed with HPLC grade methanol. The methanolic
extracts of the spots with Rf values of 0.45 and 0.35 were then filtered and subsequently
analysed by LRESIMS and resulted in the ion peaks at m/z 536 and 440, respectively.
These were characteristic of the [M+H]+ ion for the single mesylated product 167, as well
as the [M+H]+ ion for the pyrrolizidine 165, respectively. After purification, the suspected
pyrrolizidine 165 was the subject of extensive spectroscopic analysis and deduced to be
the target compound. Shown in Figure 3.11, the ROESY analysis of pyrrolizidine 165
displays clear correlations between H1′′‒H3a, H3a‒H8b, H8b‒H8a, H8a‒H7 and H7‒H1′,
suggesting the desired absolute configuration had formed on both A and B-rings of the
pyrrolizidine product.

Figure 3.10: The thin-layer-chromatography plate (solvent: 5:95 MeOH/CH2Cl2) showing
the different spots for products 167 and 165 according to their respective Rf values. The
reaction mixture was spotted on both halves of the TLC plate, but only one side was
processed as indicated by the blue shading. The unprocessed half had the silica removed
at Rf values of 0.45 and 0.35 and underwent subsequent analysis via LRESIMS.
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Figure 3.11: 2D ROESY NMR (500 MHz, CDCl3) with key observed correlations
projected onto a DFT minimized molecular model [B3LYP/6-31G(d)] of 165.

Comparatively, the suspected singularly mesylated compound was determined to be the
mesylated amino-diol 167. In addition to the LRESIMS, examination of the 1H NMR
spectrum also indicated the formation of this product. Interestingly, it was initially thought
that the mesylate chemical shift in the 1H NMR spectrum at δH ~2.95 (3H, s) was reflective
of N-mesylation and so prevented annulation. However, on closer inspection of the 1H
NMR spectrum for both the starting amino-diol 166 and the mesylate adduct 167, strong
evidence suggested that the hydroxy group at C3′ had undergone mesylation. More
specifically, it was noted that the proton resonances deduced to be H1′′, H6, and H4
remained relatively unshifted between both spectra at δH ~ 1.00, 3.20 and 3.09, respectively
(Figure 3.12). In our earlier finding, the same proton chemical shifts for the N-mesylate
154 were significantly deshielded in the 1H NMR spectrum. It was therefore confidently
deduced that N-mesylation was not apparent in 167. The only other sites that mesylation
could occur were at the hydroxy groups at C1′ and C3′. From the 1H NMR spectrum
comparison between the parent amino-diol 166 and the mesylate adduct, convincing
evidence was found to support C3′ hydroxy mesylation. More specifically, the resonance
labelled as H1′ in 167 remained relatively unshifted at δH ~ 4.00 when compared with the
1

H NMR spectrum of the parent amino-diol 166. Comparatively, the 1H NMR chemical

shifts for the resonances labelled H3′ in both 166 and 167 were significantly different at
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δH ~ 4.00 (1H, m) and 5.00 (1H, bs), respectively. This was consistent with the C3′ hydroxy
mesylation deshielding effect and true for structure 167. To further strengthen this
argument, it was hypothesized that if the proposed structure was in fact mesylate 167, then
subjecting this compound to heat in the presence of a non-nucleophilic base should induce
cyclization to afford the previously obtained pyrrolizidine 165. Therefore, compound 167
was dissolved in DCE, followed by the stoichiometric addition of Et3N and heating the
solution at reflux overnight. After this time, the starting material spot had completely
disappeared to quantitatively return a TLC spot characteristic of pyrrolizidine 165. After
purification by column chromatography, the resultant product was obtained in a high yield
(76%) and confirmed to be the desired pyrrolizidine 165 by 1H and 13C NMR spectroscopic
analysis.

A)
H1′′
H3′ H1′
H2′ H4′
H6a
H3a

H6 H4

OMs

B)
H1′′
H3a
H3′

H1′ H2′ H4′

H6a

H6 H4

Figure 3.12: A) 1H NMR spectrum (500 MHz, CDCl3) of 166 and B) 1H NMR spectrum
(500 MHz, CDCl3) of 167.
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3.10. Synthesis of (‒)-5,6-di-epi-hyacinthacine C5 169
With a suitable amount of the pyrrolizidine 165 in hand, the final step in the synthesis was
to globally deprotect this compound. The pyrrolizidines 149 and 151 synthesized in
Chapter 2 were converted to their corresponding hyacinthacine C5-type analogues via
hydrogenolysis over PdCl2. After cleaving the O-benzyl ethers, the in situ generated HCl
eventually deprotects the acetonide and reveals the final products after the hydrochloride
salt is neutralized by basic ion-exchange chromatography. However, deprotection of
pyrrolizidine 165 occurred over two steps to reveal (‒)-5,6-di-epi-hyacinthacine C5 169
(Scheme 3.11). This entailed first deprotecting the acetonide moiety of pyrrolizidine 165
followed by hydrogenolysis of both O-benzyl ethers. Although it was likely that a one-pot
global deprotection of pyrrolizidine 165 would have resulted using our initial procedure,
deprotection of the acetonide first provided the intermediate 168 which was extensively
characterized prior to the final deprotection. Considering the stereogenic complexity of the
final products, it is of paramount importance that the synthesis of the correct structure and
absolute configuration at each stage has been achieved; all final structures and any possible
intermediates should be subject to extensive NMR spectroscopic analysis. More
specifically, pyrrolizidine 165 was dissolved in an EtOH/H2O (1:9, respectively) solution
followed by the addition of a few drops of HCl. After stirring at room temperature for 4 h,
the desired product 168 was obtained in near quantitative yield after neutralizing the HCl
salt with aqueous NaHCO3. Compound 168 was then subject to various spectroscopic
experiments. Of these, an extensive ROESY NMR analysis (Figure 3.13) displayed key
correlations between H1′′‒H6, H1′′‒H1′, H5‒H3, H6‒H7, H7‒H7a, and H1‒H3 and
therefore confirmed the absolute configuration depicted in pyrrolizidine 168. After
confirming the synthesis and absolute configuration of pyrrolizidine 168, the O-benzyl
ethers of this compound were then removed by hydrogenolysis over PdCl2, and the final
hyacinthacine

C5-type

alkaloid

169

was

neutralized

by basic

ion-exchange

chromatography. This returned (‒)-5,6-di-epi-hyacinthacine C5 [[α]25
𝐷 -6.9 (c 1.00, H2O)]
169 which was the subject of extensive NMR spectroscopic experiments and found to
spectroscopically match (consistent 0.8 – 1.4 ppm difference in the 13C NMR Table 3.1)
with its enantiomer 49 [lit.129[α]20
𝐷 +4.3 (c 0.35, H2O)] reported synthesized by Yu et al.
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in 2011129 (Figure 3.14). In a similar manner, this compound was also assessed for its
glycosidase inhibitory potential which will be discussed in Chapter 6.
Scheme 3.11: Global deprotection of pyrrolizidine 165 via two steps: acid hydrolysis of
the acetonide to give 168, then hydrogenolysis of the O-benzyl ethers to give (‒)-5,6-diepi-hyacinthacine C5 169.
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Figure 3.13: 2D ROESY NMR spectrum (500 MHz, CDCl3) with key observed
correlations projected onto a DFT minimized molecular model [B3LYP/6-31G(d)] of 168.

Figure 3.14: Our synthetic (‒)-5,6-di-epi-hyacinthacine C5 169 and its enantiomer 49
which was synthesized in 2011 by Yu et al.129
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Table 3.1: Comparison of literature 1H NMR (600 MHz, D2O) and 13C NMR (75 MHz,
D2O) data of Yu et al. Lit. (–)-7-epi-hyacinthacine C5 49129 with the 1H NMR (500 MHz,
D2O) and 13C NMR (125 MHz, D2O) of our synthetic (‒)-5,6-di-epi-hyacinthacine C5 (500
MHz, D2O) 169.
H NMR ( J in Hz)

C NMR ()

1

4.33, t (7.4)
3.89, t (8.7)

(–)-7-epihyacinthacine C5 49
(Yu et al.)129
73.0
77.7

(‒)-5,6-di-epihyacinthacine C5
169
73.8
78.7

6

2.92-3.12, m
2.92-3.12, m
3.85-3.78, m

2.78, dt (4.3, 9.1)
2.84, dq (6.4, 12.7)
3.76-3.68, m

71.0
63.5
79.0

71.5
64.0
79.8

7

4.24, t (3.6)

4.13, t (4.1)

70.0

70.6

7a

3.52-3.45, m
3.74, dd (4.2, 12.6)
3.85-3.78, m
1.31, d (6.0)

3.26, dt (2.8, 5.7)
3.65, dd (4.7, 11.9)
3.76-3.68, m
1.20, d (6.2)

68.2

68.6

60.8

62.2

17.2

18.3

position
1
2
3
5

8
9

(–)-7-epihyacinthacine C5 49
(Yu et al.)129
4.42, t (7.2)
3.97, t (7.8)

13

(‒)-5,6-di-epihyacinthacine C5 169

3.11. Chapter 3: Final remarks
The total synthesis of our third hyacinthacine C5-type analogue has been described. The
thorough spectroscopic analysis of each synthetic intermediate, as well as the X-ray
analysis of both crystal structures for 163 and 158 helped us to confidently assign the
absolute configuration for the resultant (‒)-5,6-di-epi-hyacinthacine C5 169. This products
enantiomer, 49, was synthesized in 2011 by Yu et al.129 and it was reassuring to find that
the 1H and 13C NMR spectroscopic data were a close match for both products. This further
validates our synthetic approach towards accessing the pyrrolizidine core via our
mesylation-cyclisation method. Although the chief focus of this project was to synthesize
hyacinthacine C5-type analogues containing the (5R)-methyl, we were pleased to readily
obtain the hyacinthacine C-type derivatives containing the (5S)-methyl. (‒)-5,6-Di-epihyacinthacine C5 169 was cross examined with the hyacinthacine C5-type natural products
and did not match any of the spectroscopic data reported for hyacinthacines C1, C4 or C5.
However, its synthesis provided an important foundation towards accessing the remaining
hyacinthacine C5-type analogues described in this body of work. Additionally, the inherent
glycosidase inhibitory activity of this product was assessed and provided valuable
information towards SAR studies (Chapter 6).
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Chapter 4 -Part A: Initial attempts to synthesize
hyacinthacine C5-type analogues with an anti- C6,
C7 diol
The segment that comprises Chapter 4 is disclosed in two parts. Chapter 4-Part A describes
the unsuccessful attempts towards accessing an anti-diol configuration at the C6, C7
stereocentres in the final hyacinthacine C5-type analogues. Although ineffectual, the author
notes that these attempts were an important foundation that ultimately influenced the
successful pathway towards accessing these compounds. However, this will be discussed
in greater detail in Chapter 4-Part B.

4A.1. Rationale for synthesizing hyacinthacine C5-type compounds
containing a C6, C7 anti-diol configuration
Up until this point in the Ph.D. work, three hyacinthacine C5-type analogues had been
successfully synthesized. A spectroscopic cross examination of these synthetic analogues
with the hyacinthacine C-type natural products C1, C4 and C5 revealed that they did not
match and so the true structures of these natural isolates were still yet to be discovered.
With seven stereocentres in our final products, it was calculated that 64 possible
diastereomers (excluding their enantiomers) could be synthesized. Since only a few
hyacinthacine C-type analogues had been synthesized in the literature so far, a 1H NMR
spectrum pattern that related the absolute configuration with specific proton or carbon
chemical shifts could not be generated. With reasonable certainty that most of the
originally reported stereocentres for the hyacinthacine C-type natural products would be
correct, we continued our investigation towards synthesizing closely related diastereomers
of the hyacinthacine C5-type compounds synthesized in Chapters 2 and 3. More
specifically, our chief focus was to implement an anti-diol configuration at the hydroxy
stereocentres labelled C6 and C7 in the final products. Details of this are described in our
retrosynthetic analysis shown in Scheme 4A.1. Having been influenced by the success of
our previous synthetic pathways described in Chapter 2 and 3, we envisioned that the final
pyrrolizidine core containing the C6, C7 anti-diol configuration would be obtained by
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firstly removing the protecting group 1 (PG1) of compound 170 or 171, then oxazolidinone
hydrolysis followed by cyclization of the resultant amino diol. The key reaction to ensure
that the anti-diol configuration at C6, C7 will appear in the final product, would be the
selective ring-opening of the epoxide 172. It was envisioned that the ring-opening the
epoxides 172-(6S)-methyl and 172-(6R)-methyl could each afford two potential (four in
total) C6, C7 anti-diol diastereomers 170 and 171. The acetonide protecting group
described in Chapters 2 and 3 would not work for the resultant C6, C7 anti-diols 170 and
171 since they contain an opposite stereoconfiguration and so a different protecting group
synthesis [protecting group 2 (PG2)] would be trialled. The desired epoxide 172 would
form across the alkene of either RCM products 173 or 174, as the alkene displayed
susceptibility

towards

syn-dihydroxylation

using

UpJohn

cis-dihydroxylation

conditions157 and so a similar reactivity towards epoxidation was envisioned. For this
reason, we believed the alkene in RCM products 173 or 174 would undergo a
stereoselective epoxidation that would occur opposite to either the (5R)-methyl (173) or
(5S)-methyl (174) based on precedent work within the Pyne research group.183
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Scheme 4A.1: Retrosynthetic analysis for hyacinthacine C5-type analogues containing a
C6, C7 anti-diol.

4A.2. O-PMB protection of 137 to give 175
At the time this reaction pathway was considered, a substantial amount of the
oxazolidinone intermediate 137 was on hand and so this compound became the model
study to explore the feasibility of this reaction pathway. With 137 in hand, we considered
protecting the compounds only free hydroxy group at C2′′′′ as the O-PMB ether for several
reasons. The PMB protecting group presented itself as a suitable candidate for this pathway
as it has been thoroughly explored (synthesized and selectively removed) on similar
substrates by previous members from the Pyne research group.184 Its primary purpose in
this pathway was to prevent the hydroxy group at C2′′′′ from intramolecularly attacking
and cyclising at C6 or C7 during the ring-opening of the epoxide 172. In addition to this,
synthesizing the O-PMB ether factors a selective deprotection of this hydroxy group prior
to cyclization to afford the pyrrolizidine core. Using this basis, the hydroxy group at C2′′′′
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of oxazolidinone 137 was subject to O-PMB protection by dissolving compound 137 in
THF, followed by heating to 30 oC for 18 h after the addition of NaH, 4-methoxybenzyl
chloride and a catalytic amount tetrabutylammonium iodide (TBAI) (Scheme 4A.2A). In
this example, addition of TBAI is used to displace the chlorine atom in the 4methoxybenzyl chloride reagent; this forms 4-methoxybenzyl iodide (PMBI) which is far
more reactive and can readily react with the present nucleophilic hydroxy group at C2′′′′.
This salt also acts as a phase transfer catalyst in this reaction by solubilizing the alkoxide
anion. After a TLC analysis indicated full consumption of the starting material, the crude
mixture was purified by column chromatography and the O-PMB protected product 175
was obtained in a good yield of 86%. An LRESIMS experiment of the sample initially
confirmed the successfulness of this reaction, as it displayed a characteristic LRESIMS
[M+Na]+ ion peak at m/z 656. The 1H NMR spectrum also displayed a characteristic singlet
resonance at δH 3.87 (3H) which was identified to be the OCH3 of the newly added PMB
group. This evidence and the additional aromatic resonances δH 7.38 – 7.06 (17H, m, ArH)
and δH 6.88 (2H, dd, J = 8.2, 4.7 Hz, ArH) suggested the successful synthesis of product
175.

Scheme 4A.2: O-PMB protection of the oxazolidinone 137.

4A.3. Synthesis of compound 176
Compound 175 was then subject to our established RCM reaction conditions (Scheme
4A.3). As anticipated, employing this procedure returned the RCM product 176 in a high
yield of 78%. Formation of the respective pyrrole was initially disregarded on the basis of
a HRESIMS experiment which found a [M+H]+ ion peak at m/z 530.2540. Additionally,
the 1H NMR spectrum showed that the multiplicity of the resonance labelled H1′′ at δ H
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1.24 (3H, J = 6.8 Hz), appeared as a doublet and so was concluded to be the intended RCM
product 176.

Scheme 4A.3: Synthesis of RCM product 176.

OCH3
H1′′

H1′′
H7 H6

Figure 4A.1: 1H NMR spectrum (500 MHz, CDCl3) of 176.

4A.4. Attempts to synthesize epoxide 179
The RCM compound 176 was then considered for epoxidation of the alkene at C6, C7.
Deciding the appropriate reaction conditions was largely influenced by precedent results
reported by a previous group member Thunwadee Ritthiwigrom.183 Shown in Scheme
4A.4, Ritthiwigrom found that epoxidation of the alkene moiety of 177, using 1,1,1trifluoroacetone and oxone,185-188 returned exclusively the desired β-epoxide 178 in a high
yield (81%). The high d.r. was attributed to the steric influence exerted by the C2 α-side
chain.
Scheme 4A.4: Ritthirigrom’s synthesis of epoxide 178.183
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In this example, we noticed that both the starting material 177 and final product 178 from
Ritthiwigrom’s work were analogous to our RCM intermediate 176 and the desired
epoxide 179, respectively. We therefore hypothesized that subjecting 176 to the procedure
described by Ritthiwigrom would result in a highly stereoselective synthesis of epoxide
179. The envisioned diastereoselectivity can be explained considering the mechanism
shown in Scheme 4A.5. More specifically, the dioxirane E is formed in situ from an initial
reaction between 1,1,1-trifluoroacetone A and oxone® B to give intermediate D. After the
sulfate ion is lost from D, the dioxirane E will then collapse back to give 1,1,1trifluoroacetone A after it has attacked the alkene at the less sterically hindered face present
in the olefin containing species such as the RCM compound 176. For RCM 176, the
envisioned stereochemistry proposed in 179 would be due to the potential steric hindrance
that the C1 α-side chain might offer. In addition to this, the orientation of the (5R)-methyl
group in 176 would also be a determining factor towards this diastereoselectivity as
depicted in Scheme 4A.5.

Scheme 4A.5: Mechanism for epoxidation of 176 using 1,1,1-trifluoroacetone A and
oxone® B.
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Therefore, the RCM product 176 was subject to the epoxidation procedure reported by
Ritthiwigrom but no product 179 was observed. Instead, only starting material 176 was
recovered along with initial signs of degradation to a complex mixture. Although several
attempts to synthesize epoxide 179 are summarised in Table 4A.1, it was clear that only
starting material 176 would be recovered each time (Scheme 4A.6). Therefore, an attempt
to synthesize epoxide 179 was performed using the peracid mCPBA (Table 4A.1). Known
as the Prilezhaev reaction, peracids such as mCPBA contain a high degree of polarisation
within their peracid moiety.189 This results in a strong electrophilic oxygen atom that can
add to alkenes. Shown in Scheme 4A.7, the electrophilic hydroxy group in mCPBA would
ideally react with 176 by adding the electrophilic oxygen to the C6, C7 alkene to form a
cyclic “butterfly” transition state A. This procedure and mechanism is believed to be
concerted and ultimately results in the synthesis of the desired epoxide as well as 3chlorobenzoic acid as a by-product. Unfortunately, this proved unsuccessful even when
freshly recrystalized mCPBA was used and only returned a series of complex mixtures as
deduced by TLC analysis and 1H NMR experiments of the crude reaction mixtures. After
several attempts and various reaction conditions (Table 4A.1) we concluded that our
substrate 176 would not readily undergo the formation of epoxide 179 and so our
retrosynthetic analysis was reconsidered.
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Scheme 4A.6: Attempts to synthesize epoxide 179.

Scheme 4A.7: Proposed mechanism of the epoxidation of 176 using mCPBA.

Table 4A.1: Epoxidation reaction conditions and attempts towards synthesizing epoxide
179.
Entry

Reagents used

Solvent

Temp.

Time

Yield of 179

123

Na2EDTA.2H2O,
1

CF3C(O)CH3, oxone

MeCN

0 oC

1h

NaHCO3
Na2EDTA.2H2O,
2

CF3C(O)CH3, oxone

3

oxone NaHCO3

MeCN

0 oC

2h

CF3C(O)CH3, oxone

Starting material
MeCN

0 oC

1h

6

mCPBA
mCPBA, 2 6-di-tert-butyl4-methylphenol

176 + complex
mixture
Starting material

MeCN

45 oC

1h

NaHCO3
5

176 + complex
mixture

Na2EDTA.2H2O,
4

material 176
Starting material

NaHCO3
EDTA, CF3C(O)CH3,

0 % + Starting

176 + complex
mixture

DCM

rt

1h

Complex mixture

DCE

60 oC

1h

Complex mixture

4A.5. Cis-dihydroxylation then cyclic sulfate synthesis of RCM product
176
Despite our unsuccessful attempts to synthesize the epoxide 179, a review of previous
Ph.D. students works within our laboratory found that related anti-diol products were not
always obtained from ring-opening the respective epoxide. Since 2003, Sharpless cyclic
sulfate chemistry has become an integral procedure within the Pyne research group and
has undoubtedly led to the synthesis of many natural products that contain anti-diol
relationships.174, 183, 190-191 Shown in Scheme 4A.8 and considering syn-diol 180 as an
example, this procedure operates through the conversion of the syn-diol 180 to the
corresponding cyclic sulfate 181. Cyclic sulfate 181 then undergoes a regioselective SN2
ring-opening of the cyclic sulfate with an oxygen nucleophile like cesium benzoate
(Scheme 4A.8). Acid hydrolysis then cleaves the resultant sulfate ester which in this
example, reveals the C6, C7 anti-protected-diol product 182.
Having experienced reasonable success with our earlier established syn-dihydroxylation
procedure described in Chapters 2 and 3, we envisaged that synthesizing the C6, C7 syn124

diol 180 followed by its conversion to the C6, C7 anti-protected-diol 182 via Sharpless
cyclic sulfate chemistry190 might prove to be a more reliable approach than epoxidation.
We were particularly confident this would work, especially since the literature regarding
the synthesis of cyclic sulfites and cyclic sulfates suggests they readily form from syn-1,2diols and are considered to be a more reactive variant of their related epoxides.190

Scheme 4A.8: The mechanism for the formation of cyclic sulfate 181 and its ring-opening
with cesium benzoate.

Therefore, the RCM product 176 was initially subject to UpJohn cis-dihydroxylation157
reaction conditions and returned two separable products which were spectroscopically
deduced to be diol diastereomers 180 (62% yield) and 183 (18% yield) (Scheme 4A.9).
The resultant d.r. was expected since a similar result was obtained and described in Chapter
2. Since a larger portion of 180 was acquired, it was decided that this diastereomer would
be used as the pilot study for the conversion to its respective C6, C7 anti-protected-diol
182. Therefore, the ROESY NMR analysis of the parent diol 180 is shown in Figure 4A.2
and will be referred to in a later comparison of the resultant products. Key correlations for
180 were observed between H1′′‒H6 and H1′′‒H7 and so confirm the designated C6, C7
syn-diol configuration for this compound.
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Scheme 4A.9: Synthesis of diols 180 and 183.
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H6
H7

180

Figure 4A.2: 2D ROESY NMR spectrum (500 MHz, CDCl3) with key observed
correlations projected onto a DFT minimized molecular model [B3LYP/6-31G(d)] of 180
(PMB ether not shown).

Following our synthetic plan, diol 180 was then converted to the respective cyclic sulfate
181. This was successfully performed by dissolving diol 180 in CH2Cl2, followed by the
addition of an excess amount of Et3N and sulfuryl chloride (Scheme 4A.10). After stirring
at 0 oC for 1 h, a TLC analysis indicated that the diol had quantitatively converted to a new
product. An initial LRESIMS [M+H]+ ion peak at m/z 626 was observed and matched with
the cyclic sulfate 181. Upon standing at room temperature over-night, the product had
changed from a light-yellow oil colour to an orange brown and so a second TLC analysis
indicated the products unfortunate tendency to readily decompose. This was detrimental
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to the yield and so for the remainder of this Ph.D. work, it was decided that the crude
mixture of future cyclic sulfate derivatives should be subject to ring-opening as soon as
they are synthesized. Despite the loss of the product, the cyclic sulfate 181 was quickly
purified by column chromatography and subsequently subject to an SN2 ring-opening of
the cyclic sulfate.

Scheme 4A.10: Synthesis of the cyclic sulfate 181.

4A.6. Ring-opening the cyclic sulfate 181 with cesium benzoate
The cyclic sulfate 181 was then subject to ring-opening reaction conditions using an in situ
formed benzoate anion as the nucleophile (Scheme 4A.11). More specifically, compound
180 was dissolved in anhydrous DMSO followed by the addition of benzoic acid and
cesium carbonate and heated at 40 oC for 3 h. After this time, a solution of THF, H2O and
H2SO4 (8:3:1) was added to the reaction and the mixture was stirred at 40 oC for 24 h. After
a TLC analysis indicated full consumption of the starting material, the reaction mixture
was neutralized with NaHCO3 and extracted using EtOAc. Unfortunately, an initial 1H
NMR spectrum of the crude reaction mixture indicated a largely complex mixture of
products had formed. Regardless, the reaction was purified by column chromatography
and a small amount of an inseparable mixture of single benzoate regioisomers 182 and 184
was obtained. Although the TLC analysis indicated a single spot which had a LRESIMS
[M+H]+ ion peak at m/z 668, there were many convoluted 1H NMR resonances; this was
characteristic of two products. Unfortunately, the resolution was not clear enough to
determine the diastereotopic ratio between both regioisomers. Since the mixture remained
inseparable, we were persuaded to hydrolyse the benzoate in 182 and 184 to give the
corresponding diol diastereomers 185 and 186, respectively. It was envisioned that both
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diol products might be easier to separate, and so each resultant diastereomer could then be
extensively characterised and also compared with the parent diol 180.

Scheme 4A.11: Ring-opening of cyclic sulfate 181 with in situ formed cesium benzoate,
then sulfate hydrolysis to give benzoate regioisomers 182 and 184.

4A.7. Methanolysis of benzoates 182 and 184
The inseparable mixture of benzoate regioisomers 182 and 184 was therefore subject to
methanolysis using K2CO3 (1.5 eq.) in methanol which returned a near quantitative mixture
of separable diols 185 and 186, respectively (17% and 7% yield, respectively over two
steps) (Scheme 4A.12).183 Although the Rf for both products were considerably close, their
successful separation was achieved and so extensive characterisation for both
diastereomers was performed. For products 185 and 186, individual HRESIMS
experiments found [M+H]+ ion peaks at m/z 564.6401 and 564.6498, respectively. More
importantly, the 1H NMR spectra of both products were comparatively different from one
another and did not match either of the earlier synthesized diol products 180 and 183. At
this point, through comparison of the 1H NMR spectra in conjunction with the wellestablished mechanisms of this reaction, it was confidently ascertained that both diols 185
and 186 were diastereomeric C6, C7 anti-diol products. It was rationalized that the
benzoate nucleophile would regioselectively ring-open the cyclic sulfate 181 at the
relatively less hindered stereocentre C3a. Therefore, our initial suspicion was that the
larger yielding of the two diol products was the C6, C7 anti-diol 185. This was confirmed
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based on an extensive ROESY analysis, whereby strong resonance correlations were
observed between H1′′‒H6 and H7‒H7a (Figure 4A.3). The configuration of the minor
diastereomer 186 was deduced in a similar manner with the finding of a key resonance
correlation between H1′′‒H7 (Figure 4A.4).

Scheme 4A.12: Methanolysis of 182 and 183 to give diol products 185 and 186.
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Figure 4A.3: 2D ROESY NMR spectrum (500 MHz, CDCl3) with key observed
correlations projected onto a DFT minimized molecular model [B3LYP/6-31G(d)] of 185
(PMB ether not shown).
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Figure 4A.4: 2D ROESY NMR spectrum (500 MHz, CDCl3) with key observed
correlations projected onto a DFT minimized molecular model [B3LYP/6-31G(d)] of 186
(PMB ether not shown).

4A.8. O-Benzyl ether synthesis at C6, C7 of 185 and 186
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To ensure that the C3′ hydroxy group undergoes a selective mesylation, both diols 185 and
186 were individually subject to C6, C7 hydroxy group protection. Since the acetonide is
only suited for synthesizing cyclic syn-diols, it was decided that both these hydroxy groups
would undergo the conversion to their respective O-benzyl ethers which would later be
removed in the final hydrogenolysis deprotection step. We envisioned that this would then
allow for selective O-PMB deprotection, followed by subsequent oxazolidinone hydrolysis
then annulation to give the desired pyrrolizidine core. Using our already established Obenzyl ether synthetic procedure, (NaH, TBAI, BnBr, THF), both diols 185 and 186 were
individually subject to this methodology (Scheme 4A.13). When attempted, only 185 was
successfully protected and purified by column chromatography to give 187. Unfortunately,
the other diastereomer 186 proved relatively inert to these reaction conditions (mostly
starting material recovered). Although the desired product 188 may have been synthesized
in small amounts, its recovery by column chromatography proved inefficient and the
synthesis of 188 was unable to be confirmed. An attempt to synthesize 188 was only
performed once and so further investigation is required to determine the seemingly inert
starting material 186. Therefore, only 187 was available for an extensive ROESY NMR
analysis. However, the significant closeness and overlap of key proton resonances (H7
overlapping with H6 and H2′ overlapping with H5) made these stereochemical analyses
difficult for 187 (Figure 4A.5). Since this was only a protective step, there was no reason
to doubt the stereochemical assignments deduced in Section 4A.7. For this reason,
compound 187 was taken through to the next stage of the synthesis which entailed the
selective hydrolysis of the O-PMB ether at C2′.

Scheme 4A.13: Synthesis of compound 187 and attempted synthesis of compound 188.
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OCH2Ph,
H7
OCH2Ph,
H1

H1′′

Figure 4A.5: 1H NMR spectrum (500 MHz, CDCl3) of 187 with overlapping key
resonances highlighted in red.

4A.9. O-PMB deprotection of 187
It was unfortunate that diol 186 seemed inert to the O-benzyl ether conversion of the
hydroxy groups at both C6 and C7. However, this procedure and set of conditions for the
O-benzyl ether synthesis of diol 186 was only performed once and so these preliminary
results may be unreliable. Further attempts could not be explored as this material was
difficult to generate since it was the minor isomer of a relatively low yielding ring-opening
of the cyclic sulfate 181. If the C6, C7 hydroxy benzylation of 186 was successful, the
inefficiency of generating this material proved impractical. In contrast, the benzyl-ethers
at C6, C7 readily formed to give 187 and so this product was subject to O-PMB ether
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hydrolysis. Following a similar procedure reported by a previous group member, Karl
Lindsay, compound 187 was treated with DDQ (2 eq.) in a CH2Cl2 and H2O (20:1)
mixture.184 The reaction was stirred at 30 oC for 4 h and the full consumption of the starting
material after this time was determined by TLC analysis. Unfortunately, the 1H NMR
spectrum and the TLC analysis of the crude reaction mixture displayed a complex
combination of products. Ideally, the desired product 189 would have formed via a single
electron transfer (SET) resulting in complexs B-D (Scheme 4A.15). Complex D would
then aromatize to generate complex E which would decompose to give the desired alcohol
189 and the p-anisaldehyde by-product. However, the substrate 187 seemed to have
undergone several different chemical transformations that were not extensively explored.
Due to the small scale that this reaction was performed on (30 mg of compound 187), OPMB deprotection was never re-considered and so this pathway was discontinued. In the
interest of time and reaction economy, this reaction pathway ultimately proved to be an
unjustified expense. For these reasons, access to the hyacinthacine C-type analogues was
reconsidered and will be discussed in detail in Chapter 4-Part B.

Scheme 4A.14: Attempted O-PMB hydrolysis of compound 187.

Scheme 4A.15: Mechanism for DDQ assisted O-PMB hydrolysis of 187.
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4A.10. Chapter 4-Part A: Final remarks
The initial attempt to access the hyacinthacine C5-type analogues containing a C6, C7 antidiol configuration has been described in this Chapter. Although it might not be apparent at
first, exploring the feasibility of this pathway consumed a large portion of time and
material allocated for the Ph.D. work described. The poor yield of the ring-opening of the
cyclic sulfate 181 with the in situ formed benzoate anion delayed the progress of the
pathway significantly and so this resulted in a lack of experimental conditions explored.
The difficulty to synthesize more of the benzoate regioisomers 182 and 184 in conjunction
with the seemingly difficult O-PMB removal of the diastereomer 187, diminished any
enthusiasm to repeat this reaction series. These factors in conjunction with the short time
remaining for this Ph.D. work led to a revision of the described pathway. This decision
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proved successful and resulted in the synthesis of four C6, C7, anti-diol hyacinthacine C5type analogues. These will be discussed in detail in Chapter 4-Part B.
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Chapter 4 -Part B : Synthesis of putative (+)hyacinthacine C5, (+)-5-epi-hyacinthacine C5, the
corrected structure of natural hyacinthacine C5
and (+)-6,7-di-epi-hyacinthacine C5
The unsuccessful attempts towards synthesizing hyacinthacine C5-type analogues
containing a C6, C7 anti-diol configuration were described in Chapter 4-Part A. The
pathway was discontinued largely based on its uneconomical yields, the unreactivity of
key intermediates and the limited remaining timeframe for this work. However, these
results helped influence the new revised pathway which ultimately led to the synthesis of
our desired products. More specifically, it was found that the C6, C7 anti-diol
configuration could be implemented after the pyrrolizidine core had been formed. Herein,
the synthesis of the putative structure of hyacinthacine C5, the corrected structure of
hyacinthacine C5, and two analogues that had been previously synthesized in the literature
are described. These results in addition to the successful pathways described in Chapters
2 and 3 were summarised as a manuscript and accepted for publication in the ACS Journal
of Organic Chemistry.132 Full NMR spectroscopic experiment data are available in the
related Supporting Information for this article.

4B.1. Revised synthetic strategy towards hyacinthacine C5-type
analogues containing a C6, C7 anti-diol configuration
Chapter 4-Part A concluded that the C6, C7 alkene of RCM compound 176 was not
susceptible to epoxidation. However, when 176 was subject to UpJohn cis-dihydroxylation
parameters, the diol(s) 180 and 183 readily formed. Diol 180 was then converted to the
respective cyclic sulfate 181, which then underwent a SN2 ring-opening of the cyclic
sulfate moiety with benzoate and returned two benzoate regioisomers 182 and 184.
Unfortunately, this was a low yielding reaction and so in conjunction with other
contributing factors, this reaction pathway was discontinued. In contrast, Chapters 2 and 3
demonstrated that the pyrrolizidine core containing the C6, C7 syn-diol was readily
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accessible. It was therefore decided that the pyrrolizidine core would need to be
synthesized first prior to establishing the C6, C7 anti-diol. After reviewing the successful
synthetic pathway described in Chapters 2 and 3, an opportunity to perform our established
C6, C7 anti-diol chemistry using pyrrolizidines 165, 149 and 151 was recognized and is
shown in Scheme 4B.1. More specifically, pyrrolizidines 165, 149 and 151 contain two
different hydroxy protecting groups within the compound and are specific to either the A
or B ring of the bicyclic compound. On the A-ring of the pyrrolizidine, the hydroxy groups
at C6 and C7 were protected as their respective O-benzyl ethers. On the B-ring of the
pyrrolizidine, the syn-diol moiety at C8b and C3a was protected as the respective
acetonide. The only remaining hydroxy group that is unprotected is found at C8. We
therefore envisioned protecting this hydroxy group at C8 to give 190, followed by a
selective deprotection of the acetonide under acidic conditions. Then, employing our
procedure to synthesize the cyclic sulfate 191, followed by an SN2 ring-opening of the
cyclic sulfate moiety with benzoate would likely result in the synthesis of potentially six
benzoate regioisomers. Methanolysis of the C6 or C7 benzoate group would return four
diols, 192, 193, 194 and 195 which after hydrogenolysis and purification by ion-exchange
chromatography would give their respective hyacinthacine C5-type analogues.
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Scheme 4B.16: Revised Synthetic plan towards the C6, C7 anti-diol containing
hyacinthacine C5-type analogues.

At the time this reaction pathway was considered, pyrrolizidine 165 was on hand and so
became the model study for this work. This led to the successful synthesis of the proposed
structure for (+)-hyacinthacine C5 and (+)-5-epi-hyacinthacine C5. However, for clarity,
the results and procedures employed on each pyrrolizidine analogue 165, 149 and 151 will
be presented at their appropriate segments. It is also noted that employing this synthetic
pathway for pyrrolizidines 149 and 151 ultimately lead to the same hyacinthacine C5-type
products. Both pyrrolizidines were still subject to the same procedures and have been
included since they resulted in noteworthy diastereotopic ratios of the desired C6, C7 antidiol related hyacinthacine C5-type analogues.
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4B.2. O-Benzyl ether synthesis at C8 of pyrrolizidines 165, 149 and 151
The pyrrolizidines 165, 149 and 151 were considered for the protection of their remaining
free hydroxy group at C8 due to foreseen selectivity issues during the formation of their
respective cyclic sulfate. The decision was made to convert the hydroxy group to its Obenzyl ether since we were familiar with this procedure and had previously obtained
reasonably reliable results and overall high yields. Therefore, individual samples of
pyrrolizidine 165, 149 and 151 were subject to O-benzyl protection using NaH, TBAI,
BnBr, THF, and were successful after returning products 196, 197 and 198, respectively
in yields of 87%, 89% and 78%, respectively (Scheme 4B.2). After purification, each
product was extensively characterized but will be discussed in further detail in the next
Section 4B.3.

Scheme 4B.17: Synthesis of 196, 197 and 198.
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4B.3. Acid hydrolysis of the acetonide from pyrrolizidines 196, 197 and
198
With the protected pyrrolizidines 196, 197 and 198 in hand, each was individually subject
to acid hydrolysis of the acetonide. This was performed in a similar manner to the
acetonide hydrolysis of pyrrolizidine 165 described in Chapter 3 which entailed dissolving
the compound in a solution of EtOH/H2O (9:1, respectively), followed by the addition of
several drops of 5 M HCl (Scheme 4B.3). The reaction was then stirred at room
temperature until full consumption of the starting material was confirmed by TLC analysis.
After neutralizing the HCl salt with aqueous NaHCO3 a generally high yield was obtained
for each resultant diol, 199, 200 and 201. In addition to this, the full consumption of the
starting material was easily confirmed by the Rf change since each new product became
significantly more polar.

Scheme 4B.18: Acid hydrolysis of the acetonide from pyrrolizidines 196, 197 and 198.
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All three pyrrolizidine diols were extensively characterized. Although we were confident
their relative configurations assigned in both Chapters 2 and 3 had not changed, their
characterisation is included for a later comparison and proof of the respective resultant C6,
C7 anti-diol products formation. More specifically, syn-diol 199 was subject to an
extensive ROESY NMR analysis where key correlations between H1''‒H6, H1''‒H7a
(weak), H6‒H7 and H5‒H3 are shown below (Figure 4B.1).
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H7 H7a H6
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(H1′′-H6)
(H1′′-H7a)
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6

7a
H5

5
(H5-H3)

H3

1''

3

H1′

H6
H7a
H7
H2

(H7-H6)

199
Figure 4B.6: 2D ROESY NMR spectrum (500 MHz, CDCl3) with key observed
correlations projected onto a DFT minimized molecular model [B3LYP/6-31G(d)] of 199
(C1 O-benzyl ether not shown).

Syn-diols 200 and 201 were also extensively characterized through NOE experiments to
confirm their relative configurations. These results can be found in the Supporting
Information accompanying the resultant ACS Journal of Organic Chemistry publication,
but the for the purpose of this work, selected NOE enhancements for 200 are included and
display key correlations between H7‒H1'', H7‒H6, H6‒H3, and H6‒ H1'' (Figure 4B.2).
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Figure 4B.7: Top: Selected 1D-NOE spectra (500 MHz, CDCl3) of 200 of A) H7 and B)
H6 and their respective key observed correlations projected onto Bottom: a DFT
minimized molecular model [B3LYP/6-31G(d)] of 200 (C1 O-benzyl ether not shown).

Similarly, 201 was also subject to extensive NOE experiments, but for brevity only the
enhancements for H6 and H7 are included and display key positive correlations between
H7‒H6, H7‒H7a, H7‒H5 and H6‒H5 (Figure 4B.3) as expected for this structure.
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Figure 4B.8: Top: Selected 1D-NOE spectra (500 MHz, CDCl3) of 201 of A) H7 and B)
H6 and their respective key observed correlations projected onto Bottom: a DFT
minimized molecular model [B3LYP/6-31G(d)] of 201 (C1 O-benzyl ether not shown).

4B.4. Synthesis of cyclic sulfates 202, 203 and 204, then ring-opening
with in situ formed cesium benzoate
In three separate reactions, the diols 199, 200 and 201 were each dissolved in CH2Cl2,
followed by the addition of an excess amount of Et3N (2.5 eq.) and sulfuryl chloride (1.5
eq.) (Scheme 4B.4). These reaction conditions converted 199, 200 and 201 to the
corresponding cyclic sulfates 202, 203 and 204, respectively. Described in Chapter 4A,
our previous experience with the fast degrading nature of the cyclic sulfate 181 influenced
the decision to use the crude reaction mixture in the next step of the synthetic pathway
without further purification. Indication that the cyclic sulfate had formed was inferred by
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the LRESIMS [M+H]+ ion peak at m/z 552 and TLC analysis to indicate full consumption
each starting diol and formation of their respective cyclic sulfate products. Each cyclic
sulfate then underwent subsequent SN2 ring-opening with CsOBz (prepared in situ from
Cs2CO3 and BzOH) and each individual result is discussed below.

Scheme 4B.19: Synthesis of of cyclic sulfates 202, 203 and 204.

4B.4.1. Ring opening cyclic sulfate 202
Ring opening the cyclic sufate 202 with the in situ generated CsOBz returned regioisomers
205 and 206 in isolatable yields of 61% and 12%, respectively (Scheme 4B.5). The regioand stereochemistry of 205 was determined through observed correlations from both
gCOSY and ROESY NMR analysis. More speciﬁcally, it was observed that the resonance
for the proton sharing the stereogenic carbon with the newly added benzoate proved the
most deshielded and characteristically appeared slightly above δH 5.0 ppm. Analysis of the
gCOSY of 205 found a strong correlation between H1″ (δH 1.24 ppm) and H5 (δH 3.21
ppm), which was subsequently found to correlate with H6 (δH 3.94 ppm) (Figure 4B.4).
The H6 correlation with the lone triplet resonance at δH 5.13 ppm (otherwise H7) clearly
indicated that the benzoate group was at C7 as opposed to C6. With the regiochemistry
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established, our focus turned to conﬁrming the stereoconﬁguration of the benzoate at C7.
Consulting the ROESY experiment for 205, we noted a relatively weaker correlation
between H6−H7 than that observed between H6−H7 in the parent diol 199. Additionally,
the H1″−H6 relationship showed to be far more intense and so collectively suggested
successful inversion at C7 (Figure 4B.5). Similarly, the gCOSY analysis of compound 206
identiﬁed H5 to strongly correlate with the doublet resonance at δH 5.31 ppm, which was
logically assigned H6 (Figure 4B.6). Although the ROESY analysis showed a weak
correlation between H6−H7, it undoubtedly found that the correlation between H5−H6 was
of stronger intensity (Figure 4B.7). Here, the diastereoselectivity of the synthesized
regioisomers 205 and 206 is a result of steric hindrance induced by the C4 methyl
stereochemistry from the cyclic sulfate 202. These results suggest that the large benzoate
nucleophile attacks the less sterically hindered carbon at C7 resulting in the dominant
product 205. The reaction is not completely selective since the C6 benzoate regioisomer
206 was also obtained.

Scheme 4B.20: Ring-opening of cyclic sulfate 202 with in situ formed cesium benzoate,
then sulfate hydrolysis to give benzoate regioisomers 205 and 206.
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Figure 4B.9: gCOSY NMR spectrum (500 MHz, CDCl3) of 205 and a DFT minimized
molecular model [B3LYP/6-31G(d)] of 205 (O-benzyl ethers not shown).
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Figure 4B.10: 2D ROESY NMR spectrum (500 MHz, CDCl3) with the H1″−H6
correlation projected onto a DFT minimized molecular model [B3LYP/6-31G(d)] of 205
(C1, C2 and C1′ O-benzyl ethers not shown).
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Figure 4B.11: gCOSY NMR spectrum (500 MHz, CDCl3) of 206 and a DFT minimized
molecular model [B3LYP/6-31G(d)] of 206 (O-benzyl ethers not shown).
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correlations projected onto a DFT minimized molecular model [B3LYP/6-31G(d)] of 206
(C1, C2 and C1′ O-benzyl ethers not shown).
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1

4B.4.2. Ring opening of cyclic sulfate 203
Ring-opening of 203 gave an inseparable mixture of two pyrrolizidines, 207 and 208, in a
49% yield (Scheme 4B.6). We were confident both these regioisomers had formed on the
basis of LRESIMS [M+H]+ ion peak at m/z 594 of the purified product, as well as the
appearance of characteristic resonance peaks for two regioisomers displayed in the 1H
NMR spectra of the purified products. Unfortunately, the ratio between both diastereomers
was difficult to ascertain by 1H NMR analysis and so the mixture was taken through to the
next step in hope that the resultant C6, C7 diols would separate.

Scheme 4B.21: Ring-opening of cyclic sulfate 203 with in situ formed cesium benzoate,
then sulfate hydrolysis to give benzoate regioisomers 207 and 208.

4B.4.3. Ring opening of cyclic sulfate 204
Ring opening the cyclic sufate 204 with in situ formed CsOBz returned a 2:1 mixture of
separable benzoate pyrrolizidines regioisomers 209 and 210, in yields of 39% and 23%,
respectively (Scheme 4B.7). Due to their ease of separation, compounds 209 and 210 were
the attention of gCOSY and extensive NOE analysis. It was observed that the proton
sharing the stereogenic carbon with the newly added benzoate proved the most deshielded
and characteristically appeared at δH >5.0 ppm. More speciﬁcally, the gCOSY analysis of
209 identiﬁed a strong correlation between H1″ (δH 1.32 ppm) and H5 (δH 3.42−3.30 ppm)
which was subsequently found to correlate with the most deshielded proton at δH 5.04 ppm,
namely H6 (Figure 4B.8). After the remaining protons were identiﬁed in a similar manner,
NOE experiments of 209 identify key correlations between H6−H1″, H6−H3, H7a−H7,
and H7a−H5 (Figure 4B.8). Using a similar method of reasoning, 210 was identiﬁed to
have resulted from SN2 attack of the benzoate anion at the C8b position of the cyclic sulfate
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204. Subsequent NOE experiments included in this Chapter display key correlations
between H1″−H3, H5−H6, H7−H1, H7a−H2, and H1′−H2 (Figure 4B.9). The reigoselectivity of the products formed is similar to the results obtained for the ring opening of
cyclic sulfate 202. More specifically in cyclic sulfate 204, the benzoate nucleophile slightly
favours attack at C8b. However, because the C4 methyl of the cyclic sulfate 204 is on the
concave face of the molecule, the regioisomeric ratio is relatively closer to equal amounts
for each regio-isomer 209 and 210 obtained.

Scheme 4B.22: Ring-opening of cyclic sulfate 204 with in situ formed cesium benzoate,
then sulfate hydrolysis to give benzoate regioisomers 209 and 210.
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1D-NOE spectra (500 MHz, CDCl3) of 209 of A) H6 and B) H7a and their respective key
observed correlations projected a DFT minimized molecular model [B3LYP/6-31G(d)] of
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4B.5. Methanolysis of the benzoates 205, 206, 209, 210 and the
inseparable mixture of 207 and 208
The individual benzoate regio-isomers 205, 206, 209, 210 and the inseparable mixture of
207 and 208 were next subject to methanolysis of the benzoate group. This was performed
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by using the same procedure described in Chapter 4A, which involved dissolving each
compound in methanol, followed by the addition of K2CO3.

4B.5.1. Methanolysis of benzoates 205 and 206
Methanolysis of the benzoate regio-isomers 205 and 206 returned diols 211 (79% yield)
and 212 (90% yield), respectively (Scheme 4B.8).

Scheme 4B.23: Methanolysis of 205 and 206 to give diol products 211 and 212,
respectively.

The HRESIMS of 211 and 212 displayed [M+H]+ ion peaks at m/z 490.2617 and 490.2613,
respectively. An initial comparison of the 1H NMR spectra of 211 and 212 with that of the
parent syn-diol 199 clearly indicated that these were not the same product. This, in
combination with an extensive NMR analysis, suggested that the single-stereocentre at
either C6 or C7 for compounds 211 and 212, respectively had undergone inversion.
Interestingly, diol 211 was found to be the enantiomer of the pyrrolizidine 45 reported by
Yu et al. in 2011 (Figure 4B.10) and so it was reassuring to find an identical match in both
the 1H and

13

C NMR (Δ δH = 0.01−0.03 ppm, Δ δC = 0.1−0.2 ppm) spectroscopic data

when compared with this reported literature compound (Table 4B.1).129 In addition to this,
compound 211 fortuitously crystallized and so allowed the unequivocal confirmation of its
stereochemistry by single-crystal X-ray analysis (Figure 4B.11).
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Figure 4B.15: Our synthetic 211 and its enantiomer 45 which was synthesized in 2011 by
Yu et al.129

Figure 4B.16: Crystals of 211 (left) and the ORTEP plot of the crystal structure of the
C30H35NO5 molecule of 211 with labelling of selected atoms, showing only one set of sites
for the disorder in the benzyl groups. Anisotropic displacement ellipsoids display 30%
probability levels. Hydrogen atoms are drawn as circles with small radii.
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Table 4B.2: Comparison of literature 1H NMR (600 MHz, CDCl3) and 13C NMR (75 MHz,
CDCl3) data of Yu et al. Lit. 45129 with the 1H NMR (500 MHz, CDCl3) and 13C NMR
(125 MHz, CDCl3) of our synthetic 211.
H NMR ( J in Hz)

C NMR ()

1

13

position

45 (Yu et al.)129

211

45 (Yu et al.)129

211

1

4.08, t (3.3)

4.07, t (3.6)

87.4

87.2

2

4.12, t (3.4)

4.10, t (3.6)

86.0

86.0

3
6

3.27-3.22, m
2.99-2.91, m
3.67, t (8.0)

3.23, dt (4.5, 9.8)
2.93, dq (6.4, 12.6)
3.68, t (8.1)

69.1
65.2
83.2

69.2
65.3
83.1

7

3.98, t (7.5)

3.97, t (7.5)

80.2

80.2

7a

3.41, dd (3.9, 7.4)

3.48-3.40, m

72.2

72.3

1´

3.47, d (6.5)

3.48-3.40, m

71.5

71.3

1´´

1.20, d (6.2)

1.17, d (6.2)

19.1

19.0

5

Focusing our attention to the related diol 212, a ROESY analysis displayed a key
correlation between H5−H6 which corroborated with the fact that the earlier benzoate
inversion had successfully occurred at C6 (Figure 4B.12).
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Figure 4B.17: 2D ROESY NMR spectrum (500 MHz, CDCl3) with key observed
correlations projected onto a DFT minimized molecular model [B3LYP/6-31G(d)] of 212.
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4B.5.2. Methanolysis of benzoates 209 and 210
Individual base-mediate hydrolysis of the benzoate group in pyrrolizidines 209 and 210
returned their respective diols 213 (90%) and 214 (83%) (Scheme 4B.9). The HRESIMS
of 213 and 214 found [M+H]+ ion peaks at m/z 490.2608 and 490.2615, respectively.

Scheme 4B.24: Methanolysis of benzoates 209 and 210 to give diol products 213 and 214,
respectively.

After conducting NMR spectroscopic experiments for both products, it was noted that the
1

H and

C NMR spectra of these pyrrolizidines were diﬀerent to that of their parent

13

pyrrolizidines 200 and 201, and so clearly indicated successful conﬁgurational inversion
at either C6 or C7, respectively.
For diol 213, a ROESY NMR analysis indicated the successful inversion at C6, as key
correlations between H1′′−H6 and H7−H7a were identified (Figure 4B.13).
Comparatively, a ROESY NMR analysis for diol 214 displayed a distinct correlation
between H5−H6 indicating a syn-relationship between the protons, suggesting that the C6
hydroxy group is on same face as the (5R)-methyl group and has not inverted (Figure
4B.14). This evidence therefore suggested the inversion at C7 since it is the only other site
that the benzoate could have attacked.
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4B.5.3. Methanolysis of the inseparable mixture of benzoates 207 and 208
The inseparable mixture of benzoates 207 and 208 was also subject to methanolysis which
resulted in a clean hydrolysis of their benzoate moieties to give the separable pyrrolizidine
diols 213 and 214 in a 1:4 ratio. The 1H and 13C NMR spectra of both products matched
the respective diols obtained from hydrolysis of benzoates 209 and 210 described above.
This led us to believe their respective benzoate pyrrolizidines, 207 and 208, were originally
synthesized in an approximately 1:4 ratio. Here, the ring-opening of cyclic sulfate 203
seems to return a contrasting regio-selectivity to our prior results. More specifically, the
regiochemical outcome of the ring-opening reaction of the cyclic sulfate 203 with CsOBz
can be best described by considering the two possible reactive conformations 203A and
203B of cyclic sulfate 203, and the preference for 1,2-diaxial-like ring opening as shown
in Scheme 4B.10. In this example, attack predominates at C3a of conformer 203A resulting
in 208 as the major regioisomer. When considering conformation 203B, attack at C8b is
less likely to occur (to give 207) due to unfavourable steric interactions between the
nucleophile (−OBz) and the pseudoaxial C4 methyl group and the pseudoaxial proton H8a.

Scheme 4B.25: Proposed reactive conformers of 203 to give the major benzoate 208 along
with the minor benzoate 207.
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4B.6. Hydrogenolysis of pyrrolizidines 211, 212, 213 and 214
Confident that we had successfully synthesized all four diastereomers 211, 212, 213 and
214, the final step in the synthesis was to hydrolyse the O-benzyl ethers from each of these
compounds. To do this, each pyrrolizidine was individually subject to hydrogenolysis over
PdCl2 and stirred until LRESIMS confirmed full consumption of the starting material. All
final products were then neutralized by basic ion-exchange chromatography and returned
the hyacinthacine C5-type related alkaloids as described.

4B.6.1. Hydrogenation of pyrrolizidines 211 and 212
Debenzylation of pyrrolizidines 211 and 212 returned the putative structure of
hyacinthacine C5 [[α]25
𝐷 +9.5 (c 1.00, H2O)] along with its (+)-5-epi-hyacinthacine C5 215
[[α]25
𝐷 +10.3 (c 1.00, H2O)], respectively (Scheme 4B.11). Since we were confident in their
structures and absolute configurations, it was unsurprising to find that the 1H and 13C NMR
spectroscopic data of our synthetic purported hyacinthacine C5 and 215 matched their
literature reported structures. More specifically, a close spectroscopic match was noted for
our synthetic purported hyacinthacine C5 and the previously synthesized proposed
structure of (+)‒hyacinthacine C5 (Table 4B.2: Δ δH = 0.01−0.04 ppm, Δ δC = 0.6− 0.7
ppm) [lit.130 [α]30
𝐷 +8.0 (c 1.00, H2O)]. Synthetic 215 also proved to be a close
spectroscopic match with Tamayo and coworkers synthetic hyacinthacine C-type analogue
64 (lit.130 [α]30
𝐷 +1.5 (c 1.00, H2O)] An internal reference was not included in the NMR
sample of 215 since it would be difficult to remove prior to glycosidase testing. Therefore,
the 1H NMR spectrum of 215 was referenced to the D2O solvent residual peak at 4.79 ppm
and the 1H NMR spectrum resonance peaks were consistently close with those of 64 (Table
4B.3: Δ δH = 0.02−0.03 ppm). The 13C NMR of 215 was referenced to internal MeOH, but
the chemical shifts shown in Table 4B.3 were consistently shifted 2.5−2.6 ppm when
compared with the 13C NMR of 64. Comparatively, the 1H and 13C NMR chemical shifts
reported for 64 are expressed in reference to the internal standard sodium 3(trimethylsilyl)propionate (TPS) in D2O.130 This satisfactorily explains the slight NMR
spectroscopic differences observed between synthetic 215 and 64.
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Scheme 4B.26: Hydrogenolysis of 211 and 212 to give the putative structure of
hyacinthacine C5 and hyacinthacine C5-type analogue 215, respectively.

Table 4B.3: Comparison of the literature 1H NMR (500 MHz, D2O) and 13C NMR (125
MHz, D2O) spectroscopic data of Tamayo et al. Lit. (+)-hyacinthacine C5130 with the 1H
NMR (500 MHz, D2O) and 13C NMR (125 MHz, D2O) data of our synthetic purported
compound for (+)-hyacinthacine C5.
H NMR ( J in Hz)

C NMR ()

1

13

position

(+)-hyacinthacine C5
(Tamayo et al.)130

1

4.19, t (6.9)

The purported (+)hyacinthacine C5
from this work
4.15, t (7.0)

79.6

The purported (+)hyacinthacine C5
from this work
80.2

2

3.99, t (6.9)

3.96, t (7.0)

78.7

79.3

3
6

2.97-2.93, m
2.97-2.93, m
3.72-3.66, m

2.96-2.87, m
2.96-2.87, m
3.74-3.61, m

65.3
70.4
82.3

66.0
71.1
82.9

7

4.15, t (6.9)

4.11, t (7.1)

79.0

79.6

7a

3.08, t

3.05, t (6.8)

70.5

71.2

8

3.72-3.66, m

3.74-3.61, m

62.2

62.9

9

1.24, d (6.3)

1.20, d (6.2)

17.2

17.8

5

(+)-hyacinthacine C5
(Tamayo et al.)130
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Table 4B.4: Comparison of the literature 1H NMR (500 MHz, D2O) and 13C NMR (125
MHz, D2O) spectroscopic data of Tamayo et al. Lit. 64130 with the 1H NMR (500 MHz,
D2O) and 13C NMR (125 MHz, D2O) data of our synthetic 215.
H NMR ( J in Hz)

C NMR ()

1

position

64 (Tamayo et
al.)130

1

4.31, t (7.5)

(+)-5-epihyacinthacine C5
215
4.28, t (7.5)

2

3.99, t (7.5)

3

13

73.1

(+)-5-epihyacinthacine C5
215
75.6

3.96, t (8.4)

78.7

81.2

2.5

6

2.81, m
3.16, m
4.15, m

2.78, dd (4.6, 9.3)
3.14, q (4.9, 6.1)
4.13, dd (2.4, 4.2)

70.6
62.7
79.7

73.1
65.2
82.2

2.5
2.5
2.5

7

4.24, m

4.21, dd (2.4, 4.7)

74.3

76.8

2.5

7a

3.49, m

3.46, dd (4.6, 7.2)

69.1

71.6

2.5

3.71, dd (4.7)
3.80, dd (4.0, 11.9)
1.19, d (6.7)

3.68, dd (4.6, 12.0)
3.78, dd (4.0, 12.3)
1.17, d (6.9)

61.6

64.2

2.6

14.0

16.5

2.5

5

8
9

64 (Tamayo et
al.)130

C
2.5

4B.6.2. Hydrogenation of pyrrolizidines 213 and 214
Debenzylation of 213 and 214 returned hyacinthacine C5-type compounds (+)-6,7-di-epi25
hyacinthacine C5 216 [[α]25
𝐷 +5.2 (c 1.00, H2O)] and 217 [[α]𝐷 +6.8 (c 1.00, H2O)]

(Scheme 4B.12). To our fortune and as hypothesized by Reissig and Goti et al.,131 the 1H
and 13C NMR spectroscopic data of our synthetic 216 were found to be essentially identical
with those of the isolate labelled hyacinthacine C5 [lit.117 [α]𝐷 +1.5 (c 0.22, H2O)] in 2007
(Table 4B.4). An internal standard was not included in the NMR sample of 216 since it
would be difficult to remove prior to glycosidase testing. Therefore, the 1H NMR chemical
shifts of 216 were referenced to the D2O solvent residual peak at 4.79 ppm and the 1H
NMR spectrum resonance peaks were consistently close with those of the isolate labelled
hyacinthacine C5 (Table 4B.4: Δ δH = 0.11−0.15 ppm). The

13

C NMR of 216 was

referenced to internal MeOH, but the chemical shifts shown in Table 4B.4 were
consistently shifted 2.9−3.0 ppm when compared with the 13C NMR of the isolate labelled
hyacinthacine C5. Comparatively, the 1H and

13

C NMR chemical shifts reported for the

natural isolate labelled hyacinthacine C5 are expressed in reference to the internal standard
sodium 3-(trimethylsilyl)propionate (TPS) in D2O.117
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Thus, the correct structure of natural hyacinthacine C5 has the opposite conﬁguration at the
three contiguous stereogenic centres, C5, C6, and C7, to that of the originally proposed
structure. The authors on the isolation of this natural product had determined the correct
relative conﬁgurations of the individual A and B-rings of hyacinthacine C5 but had
incorrectly assigned the absolute conﬁguration of the A-ring. Conﬁrmation of these
assignments were made through detailed NOESY studies which unequivocally showed
216 to be the correct structure (included in the Appendix for this work).

Scheme 4B.27: Hydrogenolysis of 213 and 214 to give the corrected structure of
hyacinthacine C5 216 and hyacinthacine C5-type analogue 217, respectively.
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Table 4B.5: Comparison of literature 1H NMR (500 MHz, D2O) and 13C NMR (125 MHz,
D2O) spectroscopic data of Kato et al. Lit. (+)-hyacinthacine C5117 with the 1H NMR (500
MHz, D2O) and 13C NMR (125 MHz, D2O) data of our synthetic 216.
1

13

H NMR ( J in Hz)
Corrected structure
of natural (+)hyacinthacine C5
216
4.14, apparent q
(7.7)

C NMR ()

(+)-hyacinthacine
C5 (Kato et al.)117

Corrected structure
of natural (+)hyacinthacine C5
216

C

78.2

75.2

3.0

position

(+)-hyacinthacine
C5 (Kato et al.)117

1

4.01, t (7.6)

2

3.80, t (7.6)

3.94, t (7.8)

81.0

78.1

2.9

3
6

3.01, m
2.81, dq (6.9, 7.6)
3.60, t (7.6)

65.1
61.4
81.7

62.1
58.4
78.8

3.0
3.0
2.9

7

3.99, t (7.6)

3.14, td (4.0, 9.1)
2.95, dq (6.6, 7.4)
3.74, t (7.7)
4.14, apparent q
(7.7)

77.8

74.8

3.0

3.38, t (7.6)

69.2

66.3

2.9

3.66, dd (4.7, 9.5)

65.7

62.8

2.9

1.27, d (6.7)

15.7

12.8

2.9

5

7a

8

9

3.24, t (7.6)
3.55, dd (4.1,
12.0)
3.50, dd (5.3,
12.0)
1.13, d (6.9)

However, when comparing the NMR spectroscopic data of our synthetic hyacinthacine C525
type analogue 217 [[α]25
𝐷 +6.8 (c 1.00, H2O)] and its HCl salt 217.HCl [[α]𝐷 -4.5 (c 1.00,

H2O)] with those reported for the same compound 120 [lit.131 [α]21
𝐷 +0.75 (c 0.48, H2O)],
prepared by Reissig and Goti et al. we noted significant spectroscopic differences (Table
4B.5 and Table 4B.6). In the 1H NMR spectrum of compound 217, the chemical shifts of
H3, H5, and H7a appeared upﬁeld in comparison to those for 120 (Table 4B.5).
Additionally, the chemical shifts of the aforementioned protons in 217·HCl appeared
signiﬁcantly downﬁeld when compared with compound 120 (Table 4B.5). Comparison of
the 13C NMR spectroscopic data of both 217 and 217·HCl with those published for 120
seems to more closely aligned with 217·HCl (Table 4B.6). However, it was concluded that
Reissig and Goti et al. did not make this salt, as there was still signiﬁcant diﬀerences
between both spectra (especially for the carbons identified in the product as C2, C3, C5,
C7a, and C8). Despite both having been proposed to contain the same stereochemistry and
absolute configuration, we could not conclude that our synthetic 217 was the same
structure as 120 reported by Reissig and Goti et al.
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Table 4B.6: Comparison of literature 1H NMR (400 MHz, D2O) spectroscopic data of
Reissig and Goti et al. Lit. 120131 with the 1H NMR (500 MHz, D2O) data of our synthetic
217 and 217·HCl.
H NMR ( J in Hz)

1

1

120 (Reissig and Goti et
al.)131
3.99, t (8.6)

(+)-6,7-di-epi-hyacinthacine
C5 217
4.07-3.97, m

(+)-6,7-di-epihyacinthacine C5 217·HCl
4.24, t (8.7)

2

3.80, dd (8.4, 9.6)

3.90, t (8.1)

3.99, dd (8.5, 10.2)

3
6

3.41, dt (3.6, 9.6)
3.64-3.56, m
3.95, t (3.0)

3.33, dt (4.9, 9.0)
3.41, dt (5.7, 11.7)
4.07-3.97, m

3.78-3.70, m
4.06, qd (2.9, 7.0)
4.15, d (2.9)

7

4.15, t (2.4)

4.18, t (4.0)

4.40, s

7a

3.28, dd (1.0, 8.4)

3.07, dd (3.7, 8.1)

3.78-3.70, m

8

3.64-3.56, m

3.67, t (4.0)

3.81, t (2.6)

9

1.21, d (6.8)

1.24, d (7.1)

1.46, d (7.0)

position

5

Table 4B.7: Comparison of literature 13C NMR (100 MHz, D2O) spectroscopic data of
Reissig and Goti et al. Lit. 120131 with the 13C NMR (125 MHz, D2O) data of our synthetic
217 and 217·HCl.
13

C NMR ()

1

120 (Reissig and Goti et
al.)131
76.7

(+)-6,7-di-epi-hyacinthacine
C5 217
78.0

(+)-6,7-di-epihyacinthacine C5 217·HCl
75.6

2

75.3

77.9

73.6

3
6

63.4
60.8
79.1

62.2
58.1
79.7 or 78.6

65.2
64.0
79.4

7

76.8

79.7 or 78.6

76.50

7a

74.1

72.1

76.46

8

59.1

62.9

56.5

9

9.5

10.7

9.2

position

5

Since there is disagreement in the NMR spectroscopic data between compound 217 and its
literature reported compound 120131 by Reissig and Goti et al. the structural elucidation of
compound 217 is detailed below. All NOE enhancements for 217 can be found in the
Appendix for this work but for brevity, only key correlations for compound compound 217
are shown in Figure 4B.15. These correlations are observed between H7−H9, H7−H1,
H5−H6, and H5−H7a; this suggested we had assigned the correct stereochemistry for the
A-ring of 217.
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H1

A)
H7a

H9

H7

B)

H9

H6
H7a
H5

7

7a

1

6
2

5
1'

217
Figure 4B.20: Top: Selected 1D-NOE spectra (500 MHz, CDCl3) of 217 of A) H7 and B)
H5 and their respective key observed correlations projected onto Bottom: a DFT
minimized molecular model [B3LYP/6-31G(d)] of 217.

4B.7. Peracetylation of 217
To further support the absolute configuration assigned to this structure, synthetic 217 was
peracetylated to the pentaacetate 218. This procedure was based on precedent literature
from previous members of the Pyne research group183 and involved dissolving 217 in a
solution of pyridine and adding acetic anhydride along with 4-dimethylaminopyridine
(Scheme 4B.13). The reaction returned a near quantitative yield of the desired pentaacetate
product, as indicated by the LRESIMS [M+H]+ ion peak at m/z 430. After column
chromatography purification, 218 was subject to extensive NOE NMR studies which
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displayed signiﬁcant correlations between H1−H7, H2−H7a, H5−H6, H2−H8, H6−H7a,
and Me−H3 (See Appendix). For brevity, only the 1D NOE enhancements for H6 and H7
have been included in this Chapter (Figure 4B.16). These correlations are consistent with
our proposed structures for 218 and indirectly support the absolute configuration of 217.

Scheme 4B.28: Synthesis of peracetylate 218.
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A)
H5

H6

B)

H1

H7

7
7a

1

2
5
1''

3
1'

Figure 4B.21: Top: Selected 1D-NOE spectra (500 MHz, CDCl3) of 218 of A) H6 and B)
H7 and their respective key observed correlations projected onto Bottom: a DFT
minimized molecular model [B3LYP/6-31G(d)] of 218.

Throughout the course of this work, the relative configurations assigned for each
intermediate as well as each final product have been consistent with our NOE/ROESY
NMR analyses. Moreover, the pyrrolizidines obtained in this work have been anticipated
as their synthesis has been based on precedent work within the Pyne research group as well
as the established mechanism of the O-mesylation then cyclization reaction. This
specifically involves an initial O-mesylation of the less-hindered hydroxy of the aminodiols 152, 153 and 166 (described in Chapter 2 and 3), followed by an SN2-type ring closure
to form the desired pyrrolizidine products 165, 149 and 151. Although there is the potential
for double inversion at the participating carbinol carbon, this only occurs if the secondary
mesylate is displaced by a chloride ion prior to ring-closure. We are confident this did not
happen particularly since the synthesis of pyrrolizidine 149 described in Chapter 2 and the
166

C6, C7 anti-diol 211 described in this Chapter fortuitously crystalized and unequivocally
confirmed the stereochemistry and pyrrolizidine structure.
Interestingly, it is noted that Reissig and Goti et al. successfully synthesised the proposed
structure of hyacinthacine C5 but did not employ the same procedure to obtain its C5
epimer 120. Instead they cyclized the bis-mesylated amino product 117A described earlier
in Chapter 1 and so there is the possibility that cyclization could afford the surprisingly
stable 4-membered bicyclic N-heterocycle192 219 (Scheme 4B.14). This issue has not yet
been resolved and so highlights the difficulty often associated with assigning the structures
of the hyacinthacine C-type analogues, synthetic or naturally derived. Further investigation
is certainly required.

Scheme 4B.29: Proposed synthesis of the alternative 4-membered bicyclic N-heterocycle
220 that Reissig and Goti et al. may have unintentionally synthesized.

Regardless, our synthetic purported compound for hyacinthacine C5, (+)-5-epihyacinthacine C5 215 and (+)-6,7-di-epi-hyacinthacine C5 217 were cross examined with
the hyacinthacine C-type natural products labelled hyacinthacines C1105 or C4,117 but no
NMR spectroscopic match was apparent with any of the natural isolates. All final products
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synthesized in this Chapter were subsequently assessed for their glycosidase inhibitory
potential and these are reported in Chapter 6.

4B.8. Chapter 4-Part B: Final remarks
Chapter 4B has disclosed the successful synthetic approach that resulted in four of the
eleven hyacinthacine C-type analogues synthesized in this Ph.D. work. A key finding was
the synthesis of compound 216 and that it spectroscopically matched the NMR spectra
obtained for natural isolate labelled hyacinthacine C5. In addition to this, the synthesis of
purported compound for hyacinthacine C5 and 215 generated spectroscopic data that
matched with those of the same compounds reported in literature, and so confirmed their
structures. At this stage, we are confident that the structure for our synthetic 217 is correct
since it, along with preceding intermediates have generated NMR spectroscopic evidence
consistent with their assigned structures. Further work is required to identify the cause of
the inconsistent spectroscopic data between 217 and compound 120 reported by Reissig
and Goti et al., especially since these should be identical compounds. Regardless, the newfound discovery of the true structure for natural hyacinthacine C5 led to its publication in
the ACS Journal of Organic Chemistry along with the six hyacinthacine C5-type analogues
described between Chapters 1-4B.132 All intermediates and final products that led to the
final hyacinthacine C5-type analogues have undergone extensive NMR spectroscopic
analysis and the reader will find almost all the 1D and 2D spectroscopic experimental
results as part of this manuscripts Supporting Information. Alternatively, a copy of all the
spectroscopic evidence of the final products has been included in the Appendix of this
thesis.
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Chapter 5 : Synthesis of (‒)-7-epi-hyacinthacine
C1, the corrected structure of natural
hyacinthacine C1, (+)-6,7-di-epi-hyacinthacine C1
and (+)-7-epi-hyacinthacine C1
Chapters 2-4B detail both the successful and unsuccessful attempts that ultimately resulted
in the synthesis of the natural (+)-hyacinthacine C5 (as well as six additional hyacinthacine
C-type compounds) which allowed correction of its initially proposed structure. These
compounds were readily accessible from two epimeric anti-1,2-amino diols 127 and 161.
Until this Chapter, the work described largely focused on the chemical manipulation of the
B-ring (stereocentres C5, C6 and C7) of the hyacinthacine C-type products through
methods of syn-dihydroxylation, SN2 ring-opening of a cyclic sulfate, and also employing
either the (R)- or (S)-α-methylallyl amine for the Petasis borono Mannich reaction. The
successful pathway that led to these results was summarised and accepted as a publication
in the ACS Journal of Organic Chemistry. Although the work towards elucidating the true
structure for hyacinthacine C5 proved successful, none of the synthesized analogues solved
the structural ambiguities between hyacinthacine C1 and C4. For this reason, our new
objective was to synthesize the proposed compounds for these natural isolates. Herein, the
report of the true structure and synthesis of the compound hyacinthacine C 1 is described.
In addition to this, our synthetic pathway also accessed another three diastereomers of
hyacinthacine C1/C4. All final products were assessed as glycosidase inhibitors and will be
discussed in Chapter 6. These results were also reported in a manuscript which at the time
of writing this Ph.D. thesis, was accepted for publication in the ACS Journal of Natural
Products. A comprehensive NMR spectroscopic experimental data set is available in the
related Supporting Information for this article.

5.1. Retrosynthetic analysis towards accessing hyacinthacine C1/C4-type
analogues
The proposed structure for hyacinthacine C1/C4 is shown in Figure 5.1. After reviewing
the successful pathway that led to the structural elucidation of hyacinthacine C5, we
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recognized that the revised structure of (+)-hyacinthacine C5 compared to hyacinthacine
C1 and C4, contained a single opposite stereocentre at C1.

Figure 5.1: The corrected structure for hyacinthacine C5 and the proposed structures for
the natural isolates labelled hyacinthacine C1 and C4 with the single stereocentre C1
difference highlighted in red.

We envisioned that using our established chemistry would access this compound. More
specifically, the retrosynthetic analysis detailing our initial synthetic approach towards
accessing hyacinthacines C1/C4 is shown below (Scheme 5.1). For our synthetic approach
to be successful, we recognized that the stereocentre at C1 would need to be subjected to
inversion at some point during the synthesis. After revising our initial pathway described
in Chapter 2, we identified that this stereocentre could be potentially inverted if the N-Boc
diol 139 was converted to the respective cyclic-sulfate 225 then to the oxazolidinone 224.
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Scheme 5.1: Retrosynthetic analysis towards accessing hyacinthacine C1/C4-type
analogues.

This idea was influenced by precedent literature reported by Kim et al.193 Shown in
Scheme 5.2, Kim and co-workers found that the carbonyl of the carbamate in the N-Boc
protected 3,4-vicinal diol could induce a hydroxy inversion at either the 3 or the 4 position,
provided the respective 5-membered cyclic sulfate 226 was synthesized. They
unequivocally proved that the nucleophilic carbonyl would induce an SN2 like attack at
either position via the formation of a hemisulfateanion/oxonium intermediate A. An
irreversible fragmentation step then leads to the oxazolidinone product 227 as desired. The
major difference between our N-Boc substrate 139 and the substrates reported by Kim et
al. was the cyclic sulfate ring size formed. More specifically, Kim et al. only demonstrated
this principle to effectively work for 5-membered cyclic sulfates. However, since it is
possible to synthesize various 6-membered cyclic sulfates,194 we considered the
overarching principle would remain true, and that either the oxazolidinone 224 or the
corresponding oxazepinone would form via this mechanism. Provided oxazolidinone 224
was successfully synthesized, using similar procedures previously described in Chapters 2
and 3 (RCM reaction, UpJohn cis-dihydroxylation, mesylation then cyclisation) would
ensure that the desired final hyacinthacine C1/4 type analogues are synthesised.
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Scheme 5.2: Kim and co-workers N-Boc conversion to the oxazolidinone 227 from the
cyclic sulfate 226.193

5.2. Synthesis of cyclic sulfate 225 and its conversion to oxazolidinone
224
Therefore, the N-Boc 139 was synthesized and converted to the corresponding cyclic
sulfate 225 via our standard procedure (Et3N, sulfuryl chloride, CH2Cl2). Indication that
the cyclic sulfate 225 had formed was inferred by a LRESIMS [M+H]+ ion peak at m/z 650
and TLC analysis confirming full consumption of the starting material. Owing to our
previous handling experiences with cyclic sulfate derivatives, the crude compound 225
was subsequently converted to oxazolidinone 224 using the same procedure described by
Kim et al.193 This procedure involved dissolving the newly formed cyclic sulfate 225 in a
solution of acetonitrile followed by stirring the mixture at 50 oC for 2 h. After this time, a
solution of THF, H2O and H2SO4 (8:3:1) was added to the mixture and was stirred at 40
o

C for 1 h. After neutralization, a TLC analysis confirmed that a new product spot had

formed with an Rf and a LRESIMS [M+H]+ ion peak at m/z 514 similar to our previous
oxazolidinone 137 described in Chapter 2. The crude reaction mixture was then purified
by column chromatography and returned the oxazolidinone 224 in 39% yield over two
steps. In the synthesis of oxazolidinones 137 and 160 described in Chapters 2 and 3, the
proton resonances at H4 and H5 were described as having a syn-relationship since they
displayed a vicinal coupling constant, J4,5, of 7.1 Hz in the 1H NMR spectrum. This is
consistent with the 4,5-cis relative conﬁguration. Unfortunately, we could not find clear
resolution for the appropriate resonance for H4 and H5 as they overlapped with other
resonances in the spectrum and so the J4,5 trans coupling constant could not be reliably
determined. Although the success of the inversion was not definitively confirmed, the 1H
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NMR spectrum (Figure 5.2) of the resultant oxazolidinone 224 was clearly different to the
1

H NMR spectrum of oxazolidinone 137 described in Chapter 2. Synthesis of the

respective oxazepinone was disregarded on the basis that the 1H NMR spectrum olefinic
resonances for H2′′′, H1′′′, H2′ and H3′ at δH 6.47, 6.02, 5.84 and 5.15 ppm, respectively,
were deshielded in a pattern consistent with formation of the oxazolidinone, rather than
the oxazepinone (Figure 5.2).

Scheme 5.3: Synthesis of N-Boc cyclic sulfate 225 and its thermal fragmentation to
oxazolidinone 224.
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A)

H2′′′

H1′′′

B)

H3′

H3′
H2′′′
H1′′′
H2′

Figure 5.2: A) 1H NMR spectrum (500 MHz, CDCl3) of 137 and B) 1H NMR spectrum
(500 MHz, CDCl3) of 224.

Unfortunately, this reaction only proved to be a one-time-success. It was speculated that
the sulfuryl chloride or the THF solvent stock used as in this reaction may have degraded
over time since it is very reactive. Despite careful preparation and ensuring that all reagent
and solvent stock containers were always stored under an inert atmosphere, the constant
use and exposure throughout the course of this work may have lessened their integrity via
unavoidable hydrolysis and or oxidation. This reaction was attempted many times but
failed to recreate oxazolidinone 224. Successive attempts only resulted in complex
mixtures. With the small amount of the oxazolidinone 224 in hand, the pathway was
continued in an attempt to explore the feasibility of this methodology. Although seemingly
high yielding reactions followed from the synthesis of the oxazolidinone 224, resultant
intermediates were eventually exhausted due to gradual loss of yield and so could not be
reliably characterised due to insufficient amounts. It was optimistically thought that we
would obtain the final product, but this proved unsuccessful. Therefore, the following work
details the results we were able to obtain before this synthetic pathway had to be ultimately
reconsidered.
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5.3. RCM reaction of oxazolidinone 224
Oxazolidinone 224 was next subjected to our procedure for ring-closing metathesis. This
afforded the RCM product 223 in a high yield of 95% (Scheme 5.4). The HRESIMS of
223 displayed the [M+Na]+ ion peak at m/z 432.1790 and so suggested the successful
synthesis of 223. In addition to this, the corresponding pyrrole was disregarded on the basis
of the 1H NMR spectrum displaying a clear doublet for the methyl resonance identified at
δH 1.55 ppm for H1′′ (Figure 5.3). More importantly, the 1H NMR spectrum resonances
for H7a and H1 clearly resolved at δH 4.98 and 4.37 ppm, respectively. The J1,7a coupling
constant between both these resonances was calculated to be 10.8 Hz and is a higher value
than the corresponding J4,5 cis coupling constant for RCM product 140 (Chapter 2). This
correlates well with the trans relationship between H1 and H7a in compound 223. In
addition to this, the 1H NMR spectrum generated for 223 was different to the RCM product
140 discussed in Chapter 2 and so suggested 223 to be the diastereomer depicted in Scheme
5.4.

Scheme 5.4: Synthesis of RCM product 223.

J1,7a = 10.8 Hz

H1′′

H7a
H1
H7a

Figure 5.3: 1H NMR spectrum (500 MHz, CDCl3) of 223.
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5.4. Syn-dihydroxylation of RCM product 223
At this stage, only a small amount (15 mg) of the RCM intermediate 223 was available to
undergo Upjohn Os(VIII)-catalyzed cis-dihydroxylation. These conditions had been well
explored and so employing the same procedure to RCM 223 that was previously described
in Chapters 2, 3 and 4, resulted in high conversion to the C6, C7 syn-diol 228 which was
obtained in a 72% yield after column chromatography (Scheme 5.5). Due to the small scale
of this reaction clear evidence to suggest formation of the minor (6S), (7R)- syn-diol was
unable to be determined. If the reaction was completed on a larger scale both diol 228 and
its minor diastereomer would have been isolated and characterised. Since it could not be
recovered, synthesis of the (6S), (7R)- syn-diol could not be confirmed and for this reason
has not been included. Regardless, diol 228 was characterised and was confirmed to be the
(6R), (7S)- syn-diol from an extensive analysis of the ROESY NMR for this product. In
particular, key proton resonance correlations were observed between H1''‒H6, H1''‒H7
(weak) and H6‒H7 and are shown in Figure 5.4.

Scheme 5.5: UpJohn cis-dihydroxylation of 223 to give diol 228.
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H1′/H6
H7a

H1′′

H3′

H5
H7
H2′

(H1′′-H6)

(H1′′-H7)

3'
2'
7
7a

6

H3′
H5
H2′
H7a
H7
H1′/H6

5
(H6-H7)

1'
1

1''

228

H1

Figure 5.4: 2D ROESY NMR spectrum (500 MHz, CDCl3) with key observed correlations
projected onto a DFT minimized molecular model [B3LYP/6-31G(d)] of 228.

5.5. The synthesis of acetonide 221 and shortfalls
After column chromatography purification, only 12 mg of diol 228 was obtained. This was
converted to its corresponding acetonide 221 by dissolving the syn-diol 228 in acetone,
followed by the addition of two equivalents of copper(II) sulfate and a catalytic amount of
sulfuric acid (Scheme 5.6).
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Scheme 5.6: Synthesis of acetonide 221.

As anticipated, the reaction returned a clean conversion (95% yield after column
chromatography) to the respective acetonide 221 as confirmed by HRESIMS, 1H and 13C
NMR spectroscopic analysis. More specifically, the HRESIMS of 221 found a [M+H]+ ion
peak at m/z 484.5720. The 13C NMR spectrum best displays the formation of the acetonide
221 and so is shown in Figure 5.5 along with the

13

C NMR spectrum of the parent diol

228. In this comparison, three additional carbon resonances at δC 112.2, 26.1 and 24.4 ppm
for the newly formed acetonide 221 are highlighted and coincide with C2 and both the C2
contingent methyl carbons, respectively.
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A)

B)
C2

Figure 5.5: A) 13C NMR spectrum (125 MHz, CDCl3) of 228 and B) 13C NMR spectrum
(125 MHz, CDCl3) of 221 with C2 and C2 contingent methyl resonances for 221
highlighted in red.

Unfortunately, it was at this point that this synthetic pathway was discontinued. The
inability to synthesize more of the starting oxazolidinone 224 in combination with the
small amount of product at this stage was considered impractical for future reactions and
product characterisation.

5.6. Revised synthetic strategy towards hyacinthacine C1/C4-type
analogues
These shortcomings led to the revision of our retrosynthetic plan towards synthesizing
hyacinthacine C1/C4 type analogues and is shown in Scheme 5.7. More specifically, the
pyrrolizidine 230 would be obtained from performing a Swern oxidation at C8 of
compounds 149, 151 or 165 then subjecting the representative ketone 229 to
diastereoselective reduction by L-selectride®. This would stereoselectively deliver a
hydride to the less hindered face of the bicyclic compound and result in an overall inversion
at this stereocentre. After this, either global deprotection or similar methodology used to
generate the C6, C7 anti-diol (via the corresponding cyclic sulfate), would access a large
number of different hyacinthacine C-type diastereomers of which one of these would be
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the proposed structure of the natural isolates labelled hyacinthacine C1/C4. This approach
was certainly considered at the beginning of this work. However, a previous group
member, Kongdech Savaspun, found that performing the Swern oxidation, then Lselectride® reduction on similar substrates returned unexpected product mixtures
containing very low yields of the desired product as well as various lactam-carboxylic
derivatives.127 On the other hand, other previous group members have demonstrated
reasonable success using this approach on similar substrates.184,
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The decision was

therefore made to implement this pathway for pyrrolizidine compounds 149, 151 and 165.
If successful, our established C6, C7 anti-diol chemistry would also be explored in an
attempt to synthesize the compound of the putative structure assigned for the natural
isolates labelled as hyacinthacine C1/C4.

Scheme 5.7: Revised retrosynthetic analysis towards accessing hyacinthacine C1/C4analougues.
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5.7. Swern oxidation of pyrrolizidines 149, 151 and 165
5.7.1 Swern oxidation of pyrrolizidine 165
The Swern oxidation was considered for all the synthesized pyrrolizidine substrates 149,
151 and 165 described in Chapters 2,3 and 4B. Since pyrrolizidine 165 (described in
Chapter 3) was on hand at the time this pathway was considered, it was used as the model
study. More specifically, pyrrolizidine 165, along with an excess amount of Et3N (40 eq.),
was added to the reaction mixture between oxalyl chloride and dimethyl sulfoxide. The
mixture was then stirred at -78 oC for 1 h (Scheme 5.8). After this time, the appearance of
a single product spot was observed by TLC analysis. After column chromatography ketone
231 was successfully obtained in an 83% yield.

Scheme 5.8: Swern oxidation of 165 to give ketone 231.

It might seem an unorthodox observation, but it was noted that the reaction mixture
contained a foul odour. Interestingly, this was a key indication that the desired ketone 231
had formed. According to the mechanism shown in Scheme 5.9, a by-product of a
successful oxidation reaction is the synthesis of dimethyl sulfide. In Scheme 5.9A, an
initial reaction between DMSO and oxalyl chloride forms the dimethylchlorosulfonium
ion B. Next (Scheme 5.9B), the addition of an alcohol (in this example, substrate 165 is
used) at -78 oC leads to the formation of an alkoxysulfonium ion C via the loss of the
chloride and alcohol proton as hydrogen chloride. In the presence of base (Et3N),
deprotonation of this intermediate returns the sulfur ylide D, which undergoes an
intramolecular deprotonation via a 5-membered transition state and ultimately fragments
into the respective ketone 231 and the odorous by-product, dimethyl sulfide. If the reaction
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is not kept near -78 oC, mixed thioacetals can result and prove detrimental to the product
yield.

Scheme 5.9: Proposed mechanism for the Swern oxidation of 165.

To confidently confirm the desired ketone 231 had formed, the crude reaction was purified
via column chromatography and the product was then subjected to extensive spectroscopic
experiments. More specifically, the HRESIMS of 231 found a [M+H]+ ion peak at m/z
438.2275 and indicated the loss of the mass of two protons. In addition to this, the gCOSY
NMR spectrum of 231 identified that the pyrrolizidine ring only contained protons at H8b,
H3a, H7, H8a, H6 and H4, at δH 5.04, 4.56, 3.94, 3.87 (2H), and 3.74 ppm, respectively
(Figure 5.6A). Additionally, the 13C NMR spectrum displayed a downfield resonance at δC
211.0 ppm, which was characteristic of the newly formed carbonyl at C8 (Figure 5.6B).
The sharp C=O stretching band at 1716 cm-1 in the IR spectrum also supported this newly
formed carbonyl moiety.
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H7

H1′′
H8a/H6
H4

H8b

H1′
H3a

B)

Figure 5.6: A) 1H NMR spectrum (500 MHz, CDCl3) of 231 and B) 13C NMR spectrum
(125 MHz, CDCl3) of 231.

5.7.2 Swern oxidation of pyrrolizidine 151

Having proved the successful oxidation at C8 of pyrrolizidine 165, the same Swern
oxidation procedure was performed on pyrrolizidine 151 and also returned a high yield
(80%) of the respective ketone product 232 (Scheme 5.10). This was confirmed after the
product was subjected to extensive spectroscopic experiments. In addition to the
HRESIMS of 232 indicating a characteristic [M+H]+ ion peak at m/z 438.2300, ketone
232 was confirmed to be successfully formed on the basis of the gCOSY NMR
spectroscopic analysis which identified that the pyrrolizidine ring only contained protons
at H8b, H3a, H7, H6, H8a, and H4 at δH 4.89, 4.54, 4.16, 3.96, 3.69 and 3.74 ppm,
respectively (Figure 5.7A) . Additionally, the

13

C NMR spectrum of 232 displayed a

downfield resonance at δC 211.8 ppm, which was characteristic of the newly formed
carbonyl at C8 (Figure 5.7B). The sharp C=O band at 1743 cm-1 in the IR spectrum also
supported this newly formed carbonyl moiety.
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Scheme 5.10: Swern oxidation of 151 to give ketone 232.
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Figure 5.7: A) 1H NMR spectrum (500 MHz, CDCl3) of 232 and B) 13C NMR spectrum
(125 MHz, CDCl3) of 232.

5.7.3 Swern oxidation of pyrrolizidine 149

In a similar manner, the pyrrolizidine 149 was subjected to our established Swern oxidation
conditions (Scheme 5.11). Unlike the aforementioned products 231 and 232, the desired
ketone 233 proved difficult to purify and seemed prone to degradation on silica medium.
The synthesis of 233 was only inferred by an LRESIMS [M+H]+ ion peak at m/z 438 which
was determined after a sample of the crude reaction mixture was analysed. For this reason,
the crude ketone 233 was unable to be completely characterised but was instead subjected
to the next step in the reaction pathway.
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Scheme 5.11: Swern oxidation of 149 to give ketone 233.

5.8. L-selectride® reduction of ketones 231, 232 and 233
With the successfully synthesized ketones 231, 232 and 233 in hand, the next stage of the
synthetic plan was to reduce the ketone moiety at C8 with the sterically hindered reagent
L-selectride®

in hope that the corresponding C8 alcohols would form. This was based on

the mechanism and results described by Zhang et al. in 2009 for their L-selectride®
reduction of ketone 234 shown in Scheme 5.12.195 In this reaction, Zhang and co-workers
obtained almost exclusively the endo epimer. They attributed this result to the fact that the
bulky hydride would attack the carbonyl predominantly at the less hindered convex face
of the ketone 234.

Scheme 5.12: Zhang and co-workers proposed mechanism of L-selectride® reduction of
ketone 234.195

5.8.1 L-selectride® reduction of ketone 231

We were confident that successful inversion at C8 would occur for our respective ketones,
especially since the O-benzyl ether at C7 was on the concave face and would also sterically
influence the delivery of the hydride in a similar manner described by Zhang et al.195
Therefore, with ketone 231 in hand, this was subjected to a reduction with L-selectride® at
185

-78 oC (Scheme 5.13). After stirring at this temperature for 2 h, the TLC analysis showed
a near complete consumption of the starting material and so the reaction was quenched
with an aqueous ammonia solution. After column chromatography purification, the
product was obtained in a 96% yield. The product was then subjected to various spectral
analyses including 1H and 13C NMR spectroscopic experiments as well as other 2D NMR
experiments in order to confirm the successful stereoinversion at C8. An initial
confirmation that this reduction had been successful was determined by a HRESIMS
analysis of the purified sample which found a characteristic [M+H]+ ion peak for 236 at
m/z 440.2446.
Unfortunately, due to the overlap of the H8 resonance with the OCH2Ph proton resonances
in the 1H NMR spectrum, the ROESY NMR of the newly formed alcohol 236 could not
be interpreted to unambiguously confirm that the hydroxy moiety at C8 had inverted.
However, the 1H NMR spectrum of the suspected alcohol 236 (Figure 5.8A) was notably
different to the 1H NMR spectrum of its parent diol 165 (Figure 5.8B), suggesting that
ketone 231 had undergone a successful stereoinversion at C8. However, to truly confirm
this had been the case, a portion of the alcohol 236 was converted to the C8 O-benzyl ether
in hope that it would clearly resolve these proton resonances. Findings from this will be
discussed further in section 5.11.

Scheme 5.13: Reduction of 231 with L-selectride® to give alcohol 236.
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Figure 5.8: A) 1H NMR spectrum (500 MHz, CDCl3) of 165 and B) 1H NMR spectrum
(500 MHz, CDCl3) of 236.

5.8.2 L-selectride® reduction of ketone 232

Pyrrolizidine ketones 232 and 233 were also individually subjected to reduction with Lselectride®. Both reactions displayed a high degree of selectivity for returning a single
diasteteromer. More specifically, reduction of ketone 232 returned exclusively the
pyrrolizidine alcohol 237 in 66% yield (Scheme 5.14). In addition to the prominent 1H
NMR spectroscopic differences between 237 and the parent C8 epimer 151, an extensive
2D-NOESY analysis was performed to confirm the inversion at C8 in 237. Key positive
correlations were observed between H4‒H3a, H4‒H8a, H1''‒H6, H8a‒H8b, H7‒H8, H8a‒
H8 and H7‒H1' (Figure 5.9), confirming formation of the intended product.

Scheme 5.14: Reduction of 232 with L-selectride® to give alcohol 237.
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Figure 5.9: 2D ROESY NMR spectrum (500 MHz, CDCl3) with key observed correlations
projected onto a DFT minimized molecular model [B3LYP/6-31G(d)] of 237 (C7 and C1'
O-benzyl ethers not shown).

5.8.3 L-selectride® reduction of ketone 233
The crude ketone product 233 was also subjected to reduction by L-selectride® which
successfully afforded the desired alcohol 238 in a 65% yield over two steps (Scheme 5.15).
This was confirmed by a comparative analysis of the 1H NMR spectra between 238 and
the parent alcohol 149 suggesting a successful inversion at the stereocentre C8. More
convincingly, alcohol 238 was subjected to extensive 1D-NOE difference experiments
which confirmed the relative configuration of the newly inverted stereocentre at C8. For
brevity, only key positive NOE enhancements for H8 and H8b are shown. More
specifically, correlations between H8‒H7, H8‒H8a and H8b‒H3a were observed (Figure
5.10). It is worth noting the relatively weak correlation between H8b‒H8a might seem
unusual since these protons are depicted on opposite faces of the pyrrolizidine core.
However, due to the torsional strain and twist of the pyrrolizidine core, unexpected
correlations such as this can be observed, but are usually of weaker intensities (note the
stronger intensity of H8b‒H3a since they are expected to be on the same side of the
pyrrolizidine core).
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Scheme 5.15: Reduction of 233 with L-selectride® to give alcohol 238.
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Figure 5.10: Top: Selected 1D-NOE spectra (500 MHz, CDCl3) of 238 of A) H8 and B)
H8b and their respective key observed correlations projected onto Bottom: a DFT
minimized molecular model [B3LYP/6-31G(d)] of 238 (C7 and C1' O-benzyl ethers not
shown).
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5.9. Synthesis of triols 239, 240 and 241
The relative configurations of alcohols 237 and 238 were confidently assigned. The
relative configuration of alcohol 236 was also confirmed through synthesis and
characterisation of its respective O-benzyl ether which is discussed later in 5.11. Therefore,
each alcohol was subjected to global deprotection. In Chapter 3, a related step-wise
deprotection was performed and involved first deprotecting the acetonide moiety of each
pyrrolizidine. This established procedure was easily transferable to pyrrolizidines 236, 237
and 238 whereby they were each individually dissolved in EtOH/H2O (9:1, respectively),
followed by the addition of several drops of 5 N HCl (Scheme 5.16). This successfully
returned triols 239, 240 and 241 in 79%, 87% and 55% yield, respectively.

Scheme 5.16: Acid hydrolysis of the acetonide moiety from pyrrolizidines 236, 237 and
238 to give the triols 239, 240 and 241, respectively.
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5.10. Hydrogenolysis of pyrrolizidines 239, 240 and 241
Individual samples of alcohols 239, 240 and 241 were then debenzylated under
hydrogenolysis conditions over PdCl2 to return novel hyacinthacine C1/C4-type
compounds (‒)-5-epi-hyacinthacine C1 242 [[α]25
𝐷 ‒14.1 (c 0.90, H2O)], the corrected
structure of (+)-hyacinthacine C1 243 [[α]25
𝐷 +13.0 (c 0.20, H2O)], and (+)-6,7-di-epihyacinthacine C1 244 [[α]25
𝐷 +13.4 (c 0.20, H2O)], respectively in moderate to high yields
of 80%, 52% and 61%, respectively following purification and neutralization by basic ionexchange chromatography (Scheme 5.17).

Scheme 5.17: Hydrogenolysis of 239, 240 and 241 to give final hyacinthacine C1/C4-type
analogues 242, 243 and 244, respectively.

Each resultant product was then subjected to extensive spectroscopic analysis. To our
delight, a comparative NMR analysis of our synthetic 243 against the spectroscopic data
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reported for the original isolates labelled hyacinthacine C1 [[α]𝐷 +14.7 (c 0.28, H2O)]105
and hyacinthacine C4 [[α]𝐷 ‒37.9 (c 0.44, H2O)],117 revealed that the 1H NMR spectrum
multiplicities and chemical shifts of the natural isolate labelled hyacinthacine C 1 were a
close match with our synthetic compound 243 (Table 5.1). Additionally, a consistent 0.4 –
0.6 ppm difference for the

13

C NMR chemical shifts between both products (Table 5.1)

was observed. The NMR sample of 243 contained a small amount of MeOH, since it would
be easily removed prior to glycosidase testing. The 1H NMR spectrum of 243 was therefore
referenced to the D2O solvent residual peak at 4.79 ppm and the 13C NMR was referenced
to internal MeOH. Comparatively, the 1H and 13C NMR spectrum chemical shifts of the
natural (+)-hyacinthacine C1 are expressed in reference to the internal standard sodium 3(trimethylsilyl)propionate (TPS) in D2O.105 This may explain the slight NMR
spectroscopic differences observed between synthetic 243 and the natural product.
Regardless, the specific rotation of synthetic 243 was found to be a close match with this
natural product. In conjunction with the fact that the natural isolates hyacinthacine C4 and
C1 cannot be the same structure, it was satisfactorily concluded that the true structure for
hyacinthacine C1 is in fact, the C6 epimer 243. We were excited to solve this nearly 20year old literature mistake and were confidently able to propose that hyacinthacine C 4 is
most likely correct in its absolute configurational assignments.

Table 5.1: Comparison of literature 1H NMR (500 MHz, D2O) and 13C NMR (125 MHz,
D2O) data of Kato et al.105 Lit. (+)‒hyacinthacine C1 with the 1H NMR (500 MHz, D2O)
and 13C NMR (125 MHz, D2O) of our synthetic 243.
H NMR ( J in Hz)

C NMR ()

1

(+)‒hyacinthacine C1

13

(+)‒hyacinthacine C1

243

C

4.18, t (3.8)

(Kato et al.)105
74.6

74.1

0.5

4.00, dd (3.9, 9.0)

4.02, dd (3.7, 9.2)

77.7

77.3

0.4

6

3.44, dt (4.4, 9.0)
3.29, dt (3.9, 7.0)
3.89, dd (3.9, 4.6)

3.47, dt (4.6, 9.2)
3.31, dt (3.9, 7.1)
3.92, t (4.4)

64.7
60.4
77.1

64.1
59.9
76.6

0.6
0.5
0.5

7

4.50, dd (4.6, 8.6)

4.53, dd (4.7, 8.6)

75.7

75.1

0.6

7a

3.66, dd (3.9, 8.6)

3.68, dd (4.2, 11.1)

68.3

67.8

0.5

8

3.66, m

3.68, dd (4.2, 11.1)

65.9

65.4

0.5

9

1.27, d (7.0)

1.29, d (7.2)

12.8

12.4

0.4

position
1

(Kato et al.)105
4.15, t (3.9)

2
3
5

243
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The remaining two hyacinthacine C-type analogues (‒)-5-epi-hyacinthacine C1 242 and
(+)-6,7-di-epi-hyacinthacine C1 244 were also cross examined with the spectroscopic data
reported for the original isolate hyacinthacine C4, however they did not match the
respective chemical shifts. A literature search also concluded these to be novel
hyacinthacine C-type analogues as they had not yet been reported to date. The 1H and 13C
NMR spectra along with 2D NMR spectroscopic data for 242, 243 and 244 are included
in the Appendix of this Ph.D. work.

5.11. Synthesis of compounds 245 and 246
It was fortunate that the corrected compound for hyacinthacine C1 was successfully
synthesized during this work. With this correction, it is suspected that the putative structure
for hyacinthacine C4 is most likely correct in its assignment. However, the only way to
confidently prove this is to synthesize this compound and then compare the obtained
spectral data of the synthetic product with the natural isolate. When reviewing the putative
structure for hyacinthacine C4, it was envisioned that we could potentially access this
compound if we combined the recently established stereoinversion at C8 with the C6, C7
cyclic sulfate ring-opening procedure described in Chapter 4A. The compounds chosen to
undergo this transformation were pyrrolizidines 236 and 238 as they were available in the
final months prior to finishing this Ph.D. work. Therefore, both pyrrolizidines were
subjected to C8 O-benzyl ether protection in a similar manner to that described in Chapter
4B, which returned the desired pyrrolizidine analogues 245 and 246 in 54% and 52% yield,
respectively (Scheme 5.18). Indication that both pyrrolizidines had undergone a successful
O-benzylation at C8 was inferred as both were found to contain a LRESIMS [M+H]+ ion
peak at m/z 530.
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Scheme 5.18: C8 O-Benzylation of pyrrolizidines 236 and 238 to give 245 and 246.

It was at this point that the stereochemistry at C8 of pyrrolizidine 245 was confirmed
through extensive spectroscopic analysis. More specifically, after purification, a clearly
resolved 1H NMR spectrum of the product 245 was obtained and subsequently subjected
to extensive 1D-NOE difference analysis. For brevity, only the NOE enhancement of H8
is shown in Figure 5.11 and clearly displays the expected positive NOE correlation
between H8‒H7 and H8‒H8a.
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245
Figure 5.11: Top: A selected 1D-NOE spectra (500 MHz, CDCl3) of 245 of H8 and its
respective key observed correlations projected onto Bottom: a DFT minimized molecular
model [B3LYP/6-31G(d)] of 245 (C8, C7 and C1' O-benzyl ethers not shown).

Indeed, similar evidence and logic was used to check the stereochemistry of pyrrolizidine
246 at the hydroxy group of C8. Since the parent compound 238 has already been described
from a stereochemical point of view, detail for this compound will be discussed after the
successful inversion at C6 or C7 has been described in Section 5.13.

5.12. Acetonide hydrolysis of 245 and 246
With the pyrrolizidines 245 and 246 in hand, each underwent individual hydrolysis of the
acetonide moiety. This was performed in a similar manner to the acetonide hydrolysis of
pyrrolizidine 165 described in Chapter 3 which entailed individually dissolving 245 and
246 in a solution of EtOH/H2O (9:1, respectively), followed by the addition of several
drops of 5 N HCl and stirred at room temperature until full consumption of the starting
material was confirmed by TLC analysis (Scheme 5.19). The HRESIMS of 247 and 248
displayed the [M+H]+ ion peaks at m/z 490.2615 and 490.2612, respectively, indicating
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that both had undergone successful hydrolysis of the acetonide moiety. Additionally, the
13

C NMR spectrum of compounds 247 and 248 clearly indicated the loss of this group

when compared with their parent acetonides 245 and 246, respectively (Figure 5.12 and
Figure 5.13).

Scheme 5.19: Acid hydrolysis of the acetonide moiety from pyrrolizidines 245 and 246.
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A)

B)

Figure 5.12: A) 13C NMR spectrum (125 MHz, CDCl3) of 245 and B) 13C NMR spectrum
(125 MHz, CDCl3) of 247 with C2 and C2 contingent methyl resonances for 245
highlighted in red.

A)

B)

Figure 5.13: A) 13C NMR spectrum (125 MHz, CDCl3) of 246 and B) 13C NMR spectrum
(125 MHz, CDCl3) of 248 with C2 and C2 contingent methyl resonances for 246
highlighted in red.
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5.13. Synthesis of Cyclic sulfates 249 and 250 and attempts to ring
opening with in situ formed CsOBz
Both diols 247 and 248 were individually converted to their respective cyclic sulfates 249
and 250 (Scheme 5.20), using our previously established methodology described in
Chapter 4B.190 Prone to degradation, both cyclic sulfates were immediately treated with
Cs2CO3 and benzoic acid and were expected to return two potential regioisomers for each
of the cyclic sulfates 249 and 250. Unfortunately, the subsequent CsOBz ring-opening of
cyclic sulfate 249 degraded the compound into an indeterminable mixture of products
(Scheme 5.20). Due to time contraints, this reaction could only be performed as a one-time
reaction trial and so the reaction conditions were not optimized nor re-attempted. In
contrast, the CsOBz ring-opening of the cyclic sulfate 250 returned in 42% yield, the
benzoate regioisomer 251 as confirmed initially by a gCOSY NMR analysis (Scheme
5.20). More specifically it was observed that the proton sharing the stereogenic carbon
with the newly added benzoate proved the most deshielded and characteristically appeared
at δH > 5.0 ppm. In this case, the gCOSY analysis of 251 identiﬁed a strong correlation
between H1″ (δH 1.25 ppm) and H5 (δH 3.93 ppm) which was subsequently found to
resonate with the most deshielded proton at δH 5.30 ppm, which was deduced to be H6
(Figure 5.14).

Scheme 5.20: Synthesis of cyclic sulfates 249 and 250 and the attempted ring opening of
cyclic sulfates 249 and 250 with the successful synthesis of benzoate 251.
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The benzoate product 251 was then subjected to a comprehensive 2D-NOESY analysis
which showed key correlations between protons H1''‒H7, H1''‒H3, H5‒H6, H1‒H7a, H1‒
H2, H7a‒H2 and H1'‒H2, suggesting the proposed relative configuration of structure 251
to be correct (Figure 5.15). Interestingly, this result was consistent with the regioselectivity
observed in the earlier proposed 1,2-diaxial-like ring-opening of the cyclic sulfate of 203
as described in Chapter 4B (Scheme 4B.10). More specifically, for cyclic sulfate 250,
attack at C8b requires a different reactive conformation in which the C4 methyl group is
pseudo-axial and sterically blocks substitution at C8b. A referee of our publication in the
ACS Journal of Natural Products suggested that the preference for nucleophilic
substitution of the CsOBz at C3a could be the result of hyperconjugative stabilisation from
the C4 methyl group (anti to the leaving group). Both these steric and stereoelectronic
effects could be clearly valid, however determining their relative contributions will require
further study. It is suspected that the C8b benzoate regioisomer was also formed but could
not be obtained due to the insufficient amount of starting material in combination with the
generally low yield for this reaction.
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Figure 5.14: gCOSY NMR spectrum (500 MHz, CDCl3) of 251 and a DFT minimized
molecular model [B3LYP/6-31G(d)] of 251 (C8, C7 and C1' O-benzyl ethers not shown).
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Figure 5.15: 2D ROESY NMR spectrum (500 MHz, CDCl3) with key observed
correlations projected onto a DFT minimized molecular model [B3LYP/6-31G(d)] of 251
(C8, C7 and C1' O-benzyl ethers not shown).
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5.14. Methanolysis of the benzoate 251
After the Ph.D. stipend had exhausted, attempts to synthesize larger quantities of cyclic
sulfates 249 and 250 were never revisited. This work therefore ended with the successful
two-step global deprotection of benzoate regioisomer 251. More specifically, the C6
benzoate of pyrrolizidine 251 was subjected to our previously established methanolysis
procedure to give the diol product 252 in an 87% yield (Scheme 5.21). The HRESIMS of
252 displayed the [M+H]+ ion peak at m/z 490.2597, thus confirming the successful debenzoylation.

Scheme 5.21: Methanolysis of 251 to give diol 252

The 1H NMR spectrum of the parent C6, C7 syn-diol 248 was then compared with the 1H
NMR spectrum of the newly revealed C6, C7 anti-diol 252, where significant differences
between these spectra were observed. From these results, we concluded that they were not
the same product and that 252 was the C6, C7 anti-diol. Unfortunately, the relative
closeness of the chemical shifts of each proton resonance in the 1H NMR spectrum of 252
led to difficulties in definitively establishing the C6, C7 anti-diol relationship. However,
we were confident that the proposed compound had been synthesized based on the previous
spectroscopic investigation of benzoate 251. For this reason, diol 252 was taken through
to the next step and subjected to hydrogenolysis.

5.15. Synthesis of (+)-7-epi-hyacinthacine C1 253
The final reaction reported in this Ph.D. work is the debenzylation of alcohol 252 under
hydrogenolysis conditions over PdCl2 (Scheme 5.22). This was completed after 4 h and
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confirmed to have successfully formed the desired product as the LRESIMS of 253 found
a [M+H]+ ion peak at m/z 220. Purification of 253 and neutralization by basic ionexchange chromatography returned the expected hyacinthacine C1/C4-type analogue (+)7-epi-hyacinthacine C1 253 [[α]25
𝐷 +6.5 (c 0.10, H2O)] in 75% yield and was confirmed
through extensive spectroscopic evidence (included in the Appendix for this Ph.D. work).

Scheme 5.22: Hydrogenolysis of 252 to give final hyacinthacine C1/ C4-type analogue
253.

With this compound, a Scifinder® search indicated that this compound and structure was
novel. As with all the final hyacinthacine C-type products synthesized in this Ph.D. work,
it was also assessed and characterised for its glycosidase inhibitory potential. When
spectroscopically compared to hyacinthacine C4, the 1H and 13C NMR spectroscopic data
were notably different (Table 5.2), and so the hypothesis that the structure proposed for
the naturally isolated hyacinthacine C4 is correct, is still applicable.
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Table 5.2: Comparison of literature 1H NMR (500 MHz, D2O) and 13C NMR (125 MHz,
D2O) data of Kato et al. Lit. (+)‒hyacinthacine C4117 with the 1H NMR (500 MHz, D2O)
and 13C NMR (125 MHz, D2O) of our synthetic 253.
H NMR ( J in Hz)

C NMR ()

1

1

(+)‒hyacinthacine C4
(Kato et al.)117
4.18, t (4.0)

2
3

13

4.15, t (3.9)

(+)‒hyacinthacine C4
(Kato et al.) 117
75.2

69.3

4.00, dd (4.0, 8.7)

3.97, dd (3.9, 9.1)

77.3

74.9

6

3.38, dt (4.6, 8.7)
2.96, dq (6.9, 9.2)
3.90, dd (8.2, 9.2)

3.33-3.26, m
3.46, p (6.8)
4.11, dd (6.0, 7.4)

65.1
62.0
82.9

60.6
57.0
78.4

7

4.15, t (8.2)

4.29, d (5.8)

80.0

71.4

7a

3.57, dd (3.7, 8.2)

3.33-3.26, m

67.3

68.8

8

3.65, d (4.6)

66.4

63.0

9

1.29, d (6.9)

16.0

10.3

position

5

253

3.74, dd (4.3, 11.6)
3.61, dd (6.4, 11.7)
1.12, d (7.0)

253

5.16. Chapter 5: Final remarks
The successful synthesis of four novel analogues of the hyacinthacine C1/C4 analogues,
242, 243, 244 and 253, is described in this Chapter. The initial attempts to invert the cyclic
sulfate of the N-Boc product 139 seemed promising but only worked once and so resulted
in insufficient foundational products towards the synthesis of the hyacinthacine C1/C4-type
analogues. Its inclusion in this Chapter helps the reader to understand the basis that
ultimately resulted in the successful synthesis of the four hyacinthacine C 1/C4 -type
analogues. Unfortunately, due to the time constraints, the synthesis of hyacinthacine C4
was not achieved despite the inkling that its parent benzoate regiosiomer was synthesized
as a minor product from the ring-opening of the cyclic sulfate 250. In addition to this, it
was also unfortunate that trying to ring-open the cyclic sulfate 249 resulted in a complex
mixture of products and could not be further investigated. Regardless, the key highlight
was serendipitously synthesizing compound 243 which turned out to be the true and
corrected structure for hyacinthacine C1. This new finding in addition to the other
diastereomers synthesized in this study means that there is a strong possibility that the
structure for hyacinthacine C4 proposed in 2007117 is correct. This certainly warrants
further exploration, but more importantly presents itself as a synthetic target for future
projects. Obtainment of four novel stereoisomers helped shed further light to the recently
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discovered field of hyacinthacine alkaloids, where now only a few structural assignment
puzzles remain unsolved. On this respect, the most valuable contribution of this Chapter
rests in the found evidence of identity of one of the synthesized pyrrolizidines with natural
hyacinthacine C1, to which identical structure as hyacinthacine C4 had been assigned. The
full characterization of all products leading to this structural correction have been included
as part of our current J. Nat. Prod. manuscript (Supporting Information). Additionally, a
copy of all the spectroscopic evidence of the final products has been included in the
Appendix of this Ph. D. thesis.
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Chapter 6 : Glycosidase Inhibitory summary
After their successful synthesis and characterisation, natural (+)-hyacinthacine C5 216,
natural (+)-hyacinthacine C1 243, along with all synthesized epimers including the
originally proposed structure for hyacinthacine C5, 155, 156, 169, 215, 217, 242, 244 and
253 were sent to Japan and were assessed for their glycosidase inhibitory activities. The
collaborative effort from both Assoc. Prof. Atsushi Kato and his student Masako Hoshino
saw our final products tested against a panel of enzymes summarized in Tables 6.1, 6.2
and 6.3. As a measure of their anti-diabetic and anti-obesity potential, our results were
compared with the glycosidase inhibitory results from casuarine (Table 6.2). For clarity,
the SAR will be discussed in two sections: the hyacinthacine C5-type analogues then the
hyacinthacine C1/C4-type analogues synthesized.

6.1. Glycosidase inhibitory potential of the hyacinthacine C5-type
analogues (Table 6.1 and Table 6.2)
The anti-diabetic and anti-obesity characteristics of our synthetic products are ultimately
dependant on how well they can inhibit the α-glucosidases.196 This is because these
enzymes are the key enzymes in catalysing the final step in the digestive process of
carbohydrates. Inhibiting these enzymes can result in a reduction of postprandial plasma
glucose concentrations and ultimately supress postprandial hyperglycemia.196 In this
glycosidase inhibition study, a panel of enzymes, including key α-glucosidases were
chosen. In this section, the glycosidase inhibitory activities of the seven hyacinthacine C5type analogues described in Chapters 2, 3 and 4B are discussed and summarised in Tables
6.1 and 6.2. Considering first the C6, C7 syn-diol pyrrolizidines 155, 156, and 169,
pyrrolizidines 155 and 156 showed weak to moderate inhibition of the α-glucosidase of rat
intestinal isomaltase (IC50 values of 20 μM and 42 μM, respectively) and moderate
inhibition against the α-glucosidase of rat intestinal sucrase (IC50 values of 13 μM and 9.9
μM, respectively). Compound 155 displayed a weak inhibition of yeast α-glucosidase (IC50
value of 83 μM) and rat intestinal maltase (IC50 value of 61 μM). It also displayed a
moderate activity against the amylglucosidases from Aspergillus niger and Rhizopus sp.
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(IC50 values of 25 μM and 16 μM, respectively). Compound 169 proved relatively inactive
among the entire panel of enzymes.
Upon testing the glycosidase inhibition for the C6, C7 anti-diol series (the originally
proposed structure for hyacinthacine C5, 216, 217, and 215) results showed that compound
215 proved relatively inactive among the entire panel of enzymes. Compound 217
displayed a weak to moderate inhibition against α-glucosidases of yeast, rice, rat intestinal
maltase and human lysosome (IC50 values of 123 μM, 99 μM, 21 μM and 15 μM,
respectively) and weak inhibition against the amylglucosidase of Aspergillus niger (IC 50
value of 41 μM). From this series, only the putative hyacinthacine C5 and compound 216
showed inhibition against the α-L-rhamnosidase of Penicillium decumbens (IC50 values of
74 μM and 197 μM, respectively), however, the putative hyacinthacine C5 was only
selective for this enzyme. Contrastingly, compound 216 proved less selective since it
displayed a similar range of activities for yeast and rat intestinal maltase α-glucosidase
(IC50 values of 195 μM and 108 μM, respectively). Compound 216 is the corrected
structure for the natural isolate labelled as hyacinthacine C5 and so it was interesting to
compare the glycosidase tests between our synthetic 216 and the 2007 natural isolate.117
From the common enzymes tested, results seemed to differ between 216 and the natural
isolate. For example, the 2007 natural isolate displayed a moderate activity against the
amylglucosidases from Aspergillus niger (IC50 value of 57 μM), whereas synthetic 216
displayed an IC50 value of 370 μM against this enzyme. The 2007 natural isolate was
recorded as being relatively inert against the α-glucosidase of rat intestinal maltase (IC50
value in excess of 1000 μM) and also against the β-galactosidase of bovine liver (IC50 value
of 900 μM). Although we have unequivocally proven that compound 216 is the same
structure, this compound was found to be relatively more active against these two enzymes
with IC50 values of 630 μM and 42 μM, respectively. To account for these differences, we
can only speculate that either provision of more sample was required for a more accurate
result, or that the natural isolate may have been contaminated with extra-cellular plant
matrix that may not have been evident in the NMR analysis; this could lead to an
unknowingly impure sample and misleading mass and IC50 of product. Moreover, the
enzyme purities between our study and the 2007 study by Kato et al.,117 may have been
different, thus affecting functional activities. Further study towards this uncertainly is
required.
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Table 6.1: Concentration of hyacinthacine C5-type analogues 216, 155, 156 and 217 giving
50% inhibition of various glycosidases.

a
c

“-” : Not tested, bNI : No inhibition (less than 50 % inhibition at 1000 µM),
( ) : Inhibition % at 1000 µM
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Table 6.2: Concentration of hyacinthacine C5-type analogues the putative structure for
hyacinthacine C5, 169, 215 and Casuarine giving 50% inhibition of various glycosidases.

a

NI : No inhibition (less than 50 % inhibition at 1000 µM), b( ) : Inhibition % at 1000
µM, c “-” : Not tested
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6.2. Glycosidase inhibitory potential of the hyacinthacine C1/C4-type
analogues (Table 6.3)
In this section, the glycosidase inhibitory activities of the four hyacinthacine C 1/C4-type
analogues, 242, 243, 244 and 253 described in Chapter 5 are discussed and are summarised
in Table 6.3. From these four analogues, analogue 244 was found to be selective for the
amyloglucosidase of Aspergillus niger and displayed a weak inhibition with an IC50 value
of 95.5 µM. The corrected structure for hyacinthacine C1 243 displayed a weak to moderate
inhibition for the α-glucosidase of rice, rat intestinal maltase and human lysosome (IC50
values of 33.7, 78.2 and 55 µM, respectively). These results were then compared with
glycosidase inhibitory results of the naturally occurring hyacinthacine C1.105 Interestingly,
a notable difference was found between the natural isolate and our synthetic 243. In 1999,
the natural isolate was found to be relatively inert against the α-glucosidase of rice and rat
intestinal maltase (IC50 values for both enzymes were in excess of 1000 μM), but selective
and active against the amylglucosidase of Aspergillus niger (IC50 value of 84 μM).
Comparatively, synthetic 243 was found to display the aforementioned α-glucosidase
activities but proved inactive against the amylglucosidase of Aspergillus niger (IC50 value
in excess of 1000 μM). These differences may have been the result of not enough sample
being provided for a reliable glycosidase inhibition assessment, or maybe extra-cellular
plant matrix that may not have been evident in the NMR analysis was apparent in the
natural isolate sample. Regardless, there are too many variables, and this certainly warrants
further investigation since we have unequivocally proven our synthetic 243 to be the same
structure as the natural isolate labelled hyacinthacine C1 from 1999.105 In contrast with
compounds 243 and 244, compounds 242 and 253 were relatively inactive against all
glycosidases tested.
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Table 6.3: Concentration of hyacinthacine C1/C4-type analogues 242, 243, 244 and 253
giving 50% inhibition of various glycosidases.

a

NI : No inhibition (less than 50 % inhibition at 1000 µM), b( ) : Inhibition % at 1000
µM, c “-” : Not tested
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6.3. Assessing the anti-diabetic and anti-obesity potential of our 11
hyacinthacine C-type analogues
To gain a better understanding of the structure-activity-relationship (SAR), all
hyacinthacine C-type analogues synthesized in this Ph.D. were collectively compared.

6.3.1. SAR Effects of the stereochemistry of the C5 methyl group
From our results of all the enzyme inhibition results, we noted correlation between the
orientation of the C5 methyl group and the IC50 against each glycosidase tested. More
speciﬁcally, if the hyacinthacine C-type alkaloid contains a (5S)-methyl, the IC50 values
increase with consequently a reduction in the selectivity and potency of the compound as
a glycosidase inhibitor. Comparatively, for a decrease in the IC50, the hyacinthacine Ctype compounds containing an (5R)-methyl proved to be more suitable candidates for
potential as glycosidase inhibitors.

6.3.2. SAR Effects of the stereocentres at C1, C2 and C3
Our observed glycosidase activities seemed to be influenced largely by the C1, C2 and C3
stereocentres which are originally sourced from the starting sugar L-xylose.132 This trend
can be best explained through comparison of the synthetic hyacinthacine C-type analogues
described in this work, with the structurally analogous casuarine (one of the most powerful
glucosidase inhibitors) shown in Table 6.2. More specifically, the glycosidase activities of
our synthetic hyacinthacine C-type analogues were generally less potent than casuarine.
Interestingly, it has been proven by crystal structure determination and computational
methods, that casuarine perfectly mimics the stereochemical arrangement of glucose, with
the A-ring overlapping the C3 to C6 portion of glucose.197-198
In this Ph.D. work, the hyacinthacine C-type analogues discussed in section 6.1 contain an
A-ring configuration to that of L-xylose. Inverting the configuration at C1 as operated in
Chapter 5, leads to another related carbohydrate, namely L-lyxose. Both L-xylose and Llyxose are non-natural sugars. Since glucosidases are functionally deputed to recognize
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glucose, it can be therefore generalized that iminosugars containing any configurational
deviation from glucose (such as L-xylose and L-lyxose), decreases the glucose nature of
the iminosugar, and so will diminish glucosidase inhibition activity.
When the hyacinthacine C-type analogues described in section 6.1 were compared with
the hyacinthacine C-type analogues described in section 6.2, it was observed that the
potency and selectivity of the latter were relatively weak. Therefore, inverting the C1
stereocentre decreases the potency and selectivity of the iminosugar as a glycosidase
inhibitor. More specifically, hyacinthacine C5-type compounds 155, 156, 169, 215, 216,
217 and the putative structure of hyacinthacine C5 contain identical configurations with
that of casuarine at C7a, C1, C2 and C3.132 The relatively diminished glycosidase activity
discussed in section 6.2 for compounds 242, 243, 244 and 253 can be compared with a
worse mimicry of casuarine (and ultimately glucose), since only configurations at C7a, C2
and C3 were preserved. Similarly, inverting C1 of casuarine gives rise to an allose related
configuration and is responsible for a similar diminished glycosidase inhibition activity.197198

6.3.3. SAR Effects of the C5 methyl group
When all hyacinthacine C-type analogues synthesized in this study were compared with
casuarine, it was observed that containing a methyl substituent at C5 resulted in a decrease
in glycosidase inhibition properties.132 This behaviour appears to be general for related
pyrrolizidines reported in literature. For example, a comparison of 7-deoxycasuarine198 and
its 5-methyl substituted homologue199 shows a one order magnitude loss of activity
towards the amyloglucosidase of A. niger (IC50 value of 4.5 µM and 39 µM, respectively).
In another example, australine200 and its 5-methyl substituted homologue, hyacinthacine
B4113 display a similar loss of activity towards the amyloglucosidase of A. niger (IC50 value
of 5.8 µM and 89 µM, respectively). It is therefore reasonable to suggest that in general,
this moiety sterically prevents the pyrrolizidine from effectively binding to the glycosidase
active site.
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Chapter 7 : Conclusions
The initial aims for this project were to:
1. Develop a novel synthetic strategy to prepare hyacinthacine C-type analogues in
an efficient and flexible manner
2. Elucidate and correct the structure for either hyacinthacine C1, C4 or C5.
3. Generate a moderate number of hyacinthacine C-type configurational analogues
and use the data generated from glycosidase inhibition studies to determine a
general structure-activity relationship.
Chapters 2 and 3 report the synthetic strategy employed towards the synthesis of the
hyacinthacine C-type analogues. These Chapters detail the successful synthesis of (+)-7epi-hyacinthacine C5 155, (‒)-6-epi-hyacinthacine C5 156 and (+)-5,6-di-epihyacinthacine C5 169. The spectroscopic data for these compounds did not match any of
the spectroscopic data reported for hyacinthacines C1, C4 or C5. However, these results led
us to consider implementing a C6, C7 anti-diol configuration in the final hyacinthacine Ctype analogues.
Chapter 4A describes our unsuccessful attempts towards generating the C6, C7 anti-diol
within the final hyacinthacine C-type analogues. These results led to the conclusion that
installing the C6, C7 anti-diol is most effective after the pyrrolizidine core has been formed
and can be achieved via synthesis of the corresponding cyclic sulfate then subsequent SN2
ring-opening of the cyclic sulfate moiety with a benzoate nucleophile. This approach is
discussed in Chapter 4B and details the successful synthesis of four hyacinthacine C-type
products which include: the corrected structure of the natural (+)-hyacinthacine C5 216,
(+)-6,7-di-epi-hyacinthacine C5 217, the originally proposed structure for (+)hyacinthacine C5 and (+)-5-epi-hyacinthacine C5 215. Our synthetic product 216 displayed
essentially identical 1H and

13

C NMR spectroscopic data for the natural isolate labelled

hyacinthacine C5. Thus, the correct structure of hyacinthacine C5 has the opposite
conﬁguration at the three contiguous stereogenic centres, C5, C6, and C7, to that of the
originally proposed structure (Figure 7.1).
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Figure 7.1: DFT minimized molecular models [B3LYP/6-31G(d)] of the putative structure
of hyacinthacine C5 and its corrected structure 216 (hydroxy protons not shown).

Unfortunately, we could not conclude that our synthetic hyacinthacine C5-type analogue
217 was the same as the compound 120 reported by Reissig and Goti et al.131 More
specifically, there was a significant spectroscopic difference between the 1H and 13C NMR
spectroscopic data for both products. The parent crystalline compound 149 that led to the
synthesis of compound 217, was unequivocally confirmed to be correct by X-ray
crystallographic analysis and so in addition to the extensive spectroscopic analysis of 217,
we were confident that we had synthesized the correct structure. After reviewing the
pathway reported by Reissig and Goti et al.,131 we were able to propose that they may have
unexpectedly synthesized and isolated the 4-membered bicyclic N-heterocycle 220 rather
than 120 (Scheme 7.1).
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Scheme 7.1: The unconfirmed but potential synthesis of N-heterocycle 220 by Reissig
and Goti et al.131

The remaining four hyacinthacine C-type analogues synthesized in this work are detailed
in Chapter 5. These include (‒)-5-epi-hyacinthacine C1 242, the corrected structure of
hyacinthacine C1 243, (+)-6,7-di-epi-hyacinthacine C1 244 and (+)-7-epi-hyacinthacine C1
253. Our synthetic product 243 displayed essentially identical 1H and

13

C NMR

spectroscopic for the natural isolate labelled hyacinthacine C1.105 Thus, the correct
structure of hyacinthacine C1 has the opposite conﬁguration at C6 to that of the originally
proposed structure (Figure 7.2). It is suspected that the torsional strain and twist of the
pyrrolizidine core may have resulted in either an observed (or absence of) several NOESY
correlations for this natural isolate thus resulting in the incorrect proposed stereochemistry.
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Figure 7.2: DFT minimized molecular models [B3LYP/6-31G(d)] of the putative structure
of hyacinthacine C1 and its corrected structure 243 (hydroxy protons not shown).

The successful synthesis of all eleven hyacinthacine C-type analogues in this work is
summarised in Scheme 7.2.
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Scheme 7.2: A summary of the synthesis of the natural and unnatural hyacinthacine C-type iminosugars reported in this Ph.D. work.
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All eleven hyacinthacine C-type analogues synthesized in this work were each assessed
for their glycosidase inhibitory activities. The hyacinthacine C-type analogues described
in Chapters 2-4B were derived from L-xylose. Inverting the stereocentre at C1 as described
for the hyacinthacine C-type analogues synthesized in Chapter 5, led to another related
carbohydrate, namely L-lyxose. In comparison to the structurally analogous casuarine (one
of the most powerful glucosidase inhibitors), the synthetic hyacinthacine C-type analogues
synthesize in this Ph.D. work were generally less potent than casuarine. The SAR for these
compounds suggest that the diminished glycosidase activity was a result of steric hindrance
induced by the C5-methyl (regardless of orientation), as well as configurational deviations
away from glucose (such as L-xylose and L-lyxose). Both these factors seem to decrease
the glucose nature of the iminosugar, and so will diminish glucosidase inhibition activity.
However, both (‒)-6-epi-hyacinthacine C5 156 and (+)-7-epi-hyacinthacine C5 155
displayed noteworthy inhibition against the α-glucosidase of rat intestinal sucrase (IC50
values of 13 μM and 9.9 μM, respectively) and so can be used as a foundation towards
investigating suitable drug candidates for anti-diabetic and anti-obesity medications.
The work described in this thesis is believed to satisfactorily meet the aforementioned aims
initially proposed in 2015. Although we were unable to synthesize the putative structure
for hyacinthacine C1/C4, the correction of the structure of hyacinthacine C1 means that
there is a strong possibility that the structure for the 2007 natural isolate labelled as
hyacinthacine C4 is correctly assigned.117 This certainly warrants further exploration.
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Chapter 8 : Experimental
General Methods
Silica gel 60 230–400 Mesh was used for flash column chromatography (FCC)
purifications. LRESIMS data was aquired on a single quadrupole, (MeOH as solvent) mass
spectrometer. HRESIMS were determined on a quadrupole time–of–flight mass
spectrometer. FTIR data were determined on neat samples. The optical rotation was
measured using a 2 mL cell at room temperature. An average of 40 measurements was
used to calculate the specific rotation. 1H NMR (500 MHz) and 13C NMR (125 MHz)
spectra were recorded in deuterochloroform (CDCl3), deuterium oxide (D2O) or deuterated
methanol (CD3OD) solutions. All signals obtained in CDCl3 were relative to the
tetramethylsilane (TMS) signal for 1H NMR and the CDCl3 signal for 13C NMR, referenced
at 0.00 ppm and 77.16 ppm, respectively. All signals which were recorded in CD3OD were
relative to the CD2HOD signal for 1H NMR and the CD3OD for 13C NMR, referenced at
3.31 and 49.00 ppm, respectively. All signals which were recorded in D2O were relative
to the D2O signal for 1H NMR, referenced at 4.49 ppm. For 13C NMR the referencing of
peaks is relative to internal MeOH ( 49.50 ppm). NMR assignments were based upon
gCOSY, APT, gHSQC, and NOESY or ROESY experiments. In some cases, 13C NMR
signals that were absent in the standard 13C NMR spectrum were identified using gHSQC
experiments. Pyrrolizidine compounds are named using systematic nomenclature. The
NMR assignments of those compounds are based on the numbering system of the
hyacinthacine alkaloids and not the systematic name. The three–dimensional structures
generated were prepared with ChemDraw 16.0 and Avogadro: an open–source molecular
builder and visualization tool. Version 1.2.0.201 The Density Functional Theory (DFT)
used to minimize the 3D structures was calculated with B3LYP/6–31G(d)202-204 using the
Gaussian 09 basis set.205 ORTEP representations shown for the crystal structures were
generated in accordance with CrysAlis PRO 1.171.38.46; cell refinement: CrysAlis PRO
1.171.38.46; data reduction: CrysAlis PRO 1.171.38.46, CrysAlis PRO 1.171.38.43; cell
refinement: CrysAlis PRO 1.171.38.43; data reduction: CrysAlis PRO 1.171.38.43.206
Program(s) used to solve the structure: SIR92;207 program(s) used to refine structure:
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CRYSTALS;208 molecular graphics: PLATON;209 software and other references used to
prepare material for this document and resultant publication(s): CRYSTALS.210-215

Chapter 2
(-)-1,2-O-Isopropylidene-α-L-xylofuranose (129)149-151, 216

In this order, concentrated H2SO4 (0.10 mL, 1.9 mmol), CuSO4 (2.1 g, 13.4 mmol) and L–
xylose (1.0 g, 6.7 mmol) were added to anhydrous acetone (20 mL). The mixture was
vigorously stirred under a nitrogen atmosphere at rt for 28 h, causing the solution to turn
yellow. TLC analysis indicated full consumption of the starting material. The CuSO 4 was
removed via vacuum filtration through a celite pad. The filter cake was washed with
additional acetone (3 x 5 mL) and the combined filtrate and washings were basified by the
addition of concentrated NH3 solution (0.4 mL). The precipitated (NH4)2SO4 was filtered
and the solvent was concentrated in vacuo to give at yellow syrup. After treatment with
HCl (11 mL, 0.24 M) and continual stirring at rt for 45 min, TLC analysis confirmed the
formation of the desired product. The solution was neutralised with NaHCO3 to pH 7–8,
followed by concentration in vacuo. The resultant residue was then dissolved in
chloroform, dried (MgSO4), filtered and concentrated in vacuo to give the desired
acetonide 129 as a pale–yellow oil (1.3 g, quant.) which was used for the next step without
any purification. The 1H and 13C NMR spectroscopic data of this product were consistent
with those published.149-151, 216

Rf (EtOAc) = 0.40
LRESIMS m/z 191 (100%) [M+H]+
1H

NMR (500 MHz, CDCl3) δ 5.99 (1H, d, J = 3.5 Hz, H1), 4.53 (1H, d, J = 3.5 Hz, H2),

4.33 (1H, s, H3), 4.22 – 4.11 (3H, m, H4, H5), 4.09 – 4.04 (1H, m, OH), 3.84 (1H, bs,
OH), 1.49 (3H, s, Ac–CH3), 1.32 (3H, s, Ac–CH3).
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13C

NMR (125 MHz, CDCl3) δ 111.8 (AcC), 104.7 (C1), 85.3 (C2), 79.8 (C4), 75.6 (C3),

60.3 (C5), 26.6 (AcCH3), 26.1 (AcCH3). [Ac = acetonide]

General method for O-benzylation
(-)-3,5-Di-O-benzyl-1,2-O-isopropylidene-α-L-xylofuranose (130)149-151, 216

A solution of the acetonide 129 (0.50 g, 2.6 mmol) in THF (3 mL) was slowly added to a
cooled (0 oC) and stirred suspension of sodium hydride (0.38 g, 9.5 mmol) (60% dispersion
in mineral oil) in anhydrous THF (15 mL) under a nitrogen atmosphere. The reaction
mixture was heated at reflux for 5 min and then cooled to rt. Benzyl bromide (0.75 mL,
6.31 mmol) and TBAI (0.15 g, 0.39 mmol) were added to the mixture, which was heated
at reflux for 15 min. By this time, TLC analysis had confirmed full consumption of the
starting material. The reaction mixture was cooled to 0 oC, and quenched dropwise with
water (10 mL). The mixture was extracted with Et2O (3 x 10 mL) and the combined
extracts were dried (MgSO4), filtered and concentrated in vacuo. The resultant brown oil
was purified by FCC (gradient of 3:20 EtOAc/ n-hexane to 1:5 EtOAc/n-hexane) to afford
the bis–benzylated acetonide 130, as a pale–yellow oil (0.83 g, 86%). The 1H and 13C NMR
spectroscopic data of this product were consistent with those published.149-151, 216

Rf (1:5 EtOAc/n-hexane) = 0.30
LRESIMS m/z 371 (100%) [M+H]+
1H

NMR (500 MHz, CDCl3) δ 7.41 – 7.17 (10H, m, ArH), 5.93 (1H, d, J = 3.7 Hz, H1),

4.68 – 4.54 (3H, m, H2, H3՛), 4.49 (2H, 2 x d, J = 12.0, 9.9 Hz, H5՛), 4.41 (1H, td, J = 6.1,
3.2 Hz, H4), 3.96 (1H, d, J = 3.2 Hz, H3), 3.77 (2H, qd, J = 9.9, 6.1 Hz, H5,), 1.47 (3H, s,
AcCH3), 1.30 (3H, s, AcCH3).
13C

NMR (125 MHz, CDCl3) δ 138.2 (ArC), 137.7 (ArC), 128.5 (2 x ArCH), 128.5 (2 x

ArCH), 128.0 (2 x ArCH), 127.9 (2 x ArCH), 127.7 (2 x ArCH), 111.7 (AcC), 105.2 (C1),
82.4 (C2), 81.8 (C3), 79.3 (C4), 73.6 (C5՛), 72.0 (C3՛), 67.7 (C5), 26.9 (AcCH3), 26.4
(AcCH3). [Ac = acetonide].
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(+)-3,4-Di-O-benzyl-α,β-L-xylofuranose (a and b)149-151, 216

To a solution of 130, (0.880 g, 2.38 mmol) in AcOH/H2O (20 mL, 30% v/v) was added 5
M HCl (1 mL). TLC analysis confirmed full consumption of the starting material after
heating the reaction to 45 oC for 3 h by which this time the solution was neutralised by the
addition of NaHCO3 (0.5 g or until pH 7). The solution was then evaporated under reduced
pressure to 20 mL and extracted with CH2Cl2 (3 x 15 mL), the combined extracts were
dried (MgSO4), filtered and concentrated in vacuo. FCC (1:5 EtOAc/n-hexane) resulted in
a mixture of anomers (3:1, a:b, respectively) as a clear oil that solidified to a waxy solid
overnight (0.52 g, 83%). The 1H and
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C NMR spectroscopic data of this product were

consistent with those published.149-151, 216

Rf (1:5 EtOAc/n-hexane) = 0.20
LRESIMS m/z 331 (100%) [M+H]+
1H

NMR (500 MHz, CDCl3) δ 7.37 – 7.21 (20H, m, ArH), 5.45 (1H, d, J = 4.2 Hz H1a),

5.11 (1H, d, J = 3.3 Hz, H1b), 4.69 – 4.43 (9H, m, H3՛a, b, H5՛a, b, H4a), 4.41 (1H, tt, J =
5.1, 3.3 Hz, H4b), 4.20 (1H, d, J = 2.6 Hz, H2b), 4.17 – 4.10 (2H, m, H2a, H3b), 4.01 –
3.91 (2H, m, OHa, H3a), 3.75 (1H, q, J = 5.1Hz, H4a ), 3.86– 3.62 (4H, m, H5a, H5b),
3.21 (1H, s, OH), 2.03 (1H, s, OH).
13C

NMR (125 MHz, CDCl3) δ 137.9 (ArCa), 137.9 (ArCb), 137.6 (ArCa), 137.4 (ArCb),

128.6, 128.5, 128.4, 128.1, 128.0, 127.9, 127.8, 127.8, 127.6 (20 x ArCH), 103.5 (C1b),
96.0 (C1a), 83.6 (C3a), 82.9 (C3b), 79.9 (C4b), 79.3 (C2b), 77.5 (C4a), 75.6 (C2a), 73.7
(C5b), 73.6 (C5a), 72.8 (C3b), 72.0 (C3a), 69.1 (C5a), 69.0 (C5b).
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General Method for the Petasis (Borono-Mannich) reaction

(2S,3S,4R,5R,E)-1,3-Bis(benzyloxy)-5-(((R)-but-3-en-2-yl)amino)-7-phenylhept-6ene-2,4-diol (127)149

Triethylamine (434 µL, 2.83 mmol) was added to a solution of (R)–α–methylallyl
amine·HCl (0.220 g, 3.12 mmol) in EtOH (50 mL) and the solution was stirred at rt for 20
min. (+)–3,4–Di–O–benzyl–α,β–L–xylofuranose (0.930 g, 2.83 mmol) was added to the
reaction mixture, followed by the addition of (E)–2–phenylvinylboronic acid (0.460 g,
3.12 mmol). TLC analysis confirmed complete consumption of the starting material after
stirring at rt for 3 d, whereby the mixture was concentrated in vacuo, affording a brown
viscous oil. The crude product was dissolved in EtOAc (50 mL) and washed with 0.5 M
NaOH (2 x 40 mL) solution. The organic fraction was dried (MgSO4), filtered,
concentrated in vacuo and purified by FCC (3:97 MeOH/CH2Cl2) affording the desired
product 127 as a brown oil (0.900 g, 65%). To prepare the crystalline hydrochloride salt
of 127, a portion of 127 (0.100 g) was dissolved in CH2Cl2 (5 mL) and washed with 1N
HCl (3 x 10 mL). The CH2Cl2 solution was concentrated in vacuo to give 127.HCl as white
needle–like crystals.

127
Rf 0.20 (3:97 MeOH/CH2Cl2).
LRESIMS m/z 488 (100%) [M+H]+. 1H NMR (500 MHz, CDCl3) δ 7.37 – 7.20 (15H, m,
ArH), 6.48 (1H, d, J = 16.0 Hz, H7), 6.10 (1H, dd, J = 16.0, 8.7 Hz, H6), 5.72 (1H, ddd, J
= 17.3, 10.2, 7.2 Hz, H2՛), 5.09 (1H, d, J = 10.2 Hz, H3՛cis), 4.98 (1H, d, J = 16.8 Hz,
H3՛trans), 4.64 (2H, s, OCH2Ph), 4.51 – 4.42 (2H, m, OCH2Ph), 4.05 (1H, dd, J = 8.3, 5.5
Hz, H2), 3.97 (1H, t, J = 4.6 Hz, H4), 3.69 – 3.49 (4H, m, H3, H1, H5), 3.30 (1H, dq, J =
12.6, 6.2, Hz, H1՛), 1.10 (3H, d, J = 6.4 Hz, H1՛՛).
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13C NMR (125 MHz, CDCl

3) δ

142.0 (C2՛), 138.3 (ArC), 138.2 (ArC), 136.8 (ArC), 133.6

(C7), 128.8 (ArCH), 128.3 (ArCH), 128.0 (C6, ArCH), 128.0 (ArCH), 127.0 (ArCH),
126.7 (ArCH), 114.9 (C3՛), 80.1 (C3), 74.5 (OCH2Ph), 73.6 (OCH2Ph), 72.4 (C4), 71.5
(C1), 70.3 (C2), 60.6 (C5), 53.0 (C1՛), 20.3 (C1՛՛).

127.HCl
Rf 0.15 (5:97 MeOH/CH2Cl2).
MP: 165 – 170 oC.
1

H NMR (500 MHz, CDCl3) δ 7.47 – 7.07 (15H, m, ArH), 6.69 (1H, d, J = 16.0 Hz, H7),

6.43 (1H, dd, J = 16.0, 9.9 Hz, H6), 6.03 (1H, ddd, J = 17.5, 10.4, 7.4 Hz, H2՛), 5.32 – 5.20
(2H, m, H3՛), 4.80 (1H, d, J = 10.9 Hz, OCH2Ph), 4.68 – 4.57 (1H, m, H5), 4.55 – 4.29
(3H, m, OCH2Ph, H4), 4.20 (1H, dd, J = 9.9, 3.4 Hz), 4.10 (2H, dd, J = 6.3, 4.3 Hz), 3.81
– 3.68 (2H, m, H3, H1՛), 3.63 (1H, dd, J = 6.8, 1.9 Hz, H2), 3.53 (1H, dd, J = 9.4, 6.5 Hz,
H1), 3.42 (1H, dd, J = 9.4, 6.0 Hz, H1), 1.46 (3H, d, J = 6.8 Hz, H1՛՛).
C NMR (125 MHz, CDCl3) δ 138.7 (C2՛), 137.9 (ArC), 137.6 (ArC), 135.2 (ArC), 134.7
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(C7), 128.9 (ArCH), 128.8 (ArCH), 128.4 (ArCH), 127.9 (ArCH), 127.69 (ArCH), 127.68
(ArCH), 127.19 (ArCH), 120.18 (C3՛), 78.8 (C3), 74.8 (OCH2Ph), 73.2 (OCH2Ph), 70.9
(C4), 69.9 (C1), 68.6 (C2), 62.1(C5), 54.9 (C1՛), 16.7 (C1՛՛).

(2R,3R,4R,5R)-4-(Benzyloxy)-5-((benzyloxy)methyl)-1-((R)-but-3-en-2-yl)-2-((E)styryl)pyrrolidin-3-ol (131)149

Triethylamine (47 µL, 0.34 mmol) was slowly added to a solution of 127 (166 mg, 0.340
mmol) in anhydrous CH2Cl2 (5 mL) at 0 oC under a N2 atmosphere. Whilst stirring, a 0.13
M solution of methanesulfonyl chloride in anhydrous CH2Cl2 (2.62 mL, 0.340 mmol) was
slowly added to the reaction mixture. The reaction mixture was heated at 40 oC and stirred
for 10 h or until TLC analysis confirmed full consumption of the starting material. The
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reaction was quenched through the addition of a sat. NaHCO3 solution (4 mL) and
extracted with CH2Cl2 (3 x 5 mL). The combined organic extracts were dried over MgSO4,
gravity filtered and concentrated in vacuo to give an orange oil. Purification by FCC
(5%MeOH/CH2Cl2) gave 131 as a yellow oil (101 mg, 63%).

Rf (5%MeOH/CH2Cl2) = 0.45
LRESIMS m/z 470 [M+H]+.
1H

NMR (500 MHz, CDCl3) δ 7.42 – 7.14 (15H, m, ArH), 6.58 (1H, dd, J = 16.0, 9.7 Hz,

H1՛՛՛), 6.48 (1H, d, J = 16.0 Hz, H2՛՛՛), 5.80 (1H, ddd, J = 17.4, 10.3, 7.6 Hz, H2՛), 5.06 (1H,
d, J = 17.4 Hz, H3՛trans), 4.94 (1H, d, J = 10.3 Hz, H3՛cis), 4.63 – 4.46 (4H, m, OCH2Ph),
4.01 – 3.89 (3H, m, H2, H3, H4), 3.57 (1H, dd, J = 9.7, 3.4 Hz, H1՛՛՛՛), 3.53 – 3.43 (2H, m,
H1՛, H1՛՛՛՛), 3.33 (1H, s, H5), 1.15 (3H, d, J = 6.3 Hz, H1՛՛).
13C NMR (125 MHz, CDCl

3) δ

142.8 (C2′), 138.5 (ArC), 137.8 (ArC), 137.4 (ArC), 131.3

(C2‴), 130.3 (C1‴), 128.7 (ArCH), 128.5 (ArCH), 128.0 (ArCH), 127.9 (ArCH), 127.8 (2
x ArCH), 127.7 (ArCH), 127.3 (ArCH), 126.4 (ArCH), 114.5 (C3′), 88.6 (C4), 77.9 (C3),
73.6 (OCH2Ph), 72.8 (C2), 71.7 (OCH2Ph), 71.5 (C1‴′), 66.2 (C5), 56.9 (C1′), 19.6 (C1′′).

(1R,2R,3R,5R,7aR)-2-(Benzyloxy)-3-((benzyloxy)methyl)-5-methyl-2,3,5,7atetrahydro-1H-pyrrolizin-1-ol (132)

To a solution of 131 (120 mg, 0.255 mmol) in anhydrous CH2Cl2 (20 mL) under N2
conditions was added p–toluenesulfonic acid monohydrate (73 mg, 0.384 mmol). The
reaction mixture was held at reflux for 30 min or until TLC confirmed the full consumption
of the starting material. After cooling to room temperature, the reaction mixture was
concentrated in vacuo to give a dark brown oil. The oil was dissolved in anhydrous CH2Cl2
(20 mL) and purged with a balloon of argon gas. Hoveda Grubb’s II generation ruthenium
catalyst (11 mg, 0.051 mmol) was added to the solution and purged with another balloon
of argon gas. The reaction mixture was heated at reflux for 3 days under an argon gas
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atmosphere. After TLC confirmed the full consumption of the starting material, the
reaction mixture was washed with Na2CO3 (3 x 5 mL), dried over MgSO4 followed by
concentration in vacuo to give a black oil. Purification by FCC (2% MeOH/CH2Cl2) gave
the title compound 132 as a black oil (61 mg, 65%).

Rf (2%MeOH/CH2Cl2) = 0.27
[α]25
𝐷 –27.0 (c 0.75, CHCl3).
IR max (cm-1): 3390, 2980, 2862, 1110, 896, 733 cm–1
LRESIMS m/z 366 (100%) [M+H]+.
HRESIMS found 366.2075, calcd for C23H28NO3, 366.2069 [M+H]+.
1H

NMR (500 MHz, CDCl3) δ 7.42 – 7.20 (10H, m, ArH), 5.84 (1H, d, J = 5.9 Hz, H7),

5.69 (1H, d, J = 5.9 Hz, H6), 4.73 – 4.49 (4H, m, OCH2Ph), 4.37 – 4.27 (2H, m, H7a, H5),
3.98 (1H, s, H1), 3.88 (1H, t, J = 4.3 Hz, H2), 3.67 – 3.49 (3H, m, H3, H1′), 1.26 (3H, d,
J = 5.3 Hz, H1′′).
13C

NMR (125 MHz, CDCl3) δ 137.7 (ArC), 136.1 (ArC), 133.8 (C6), 128.47 (ArCH),

128.4 (ArCH), 127.9 (ArCH), 127.78 (ArCH), 127.75 (ArCH), 127.6 (ArCH), 127.4 (C7),
89.1 (C2), 80.7 (C1), 73.8 (OCH2Ph), 73.5 (C1′′), 72.5 (OCH2Ph), 64.2 (C5 or C7a), 64.0
(C5 or C7a), 62.1 (C3), 18.0 (C1′).

(1R,2R,3R)-2-(Benzyloxy)-3-((benzyloxy)methyl)-5-methyl-2,3-dihydro-1Hpyrrolizin-1-ol (133)149

Compound 132 (55 mg, 0.15 mmol) was dissolved in acetone/water (3:1, 12 mL,) and the
solution was cooled to 0 oC. N–methylmorpholine–N–oxide (35 mg, 0.30 mmol) and
potassium osmate dihydrate (4 mg, 0.011 mmol) were added and the solution was stirred
vigorously at 35 oC for 48 h. The reaction was concentrated in vacuo, affording a black
viscous oil which was diluted with H2O (20 mL) and extracted with EtOAc (3 x 15 mL).
The combined extracts were dried (MgSO4), filtered and concentrated in vacuo to afford a
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black oil which was subsequently purified by FCC (5:95 MeOH/CH2Cl2). This gave pure
compound 133 (37 mg, 68%) as a black oil and recovered starting material 132 (8 mg,
15%).
Rf (5%MeOH/CH2Cl2) = 0.70
LRESIMS m/z 386 [M+Na]+.
1H

NMR (500 MHz, CDCl3) δ 7.37 – 7.23 (9H, m, ArH), 7.14 – 7.08 (1H, m, ArH), 6.04

(1H, d, J = 2.9 Hz, H7), 5.97 (1H, bs, H6), 4.92 – 4.84 (1H, m, H1), 4.73 (1H, d, J = 12.0
Hz, OCH2Ph), 4.61 (1H, d, J = 12.0 Hz, OCH2Ph), 4.47 (1H, d, J = 12.1 Hz, OCH2Ph),
4.41 (1H, d, J =12.1 Hz, OCH2Ph), 4.35 (1H, s, H2), 4.26 (1H, bs, H3), 3.71 (2H, bs, H1′),
3.22 (1H, d, J = 10.4 Hz, OH), 2.11 (3H, s, H1′′).
13C NMR (125

MHz, CDCl3) δ 137.7 (ArC), 136.8 (ArC), 136.7 (C7a), 128.7 (2 x ArCH),

128.6 (2 x ArCH), 128.2 (ArCH), 128.0 (ArCH), 127.9 (4 x ArCH), 123.5 (C5), 111.5
(C6), 101.6 (C7), 93.2 (C2), 73.6 (OCH2Ph), 71.8 (OCH2Ph), 71.0 (C1), 69.4 (C8), 62.7
(C3), 11.9 (C9).

(4R,5R)-5-((1R,2S)-1,3-Bis(benzyloxy)-2-hydroxypropyl)-3-((R)-but-3-en-2-yl)-4((E)-styryl)oxazolidin-2-one

(137)

and

(4R,5R,6S,7S)-6-(benzyloxy)-7-

((benzyloxy)methyl)-3-((R)-but-3-en-2-yl)-5-hydroxy-4-((E)-styryl)-1,3-oxazepan-2one (138)149

Procedure A: Compound 127 (540 mg, 1.11 mmol) was dissolved in anhydrous CH2Cl2
(40 mL) and cooled to 0 oC under an atmosphere of nitrogen. Triethylamine (310 µL, 2.22
mmol) was added and after 15 min triphosgene (164 mg, 0.555 mmol) was added
portionwise and the solution was allowed to warm to rt. After stirring for 1 h, TLC analysis
confirmed full consumption of the starting material. The reaction was diluted with H2O
(15 mL) and extracted with CH2Cl2 (3 x 15 mL). The combined extracts were dried
(MgSO4), filtered and concentrated in vacuo to afford a brown oil which whereby
purification by FCC (gradient of 1:5 EtOAc/n-hexane to 1:1 EtOAc/n-hexane) produced
227

an inseparable mixture of isomers (37%, 1:2) consisting of the oxazolidinone and the
oxazepinone respectively. Pure samples of 137 (12 mg) and 138 (20 mg) could be obtained
for analytical purposes.
Procedure B: To solution of 139 (500 mg, 0.851 mmol) in dry THF (15 mL) at 0 oC was
added NaH (85.0 mg, 2.13 mmol, 60% in mineral oil). The mixture was heated at 65 oC
for 45 min, or until full consumption of 139 by TLC analysis. The reaction mixture was
cooled to 0 oC, and quenched by the slow addition of water (10 mL). The solution was
extracted with EtOAc (3 x 20 mL). The combined extracts were dried (MgSO4), filtered
and concentrated in vacuo. Purification by FCC (1:1 EtOAc/n-hexane) returned the
oxozolidinone 137 as a pale–yellow oil (372 mg, 85%).

137:
Rf 0.65 (1:1 EtOAc/n-hexane).
LRESIMS m/z 536 (100%) [M+Na]+.
1H

NMR (500 MHz, CDCl3) δ 7.39 – 7.19 (13H, m, ArH), 7.18 – 7.00 (2H, m, ArH), 6.56

(1H, d, J = 15.8 Hz, H2՛՛՛), 6.12 (1H, dd, J = 15.8, 10.9 Hz, H1՛՛՛), 5.99 – 5.89 (1H, m, H2՛),
5.25 – 5.09 (2H, m, H3՛), 4.87 – 4.76 (2H, m, H5, OCH2Ph), 4.56 (1H, d, J = 11.2 Hz,
OCH2Ph), 4.47– 4.39 (2H, m, H4, H1՛), 4.32 (2H, s, OCH2Ph), 3.96 (1H, s, H2՛՛՛՛), 3.79
(1H, dd, J = 7.0, 2.3 Hz, H1՛՛՛՛), 3.53 – 3.39 (2H, m, H3՛՛՛՛), 2.37 (1H, s, OH), 1.30 (3H, d,
J = 6.5 Hz, H1՛՛). 13C NMR (125 MHz, CDCl3) δ 156.9 (C2), 137.93 (ArC), 137.89 (ArC),
136.9 (C2՛), 135.6 (ArC), 135.4 (C2՛՛՛), 129.2 (2 x ArCH), 128.9 (ArCH), 128.7 (4 x ArCH),
128.5 (2 x ArCH), 127.9 (ArCH ), 127.2 (ArCH), 127.3 (2 x ArCH), 126.7 (2 x ArCH),
124.7 (C1՛՛՛), 117.1 (C3՛), 77.8 (C5), 76.5 (C1՛՛՛՛), 74.2 (OCH2Ph), 73.1 (OCH2Ph), 70.6
(C3՛՛՛՛), 68.9 (C2՛՛՛՛), 60.0 (C4), 51.7 (C1՛), 18.4 (C1՛՛).

138:
Rf 0.65 (1:1 EtOAc/n-hexane).
LRESIMS m/z 536 (100%) [M+Na]+.
1H

NMR (500 MHz, CDCl3) δ 7.35 – 7.16 (13H, m, ArH), 7.12 – 7.06 (2H, m, ArH), 6.69

(1H, dd, J = 15.9, 9.0 Hz, H1‴), 6.43 (1H, d, J = 15.9 Hz, H2‴), 6.06 (1H, ddd, J = 17.4,
10.5, 5.1 Hz, H2′), 5.34 (1H, d, J = 10.0 Hz, H3′cis), 5.31 (1 H, d, J = 16.2 Hz, H3′trans),
4.79 (1H, td, J = 6.8, 1.8 Hz, H1′), 4.62 (1H, d, J = 11.8 Hz, OCH2Ph), 4.53 – 4.50 (3H,
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m, H7 and 2 x OCH2Ph), 4.40 (1 H, d, J = 11.2 Hz, OCH2Ph), 4.07 – 4.04 (1H, m, H5),
4.01 (1 H, dd, J = 9.0, 4.3 Hz, H4), 3.83 (1H, dd, J = 9.3, 6.0 Hz, H1‴′), 3.78 (1H, d, J =
9.3 Hz, H1‴′), 3.75 – 3.73 (1H, m, H6), 1.84 (1H, d, J = 5.8 Hz, OH), 1.28 (3H, d, J = 6.8
Hz, H1″).
13C

NMR (125 MHz, CDCl3) δ 158.4 (C2), 139.2 (C2′), 138.0 (ArC), 137.6 (ArC), 136.5

(ArC), 131.6 (C2‴), 128.7 (ArCH), 128.6 (2 x ArCH), 128.3 (ArCH), 128.1 (ArCH), 128.0
(ArCH), 127.9 (ArCH), 127.8 (ArCH), 127.3 (C1‴), 126.8 (ArCH), 118.1 (C3′), 78.2 (C6),
74.8 (C7), 73.6 (OCH2Ph), 72.9 (OCH2Ph), 69.0 (C5), 68.4 (C1‴′), 61.6 (C4), 55.6 (C1′),
16.1 (C1″).

tert-Butyl ((3R,4R,5S,6S,E)-5,7-Bis(benzyloxy)-4,6-dihydroxy-1-phenylhept-1-en-3yl)((R)-but-3-en-2-yl)carbamate (139).

To a solution of 127 (1.10 g, 2.25 mmol) in dry 1,2–dichloroethane (10 mL) was added
dry N,N–diisopropylethylamine (784 µL, 4.50 mmol) and di–tert–butyl–dicarbonate
(0.980 g, 4.50 mmol). The reaction mixture was stirred at 70 oC for 48 h. CH2Cl2 (15 mL)
was added and the solution was washed with 1 M HCl (2 x 20 mL), and brine. The organic
fraction was dried (MgSO4), filtered and concentrated in vacuo. Purification by FCC (1:4
EtOAc/n-hexane, then to 5:95 MeOH/CH2Cl2) gave 139 (0.820 g, 62%) and recovered
starting material 127 (0.250 g, 23%) as pale–yellow and brown oils, respectively.

Rf 0.30 (3:7 EtOAc/n-hexane).
[α]25
𝐷 +46.5 (c 1.00, CHCl3).
IR max (cm-1): 3383, 3029, 2976, 2869, 1680, 1253, 1094 cm–1
LRESIMS m/z 588 (100%) [M+H]+.
HRESIMS found 588.3311, calcd for C36H46NO6, 588.3325 [M+H]+.
1H

NMR (500 MHz, CDCl3) δ 7.40 – 7.19 (15H, m, ArH), 6.59 (1H, dd, J = 16.1, 7.0 Hz,

H6), 6.49 (1H, d, J = 16.1 Hz, H7), 5.97 (1H, ddd, J = 17.0, 10.7, 4.9 Hz, H2՛), 5.06 (1H,
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t, J = 13.8 Hz, H3՛), 4.74 (1H, d, J = 11.2 Hz, OCH2Ph), 4.67 (1H, d, J = 11.2 Hz, OCH2Ph),
4.51 (1H, d, J = 11.8 Hz, OCH2Ph), 4.46 (1H, d, J = 11.8 Hz, OCH2Ph), 4.40 – 4.27 (2H,
m, H1՛, H5), 4.09 (2H, s, H4, H2), 3.65 (1H, bs, H3), 3.56 (2H, app. q, J = 9.5, 8.2 Hz,
H1A,B), 1.47 (9H, s, (CH3)3C), 1.26 (2H, d, J = 6.7 Hz, H1՛՛).
13C NMR (125 MHz, CDCl

3) δ 139.8 (C2՛), 138.2 (CO), 138.1 (ArC), 137.0 (ArC), 133.25

(C7), 128.5 (ArCH), 128.4 (ArCH), 128.4 (ArCH), 127.9 (ArCH), 127.8 (ArCH), 127.7
(ArCH), 127.6 (ArCH), 126.6 (C6), 115.4 (C3՛), 80.8 (CH3)3C), 78.5 (C3), 74.9 (C4 or
C2), 74.5 (OCH2Ph), 73.4 (OCH2Ph), 71.4 (C1), 70.8 (C4 or C2), 59.6 (C1՛), 54.5 (C5),
28.6 (CH3)3C), 18.2 (C1՛՛).

General method for Ring-closing Metathesis
(1R,5R,7aR)-1-((1R,2S)-1,3-Bis(benzyloxy)-2-hydroxypropyl)-5-methyl-5,7adihydro-1H,3H-pyrrolo[1,2-c]oxazol-3-one (140)149

A solution of 137 (162 mg, 0.316 mmol) in anhydrous CH2Cl2 (10 mL) was treated with
Grubbs’ II ruthenium catalyst (14 mg, 0.016 mmol). The mixture was heated at reflux for
4 h under a nitrogen atmosphere, by which time, TLC analysis confirmed full consumption
of the starting material. The solution was concentrated in vacuo to afford a black oil.
Purification by FCC (gradient of 1:1 EtOAc/n-hexane to 4:1 EtOAc/n-hexane) afforded
the title compound 140 as a pale–brown gum (110 mg, 85%).

Rf 0.19 (1:1 EtOAc/n-hexane).
LRESIMS m/z 432 (100%) [M+Na]+.
1H

NMR (500 MHz, CDCl3) δ 7.40 – 7.19 (10H, m, ArH), 5.81 (1H, d, J = 6.6 Hz, H7),

5.79 (1H, d, J = 6.6 Hz, H6), 5.04 (1H, s, H1), 4.86 (1H, dd, J = 8.5, 4.8, H7a), 4.68 (1H,
d, J = 11.2, OCH2Ph), 4.54 (1H, d, J = 11.2 Hz, OCH2Ph), 4.50 (1H, d, J = 11.8 Hz,
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OCH2Ph), 4.45 (1H, d, J = 11.8 Hz, OCH2Ph), 4.26 (1H, app. t, J = 6.3 Hz, H5), 3.95 (1H,
dd, J = 6.1, 3.7 Hz, H2՛), 3.65 – 3.56 (3H, m, H3՛, H1՛), 2.51 (1H, d, J = 5.7, OH), 1.39
(3H, d, J = 6.8, H1՛՛).
13C

NMR (125 MHz, CDCl3) δ 156.5 (C3), 137.9 (ArC), 137.5 (ArC), 137.4 (C6), 128.5

(2 x ArCH), 128.4 (2 x ArCH), 128.2 (2 x ArCH), 128.0 (ArCH), 127.9 (ArCH), 127.8 (2
x ArCH), 123.8 (C7), 77.0 (C1՛), 75.9 (C7a), 73.9 (OCH2Ph), 73.4 (OCH2Ph), 71.1 (C3՛),
69.3 (C2՛), 68.6 (C1), 60.0 (C5), 16.1 (C1՛՛).

Tert-butyl

(2R,5R)-2-((1R,2S,3S)-2,4-bis(benzyloxy)-1,3-dihydroxybutyl)-5-methyl-

2,5-dihydro-1H-pyrrole-1-carboxylate (141)

Compound 141 was synthesized from 139 (305 mg, 0.519 mmol), using the general
method for ring–closing metathesis. The crude black oil was purified by FCC
(5%MeOH/CH2Cl2) to give 141 as a grey oil (175 mg, 70%).

Rf (2:5 EtOAc/n-hexane) = 0.64
[α]25
𝐷 +73.5 (c 0.27, CHCl3).
IR max (cm-1): 3300, 2956, 2847, 1823, 1590, 1009 cm–1
LRESIMS m/z 506 (100%) [M+Na]+
HRESIMS found 506.2542, calcd for C28H37NO6Na, 506.2519 [M+Na]+.
1H

NMR (500 MHz, CDCl3) δ 7.4 – 7.2 (10H, m, ArH), 5.9 – 5.6 (2H, m, H3, H4), 4.7

(2H, bs, OCH2Ph), 4.6 – 4.4 (3H, m, OCH2Ph, H5), 4.1 (2H, bs, H3′, H1′), 3.8 – 3.5 (3H,
m, H2′, H4′), 1.5 (9H, s, (CH3)3C), 1.3 – 1.2 (3H, m, H1′′).
13C

NMR (125 MHz, CDCl3) δ 139.0 (ArC), 138.8 (CO) 137.2 (ArC), 134.2 (C4), 128.6

(ArCH), 128.2 (ArCH), 128.0 (ArCH), 125.1 (C3), 79.9 (C2′), 74.7 (OCH2Ph), 73.6
(OCH2Ph), 72.5 (C3′ or C1′), 71.7 (C4′), 71.5 (C3′ or C1′), 60.8 (C5), 28.7 (CH3)3C), 21.2
(C1′′).
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General method for cis-dihydroxylation
(1R,5R,6S,7R,7aR)-1-((1R,2S)-1,3-Bis(benzyloxy)-2-hydroxypropyl)-6,7-dihydroxy5-methyltetrahydro-1H,3H-pyrrolo[1,2-c]oxazol-3-one (142) and (1R,5R,6R,7S,7aR)1-((1R,2S)-1,3-bis(benzyloxy)-2-hydroxypropyl)-6,7-dihydroxy-5-methyltetrahydro1H,3H-pyrrolo[1,2-c]oxazol-3-one (143).

Compound 140 (177 mg, 0.432 mmol) was dissolved in acetone/water (3:1, 12 mL,) and
the solution was cooled to 0 oC. N–methylmorpholine–N–oxide (103 mg, 0.879 mmol) and
potassium osmate dihydrate (9.6 mg, 0.026 mmol) were added and the solution was stirred
vigorously at 35 oC for 48 h. The reaction was concentrated in vacuo, affording a black
viscous oil which was diluted with H2O (20 mL) and extracted with EtOAc (3 x 15 mL).
The combined extracts were dried (MgSO4), filtered and concentrated in vacuo to afford a
black oil which was subsequently purified by FCC (gradient of 5:95 MeOH/CH2Cl2 to 1:9
MeOH/CH2Cl2). This gave pure samples of the title compounds 142 (10 mg, 5%), and 143
(7 mg, 4%), as colourless oils, and a 3.5:1 mixture of 142 and 143 (132 mg, 69%).

142:
Rf 0.10 (5:95 MeOH/CH2Cl2).
[α]25
𝐷 –4.1 (c 1.00, CHCl3).
IR max (cm-1): 3394, 2940, 1454, 1375, 1259, 1212, 1154, 1071, 1028, 866 cm–1
LRESIMS m/z 466 (100%) [M+Na]+.
HRESIMS found 466.1858, calcd for C24H29NO7Na, 466.1842 [M+Na]+.
1H

NMR (500 MHz, CDCl3) δ 7.41 – 7.21 (10H, m, ArH), 4.93 – 4.81 (2H, m, H1,

OCH2Ph), 4.62 (1H, d, J = 11.3 Hz, OCH2Ph), 4.43 (1H, d, J = 11.5 Hz, OCH2Ph), 4.35
(1H, d, J = 11.5 Hz, OCH2Ph), 4.08 (1H, t, J = 8.4, H7a) 4.05– 3.98 (2H, m, H6, H2՛), 3.89
(1H, dd, J = 8.0, 1.8 Hz, H1՛), 3.78 (1H, d, J = 4.4 Hz, H7), 3.60 – 3.51 (2H, m, H5, H3՛),
3.38 (1H, dd, J = 9.0, 7.3 Hz, H3՛), 2.86 – 2.70 (2H, m, 2 x OH), 1.46 (3H, d, J = 8.9 Hz,
H1՛՛).
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13C

NMR (125 MHz, CDCl3) δ 156.7 (C3), 137.5 (ArC), 137.2 (ArC), 128.9 (ArCH),

128.8 (ArCH), 128.7 (ArCH), 128.5 (ArCH), 128.5 (ArCH), 128.3 (ArCH), 79.6 (C7),
75.6 (C1՛), 74.6 (C1), 74.5 (OCH2Ph), 73.8 (OCH2Ph), 70.7 (C3՛), 68.4 (C6, C2՛), 65.1
(C7a), 59.7 (C5), 15.4 (C1՛՛).

143:
Rf 0.08 (5:95 MeOH/CH2Cl2).
[α]25
𝐷 +24.9 (c 1.00, CHCl3).
LRESIMS m/z 466 (100%) [M+Na]+.
1H

NMR (500 MHz, CDCl3) δ 7.42 – 7.29 (8H, m, ArH), 7.29 – 7.15 (2H, m, ArH), 4.99

– 4.86 (2H, m, H1, OCH2Ph), 4.56 (1H, d, J = 11.2 Hz, OCH2Ph), 4.42 (1H, d, J = 11.4
Hz, OCH2Ph), 4.38 (1H, d, J = 9.0 Hz, H1՛), 4.33 (1H, d, J = 11.4 Hz, OCH2Ph), 4.28 (1H,
ddd, J = 10.7, 9.6, 3.8 Hz, H6), 4.04 (1H, d, J = 2.1 Hz, H7), 3.92 – 3.84 (2H, m, H7a,
OH), 3.82 – 3.70 (2H, m, H5, H2՛), 3.49 (1H, dd, J = 8.6, 5.0 Hz, H3՛), 3.23 (1H, t, J = 8.5
Hz, H3՛), 2.75 (1H, d, J = 10.5 Hz, OH), 2.72 (1H, d, J = 9.2 Hz, OH), 1.48 (3H, d, J = 7.0
Hz, H1՛՛).
13C

NMR (125 MHz, CDCl3) δ 156.7 (C3), 137.6 (ArC), 136.8 (ArC), 129.0 (ArCH),

128.9 (ArCH), 128.7 (ArCH), 128.7 (ArCH), 128.5 (ArCH), 128.4 (ArCH), 77.1 (C1),
75.2 (C1՛), 74.9 (C6), 74.9 (OCH2Ph), 73.9 (OCH2Ph), 70.8 (C7), 70.8 (C3՛), 68.7 (C2՛),
62.5 (C7a), 54.5 (C5), 11.9 (C1՛՛).

tert-Butyl

(2R,3S,4R,5R)-2-((1R,2S,3S)-2,4-bis(benzyloxy)-1,3-dihydroxybutyl)-3,4-

dihydroxy-5-methylpyrrolidine-1-carboxylate (144)

Compound 144 was synthesized from 141 (20.0 mg, 0.0414 mmol) using the general
method for cis–dihydroxylation. The product 144 was purified by FCC (5:95
MeOH/CH2Cl2) to give the title compound as a clear oil (20 mg, 95%).

Rf (5:95 MeOH/CH2Cl2) = 0.23
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[α]25
𝐷 +25.5 (c 1.50, CHCl3).
IR max (cm-1): 3431, 2908, 2793, 1609, 1101, 1065, 1031, 949 cm–1
LRESIMS m/z 540 (100%) [M+Na]+
HRESIMS found 540.2597, calcd for C28H39NO8Na, 540.2573 [M+Na]+.
1H

NMR (500 MHz, CDCl3) δ 7.42 – 7.19 (10H, m, ArH), 4.72 (2H, s, OCH2Ph), 4.57

(1H, d, J = 11.7 Hz, OCH2Ph), 4.51 (1H, d, J = 11.7 Hz, OCH2Ph), 4.45 (1H, t, J = 4.7 Hz,
H3), 4.27 – 4.19 (1H, m, H2′), 4.14 (1H, bs, H3′), 3.95 – 3.76 (3H, m, H4, H2, H5), 3.76
– 3.61 (3H, m, H4′, H1′), 1.45 (9H, s, (CH3)3C), 1.22 (3H, d, J = 6.8 Hz, H1′′).
13C

NMR (125 MHz, CDCl3) δ 138.7 (ArC), 138.6 (CO) 137.0 (ArC), 129.0 (ArCH),

128.9 (ArCH), 128.7 (ArCH), 128.6 (ArCH), 128.5 (ArCH), 128.3 (ArCH), 128.24
(ArCH), 128.22 (ArCH), 128.0 (ArCH), 80.0 (C1′), 77.4 (C4), 74.7 (OCH2Ph), 73.8
(OCH2Ph), 71.4 (C4′), 70.80 (C3′), 70.79 (C2′), 70.78 (C3), 65.8 (C2), 59.8 (C5), 28.8
(CH3)3C), 18.7 (C1′′).

General method for acetonide protection of cis-diols
(3aS,3bR,4R,8R,8aR)-4-((1R,2S)-1,3-Bis(benzyloxy)-2-hydroxypropyl)-2,2,8trimethyltetrahydro-4H,6H-[1,3]dioxolo[4',5':3,4]pyrrolo[1,2-c]oxazol-6-one
and

(146)

(3aR,3bR,4R,8R,8aS)-4-((1R,2S)-1,3-bis(benzyloxy)-2-hydroxypropyl)-2,2,8-

trimethyltetrahydro-4H,6H-[1,3]dioxolo[4',5':3,4]pyrrolo[1,2-c]oxazol-6-one (147).

To anhydrous acetone (2 mL) was added in order, concentrated H2SO4 (1.6 µL, 0.032
mmol), anhydrous CuSO4 (36 mg, 0.23 mmol) and a solution of compound 142 (51 mg,
0.11 mmol) in acetone (1 mL). After vigorous stirring at rt for 1 h under a nitrogen
atmosphere, TLC analysis confirmed full consumption of the starting diol. The reaction
mixture was vacuum filtrated through a celite pad, and the pad was washed with additional
acetone (3 x 2 mL). The filtrate was basified with 30% NH3 solution (10.5 µL) and the
(NH4)2SO4 precipitate was separated from the solution by gravity filtration. The filtrate
was concentrated in vacuo and purified by FCC (2:98 MeOH/diethyl ether) to afford
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compound 146 as a clear oil (52 mg, 99%). Using this exact same method, compound 143
(40 mg, 0.088 mmol), was also treated under similar conditions, using acetone (2 mL),
H2SO4 (1.3 µL, 0.026 mmol), anhydrous CuSO4 (29 mg, 0.18 mmol), additional acetone
(3 x 2 mL) and concentrated NH3 (8.4 µL). Purification by FCC (2:98 MeOH/diethyl
ether), afforded compound 147 as a clear oil (42 mg, 99%). This method was also used on
a mixture of the two isomers 142 and 143. More specifically, to dry acetone (5 mL) was
added in order, concentrated H2SO4 (4 µL, 0.076 mmol), anhydrous CuSO4 (95 mg, 0.596
mmol) and a solution of 3.5:1 respective mixture of 142 and 143 (132 mg, 0.298 mmol) in
acetone (2 mL). Using the same method as above, the title compounds 146 (102 mg, 71%)
and 147 were separated (34 mg, 24%) as colourless oils after purification by FCC (2:98
MeOH/diethyl ether).

146:
Rf 0.60 (2:98 MeOH/diethyl ether).
[α]25
𝐷 –43.8 (c 1.00, CHCl3).
IR max (cm-1): 3301, 2890, 1454, 1372, 1210, 1152, 733 cm–1.
LRESIMS m/z 506 (100%) [M+Na]+.
HRESIMS found 506.2180, calcd for C27H33NO7Na, 506.2155 [M+Na]+.
1H

NMR (500 MHz, CDCl3) δ 7.42 – 7.19 (10H, m, ArH), 4.90 (1H, dd, J = 8.4, 6.1 Hz,

H4), 4.73 (2H, q, J = 11.1 Hz, OCH2Ph), 4.59 (1H, app. t, J = 8.7 Hz, H3a), 4.50 (2H, q, J
= 11.8 Hz, OCH2Ph), 4.19 – 4.06 (3H, m, H3b, H8a, H2՛), 3.89 (1H, dd, J = 5.9, 2.9 Hz,
H1՛), 3.60 (2H, qd, J = 9.6, 6.2 Hz, H3՛), 3.52 (1H, qd, J = 7.0, 4.4 Hz, H8), 2.52 (1H, d, J
= 7.1 Hz, OH), 1.54 – 1.46 (6H, m, C2–CH3, H1՛՛), 1.26 (3H, s, C2–CH3).
13C

NMR (125 MHz, CDCl3) δ 156.2 (C6), 138.1 (ArC), 137.7 (ArC), 128.7 (ArCH),

128.7 (ArCH), 128.5 (ArCH), 128.3 (ArCH), 128.1 (ArCH), 127.9 (ArCH), 114.8 (C2),
88.3 (C8a), 77.8 (C3a), 77.5 (C1՛), 75.2 (C4), 74.0 (OCH2Ph), 73.5 (OCH2Ph), 71.0 (C3՛),
69.2 (C2՛), 67.5 (C3b), 59.4 (C8), 27.6 (C2–CH3), 25.5 (C2–CH3), 15.0 (C1՛՛).

147:
Rf 0.17 (2:98 MeOH/diethyl ether).
[α]25
𝐷 +52.7 (c 1.00, CHCl3).
IR max (cm-1): 3239, 2916, 1454, 1380, 1246, 1208, 753 cm–1.
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LRESIMS m/z 506 (100%) [M+Na]+.
1H

NMR (500 MHz, CDCl3) δ 7.42 – 7.21 (10H, m, ArH), 4.98 (1H, t, J = 8.0 Hz, H4),

4.92 (1H, d, J = 11.4 Hz, OCH2Ph), 4.66 (1H, dd, J = 5.5, 3.7 Hz, H3a ), 4.60 – 4.47 (3H,
m, H8a, OCH2Ph), 4.41 (2H, m, OCH2Ph, H1՛), 3.88 (1H, d, J = 5.8 Hz, H2՛), 3.68 (1H,
dd, J = 7.1, 3.5 Hz, H3b), 3.57 (1H, dd, J = 9.4, 7.0 Hz, H3՛), 3.41 (1H, dd, J = 9.4, 5.6 Hz,
H3՛), 3.33 (1H, dt, J = 11.1, 5.6 Hz, H8), 2.43 (1H, d, J = 7.4 Hz, OH), 1.69 (3H, d, J = 7.0
Hz, H1՛՛), 1.48 (3H, s, C2–CH3), 1.21 (3H, s, C2–CH3).
13C

NMR (125 MHz, CDCl3) δ 154.5 (C6), 138.2 (ArC), 137.3 (ArC), 128.9 (ArCH),

128.6 (ArCH), 128.5 (ArCH), 128.1 (ArCH), 128.0 (ArCH), 127.8 (ArCH), 95.0 (C2),
83.3 (C8a), 80.5 (C3a), 78.2 (C4), 75.7 (C1՛), 74.2 (OCH2Ph), 73.6 (OCH2Ph), 71.6 (C3՛),
70.6 (C2՛), 64.6 (C3b), 58.7 (C8), 26.1 (C2–CH3), 24.2 (C2–CH3), 10.3 (C1՛՛).

(1S,2S)-1,3-Bis(benzyloxy)-1-((3aS,3bR,4R,8R,8aR)-2,2,8-trimethyl-6oxotetrahydro-4H,6H-[1,3]dioxolo[4',5':3,4]pyrrolo[1,2-c]oxazol-4-yl)propan-2-yl
methanesulfonate (148)

Triethylamine (20.0 µL, 0.145 mmol) was slowly added to a solution of 146, (70 mg, 0.145
mmol) in anhydrous CH2Cl2 (10 mL) at 0 oC under a N2 atmosphere. Whilst stirring, a
0.13M solution of methanesulfonyl chloride in anhydrous CH2Cl2 (5.58 mL, 0.725 mmol)
was slowly added to the reaction mixture. After stirring at 0 oC for 3 h, TLC analysis
confirmed full consumption of the starting material and so the reaction was quenched
through the addition of sat. NaHCO3 solution (15 mL) and extracted with CH2Cl2 (3 x 15
mL) to give a pale–yellow oil. Purification of the residue by FCC (5%MeOH/CH2Cl2) gave
148 as a pale–yellow oil (81 mg, 99%).

Rf (5%MeOH/CH2Cl2) = 0.63
[α]25
𝐷 –64.1 (c 1.00, CHCl3)
IR max (cm-1): 3024, 2932, 2856, 1743, 1508, 1098, 1043, 961 cm–1.
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LRESIMS m/z 584 [M+Na]+.
HRESIMS found 584.2040, calcd for C28H35NO9SNa, 584.1930 [M+Na]+.
1H

NMR (500 MHz, CDCl3) δ 7.43 – 7.21 (10H, m, ArH), 5.15 (1H, ddd, J = 8.1, 4.4, 2.4

Hz, H2՛), 4.88 (1H, dd, J = 8.9, 2.0 Hz, H4), 4.78 (1H, d, J = 11.2 Hz, OCH2Ph), 4.59 (1H,
d, J = 11.2 Hz, OCH2Ph), 4.52 (2H, s, OCH2Ph), 4.46 (1H, t, J = 5.8 Hz, H3a), 4.29 (1H,
dd, J = 9.0, 4.8 Hz, H3b), 4.00 – 3.87 (4H, m, H8a, H1՛, H3՛), 3.51 (1H, qd, J = 7.1, 4.0
Hz, H8), 3.05 (3H, s, OMs), 1.50 (3H, s, C2–CH3), 1.35 (3H, d, J = 6.9 Hz, H1՛՛), 1.26 (3H,
s, C2–CH3).
13C

NMR (125 MHz, CDCl3) δ 155.0 (C6), 137.4 (ArC), 136.3 (ArC), 128.8 (ArCH),

128.62 (ArCH), 128.64 (ArCH), 128.3 (ArCH), 128.0 (ArCH), 127.8 (ArCH), 114.1 (C2),
88.9 (C1՛), 79.1 (C2՛), 77.3 (C3a), 77.1 (C8a), 73.4 (OCH2Ph), 72.6 (OCH2Ph), 72.5 (C4),
68.7 (C3՛), 67.1 (C3b), 58.4 (C8), 38.4 (OMs), 27.5 (C2–CH3), 25.4 (C2–CH3), 14.8 (C1՛՛).

(1S,2S)-1,3-Bis(benzyloxy)-1-((3aR,3bR,4R,8R,8aS)-2,2,8-trimethyl-6oxotetrahydro-4H,6H-[1,3]dioxolo[4',5':3,4]pyrrolo[1,2-c]oxazol-4-yl)propan-2-yl
methanesulfonate (150)

Triethylamine (49 µL, 0.35 mmol) was slowly added to a solution of 147, (32 mg, 0.066
mmol) in anhydrous CH2Cl2 (8 mL) at 0 oC under a N2 atmosphere. Whilst stirring, a 0.13M
solution of methanesulfonyl chloride in anhydrous CH2Cl2 (2.69 mL, 0.351 mmol) was
slowly added to the reaction mixture. After stirring at 0 oC for 3 h, TLC analysis confirmed
full consumption of the starting material and so the reaction was quenched through the
addition of sat. NaHCO3 solution (15 mL) and extracted with CH2Cl2 (3 x 15 mL) to give
a pale–yellow oil. Purification of the residue by FCC (5%MeOH/CH2Cl2) gave 150 as a
pale–yellow oil (31 mg, 83%).

Rf (5%MeOH/CH2Cl2) = 0.73
[α]25
𝐷 +33.8 (c 1.00, CHCl3)
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IR max (cm-1): 3024, 2953, 2850, 1758, 1512, 1102, 967 cm–1.
LRESIMS m/z 584 [M+Na]+.
HRESIMS found 584.1986, calcd for C28H35NO9SNa, 584.1930 [M+Na]+.
1H

NMR (500 MHz, CDCl3) δ 7.42 – 7.29 (10H, m, ArH), 5.04 (1H, d, J = 7.0 Hz, H2՛),

5.01 – 4.92 (2H, m, H4, OCH2Ph), 4.85 (1H, t, J = 4.5 Hz, H8b), 4.66 (1H, d, J = 11.7 Hz,
OCH2Ph), 4.62 (1H, t, J = 4.5 Hz, H8a), 4.51 – 4.44 (3H, m, H1՛, OCH2Ph), 3.91 – 3.83
(2H, m, H3՛, H3b), 3.43 – 3.32 (2H, m, H3՛, H8), 3.01 (3H, s, OMs), 1.77 (3H, d, J = 7.1
Hz, H1՛՛), 1.59 (3H, s, C2–CH3), 1.31 (3H, s, C2–CH3).
13C

NMR (125 MHz, CDCl3) δ 158.3 (C6), 137.6 (ArC), 137.2 (ArC), 129.2 (ArCH),

128.8 (ArCH), 128.6 (ArCH), 128.3 (ArCH), 128.0 (ArCH), 112.5 (C2), 83.6 (C8a), 80.42
(C8b or C2՛), 80.41 (C8b or C2՛), 77.6 (C4), 75.2 (C1՛), 74.4 (OCH2Ph), 73.5 (OCH2Ph),
69.9 (C3՛), 64.0 (C3b), 58.4 (C8), 39.1 (OMs), 26.2 (C2–CH3), 24.2 (C2–CH3), 10.2 (C1՛՛).

General method for oxazolidinone hydrolysis
(1R,2S,3S)-2,4-Bis(benzyloxy)-1-((3aS,4S,6R,6aR)-2,2,6-trimethyltetrahydro-4H[1,3]dioxolo[4,5-c]pyrrol-4-yl)butane-1,3-diol (152).

A solution of NaOH (46.0 mg, 1.15 mmol) in H2O (3 drops) was added to a solution of
oxazolidinone 146 (185 mg, 0.383 mmol) in EtOH (3 mL) in a microwave reaction tube.
The tube was capped and the solution was stirred and irradiated in a CEM microwave
reactor for 1 h (the temperature control was set at 110 oC, and the maximum applied power
at 200 W). After cooling to rt, the reaction mixture was concentrated in vacuo, diluted with
a solution of saturated NaCl (5 mL) and extracted with EtOAc (3 x 10 mL). The combined
extracts were concentrated in vacuo to give a brown oil. Purification by FCC (5:95
MeOH/CH2Cl2) gave the target compound 152 as a pale–yellow oil (151 mg, 86%).

Rf 0.27 (5:95 MeOH/CH2Cl2).
[α]25
𝐷 –65.4 (c 1.00, CHCl3).
IR max (cm-1): 3344, 3063, 2984, 1453, 1208, 1064, 607 cm–1.
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LRESIMS m/z 458 (100%) [M+H]+.
HRESIMS found 458.2554, calcd for C26H36NO6, 458.2543 [M+H]+.
1H

NMR (500 MHz, CDCl3) δ 7.41 – 7.24 (10H, m, ArH), 4.70 (2H, app. q, J = 11.3 Hz,

OCH2Ph), 4.61 (1H, dd, J = 7.0, 4.7 Hz, H3a), 4.52 (2H, app. q, J = 11.5 Hz, OCH2Ph),
4.06 (1H, dd, J = 8.8, 5.0 Hz, H3՛), 4.01 (1H, dd, J = 7.0, 5.2 Hz, H6a), 3.74 (1H, dd, J =
7.0, 5.5 Hz, H1՛), 3.70 – 3.60 (3H, m, H4՛, H2՛), 3.08 (1H, dd, J = 7.1, 4.7 Hz, H4), 3.05 –
2.98 (1H, m, H6), 2.76 (2H, bs, OH), 1.48 (3H, s, C2–CH3), 1.28 (3H, s, C2–CH3), 1.04
(3H, d, J = 6.6 Hz, H1՛՛).
13C

NMR (125 MHz, CDCl3) δ 137.9 (ArC), 137.9 (ArC), 128.6 (ArCH), 128.5 (ArCH),

128.4 (ArCH), 128.1 (ArCH), 128.0 (ArCH), 127.9 (2 x ArCH), 114.0 (C2), 86.7 (C6a),
83.0 (C3a), 80.1 (C2՛), 74.3 (OCH2Ph), 73.4 (OCH2Ph), 72.3 (C1՛), 70.9 (C4՛), 70.1 (C3՛),
66.5 (C4), 59.5 (C6), 27.4 (C2–CH3), 25.2 (C2–CH3), 18.7 (C1՛՛).

(1R,2S,3S)-2,4-Bis(benzyloxy)-1-((3aR,4S,6R,6aS)-2,2,6-trimethyltetrahydro-4H[1,3]dioxolo[4,5-c]pyrrol-4-yl)butane-1,3-diol (153).

Compound 153 was synthesized from the acetonide 147 (205 mg, 0.414 mmol) using the
general method for oxazolidinone hydrolysis. The crude product was purified by FCC
(5:95 MeOH/CH2Cl2) to give the desired product 147 as a pale–yellow oil (165 mg, 87%).

Rf 0.22 (5:95 MeOH/CH2Cl2).
[α]25
𝐷 ‒24.9 (c 1.00, CHCl3).
IR max (cm-1): 3423, 3065, 2989, 1453, 1230, 1067 cm–1.
LRESIMS m/z 458 (100%) [M+H]+.
HRESIMS found 458.2540, calcd for C26H36NO6, 458.2543 [M+H]+.
1H

NMR (500 MHz, CDCl3) δ 7.41 – 7.20 (10H, m, ArH), 4.75 – 4.70 (2H, m, H3a,

OCH2Ph), 4.63 (1H, d, J = 11.4 Hz, OCH2Ph), 4.52 (2H, s, OCH2Ph), 4.42 (1H, t, J = 4.8
Hz, H6a), 4.06 – 3.98 (2H, m, H1՛, H3՛), 3.73 (1H, dd, J = 9.9, 4.2 Hz, H4՛), 3.67 (1H, dd,
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J = 6.1, 3.9 Hz, H2՛), 3.61 (1H, dd, J = 9.8, 4.6 Hz, H4՛), 2.77 – 2.65 (2H, m, H6, H4), 1.28
(3H, s, C2–CH3), 1.25 (3H, s, C2–CH3), 1.15 (d, J = 6.6 Hz, H1՛՛).
13C

NMR (125 MHz, CDCl3) δ 138.3 (ArC), 138.2 (ArC), 128.7 (ArCH), 128.7 (ArCH),

128.2 (ArCH), 128.1 (ArCH), 128.1 (ArCH), 128.0 (ArCH), 110.8 (C2), 82.7 (C6a), 82.6
(C3a), 82.6 (C2՛), 74.1 (OCH2Ph), 73.8 (OCH2Ph), 71.0 (C4՛), 70.8 (C3՛), 70.2 (C1՛), 64.5
(C6), 58.1 (C4), 25.7 (C2–CH3), 24.1 (C2–CH3), 13.2 (C1՛՛).

(2S,3S,4R)-1,3-Bis(benzyloxy)-4-hydroxy-4-((3aS,4S,6R,6aR)-2,2,6-trimethyl-5(methylsulfonyl)tetrahydro-4H-[1,3]dioxolo[4,5-c]pyrrol-4-yl)butan-2-yl
methanesulfonate

(154)

and

(3aR,4R,6R,7R,8R,8aS,8bS)-7-(benzyloxy)-6-

((benzyloxy)methyl)-2,2,4-trimethylhexahydro-4H-[1,3]dioxolo[4,5-a]pyrrolizin-8-ol
(149).

Procedure A: Triethylamine (16 µL, 0.12 mmol) was slowly added to a solution of 152
(53.0 mg, 0.116 mmol) in anhydrous CH2Cl2 (8 mL) at 0 oC under a N2 atmosphere. Whilst
stirring, a 0.13M solution of methanesulfonyl chloride in anhydrous CH2Cl2 (0.893 mL,
0.116 mmol) was slowly added to the reaction mixture. After stirring at 0 oC for 1.5 h,
TLC analysis confirmed full consumption of the starting material and so the reaction was
quenched through the addition of a sat. NaHCO3 solution (2 mL) and extracted with
CH2Cl2 (3 x 5 mL). The combined organic extracts were dried over MgSO4, gravity filtered
from inorganic salts and concentrated in vacuo to give a yellow oil. Purification by FCC
(gradient of CH2Cl2 to 5%MeOH/CH2Cl2) gave the two title compounds, 154 as colourless
crystals (44 mg, 32%) and 149 as a yellow oil (15 mg, 30%).

Procedure B: To a solution of the amino–diol 152 (297 mg, 0.650 mmol) in dry CH2Cl2
(20 mL) at 0 oC was added Et3N (136 µL, 0.975 mmol), PPh3 (256 mg, 0.975 mmol) and
CBr4 (323 mg, 0.975 mmol). The mixture was stirred at 0 oC for 5 min then allowed to
warm to room temperature for 30 min by which time TLC analysis confirmed full
consumption of the starting material. The mixture was poured into water (15 mL) and
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subsequently extracted with CH2Cl2 (3 x 20 mL). The combined extracts were dried
(MgSO4), filtered and concentrated in vacuo to give a yellow oil. The residue was purified
by FCC (3:5 EtOAc/n-hexane) to give 149 as a pale–yellow oil (248 mg, 87%). After this,
compound 149 was dissolved in ethanol and was subjected to slow evaporation at room
temperature over 48 h, resulting in the formation of large colourless crystals.

154:
Rf 0.38 (5%MeOH/CH2Cl2).
[α]25
𝐷 –2.7 (c 1.00, CHCl3).
M.P: 75 – 80 oC.
IR max (cm-1): 3484, 3400, 3064, 2958, 1333, 1153, 913, 622 cm–1.
LRESIMS m/z 636 [M+Na]+.
HRESIMS found 636.1913, calcd for C28H39NO10S2Na, 636.1913 [M+Na]+.
1H

NMR (500 MHz, CDCl3) δ 7.45 – 7.23 (10H, m, ArH), 4.98 (2H, d, J = 4.2 Hz, H5,

H3՛), 4.78 (2H, dd, J = 44.9, 10.7 Hz, OCH2Ph), 4.53 (2H, dd, J = 25.1, 11.7 Hz, OCH2Ph),
4.38 (1H, d, J = 4.8 Hz, H4), 4.14 (1H, s, H1), 4.10 – 3.90 (2H, m, H3, H1՛), 3.85 (3H, dd,
J = 16.9, 7.3 Hz, H4՛, H2՛), 3.00 (6H, d, J = 19.3 Hz, 2 x OMs), 2.78 (1H, d, J = 7.2 Hz,
OH), 1.49 (3H, s, CH3), 1.36 (3H, d, J = 6.8 Hz, H1՛՛), 1.28 (3H, s, CH3).
13C

NMR (125 MHz, CDCl3) δ 137.7 (ArC), 137.5 (ArC), 128.7 (2 x ArCH), 128.7 (2 x

ArCH), 128.5 (2 x ArCH), 128.4 (ArCH), 128.2 (ArCH), 128.0 (2 x ArCH), 111.9 (C7),
86.3 (C4), 81.8 (C5), 79.5 (C3՛), 76.7 (C1), 74.3 (OCH2Ph), 73.7 (OCH2Ph), 71.1 (C2՛),
68.8 (C3 or C1՛), 68.5 (C4՛), 63.6 (C3 or C1՛), 38.7 (OMs), 36.8 (OMs), 26.6 (CH3), 24.4
(CH3), 21.8 (C1՛՛).

149:
Rf 0.25 (5:95 MeOH/CH2Cl2).
[α]25
𝐷 +15.6 (c 1.00, CHCl3).
M.P: 92 – 94 oC
IR max (cm-1): 3397, 2983, 1520, 1493, 1120, 1066, 866 cm–1.
LRESIMS m/z 440 (100%) [M+H]+.
HRESIMS found 440.2445, calcd for C26H34NO5, 440.2437 [M+H]+.
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1H

NMR (500 MHz, CDCl3) δ 7.44 – 7.16 (10H, m, ArH), 4.68 (1H, d, J = 12.0 Hz,

OCH2Ph), 4.63 (1H, dd, J = 6.8, 3.5 Hz, H8b), 4.58 (1H, d, J = 11.9 Hz, OCH2Ph), 4.49
(1H, d, J = 11.9 Hz, OCH2Ph), 4.45 (1H, d, J = 12.0 Hz, OCH2Ph), 4.28 (1H, s, H8), 4.17
(1H, t, J = 7.3 Hz, H3a), 3.83 (1H, s, H7), 3.63 (1H, d, J = 3.4 Hz, H8a), 3.45 (1H, dd, J =
9.2, 2.8 Hz, H1՛), 3.35 (1H, dd, J = 9.2, 4.0 Hz, H1՛), 3.31 – 3.25 (2H, m, H4, H6), 1.49
(3H, s, C2–CH3), 1.28 (6H, s, C2–CH3, H1՛՛).
13C

NMR (125 MHz, CDCl3) δ 137.7 (ArC), 137.2 (ArC), 128.5 (ArC), 128.0 (ArC),

128.0 (ArC), 127.8 (ArC), 127.4 (ArC), 114.1 (C2), 88.4 (C7), 85.7 (C3a), 83.8 (C8b),
78.3 (C8a), 76.3 (C8), 73.8 (OCH2Ph), 73.1 (C1՛), 71.5 (OCH2Ph), 63.7 (C4 or C6), 63.5
(C4 or C6), 27.8 (C2–CH3), 25.6 (C2–CH3), 14.9 (C1՛՛).

(3aS,4R,6R,7R,8R,8aS,8bR)-7-(Benzyloxy)-6-((benzyloxy)methyl)-2,2,4trimethylhexahydro-4H-[1,3]dioxolo[4,5-a]pyrrolizin-8-ol (151).

Triethylamine (7.7 µL, 0.055 mmol) was slowly added to a solution of 153 (23 mg, 0.0503
mmol) in anhydrous DCE (8 mL) at 0 oC under a N2 atmosphere. Whilst stirring, a 0.13M
solution of methanesulfonyl chloride in anhydrous CH2Cl2 (423 µL, 0.0553 mmol) was
slowly added dropwise to the reaction mixture. After stirring at 0 oC for 30 min, the
reaction mixture was quenched through the addition of a sat. NaHCO3 solution (2 mL) and
extracted with CH2Cl2 (3 x 5 mL) followed by concentration in vacuo. The crude brown
oil was dissolved in DCE followed by the addition of triethylamine (7.7 µL, 0.0553 mmol).
The reaction mixture with was heated at 80 oC for 20 h. TLC analysis confirmed full
consumption of the starting material and so the reaction was quenched through the addition
of NaHCO3 solution (10 mL) and extracted with CH2Cl2 (3 x 10 mL). The combined
extracts were dried (MgSO4), filtered and concentrated in vacuo to give a yellow oil.
Purification by FCC (5:95 MeOH/CH2Cl2) gave pyrrolizidine 151 as a clear film (19 mg,
87%).

Rf 0.38 (3:97 MeOH/CH2Cl2).
242

[α]25
𝐷 +28.7 (c 1.00, CHCl3).
IR max (cm-1): 3390, 3033, 2983, 1544, 1502, 1065, 864 cm–1.
LRESIMS m/z 462 (100%) [M+Na]+.
HRESIMS found 462.2247, calcd for C26H33NO5Na, 462.2256 [M+Na]+.
1H

NMR (500 MHz, CDCl3) δ 7.38 – 7.22 (10H, m, ArH), 4.68 (1H, d, J = 11.9 Hz,

OCH2Ph), 4.63 (1H, t, J = 5.5 Hz, H8b), 4.57 – 4.49 (4H, m, OCH2Ph, H8, H3a), 4.46 (1H,
d, J = 12.1 Hz, OCH2Ph), 4.02 (1H, dd, J = 6.4, 4.1 Hz, H7), 3.60 (1H, dt, J = 6.8, 3.6 Hz,
H6), 3.52 (1H, dd, J = 10.1, 4.1 Hz, H1՛), 3.47 (1H, dd, J = 10.1, 3.2 Hz, H1՛), 3.24 (1H,
dd, J = 5.0, 3.6 Hz, H8a), 3.06 (1H, dt, J = 7.0, 4.1 Hz, H4), 1.48 (3H, s, C2–CH3), 1.33 –
1.27 (6H, m, C2–CH3, H1՛՛).
13C

NMR (125 MHz, CDCl3) δ 138.2 (ArC), 138.2 (ArC), 128.4 (ArCH), 128.3 (ArCH),

128.0 (ArCH), 127.8 (ArCH), 127.7 (ArCH), 127.5 (ArCH), 112.0 (C2), 91.2 (C7), 85.1
(C3a or C8), 80.2 (C8b), 74.7 (C3a or C8), 74.4 (C8a), 73.4 (OCH2Ph), 72.0 (OCH2Ph),
69.8 (C1՛), 62.9 (C6), 57.6 (C4), 26.1 (C2–CH3), 24.0 (C2–CH3), 12.0 (C1՛՛).

General method for O-Benzyl and acetonide deprotection
(1R,2R,3R,5R,6R,7S,7aR)-3-(Hydroxymethyl)-5-methylhexahydro-1H-pyrrolizine1,2,6,7-tetraol [(+)-7-epi-hyacinthacine C5] (155).

To a nitrogen purged solution of compound 149 (15 mg, 0.034 mmol) in MeOH (3 mL)
was added PdCl2 (9.0 mg, 0.051 mmol). A balloon of H2 was attached to the system, and
the reaction mixture was stirred at rt for 24 h. After LRESIMS analysis confirmed full
consumption of the starting material, the mixture was filtered through a pad of celite and
washed with additional MeOH (6 mL). The combined filtrates were concentrated in vacuo
to give a yellow film. An Amberlyst A–26 resin (0.750 g) basic ion–exchange
chromatography column, was prepared by mixing the resin with a 15% aqueous ammonia
solution (v/v) and allowing it to stand for 15 min followed by washing the column with
distilled water until a pH close to 7 was achieved. The compound was dissolved in distilled
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water (2 mL) and held on the column for 15 min before its elution with water (3 x 3 mL).
Concentration in vacuo provided (+)-7-epi-hyacinthacine C5 155 (6.6 mg, 88%) as a
colourless film.
[α]25
𝐷 +5.4 (c 1.00, H2O).
IR max (cm-1): 3362, 1637, 1074, 1055 cm–1.
LRESIMS m/z 242 (100%) [M+Na]+.
HRESIMS found 242.1014, calcd for C9H17NO5Na, 242.1004 [M+Na]+.
1H

NMR (500 MHz, D2O) δ 4.15 (1H, dd, J = 5.0, 2.7 Hz, H7), 3.94 (1H, t, J = 7.3 Hz,

H2), 3.90 – 3.78 (2H, m, H1, H6), 3.71 – 3.59 (2H, m, H8), 3.21 – 3.13 (2H, m, H7a, H5),
3.10 (1H, dt, J = 7.2, 5.0 Hz, H3), 1.26 (3H, d, J = 7.0 Hz, H9).
13C

NMR (125 MHz, D2O) δ 78.5 (C1 or C6), 77.9 (C2), 75.9 (C6 or C1), 73.6 (C7), 72.6

(C7a), 62.9 (C8), 62.2 (C3), 58.8 (C5), 13.2 (C9).

(1R,2R,3R,5R,6S,7R,7aR)-3-(Hydroxymethyl)-5-methylhexahydro-1H-pyrrolizine1,2,6,7-tetraol [(–)-6-epi-hyacinthacine C5] (156).

(–)-6-Epi-hyacinthacine C5 156 was synthesized by the general method for O–benzyl
deprotection from 151 (10.0 mg, 0.0227 mmol). The crude product was filtered through a
pad of celite and washed with additional MeOH (6 mL). The combined filtrates were
concentrated in vacuo returning a yellow film. The compound was isolated through basic
ion–exchange chromatography followed by concentration in vacuo providing the title
compound 156 as a colourless film (4.8 mg, 98%).
[α]25
𝐷 –7.2 (c 1.00, H2O).
IR max (cm-1): 3300, 2909, 1420, 1098, 1055 cm–1.
LRESIMS m/z 220 (100%) [M+H]+.
HRESIMS found 220.1211, calcd for C9H18NO5, 220.1185 [M+H]+.
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1H

NMR (500 MHz, D2O) δ 4.39 – 4.28 (2H, m, H1, H7), 4.03 (1H, t, J = 4.5 Hz, H6),

3.91 (1H, t, J = 8.3 Hz, H2), 3.67 (2H, d, J = 4.8 Hz, H8), 3.38 (1H, quint, J = 4.8 Hz, H3),
3.31 (1H, t, J = 7.6 Hz, H7a), 3.24 (1H, dt, J = 7.0, 5.4 Hz, H5), 1.25 (3H, d, J = 7.1 Hz,
H9).
13C

NMR (125 MHz, D2O) δ 78.5 (C2), 74.8 (C6), 74.4 (C1), 70.8 (C7), 67.5 (C7a), 63.1

(C8), 62.2 (C3), 57.2 (C5), 10.9 (C9).
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Chapter 3
2-(But-3-en-2-yl)isoindoline-1,3-dione (157)180

To anhydrous DMF (10 mL) under an N2 atmosphere was added 3–chloro–1–butene (3.32
mL, 0.0330 mmol) and pthalimide potassium salt (6.72 g, 0.0363 mmol). The solution was
heated at reflux for 3 h and poured hot onto 200 g of ice. The reaction mixture was
extracted with chloroform (3 x 20 mL). The combined extracts were washed with 1 N KOH
(20 mL), water (20 mL), 0.5 N HCl (20 mL) and water (20 mL). The organic layer was
dried (MgSO4), filtered and concentrated in vacuo to give brown needle like crystals. The
product was recrystalised from 95% EtOH to give colourless needle shaped crystals 157
(6.64 g, quant.) which were used for the next step without further purification. The 1H and
13

C NMR spectroscopic data of this product were consistent with those published.180

LRESIMS m/z 202 (100%) [M+H]+.
1H

NMR (500 MHz, CDCl3) δ 7.83 (2H, ddt, J = 10.1, 7.7, 3.8 Hz, ArH), 7.71 (2H, dd, J

= 5.6, 3.1 Hz, ArH), 6.20 (1H, ddd, J = 17.0, 10.3, 6.6 Hz, H3՛), 5.24 (1H, d, J = 17.2 Hz,
H4՛trans), 5.17 (1H, d, J = 10.3 Hz, H4՛cis), 4.94 (1H, quint, J = 7.0 Hz, H2՛), 1.59 (3H, d, J
= 7.1 Hz, CH3).
13C NMR (125 MHz, CDCl

3) δ

167.8 (CO), 136.7 (ArC), 133.8 (ArC), 131.9 (ArC), 123.1

(C3՛), 123.0 (ArC), 116.2 (C1՛), 48.8 (C2՛), 18.1 (C1՛).
(R,S)-α-Methylallyl amine.hydrochloride180

To a solution of 157 (5.00 g, 0.0248 mmol) in 95% EtOH (5 mL) at 0 oC was added
hydrazine hydrate (3.08 mL, 0.0496 mmol as a 50–60% solution). The reaction mixture
was heated at 60 oC for 3 h whereby it formed a white gelatinous solid. The solid was
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cooled to 0 oC and treated with conc. HCl (12 mL, 0.124 mmol) until the solid turned to a
less viscous white paste. The paste was concentrated in vacuo and dissolved in water (10
mL). The phthalimide by–product was removed by washing the aqueous layer once with
diethyl ether which was discarded. The aqueous layer was made alkaline with KOH. The
product was extracted with diethyl ether (4 x 50 mL). The combined extracts were acidified
with 4 N HCl/EtOH followed by concentration in vacuo to give a brown crystalline product
which was recrystalised from EtOH/diethyl ether (1:2) to give small brown crystals (2.53
g, 95%).180
LRESIMS m/z 94 (100%) [M+Na]+.
1H

NMR (500 MHz, CDCl3) δ 8.45 (3H, s, NH3), 6.01 (1H, ddd, J = 17.1, 10.5, 6.4 Hz,

H2), 5.46 (1H, d, J = 17.2 Hz, H1trans), 5.33 (1H, d, J = 10.5 Hz, H1cis), 4.04 – 3.92 (1H,
m, H3), 1.53 (3H, d, J = 6.5 Hz, CH3).
13C

NMR (125 MHz, CDCl3) δ 134.8 (C2), 119.1 (C1), 49.8 (C3), 18.8 (CH3).

(2S,3S,4R,5R,E)-1,3-Bis(benzyloxy)-5-(((S)-but-3-en-2-yl)amino)-7-phenylhept-6ene-2,4-diol

(161)

and

(2S,3S,4R,5R,E)-1,3-bis(benzyloxy)-5-(((R)-but-3-en-2-

yl)amino)-7-phenylhept-6-ene-2,4-diol (127)

Compound 161 was synthesized by the general method for the Petasis reaction using (+)–
3,4–Di–O–benzyl–α,β–L–xylofuranose (2.00 g, 6.06 mmol), Et3N (845 µM, 6.06 mmol),
(E)–2–phenylvinylboronic acid (896 mg, 6.06 mmol) and (R,S)–α–methylallyl amine·HCl
(652 mg, 6.06 mmol) instead of the enatiomerically pure (R)–amine. The mixture was
purified by FCC (5:95 MeOH/CH2Cl2) to give inseperable diastereomers as a brown oil
(2.00 g, 65%, as a 2:1 mixture of 1՛S 161 and 1՛R 127 epimers). 1H and

13

C NMR

spectroscopic data of the formed 1՛R epimer matched the corresponding data of compound
127 described above.
Rf 0.20 (3:97 MeOH/CH2Cl2).
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LRESIMS m/z 488 (100%) [M+H]+.
1H

NMR (500 MHz, CDCl3) δ 7.54 – 7.08 (m), 6.48 (1H, d, J = 16.0 Hz, H7 (127), 6.41

[1H, d, J = 16.0 Hz, H7 (161)], 6.07 [1H, dd, J = 16.0, 8.8 Hz, H6 (127)], 6.00 [1H, dd, J
= 16.0, 8.9 Hz, H6 (161)], 5.71 [1H, ddd, J = 17.3, 10.3, 7.1 Hz, H2՛ (127)], 5.62 – 5.51
[1H, m, H2՛ (161)], 5.10 – 4.96 (m), 4.70 – 4.46 (m), 4.10 – 4.04 (m), 3.94 [1H, t, J = 5.3
Hz, H4 (127)], 3.88 [1H, t, J = 5.3 Hz, H4 (161)], 3.70 – 3.54 (m), 3.50 [1H, dd, J = 8.9,
5.2 Hz, H1, (127)], 3.44 [1H, dd, J = 8.9, 5.8 Hz, H1 (161)], 3.32 – 3.23 (m), 2.88 (s), 1.11
[3H, d, J = 6.4 Hz, H1՛՛ (127)], 1.06 [3H, d, J = 6.5 Hz, H1՛՛ (161)].
13C

NMR (125 MHz, CDCl3) δ 141.9 [C2՛ (127)], 141.5 [C2՛ (161)], 138.1 (ArC), 138.0

(ArC), 136.6 (ArC), 136.5 (ArC), 133.4 [C7 (161)], 133.2 [C7 (127)], 128.6 (ArC), 128.5
(ArC), 128.5 (ArC), 128.43 (ArC), 128.42 (ArC), 128.2 (ArC), 128.1 (ArC), 127.92 (ArC),
127.85 (ArC), 127.8 (ArC), 127.73 (ArC), 127.71 (ArC), 126.5 (ArC), 126.4 (ArC), 116.0
[C3՛ (161)], 114.5 [C3՛ (127)], 80.2 [C3 (161)], 80.0 [C3 (127)], 74.3 [OCH2Ph (127)],
74.2 [OCH2Ph (161)], 73.38 [OCH2Ph (161)], 73.35 [OCH2Ph (127)], 72.9 [C4 (161)],
72.3 [C4 (127)], 71.3 [C1 (127)], 71.2 [C1 (161)], 70.4 [C2 (161)], 70.1 [C2 (127)], 60.6
[C5 (161)], 60.3 [C5 (127)], 53.2 [C1՛ (161)], 52.7 [C1՛ (127)], 22.2 [C1՛՛ (161)], 20.2 [C1՛՛
(127)].

(4R,5R)-5-((1R,2S)-1,3-Bis(benzyloxy)-2-hydroxypropyl)-3-(1՛R,S-but-3-en-2-yl)-4((E)-styryl)oxazolidin-2-one

(137,

160)

and

(4R,5R,6S,7S)-6-(benzyloxy)-7-

((benzyloxy)methyl)-3-(but-3-en-2-yl)-5-hydroxy-4-((E)-styryl)-1,3-oxazepan-2-one
(138, 162).

A 2 : 1 mixture of 127 and 161 (50.0 mg, 0.102 mmol) were dissolved in anhydrous CH2Cl2
(15 mL) and cooled to 0 oC under an atmosphere of nitrogen. Triethylamine (28 µL, 0.204
mmol) was added and after 15 min triphosgene (15.1 mg, 0.0510 mmol) was added
portionwise and the solution was allowed to warm to rt. After stirring for 1 h, TLC analysis
confirmed full consumption of the starting material, leading to the subsequent in vacuo
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concentration of the reaction mixture. Purification via FCC (gradient of 1:5 EtOAc/nhexane to 1:1 EtOAc/n-hexane) produced an inseparable mixture of the four title isomers
consisting of the oxazolidinones 137, 160 and the oxazepinones 138, 162 as confirmed by
1

H NMR analysis and LRESIMS (43%).

Rf 0.65 (1:1 EtOAc/n-hexane).
LRESIMS m/z 536 (100%) [M+Na]+.
1H

NMR (500 MHz, CDCl3) δ 7.39 – 7.02 (m), 6.73 – 6.61 [m, H1՛՛՛ (138 and 162)], 6.60

– 6.51 [m, H2՛՛՛ (137 and 160)], 6.41 [d, J = 15.9 Hz, H2՛՛՛ (138)], 6.34 [d, J = 15.8 Hz, H2՛՛՛
(162)], 6.17 – 6.03 {m, H1՛՛՛ [137 and 160, H2՛ (138)]}, 5.93 [ddd, J = 17.4, 10.6, 4.7 Hz,
H2՛ (137 and 162)], 5.83 [ddd, J = 17.1, 10.3, 6.5 Hz, H2՛ (160)], 5.30 – 5.21 (m), 5.21 –
5.07 (m), 5.07 – 5.00 (m), 4.89 – 4.71 (m), 4.61 – 4.43 (m), 4.37 – 4.25 (m), 4.11 – 4.03
(m), 4.02 – 3.95 (m), 3.82 [dd, J = 9.5, 6.1 Hz, H1՛՛՛՛ (162)], 3.79 – 3.71 (m), 3.51 – 3.42
(m), 1.38 [d, J = 7.1 Hz, H1՛՛ (160], 1.34 [d, J = 6.9 Hz, H1՛՛ (162)], 1.29 [d, J = 7.0 Hz,
H1՛՛ (137)], 1.27 [d, J = 6.3 Hz, H1՛՛ (138)].
13C

NMR (125 MHz, CDCl3) δ 158.6 [C2 (162)], 158.5 [C2 (138)], 157.0 [C2 (137)],

156.9 [C2 (160)], 139.2 [C2՛ (138)], 138.3 [C2՛ (162)], 138.2, 137.88, 137.86, 137.8, 137.7,
137.5, 137.5, 136.8, 136.6, 136.4, 135.7, 135.5, 135.42, 135.39, 131.8, 131.2, 128.8, 128.6,
128.5, 128.4, 128.38, 128.36, 128.2, 127.91, 127.87, 127.85, 127.7, 127.6, 127.59, 127.56,
127.3, 126.70, 126.67, 126.7, 126.57, 124.55 [C1՛՛՛ (137)], 124.4 [C1՛՛՛ (160)], 117.3 , 117.2
[C3՛ (137)], 116.1, 116.0 [C3՛ (160)], 78.6, 78.2 , 77.8 [C5 (137)], 77.4, 76.5 [C1՛՛՛՛ (160)],
76.3 [C1՛՛՛՛ (137)], 74.8, 74.7, 74.1 [OCH2Ph (137)], 74.0 [OCH2Ph (160)], 73.4, 73.1
[OCH2Ph (160)], 73.1 [OCH2Ph (137)], 72.6, 72.5, 70.7 [C3՛՛՛՛ (160)], 70.6 [C3՛՛՛՛ (137)],
68.9 [C2՛՛՛՛ (160)], 68.8 [C2՛՛՛՛ (137)], 68.4, 67.9, 62.1 [C4 (162)], 61.6 [C4 (138)], 60.1 [C4
(160)], 60.0 [C4 (137)], 55.6 [C1՛ (138)], 55.3 [C1՛ (162)], 51.8 [C1՛ (160)], 51.7 [C1՛
(137)], 18.4 [C1՛՛ (137)], 17.2 [C1՛՛ (160)], 16.7 [C1՛՛ (162)], 16.0 [C1՛՛ (138)].

Conversion of 138 and 162 to 137 and 160, respectively. DBU (11.1 µL, 0.0745 mmol)
was added to a solution of the above mixture of oxazolidinones 137, 160 and oxazepinones
138, 162 (25.5 mg, 0.0497 mmol) in MeOH (3 mL) under a nitrogen atmosphere. After 4
h of stirring, TLC analysis confirmed full consumption of the starting materials. The
reaction mixture was concentrated in vacuo followed by dissolution in CH2Cl2 (5 mL). The
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solution was washed with a saturated solution of NH4Cl (2 x 3 mL), dried (MgSO4), filtered
and concentrated in vacuo. This afforded an inseparable mixture (1:2.5) of 137 and its C1՛
epimer 160 (25.3 mg, 99%). No further purification was required based on 1H NMR and
TLC analysis.

Rf (1:1 EtOAc/n-hexane) = 0.65
LRESIMS m/z 536 (100%) [M+Na]+.
1H

NMR (500 MHz, CDCl3) δ 7.38 – 7.18 (m, ArH), 7.17 – 7.04 (m, ArH), 6.61 – 6.52

(m), 6.18 – 6.05 (m), 5.95 [ddd, J = 16.8, 10.4, 5.8 Hz, H2՛ (137)], 5.84 [ddd, J = 17.0,
10.3, 6.4 Hz, H2՛ (160)], 5.24 – 5.16 (m), 5.14 – 5.07 (m), 5.06 – 4.99 (m), 4.89 – 4.81
(m), 4.80 – 4.71 (m), 4.62 – 4.53 (m), 4.53 – 4.35 (m), 4.35 – 4.23 (m), 4.03 – 3.92 (m),
3.80 – 3.72 (m), 3.55 – 3.43 (m), 1.38 [d, J = 7.1 Hz, H1՛՛ (160)], 1.29 [d, J = 7.0 Hz, H1՛՛
(137)].
13C

NMR (125 MHz, CDCl3) δ 157.0 [C2 (137)], 156.9 [C2 (160)], 138.4 [C2՛ (160)],

138.0, 137.9, 137.0 [C2՛ (137)], 135.7, 135.6 [C2՛՛՛ (160)], 135.5 [C2՛՛՛ (160)], 128.9, 128.6,
128.5, 128.02, 127.97, 127.9, 127.8, 127.72, 127.71, 126.79, 126.77, 124.9 [C2՛՛՛ (137)],
124.7 [C1՛՛՛ (160)], 117.2 [C3՛ (137)], 116.0 [C3՛ (160)], 77.8, 77.4, 76.7, 76.5, 74.2
[OCH2Ph (137)], 74.1 [OCH2Ph (160)], 73.20 [OCH2Ph (160)], 73.17 [OCH2Ph (137)],
70.84 [C3՛՛՛՛ (160)], 70.76 [C3՛՛՛՛ (137)], 69.0 [C2՛՛՛՛ (160)], 68.9 [C2՛՛՛՛ (137)], 60.2 [C4
(160)], 60.0 [C4 (137)], 51.92 [C1՛ (160)], 51.75 [C1՛ (137)], 18.53 [C1՛՛ (137)], 17.4 [C1՛՛
(160)].
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(1R,5S,7aR)-1-((1R,2S)-1,3-Bis(benzyloxy)-2-hydroxypropyl)-5-methyl-5,7adihydro-1H,3H-pyrrolo[1,2-c]oxazol-3-one (140) and
(1R,5R,7aR)-1-((1R,2S)-1,3-bis(benzyloxy)-2-hydroxypropyl)-5-methyl-5,7adihydro-1H,3H-pyrrolo[1,2-c]oxazol-3-one (159)

The title compounds 140 and 159 were synthesized from the above mixture of 137 and its
C1՛ epimer 160 (486 mg, 0.946 mmol), using the general method for ring–closing
metathesis. The crude black oil was purified by FCC (1:1 EtOAc/n-hexane) to give pure
samples of compounds 140 (105 mg, 27%) and 159 (205 mg, 53%) as grey oils. 1H and
13

C NMR spectroscopic data of the formed product matched the corresponding data of

compound 140 described above.

159:
Rf (1:1 EtOAc/n-hexane) = 0.45
[α]25
𝐷 +58.1 (c 1.00, CHCl3)
IR max (cm-1): 3340, 2937, 2870, 1643, 1414, 1329, 1210, 1073, 957 cm–1
LRESIMS m/z 432 (100%) [M+Na]+.
HRESIMS found 432.1782, calcd for C24H27NO5Na, 432.1787 [M+Na]+.
1H

NMR (500 MHz, CDCl3) δ 7.39 – 7.22 (10H, m, ArH), 5.97 (1H, dt, J = 6.1, 2.2 Hz,

H7), 5.86 (1H, dt, J = 6.0, 1.6 Hz, H6), 5.02 (1H, t, J = 7.8 Hz, H1), 4.79 (2H, app. t, J =
9.1 Hz, H7a and OCH2Ph), 4.68 (1H, dt, J = 8.8, 5.5, 4.5, 2.7 Hz, H5), 4.50 (2H, d, J = 2.9
Hz, OCH2Ph), 4.42 (1H, d, J = 11.8 Hz, OCH2Ph), 3.88 (1H, q, J = 8.0, 7.3 Hz, H2՛), 3.68
(1H, dd, J = 7.5, 2.2 Hz, H1՛), 3.56 (1H, dd, J = 9.2, 6.1 Hz, H3՛), 3.47 (1H, dd, J = 9.2,
6.8 Hz, H3՛), 2.49 (1H, d, J = 8.0 Hz, OH), 1.22 (3H, d, J = 6.8 Hz, H1՛՛).
13C

NMR (125 MHz, CDCl3) δ 162.5 (C3), 137.8 (ArC), 137.7 (ArC), 137.6 (C7), 128.5

(2 x ArCH), 128.4 (2 x ArCH), 128.1 (2 x ArCH), 127.94 (ArCH), 127.92 (ArCH), 127.82
(2 x ArCH), 124.81 (C6), 78.6 (C1), 77.2 (C1՛), 74.4 (OCH2Ph), 73.4 (OCH2Ph), 70.6
(C3՛), 69.2 (C2՛), 65.9 (C7a), 62.7 (C5), 19.6 (C1՛՛).
251

(1R,5S,6S,7R,7aR)-1-((1R,2S)-1,3-Bis(benzyloxy)-2-hydroxypropyl)-6,7-dihydroxy5-methyltetrahydro-1H,3H-pyrrolo[1,2-c]oxazol-3-one (163)

Compound 163 was synthesized from 159 (151 mg, 0.369 mmol) using the general method
for cis–dihydroxylation. The product 163 was purified by FCC (5:95 MeOH/CH2Cl2) to
give small white crystals (160 mg, 98%).

Rf (5:95 MeOH/CH2Cl2) = 0.32
[α]25
𝐷 +36.2 (c 1.00, CHCl3)
M.P: 145 – 150 oC
IR max (cm-1): 3429, 2921, 2858, 1709, 1293, 1126, 1028, 696 cm–1
LRESIMS m/z 466 (100%) [M+Na]+.
HRESIMS found 466.1863, calcd for C24H29NO7Na, 466.1842 [M+Na]+.
1H

NMR (500 MHz, CDCl3) δ 7.44 – 7.16 (10H, m, ArH), 4.91 (2H, app. dd, J = 9.4, 6.5

Hz, H1 and OCH2Ph), 4.63 (1H, d, J = 11.2 Hz, OCH2Ph), 4.46 (1H, d, J = 11.5 Hz,
OCH2Ph), 4.37 (1H, d, J = 11.5 Hz, OCH2Ph), 4.33 (1H, dd, J = 7.9, 2.0 Hz, H7a), 3.96
(1H, s, H7), 3.90 – 3.80 (3H, m, H6, H1՛, H2՛), 3.64 (1H, quint, J = 6.7 Hz, H5), 3.57 –
3.49 (2H, m, H3՛ and OH), 3.37 (1H, dd, J = 9.1, 6.7 Hz, H3՛), 2.69 (1H, s, OH), 2.61 (1H,
d, J = 8.0 Hz, OH), 1.35 (3H, d, J = 6.6 Hz, H1՛՛).
13C

NMR (125 MHz, CDCl3) δ 161.6 (C3), 137.2 (ArC), 137.2 (ArC), 128.8 (ArCH),

128.7 (ArCH), 128.6 (ArCH), 128.31 (ArCH), 128.27 (ArCH), 128.1 (ArCH), 81.3 (C6,
C1՛, C2՛), 76.8 (C1), 75.62 (C7a), 74.56 (OCH2Ph), 73.7 (OCH2Ph), 71.8 (C7), 70.9 (C3՛),
69.3 (C6, C1՛, C2՛), 62.8 (C6, C1՛, C2՛), 58.7 (C5), 19.5 (Me).
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(3aR,3bR,4R,8S,8aS)-4-((1R,2S)-1,3-Bis(benzyloxy)-2-hydroxypropyl)-2,2,8trimethyltetrahydro-4H,6H-[1,3]dioxolo[4',5':3,4]pyrrolo[1,2-c]oxazol-6-one (158)

Compound 158 was synthesized from 163 (141 mg, 0.317 mmol) by the general method
for acetonide protection of cis–diols. Purification by FCC (5:95 MeOH/CH2Cl2) returned
product 158 as large colourless crystals (150 mg, 98%).

Rf (5:95 MeOH/CH2Cl2) = 0.56
[α]25
𝐷 +26.05 (c 1.00, CHCl3)
M.P: 70 – 75 oC
IR max (cm-1): 3394, 2936, 2860, 1756, 1261, 1045, 740, 698 cm–1
LRESIMS m/z 506 (100%) [M+Na]+.
HRESIMS found 506.2211, calcd for C27H33NO7Na, 506.2155 [M+Na]+.
1H

NMR (500 MHz, CDCl3) δ 7.43 – 7.20 (10H, m, ArH), 5.03 (1H, dd, J = 8.8, 7.0 Hz,

H4), 4.94 (1H, d, J = 11.4 Hz, OCH2Ph), 4.68 (1H, dd, J = 5.2, 3.6 Hz, H3a), 4.59 (1H, d,
J = 11.4 Hz, OCH2Ph), 4.51 (1H, d, J = 11.7 Hz, OCH2Ph), 4.46 – 4.38 (3H, m, OCH2Ph,
H8a, H1՛), 4.22 (1H, q, J = 7.4 Hz, H8), 3.96 (1H, dd, J = 7.1, 3.5 Hz, H3b), 3.89 (1H, q,
J = 6.8 Hz, H2՛), 3.58 (1H, dd, J = 9.4, 6.9 Hz, H3՛), 3.43 (1H, dd, J = 9.5, 5.6 Hz, H3՛),
2.34 (1H, d, J = 7.7 Hz, OH), 1.46 (3H, s, C2–CH3), 1.20 – 1.11 (6H, m, C2–CH3, H1՛՛).
13C

NMR (125 MHz, CDCl3) δ 160.8 (C6), 137.9 (ArC), 137.8 (ArC), 128.7 (ArCH),

128.44 (ArCH), 128.35 (ArCH), 127.94 (ArCH), 127.86 (ArCH), 127.7 (ArCH), 112.7
(C2), 87.8 (C8a or C1՛), 80.7 (C3a), 79.2 (C4), 75.5 (C8a or C1՛), 74.0 (OCH2Ph), 73.4
(OCH2Ph), 71.2 (C3՛), 70.5 (C2՛), 62.4 (C3b), 59.7 (C8), 26.3 (C2–CH3), 24.1 (C2–CH3),
17.7 (C1՛՛).
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(1S,2S)-1,3-Bis(benzyloxy)-1-((3aR,3bR,4R,8S,8aS)-2,2,8-trimethyl-6-oxotetrahydro4H,6H-[1,3]dioxolo[4',5':3,4]pyrrolo[1,2-c]oxazol-4-yl)propan-2-yl
methanesulfonate (164)

Triethylamine (53 µL, 0.38 mmol) was slowly added to a solution of 158, (37 mg, 0.077
mmol) in anhydrous CH2Cl2 (10 mL) at 0 oC under a N2 atmosphere. Whilst stirring, a
0.13M solution of methanesulfonyl chloride in anhydrous CH2Cl2 (2.9 mL, 0.38 mmol)
was slowly added to the reaction mixture. After stirring at 0 oC for 1 h, TLC analysis
confirmed full consumption of the starting material and so the reaction was quenched
through the addition of sat. NaHCO3 solution (15 mL) and extracted with CH2Cl2 (3 x 15
mL) to give a pale–yellow oil. Purification of the residue by FCC (5%MeOH/CH2Cl2) gave
164 as a pale–yellow oil (43 mg, 99%).

Rf (5%MeOH/CH2Cl2) = 0.76
[α]25
𝐷 +16.7 (c 0.75, CHCl3)
IR max (cm-1): 3067, 2942, 2852, 1741, 1550, 1098, 982 cm–1.
LRESIMS m/z 584 (100%) [M+Na]+
HRESIMS found 584.1943, calcd for C28H35NO9Na, 584.1930 [M+Na]+.
1H

NMR (500 MHz, CDCl3) δ 7.49 – 7.25 (10H, m, ArH), 5.04 – 4.90 (3H, m, H2′, H4,

OCH2Ph), 4.83 (1H, dd, J = 5.3, 3.7 Hz, H3a), 4.64 (1H, d, J = 11.6 Hz, OCH2Ph), 4.55
(1H, dd, J = 8.7, 2.2 Hz, H1′), 4.52 – 4.47 (3H, m, OCH2Ph, H8a), 4.22 (1H, q, J = 7.3 Hz,
H8), 4.09 (1H, dd, J = 7.2, 3.7 Hz, H3b), 3.85 (1H, dd, J = 10.9, 7.5 Hz, H3′), 3.42 (1H,
dd, J = 11.0, 3.6 Hz, H3′), 3.01 (3H, s, OMs), 1.46 (3H, s, C2–CH3), 1.29 (3H, s, C2–CH3),
1.22 (3H, d, J = 7.4 Hz, H1′′).
13C

NMR (125 MHz, CDCl3) δ 160.2 (C6), 137.3 (ArC), 136.9 (ArC), 129.0 (ArCH),

128.6 (ArCH), 128.4 (ArCH), 128.2 (ArCH), 128.1 (ArCH), 127.8 (ArCH), 112.6 (C2),
87.9 (C8a), 80.7 (C3a), 80.1 (C4), 78.5 (C2՛), 74.8 (C1՛), 74.3 (OCH2Ph), 73.3 (OCH2Ph),
69.4 (C3՛), 61.8 (C3b), 59.6 (C8), 38.8 (OMs), 26.3 (C2–CH3), 24.0 (C2–CH3), 17.4 (C1՛՛).

254

(1R,2S,3S)-2,4-Bis(benzyloxy)-1-((3aR,4S,6S,6aS)-2,2,6-trimethyltetrahydro-4H[1,3]dioxolo[4,5-c]pyrrol-4-yl)butane-1,3-diol (166)

Compound 166 was synthesized from 158 (113 mg, 0.234 mmol) by the general method
for oxozlididnone hydrolysis. The product was purified by FCC (5:95 MeOH/CH2Cl2) to
give 166 as a pale–brown solid (90 mg, 84%).

Rf (5:95 MeOH/CH2Cl2) = 0.38
[α]25
𝐷 –2.6 (c 1.00, CHCl3)
IR max (cm-1): 3412, 3030, 2967, 1498, 1352, 1072, 1051, 647 cm–1
LRESIMS m/z 458 (100%) [M+H]+.
HRESIMS found 458.2530, calcd for C26H36NO6, 458.2543 [M+H]+.
1H

NMR (500 MHz, CDCl3) δ 7.43 – 7.18 (10H, m, ArH), 4.76 (1H, t, J = 4.0 Hz, H3a),

4.72 (1H, d, J = 11.5 Hz, OCH2Ph), 4.66 (1H, d, J = 11.5 Hz, OCH2Ph), 4.52 (2H, s,
OCH2Ph), 4.36 (1H, d, J = 5.4 Hz, H6a), 4.08 – 3.99 (2H, m, H1՛, H3՛), 3.74 – 3.68 (2H,
m, H4՛, H2՛), 3.58 (1H, dd, J = 9.8, 4.8 Hz, H4՛), 3.28 (1H, q, J = 7.4 Hz, H6), 3.09 (1H,
dd, J = 9.0, 4.0 Hz, H4), 2.32 (2H, bs, 2 x OH), 1.28 (6H, s, 2 x C2–CH3), 1.03 (3H, d, J
= 7.4 Hz, H1՛՛).
13C

NMR (125 MHz, CDCl3) δ 138.0 (ArC), 137.9 (ArC), 128.6 (ArCH), 128.5 (ArCH),

128.0 (ArCH), 128.0 (ArCH), 127.9 (ArCH), 127.8 (ArCH), 110.9 (C2), 86.5 (C6a), 82.4
(C2՛), 81.8 (C3a), 74.0 (OCH2Ph), 73.7 (OCH2Ph), 70.7 (C4՛), 69.8 (C1՛ and C3՛), 61.8
(C4), 59.1 (C6), 25.8 (C2–CH3), 23.8 (C2–CH3), 16.6 (C1՛՛).

255

(3aS,4S,6R,7R,8R,8aS,8bR)-7-(Benzyloxy)-6-((benzyloxy)methyl)-2,2,4trimethylhexahydro-4H-[1,3]dioxolo[4,5-a]pyrrolizin-8-ol (165)

Triethylamine (44 µL, 0.32 mmol) was slowly added to a solution of 166 (145.7 mg, 0.319
mmol) in anhydrous DCE (15 mL) at 0 oC under a nitrogen atmosphere. Whilst stirring, a
0.13M solution of methanesulfonyl chloride in anhydrous CH2Cl2 (2.45 mL, 0.319 mmol)
was slowly added dropwise to the reaction mixture. After stirring at 0 oC for 30 min, the
reaction mixture was quenched through the addition of a sat. NaHCO3 solution (2 mL) and
extracted with CH2Cl2 (3 x 5 mL) followed by concentration in vacuo. The crude brown
oil was dissolved in DCE followed by the addition of triethylamine (44 µL, 0.319 mmol).
The reaction mixture with was heated at 80 oC for 20 h. TLC analysis confirmed full
consumption of the starting material and so the reaction was quenched through the addition
of NaHCO3 solution (10 mL) and extracted with CH2Cl2 (3 x 10 mL). The combined
extracts were dried (MgSO4), filtered and concentrated in vacuo to give a yellow oil.
Purification by FCC (5:95 MeOH/CH2Cl2) gave the title compound 165 as a pale–yellow
oil (106 mg, 76%).

Rf (5:95 MeOH/CH2Cl2) = 0.35
[α]25
𝐷 +29.9 (c 1.00, CHCl3)
IR max (cm-1): 3358, 2981, 2862, 1702, 1643, 1211, 1089, 1023, 683 cm–1
LRESIMS m/z 440 (100%) [M+H]+.
HRESIMS found 440.2432, calcd for C26H34NO5, 440.2437 [M+H]+.
1H

NMR (500 MHz, CDCl3) δ 7.48 – 7.17 (10H, m, ArH), 4.77 (1H, t, J = 6.0 Hz, H8b),

4.72 (1H, d, J = 12.0 Hz, OCH2Ph), 4.67 (1H, t, J = 6.0 Hz, H8), 4.62 – 4.54 (2H, m, 2 x
OCH2Ph), 4.49 (1H, d, J = 12.1 Hz, OCH2Ph), 4.35 (1H, dd, J = 6.1, 3.6 Hz, H3a), 3.91
(1H, t, J = 6.5 Hz, H7), 3.54 – 3.46 (3H, m, H1՛, H8a), 3.34 – 3.24 (2H, m, H4, H6), 1.51
(3H, s, C2–CH3), 1.31 (3H, s, C2–CH3), 1.08 (3H, d, J = 6.7 Hz, H1՛՛).
13C

NMR (125 MHz, CDCl3) δ 138.5 (ArC), 138.1 (ArC), 128.4 (ArCH), 128.4 (ArCH),

127.8 (ArCH), 127.7 (ArCH), 127.6 (ArCH), 113.1 (C2), 88.7 (C7), 88.0 (C3a), 80.0
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(C8b), 76.0 (C8), 73.4 (OCH2Ph), 72.4 (OCH2Ph), 72.0 (C1՛), 71.4 (C8a), 67.2 (C6), 64.3
(C4), 26.9 (C2–CH3), 24.5 (C2–CH3), 19.0 (C1՛՛).

General method for hydrolysis of an acetonide

(1R,2S,3S,5R,6R,7R,7aR)-6-(Benzyloxy)-5-((benzyloxy)methyl)-3-methylhexahydro1H-pyrrolizine-1,2,7-triol (168)

To a solution of 165 (20 mg, 0.05 mmol) in EtOH/H2O (1/9, 5 mL), was added 5 N HCl
(0.5 mL). The mixture was stirred at room temperature for 4 h by which time TLC analysis
confirmed the consumption of starting material. The reaction mixture was neutralized by
the addition of a saturated solution of NaHCO3 until a pH of 7 was achieved. The solution
was evaporated to 5 mL under reduced pressure and extracted with EtOAc (3 x 15 mL),
the combined extracts were washed with saturated NaCl (15 mL), dried (MgSO4), filtered
and concentrated in vacuo to give a brown oil. Purification by FCC (5:95 MeOH/CH2Cl2)
gave the title compound 168 as a pale–yellow oil (16 mg, 89%).

Rf (5:95 MeOH/CH2Cl2) = 0.14
[α]25
𝐷 +13.0 (c 1.00, CHCl3)
IR max (cm-1): 3357, 2918, 2863, 1653, 1539, 1120, 1078, 698 cm–1
LRESIMS m/z 400 (100%) [M+H]+.
HRESIMS found 400.2126, calcd for C23H30NO5, 400.2124 [M+H]+.
1H

NMR (500 MHz, CDCl3) δ 7.43 – 7.18 (10H, m, ArH), 4.69 – 4.59 (2H, m, OCH2Ph),

4.57 – 4.46 (3H, m, OCH2Ph, H1), 4.06 (1H, d, J = 4.3 Hz, H7), 3.96 (1H, d, J = 2.5 Hz,
H2), 3.73 (1H, t, J = 3.5 Hz, H7a), 3.66 (1H, dd, J = 9.2, 3.8 Hz, H6), 3.59 (1H, dd, J =
9.7, 3.6 Hz, H1՛), 3.51 (1H, dd, J = 9.6, 3.7 Hz, H1՛), 3.21 (1H, q, J = 3.5 Hz, H3), 2.78
(1H, dt, J = 12.4, 6.2 Hz, H5), 1.22 (3H, d, J = 6.1 Hz, H1՛՛).
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13C

NMR (125 MHz, CDCl3) δ 137.3 (ArC), 137.0 (ArC), 128.8 (ArCH), 128.7 (ArCH),

128.4 (ArCH), 128.2 (ArCH), 128.2 (ArCH), 88.5 (C2), 79.5 (C6), 74.9 (C1), 74.7 (C7a),
74.0 (OCH2Ph), 73.0 (C1՛), 72.5 (OCH2Ph), 71.8 (C7), 70.4 (C3), 66.3 (C5), 19.0 (C1՛՛).

(1R,2R,3R,5S,6S,7R,7aR)-3-(Hydroxymethyl)-5-methylhexahydro-1H-pyrrolizine1,2,6,7-tetraol [(‒)-5,6-di-epi-hyacinthacine C5] (169)

(‒)-5,6-Di-epi-hyacinthacine C5 169 was synthesized by the general method of O–benzyl
deprotection from 168 (15 mg, 0.037 mmol). The crude product was filtered through a pad
of celite and washed with additional MeOH (6 mL). The combined filtrates were
concentrated in vacuo returning a yellow film. The title compound 169 was isolated
through basic ion–exchange chromatography followed by concentration in vacuo, as a
colourless film (8 mg, 99%).
[α]25
𝐷 –6.9 (c 1.00, H2O)
IR max (cm-1): 3332, 2981, 1623, 1578, 1478, 1065, 699 cm–1
LRESIMS m/z 220 (100%) [M+H]+.
HRESIMS found 220.1176, calcd for C9H18NO5, 220.1185 [M+H]+.
1H

NMR (500 MHz, D2O) δ 4.33 (1H, t, J = 7.4 Hz, H1), 4.13 (1H, t, J = 4.1 Hz, H7),

3.89 (1H, t, J = 8.7 Hz, H2), 3.76 – 3.68 (2H, m, H6 and H8), 3.65 (1H, dd, J = 11.9, 4.7
Hz, H8), 3.26 (1H, dt, J = 5.7, 2.8 Hz, H7a), 2.84 (1H, dq, J = 12.7, 6.4 Hz, H5), 2.78 (1H,
dt, J = 9.1, 4.3 Hz, H3), 1.20 (3H, d, J = 6.2 Hz, H9).
13C

NMR (125 MHz, D2O) δ 79.1 (C6), 78.0 (C2), 73.0 (C1), 70.8 (C3), 69.8 (C7), 67.8

(C7a), 63.2 (C5), 61.5 (C8), 17.5 (C9).
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Chapter 4A
(4R,5R)-5-((1S,2S)-1,3-Bis(benzyloxy)-2-((4-methoxybenzyl)oxy)propyl)-3-((R)-but3-en-2-yl)-4-((E)-styryl)oxazolidin-2-one (175)

To a solution of compound 137 (425 mg, 0.828 mmol) in THF (25 mL) at 0 oC, was slowly
added sodium hydride (50 mg, 1.24 mmol 60% dispersion in mineral oil). The reaction
mixture was heated at reflux under a nitrogen atmosphere for 5 min, and cooled to rt. 4–
Methoxybenzyl chloride (225 µL, 1.66 mmol) and TBAI (46 mg, 0.124 mmol) were added
and the mixture was heated at reflux for 18 h. By this time, TLC analysis had confirmed
full consumption of the starting material. The reaction mixture was cooled to 0 oC, and
quenched by the dropwise addition of water (10 mL). The mixture was extracted with
diethyl ether (3 x 15 mL) and the combined extracts were dried (MgSO 4), filtered and
concentrated in vacuo. The resultant orange oil was purified by FCC (1:1 diethyl ether/nhexane) to afford product 175 as a yellow oil (451 mg, 86%).

Rf (1:1 diethyl ether/n-hexane) = 0.17
[α]25
𝐷 +48.3 (c 0.96, CHCl3).
IR max (cm-1): 3027, 2950, 1618, 1540, 1245, 1108, 1083, 832 cm–1
LRESIMS m/z 656 (100%) [M+Na]+
HRESIMS found 656.3102, calcd for C40H43NO6Na, 656.2988 [M+Na]+.
1H

NMR (500 MHz, CDCl3) δ 7.38 – 7.06 (17H, m, ArH), 6.88 (2H, dd, J = 8.2, 4.7 Hz,

ArH), 6.10 (1H, d, J = 15.9 Hz, H2′′′), 5.99 (1H, dd, J = 15.9, 9.5 Hz, H1′′′), 5.83 (1H, ddd,
J = 17.1, 10.4, 5.7 Hz, H2′), 5.20 (1H, d, J = 10.4 Hz, H3′cis), 5.10 (1H, d, J = 17.1 Hz,
H3′trans), 4.78 – 4.52 (4H, m, OCH2Ph, H5), 4.44 – 4.28 (4H, m, OCH2Ph, OCH2Ar, H1′),
3.87 – 3.73 (5H, m, H4, H1′′′′, OCH3), 3.71 – 3.60 (3H, m, H3′′′′, H2′′′′), 1.20 (3H, d, J =
6.9 Hz, H1′′).
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13C

NMR (125 MHz, CDCl3) δ 159.7 (ArC), 157.0 (C2), 138.3 (ArC), 138.2 (ArC), 137.0

(C2′), 135.7 (ArC), 135.2 (C2′′′), 130.6 (ArCH), 130.3 (ArCH), 128.9 (ArCH), 128.6
(ArCH), 128.5 (ArCH), 128.4 (ArCH), 128.4 (ArCH), 128.0 (ArCH), 127.7 (ArCH), 127.6
(ArCH), 127.5 (ArCH), 126.7 (ArCH), 125.1 (C1′′′), 116.9 (C3′), 114.1 (ArCH), 77.4 (C5),
76.6 (C2′′′′), 74.5 (C4), 73.9 (OCH2Ph), 73.1 (OCH2Ph), 71.6 (OCH2Ar), 69.4 (C3′′′′), 59.8
(C1′′′′), 55.4 (OCH3), 51.6 (C1′), 18.4 (C1′′).

(1R,5R,7aR)-1-((1S,2S)-1,3-Bis(benzyloxy)-2-((4-methoxybenzyl)oxy)propyl)-5methyl-5,7a-dihydro-1H,3H-pyrrolo[1,2-c]oxazol-3-one (176)

Compound 176 was synthesized from 175 (330 mg, 0.521 mmol), using the general
method for ring–closing metathesis. The crude black oil was purified by FCC (3:7
EtOAc/n-hexane) to give 176 as a grey oil (215 mg,78%).

Rf (3:7 EtOAc/n-hexane) = 0.32
[α]25
𝐷 +19.9 (c 1.00, CHCl3).
IR max (cm-1): 2980, 2824, 1767, 1698, 1513, 1454, 1375, 1222, 1103, 1083, 831 cm–1
LRESIMS m/z 552 (100%) [M+Na]+
HRESIMS found 552.2375, calcd for C32H35NO6Na 552.2362 [M+Na]+.
1H

NMR (500 MHz, CDCl3) δ 7.40 – 7.14 (12H, m, ArH), 6.84 (2H, d, J = 8.6 Hz, ArH),

5.67 (1H, dt, J = 6.1, 1.9 Hz, H7), 5.57 (1H, dt, J = 6.1, 1.9 Hz, H6), 4.89 – 4.82 (1H, m,
H7a), 4.77 (1H, dd, J = 8.8, 2.4 Hz, H1), 4.71 (1H, d, J = 11.5 Hz, OCH2Ph), 4.59 (1H, d,
J = 11.3 Hz, OCH2Ph), 4.54 – 4.41 (4H, m, OCH2Ph, OCH2Ar), 4.20 (1H, dqd, J = 8.5,
6.3, 3.2 Hz, H5), 3.90 – 3.82 (2H, m, H3′, H2′), 3.79 (3H, s, OCH3), 3.73 (1H, dd, J = 11.0,
6.4 Hz, H3′), 3.46 (1H, dd, J = 5.3, 2.5 Hz, H1′), 1.24 (3H, d, J = 6.8 Hz, H1′′).
13C

NMR (125 MHz, CDCl3) δ 159.4 (ArC), 157.5 (C3), 138.4 (ArC), 137.7 (ArC), 136.8

(C7), 130.4 (ArCH), 129.8 (ArCH), 128.4 (ArCH), 128.2 (ArCH), 128.1 (ArCH), 127.7
(ArCH), 127.6 (ArCH), 123.4 (C6), 113.8 (ArCH), 77.8 (C1′), 76.9 (C2′), 75.6 (C1), 73.4
260

(OCH2Ph), 73.1 (OCH2Ph), 72.6 (OCH2Ar), 70.6 (C3′), 68.7 (C7a), 59.9 (C5), 55.3
(OCH3), 15.7 (C1′′).

(1R,5R,6S,7R,7aR)-1-((1S,2S)-1,3-Bis(benzyloxy)-2-((4-methoxybenzyl)oxy)propyl)6,7-dihydroxy-5-methyltetrahydro-1H,3H-pyrrolo[1,2-c]oxazol-3-one (180) and
(1R,5R,6R,7S,7aR)-1-((1S,2S)-1,3-Bis(benzyloxy)-2-((4-methoxybenzyl)oxy)propyl)6,7-dihydroxy-5-methyltetrahydro-1H,3H-pyrrolo[1,2-c]oxazol-3-one (183)

Compounds 180 and 183 were synthesized from 176 (202 mg, 0.381 mmol) using the
general method for cis–dihydroxylation. Both products were purified by FCC (3:97
MeOH/CH2Cl2) to give the title compounds 180 (38 mg, 18%) and 183 (134 mg, 62%) as
clear oils.

180:
Rf (3:97 MeOH/CH2Cl2) = 0.49
[α]25
𝐷 +3.2 (c 2.75, CHCl3).
IR max (cm-1): 3390, 2907, 2827, 1743, 1675, 1510, 1225, 1179, 1171, 1081 cm–1
LRESIMS m/z 586 (100%) [M+Na]+
HRESIMS found 586.2416, calcd for C32H37NO8Na 586.2417 [M+Na]+.
1H

NMR (500 MHz, CDCl3) δ 7.43 – 7.18 (12H, m, ArH), 6.87 (2H, d, J = 8.4 Hz, ArH),

4.81 – 4.64 (5H, m, OCH2Ph, H1), 4.46 – 4.32 (4H, m, OCH2Ph, OCH2Ar), 4.13 (1H, dd,
J = 6.6, 3.4 Hz, H7a), 4.06 – 3.98 (1H, m, H6), 3.84 – 3.60 (8H, m, OCH3, H5, H7, H3′,
H2′), 3.15 (1H, dd, J = 8.8, 2.1 Hz, H1′), 2.67 (1H, d, J = 10.3 Hz, OH), 1.43 (3H, d, J =
7.0 Hz, H1′′).
13C

NMR (125 MHz, CDCl3) δ 159.7 (ArC), 157.0 (C3), 137.5 (ArCH), 137.1 (ArCH),

130.4 (ArCH), 129.5 (ArCH), 128.8 (ArCH), 128.6 (ArCH), 128.5 (ArCH), 128.2 (ArCH),
128.1 (ArCH), 127.9 (ArCH), 114.0 (ArCH), 76.0 (C7a), 75.8 (C1), 75.4 (C7), 74.6 (C6),
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74.4 (OCH2Ph), 73.6 (OCH2Ph), 71.6 (OCH2Ar), 70.6 (C2′ or C5), 68.4 (C3′), 62.9 (C1′),
55.4 (OCH3), 54.7 (C2′ or C5), 11.8 (C1′′).

183:
Rf (3:97 MeOH/CH2Cl2) = 0.49
[α]25
𝐷 +14.2 (c 1.00, CHCl3).
LRESIMS m/z 564 (100%) [M+H]+
1H

NMR (500 MHz, CDCl3) δ 7.36 – 7.17 (12H, m, ArH), 6.85 (2H, d, J = 8.1 Hz, ArH),

4.83 (1H, dd, J = 8.8, 4.3 Hz, H1), 4.73 – 4.62 (2H, m, OCH2Ph), 4.58 (1H, d, J = 11.6 Hz,
OCH2Ph), 4.52 – 4.41 (3H, m, OCH2Ph, OCH2Ar), 4.11 – 4.04 (1H, t, J = 7.2 Hz, H7),
3.99 (1H, q, J = 4.6 Hz, H2′), 3.92 (1H, t, J = 8.4 Hz, H7a), 3.78 (4H, s, OCH2Ph, H3′),
3.68 (2H, td, J = 8.8, 6.8, 4.0 Hz, H3′, H6), 3.46 – 3.40 (1H, m, H5), 1.23 (3H, d, J = 6.8
Hz, H1′′).
13C

NMR (125 MHz, CDCl3) δ 159.5 (ArC), 156.6 (C3), 137.9 (ArCH), 137.5 (ArCH),

130.0 (ArCH), 129.8 (ArCH), 128.5 (ArCH), 128.1 (ArCH), 128.0 (ArCH), 127.8 (ArCH),
127.8 (ArCH), 113.9 (ArCH), 79.7 (C6), 77.3 (C1′), 76.6 (C2′), 76.3 (C1), 74.2 (OCH2Ph),
73.5 (OCH2Ph), 72.9 (OCH2Ar), 69.5 (C3′), 68.3 (C7), 65.3 (C7a), 58.9 (C5), 55.3 (OCH3),
14.8 (C1′′).

General method for the synthesis of a cyclic sulfate
(3aS,3bS,4R,8R,8aR)-4-((1S,2S)-1,3-Bis(benzyloxy)-2-((4methoxybenzyl)oxy)propyl)-8-methyltetrahydro-4H,6H[1,3,2]dioxathiolo[4',5':3,4]pyrrolo[1,2-c]oxazol-6-one 2,2-dioxide (181)

To a solution of the diol 183 (212 mg, 0.376 mmol) in anhydrous CH2Cl2 (10 mL) at 0 oC
under a nitrogen atmosphere was added Et3N (134 µL, 0.96 mmol) and SOCl2 (46 µL, 0.57
mmol) dropwise. After stirring at 0 oC for 1 h, TLC analysis confirmed the consumption
of starting material. The reaction was quenched with water (10 mL) and the mixture was
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extracted with CH2Cl2 (3 x 15 mL). The combined extracts were dried (MgSO4), filtered
and concentrated in vacuo to give 181 as a brown oil (235 mg) which was used for the next
step without further purification.
LRESIMS m/z 660 (100%) [M+Cl]–

(1R,5R,6R,7R,7aR)-1-((1S,2S)-1,3-Bis(benzyloxy)-2-((4-methoxybenzyl)oxy)propyl)6,7-dihydroxy-5-methyltetrahydro-1H,3H-pyrrolo[1,2-c]oxazol-3-one (185) and
(1R,5R,6S,7S,7aR)-1-((1S,2S)-1,3-bis(benzyloxy)-2-((4-methoxybenzyl)oxy)propyl)6,7-dihydroxy-5-methyltetrahydro-1H,3H-pyrrolo[1,2-c]oxazol-3-one (186)

To a solution of the cyclic sulfate 181 (235 mg, 0.376 mmol) in dry DMSO (5 mL) was
added benzoic acid (184 mg, 1.50 mmol) and cesium carbonate (490 mg, 1.50 mmol). The
reaction mixture was stirred under a nitrogen atmosphere at 40 oC for 20 h. After
LRESIMS confirmed the consumption of starting material, a mixture of THF (8 mL),
distilled water (3 mL) and conc. H2SO4 (1 mL) was added to the mixture and stirred at 40
o

C for 20 h. The reaction mixture was neutralized with saturated NaHCO3 until a pH of 7

was achieved, followed by extraction with CH2Cl2 (3 x 15 mL). The combined extracts
were dried (MgSO4), filtered and concentrated in vacuo to give a brown oil. The resultant
oil was eluted from a silica plug (2:3 EtOAc/n-hexane) to give a light brown oil (63 mg)
which was subsequently subjected to O–benzoyl hydrolysis to afford 185 (37 mg, 18%
over two steps) and 186 (15 mg, 7% over two steps) which were separable by FCC (5:95
MeOH/CH2Cl2).

185:
Rf (5:95 MeOH/CH2Cl2) = 0.43
[α]25
𝐷 ‒16.1 (c 2.00, CHCl3).
IR max (cm-1): 3412, 2932, 2803, 1756, 1623, 1512, 1256, 1187, 1143, 1009 cm–1
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LRESIMS m/z 564 (100%) [M+H]+.
HRESIMS found 564.2589, calcd for C32H38NO8, 564.2597 [M+H]+.
1H

NMR (500 MHz, CDCl3) δ 7.38 – 7.23 (10H, m, ArH), 7.21 (2H, d, J = 8.1 Hz, ArH),

6.85 (2H, d, J = 8.1 Hz, ArH), 4.84 (1H, dd, J = 8.6, 5.8 Hz, H1), 4.71 – 4.57 (4H, m,
OCH2Ph. OCH2Ar), 4.44 (2H, q, J = 11.3 Hz, OCH2Ph), 4.00 (1H, t, J = 6.1 Hz, H6), 3.93
(1H, t, J = 5.6 Hz, H7), 3.89 (2H, bs, H2′, OH), 3.84 – 3.71 (5H, m, OCH3, 7a, H3′), 3.71
– 3.58 (3H, m, H5, H3′, H1′), 1.31 (3H, d, J = 6.9 Hz, H1′′).
13C

NMR (125 MHz, CDCl3) δ 159.6 (ArC), 157.8 (C3), 137.8 (ArC), 137.4 (ArC), 130.1

(ArCH), 129.5 (ArCH), 128.5 (ArCH), 128.5 (ArCH), 128.5 (ArCH), 128.4 (ArCH), 128.3
(ArCH), 128.1 (ArCH), 127.9 (ArCH), 127.8 (ArCH), 114.0 (ArCH), 79.7 (C7), 76.4
(C7a), 76.2 (C2′), 75.2 (C1), 74.1 (C6), 73.5 (OCH2Ph), 73.2 (OCH2Ph), 72.5 (OCH2Ar),
69.1 (C3′), 65.2 (C1′), 55.3 (OCH3), 55.2 (C5), 11.0 (C1′′).

186:
Rf (5:95 MeOH/CH2Cl2) = 0.28
[α]25
𝐷 +68.4 (c 0.56, CHCl3).
LRESIMS m/z 564 (100%) [M+H]+.
1H

NMR (500 MHz, CDCl3) δ 7.41 – 7.19 (12H, m, ArH), 6.86 (2H, d, J = 8.0 Hz, ArH),

4.82 (1H, dd, J = 8.2, 5.0 Hz, H1), 4.77 – 4.62 (3H, m, OCH2Ph), 4.51 – 4.42 (3H, m,
OCH2Ph, OCH2Ar), 4.08 (1H, t, J = 4.6 Hz, H7a), 3.87 (2H, bs, OH, H7), 3.79 (4H, d, J =
4.9 Hz, OCH3, H6), 3.74 – 3.68 (3H, m, H3′, H1′), 3.66 – 3.56 (1H, m, H2′), 3.36 (1H, q,
J = 7.8, 7.2 Hz, H5), 1.59 (3H, d, J = 7.0 Hz, H1′′).
13C

NMR (125 MHz, CDCl3) δ 159.5 (ArC), 157.9 (C3), 137.8 (ArC), 136.7 (ArC), 130.1

(ArCH), 129.8 (ArCH), 128.79 (ArCH), 128.76 (ArCH), 128.66 (ArCH), 128.65 (ArCH),
128.5 (ArCH), 128.3 (ArCH), 128.0 (ArCH), 127.98 (ArCH), 127.97 (ArCH), 127.96
(ArCH), 127.8 (ArCH), 114.0 (ArCH), 84.2 (C6), 76.3 (C7), 76.0 (C7a), 75.4 (C2′), 74.2
(OCH2Ph), 74.1 (C1), 73.5 (OCH2Ph), 72.1 (OCH2Ar), 69.4 (C3′), 65.8 (C1′), 62.5 (C5),
55.3 (OCH3), 15.8 (C1′′).
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(1R,5R,6R,7R,7aR)-6,7-Bis(benzyloxy)-1-((1S,2S)-1,3-bis(benzyloxy)-2-((4methoxybenzyl)oxy)propyl)-5-methyltetrahydro-1H,3H-pyrrolo[1,2-c]oxazol-3-one
(187)

Compound 187 was synthesized from 185 (35 mg, 0.062 mmol) by the general method for
O–benzylation. The product 187 was purified by FCC (1:1 EtOAc/n-hexane) to give the
target compound as an orange oil (43 mg, 94%).

Rf (1:1 EtOAc/n-hexane) = 0.64
[α]25
𝐷 +102.1 (c 1.50, CHCl3).
IR max (cm-1): 3059, 2967, 2849, 1798, 1622, 1542, 1212, 1135, 1164 cm–1
LRESIMS m/z 744 (100%) [M+H]+.
HRESIMS found 744.3543, calcd for C46H50NO8, 744.3536 [M+H]+.
1H

NMR (500 MHz, CDCl3) δ 7.44 – 7.02 (22H, m, ArH), 6.79 (2H, d, J = 8.1 Hz, ArH),

4.91 – 4.81 (2H, m, OCH2Ph, H1), 4.67 (1H, d, J = 11.7 Hz, OCH2Ph), 4.48 – 4.16 (9H,
m, OCH2Ph, OCH2Ar, H7), 3.69 (3H, s, OCH3), 3.66 – 3.58 (1H, m, H3′), 3.55 (2H, bs,
H1′, H2′), 3.49 (2H, d, J = 7.8 Hz, H5, H6), 3.44 – 3.34 (2H, m, H3′, H7a), 1.56 (3H, d, J
= 7.2 Hz, H1′′).
13C

NMR (125 MHz, CDCl3) δ 159.6 (ArC), 157.9 (C3), 138.4 (ArC), 138.0 (ArC), 137.4

(ArC), 137.1 (ArC), 130.2 (ArCH), 129.8 (ArCH), 128.8 (ArCH), 128.6 (ArCH), 128.6
(ArCH), 128.4 (ArCH), 128.2 (ArCH), 128.1 (ArCH), 127.9 (ArCH), 127.86 (ArCH),
127.85 (ArCH), 127.67 (ArCH), 127.66 (ArCH), 127.2 (ArCH), 114.0 (ArCH), 87.4 (C1′
or C2′), 80.9 (C1′ or C2′), 76.6 (C1), 76.0 (C7), 75.5 (C6), 74.5 (OCH2Ph), 73.4 (OCH2Ph),
71.5 (OCH2Ar), 70.0 (OCH2Ph), 69.0 (C3′), 64.1 (C7a), 60.0 (C5), 55.2 (OCH3), 16.2
(C1′′).
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Chapter 4B
(3aS,4S,6R,7R,8R,8aS,8bR)-7,8-Bis(benzyloxy)-6-((benzyloxy)methyl)-2,2,4trimethylhexahydro-4H-[1,3]dioxolo[4,5-a]pyrrolizine (196)

Compound 196 was synthesized from 165 (115 mg, 0.262 mmol) by the general method
for O–benzylation. The product 196 was purified by FCC (1:4 EtOAc/n-hexane) to give a
yellow oil (122 mg, 87%).

Rf (3:7 EtOAc/n-hexane) =0.56
[α]25
𝐷 +19.3 (c 1.00, CHCl3)
IR max (cm-1): 2987, 1557, 1531, 1278, 1089, 695 cm–1
LRESIMS m/z 530 (100%) [M+H]+.
HRESIMS found 530.2901, calcd for C33H40NO5, 530.2906 [M+H]+.
1H

NMR (500 MHz, CDCl3) δ 7.50 – 7.15 (15H, m, ArH), 4.68 (1H, d, J = 11.8 Hz,

OCH2Ph), 4.61 (1H, t, J = 5.6 Hz, H8b), 4.59 – 4.52 (5H, m, OCH2Ph, H8), 4.47 (1H, d, J
= 12.2 Hz, OCH2Ph), 4.38 (1H, dd, J = 5.8, 2.6 Hz, H3a), 4.02 (1H, t, J = 6.2 Hz, H7),
3.60 – 3.48 (2H, m, H1՛, H8a), 3.47 – 3.36 (3H, m, H1՛, H6, H4), 1.51 (3H, s, C2–CH3),
1.31 (3H, s, C2–CH3), 1.04 (3H, d, J = 7.0 Hz, H1՛՛).
13C

NMR (125 MHz, CDCl3) δ 138.9 (ArC), 138.8 (2 x ArC), 128.6 (ArCH), 128.5

(ArCH), 128.5 (ArCH), 128.1 (ArCH), 128.04 (ArCH), 128.00 (ArCH), 127.8 (ArCH),
127.7 (ArCH), 127.7 (ArCH), 112.7 (C2), 89.2 (C3a), 87.1 (C7), 83.3 (C8), 82.0 (C8b),
73.5 (OCH2Ph), 72.6 (OCH2Ph), 72.5 (OCH2Ph), 72.5 (C1՛), 69.8 (C8a), 66.4 (C6), 62.9
(C4), 27.2 (C2–CH3), 24.6 (C2–CH3), 19.6 (C1՛՛).
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(3aR,4R,6R,7R,8R,8aS,8bS)-7,8-Bis(benzyloxy)-6-((benzyloxy)methyl)-2,2,4trimethylhexahydro-4H-[1,3]dioxolo[4,5-a]pyrrolizine (197)

Compound 197 was synthesized from 149 (19 mg, 0.043 mmol) by the general method for
O–benzylation. The product was purified by FCC (gradient of 3:20 EtOAc/n-hexane to 1:5
EtOAc/n-hexane) to give the target compound 197 as a clear oil (21 mg, 89%).

Rf (1:4 EtOAc/n-hexane) = 0.50
[α]25
𝐷 +85.5 (c 1.00, CHCl3)
IR max (cm-1): 2980, 1682, 1374, 1247, 1055 cm–1
LRESIMS m/z 530 (100%) [M+H]+.
HRESIMS found 530.2923, calcd for C33H40NO5, 530.2906 [M+H]+.
1H

NMR (500 MHz, CDCl3) δ 7.50 – 7.10 (15H, m, ArH), 4.60 (1H, dd, J = 6.9, 3.7 Hz,

H8b) 4.57 – 4.34 (6H, m, OCH2Ph), 4.21 (1H, t, J = 6.8 Hz, H3a), 4.02 (1H, s, H8), 3.99
(1H, s, H7), 3.66 (1H, t, J = 2.7 Hz, H8a), 3.48 – 3.20 (3H, m, H1՛, H6, H4), 1.50 (3H, s,
C2–CH3), 1.29 (6H, s, C2–CH3, H1՛՛).
13C

NMR (125 MHz, CDCl3) δ 138.39 (ArC), 138.11 (ArC), 137.97 (ArC), 128.41

(ArCH), 128.36 (ArCH), 128.32 (ArCH), 127.69 (ArCH), 127.64 (ArCH), 127.60 (ArCH),
127.57 (ArCH), 127.55 (ArCH), 113.95 (C2), 86.40 (C3a), 85.79 (C7), 84.89 (C8), 83.58
(C8b), 74.44 (C8a), 73.19 (OCH2Ph), 72.65 (C1՛), 71.26 (OCH2Ph), 71.20 (OCH2Ph),
62.89 (C4), 62.66 (C6), 27.71 (C2–CH3), 25.63 (C2–CH3), 15.36 (C1՛՛).
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(3aS,4R,6R,7R,8R,8aS,8bR)-7,8-Bis(benzyloxy)-6-((benzyloxy)methyl)-2,2,4trimethylhexahydro-4H-[1,3]dioxolo[4,5-a]pyrrolizine (198)

Compound 198 was synthesized from 151 (24 mg, 0.055 mmol) by the general method for
O–benzylation. The product was purified by FCC (1:4 EtOAc/n-hexane) to give the target
compound 198 as an orange oil (23 mg, 78%).

Rf (5:95 MeOH/CH2Cl2) = 0.50
[α]25
𝐷 +5.9 (c 1.00, CHCl3)
IR max (cm-1): 2995, 1679, 1443, 1256, 1055, 683 cm–1
LRESIMS m/z 530 (100%) [M+H]+.
HRESIMS found 530.2930, calcd for C33H40NO5, 530.2906 [M+H]+.
1H

NMR (500 MHz, CDCl3) δ7.39 – 7.21 (15H, m, ArH), 4.61 (1H, d, J = 11.9 Hz,

OCH2Ph), 4.56 – 4.44 (7H, m, OCH2Ph, H8b, H3a), 4.39 (1H, t, J = 4.1 Hz, H8), 4.17 (1H,
dd, J = 6.1, 4.2 Hz, H7), 3.59 (1H, dd, J = 5.8, 3.9 Hz, H6), 3.49 (2H, qd, J = 10.1, 4.2 Hz,
H1՛), 3.31 (1H, t, J = 4.0 Hz, H8a), 3.02 (1H, dt, J = 7.0, 2.8 Hz, H4), 1.49 (3H, s, C2–
CH3), 1.31 (6H, app. d, J = 4.9 Hz, C2–CH3 and H1՛՛).
13C

NMR (125 MHz, CDCl3) δ 138.8 (ArC), 138.5 (ArC), 138.4 (ArC), 128.3 (ArCH),

128.3 (ArCH), 128.2 (ArCH), 127.9 (ArCH), 127.82 (ArCH), 127.78 (ArCH), 127.6
(ArCH), 127.5 (ArCH), 127.3 (ArCH), 112.0 (C2), 89.3 (C7), 85.5 (C3a or C8b), 82.0
(C8), 80.7 (C3a or C8b), 73.3 (OCH2Ph), 72.0 (OCH2Ph), 71.9 (OCH2Ph or C8a), 71.7
(OCH2Ph or C8a), 70.1 (C1՛), 62.2 (C6), 57.3 (C4), 26.3 (C2–CH3), 24.2 (C2–CH3), 12.1
(C1՛՛).
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(1R,2S,3S,5R,6R,7R,7aR)-6,7-Bis(benzyloxy)-5-((benzyloxy)methyl)-3methylhexahydro-1H-pyrrolizine-1,2-diol (199)

Compound 199 was synthesized from 196 (122 mg, 0.230 mmol) using the general method
for hydrolysis of an acetonide. The product was purified by FCC (5:95 MeOH/CH2Cl2) to
give 199 as a brown oil (95 mg, 85%).

Rf (5:95 MeOH/CH2Cl2) = 0.26
[α]25
𝐷 +3.5 (c 1.00, CHCl3)
IR max (cm-1): 3397, 2887, 1676, 1592 1479, 1064, 687 cm–1
LRESIMS m/z 490 (100%) [M+H]+
HRESIMS found 490.2602, calcd for C30H36NO5, 490.2593 [M+H]+.
1H

NMR (500 MHz, CDCl3) δ 7.48 – 7.07 (15H, m, ArH), 4.61 (1H, d, J = 11.6 Hz,

OCH2Ph), 4.57 – 4.36 (6H, m, OCH2Ph, H1), 4.16 (1H, t, J = 4.0 Hz, H2), 3.95 (1H, t, J =
4.3 Hz, H7), 3.81 (1H, t, J = 4.1 Hz, H7a), 3.69 (1H, dd, J = 9.2, 3.9 Hz, H6), 3.51 (2H, d,
J = 6.5 Hz, H1՛), 3.26 (1H, q, J = 5.8 Hz, H3), 2.84 (1H, quint, J = 6.5 Hz, H5), 1.25 (3H,
d, J = 6.2 Hz, H1՛՛).
13C

NMR (125 MHz, CDCl3) δ 138.3 (ArC), 138.1 (ArC), 137.4 (ArC), 128.8 (ArCH),

128.7 (ArCH), 128.6 (ArCH), 128.30 (ArCH), 128.28 (ArCH), 128.1 (ArCH), 128.0
(ArCH), 127.9 (ArCH), 127.9 (ArCH), 84.3 (C2), 82.1 (C1), 79.7 (C6), 73.5 (OCH2Ph),
72.5 (OCH2Ph), 72.4 (OCH2Ph), 71.9 (C7), 71.1 (C7a), 70.7 (C1՛), 69.5 (C3), 65.4 (C5),
18.7 C1՛՛).
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(1S,2R,3R,5R,6R,7R,7aR)-6,7-Bis(benzyloxy)-5-((benzyloxy)methyl)-3methylhexahydro-1H-pyrrolizine-1,2-diol (200).

Compound 200 was synthesized from 197 (22 mg, 0.042 mmol) using the general method
for hydrolysis of an acetonide. The product was purified by FCC (5:95 MeOH/CH2Cl2) to
give the desired product 200 as a pale–yellow oil (20 mg, 98%).

Rf 0.20 (5:95 MeOH/CH2Cl2).
[α]25
𝐷 –38.9 (c 1.00, CHCl3).
IR max (cm-1): 3324, 3089, 2922, 2853, 1600, 1496, 1095, 608.
LRESIMS m/z 490 (100%) [M+H]+.
HRESIMS found 490.2577, calcd for C30H36NO5, 490.2593 [M+H]+.
1H

NMR (500 MHz, CDCl3) δ 7.41 – 7.16 (15H, m, ArH), 4.68 – 4.40 (6H, m, OCH2Ph),

4.01 (1H, t, J = 3.7 Hz, H2), 3.98 (1H, t, J = 5.0 Hz, H7), 3.91 (1H, t, J = 3.8 Hz, H1), 3.70
(1H, t, J = 6.0 Hz, H6), 3.50 (1H, t, J = 4.3 Hz, H7a), 3.44 (2H, d, J = 6.5 Hz, H1՛), 3.32
(1H, td, J = 6.5, 3.6 Hz, H3), 3.22 (1H, quint, J = 6.9 Hz, H5), 3.08 (2H, bs, OH), 1.19
(3H, d, J = 6.9 Hz, H1՛՛).
13C

NMR (125 MHz, CDCl3) δ 138.22 (ArC), 137.97 (ArC), 137.94 (ArC), 128.36

(ArCH), 128.29 (ArCH), 127.68 (ArCH), 127.65 (ArCH), 127.62 (ArCH), 127.53 (ArCH),
86.01 (C1), 85.37 (C2), 77.11 (C6), 74.76 (C7a), 73.83 (C7), 73.19 (OCH2Ph), 72.15
(OCH2Ph), 71.85 (C1՛), 71.53 (OCH2Ph), 61.52 (C3), 61.08 (C5), 15.18 (C1՛՛).
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(1R,2S,3R,5R,6R,7R,7aR)-6,7-Bis(benzyloxy)-5-((benzyloxy)methyl)-3methylhexahydro-1H-pyrrolizine-1,2-diol (201).

Compound 201 was synthesized from 198 (50 mg, 0.094 mmol) using the general method
for hydrolysis of an acetonide. The product was purified by FCC (5:95 MeOH/CH2Cl2) to
give the desired product 201 as a brown oil (39 mg, 85%).

Rf 0.26 (5:95 MeOH/CH2Cl2).
[α]25
𝐷 +24.4 (c 1.00, CHCl3).
IR max (cm-1): 3334, 3063, 2926, 1623, 1453, 1368, 1027, 737.
LRESIMS m/z 490 (100%) [M+H]+.
HRESIMS found 490.2585, calcd for C30H36NO5, 490.2593 [M+H]+.
1H

NMR (500 MHz, CDCl3) δ 7.37 – 7.21 (15H, m, ArH), 4.60 – 4.43 (6H, m, OCH2Ph),

4.31 (1H, t, J = 3.3 Hz, H1), 4.24 (1H, dd, J = 7.5, 4.8 Hz, H7), 4.11 (1H, t, J = 3.1 Hz,
H2), 3.89 (1H, t, J = 4.7 Hz, H6), 3.78 – 3.70 (2H, m, H7a, H3), 3.42 (2H, dd, J = 7.1, 3.3
Hz, H1՛), 3.37 (1H, dd, J = 7.1, 4.6 Hz, H5), 1.25 (3H, d, J = 7.0 Hz, H1՛՛).
13C

NMR (125 MHz, CDCl3) δ 138.2 (ArC), 138.1 (ArC), 137.0 (ArC), 128.6 (ArCH),

128.4 (ArCH), 128.4 (ArCH), 128.10 (ArCH), 128.08 (ArCH), 127.70 (ArCH), 127.69
(ArCH), 127.6 (ArCH), 85.3 (C2), 82.5 (C1), 75.0 (C6), 73.3 (OCH2Ph), 72.9 (C7), 72.0
(OCH2Ph), 71.9 (OCH2Ph), 71.6 (C7a or C3), 71.6 (C1՛), 62.4 (C7a or C3), 58.6 (C5), 11.9
(C1՛՛).
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(3aS,4S,6R,7R,8R,8aS,8bR)-7,8-Bis(benzyloxy)-6-((benzyloxy)methyl)-4methylhexahydro-4H-[1,3,2]dioxathiolo[4,5-a]pyrrolizine 2,2-dioxide (202)

Compound 202 was synthesized from the diol 199 (55 mg, 0.11 mmol) by using the general
method for the synthesis of a cyclic sulfate. The resultant crude brown oil 202 (61 mg) was
used for the next step without further purification.
LRESIMS m/z 586 (100%) [M+Cl]–.

(3aR,4R,6R,7R,8R,8aS,8bS)-7,8-Bis(benzyloxy)-6-((benzyloxy)methyl)-4methylhexahydro-4H-[1,3,2]dioxathiolo[4,5-a]pyrrolizine 2,2-dioxide (203)

Compound 203 was synthesized from the diol 200 (48 mg, 0.098 mmol) by using the
general method for the synthesis of a cyclic sulfate. The resultant crude brown oil 203 (54
mg) was used for the next step without further purification.
LRESIMS m/z 586 (100%) [M+Cl]–.
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(3aS,4R,6R,7R,8R,8aS,8bR)-7,8-Bis(benzyloxy)-6-((benzylo
xy)methyl)-4-methylhexahydro-4H-[1,3,2]dioxathiolo[4,5-a]pyrrolizine

2,2-dioxide

(204)

Compound 204 was synthesized from the diol 201 (40 mg, 0.082 mmol) by using the
general method for the synthesis of a cyclic sulfate. The resultant crude brown oil 204 (45
mg) was used for the next step without further purification.
LRESIMS m/z 586 (100%) [M+Cl]–.

General method for ring opening of cyclic sulfates with benzoate

(1S,2S,3S,5R,6R,7R,7aS)-6,7-Bis(benzyloxy)-5-((benzyloxy)methyl)-2-hydroxy-3methylhexahydro-1H-pyrrolizin-1-yl benzoate (205) and
(1R,2R,3S,5R,6R,7R,7aR)-6,7-bis(benzyloxy)-5-((benzyloxy)methyl)-1-hydroxy-3methylhexahydro-1H-pyrrolizin-2-yl benzoate (206)

To a solution of the cyclic sulfate 202 (61 mg, 0.11 mmol) in dry DMSO (1 mL) was added
benzoic acid (67 mg, 0.55 mmol) and cesium carbonate (180 mg, 0.55 mmol). The reaction
mixture was stirred under a nitrogen atmosphere at 50 oC for 20 h. After LRESIMS
confirmed the consumption of starting material, a mixture of THF (2 mL), distilled water
(0.75 mL) and conc. H2SO4 (0.25 mL) was added to the mixture and stirred at 60 oC for 20
h. The reaction mixture was neutralized with saturated NaHCO3 until a pH of 7 was
achieved, followed by extraction with CH2Cl2 (3 x 15 mL). The combined extracts were
dried (MgSO4), filtered and concentrated in vacuo to give a brown oil. Purification by FCC
(1:1 diethyl ether/n-hexane) gave 205 (40 mg, 61%) and 206 (8 mg, 12%) as clear films.
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205:
Rf (1:1 diethyl ether/n-hexane) = 0.26
[α]25
𝐷 –12.2 (c 1.00, CHCl3)
IR max (cm-1): 3367, 3089, 2946, 1687, 1525, 1167, 1038, 598 cm–1
LRESIMS m/z 594 (100%) [M+H]+.
HRESIMS found 594.2874, calcd for C37H40NO5, 594.2856 [M+H]+.
1H

NMR (500 MHz, CDCl3) δ 8.04 (2H, d, J = 7.7 Hz, o–Bz), 7.60 (1H, t, J = 7.5 Hz, p–

Bz), 7.46 (2H, t, J = 7.7 Hz, m–Bz), 7.36 – 7.19 (15H, m, ArH), 5.13 (1H, t, J = 5.7 Hz,
H7), 4.63 – 4.47 (6H, m, OCH2Ph), 4.28 (1H, t, J = 4.0 Hz, H1), 4.14 (1H, t, J = 3.1 Hz,
H2), 3.94 (1H, t, J = 6.7 Hz, H6), 3.73 (1H, t, J = 5.3 Hz, H7a), 3.63 (1H, s, OH), 3.52 –
3.45 (2H, q, J = 9.4, 7.4 Hz, H1՛), 3.35 (1H, t, J = 9.2, 4.5 Hz, H3), 3.21 (1H, quint, J = 6.5
Hz, H5), 1.24 (3H, d, J = 6.2 Hz, H1՛՛).
13C NMR (125 MHz, CDCl

3) δ

167.8 (CO), 138.4 (ArC), 138.0 (ArC), 137.9 (ArC), 133.6

(ArC), 129.9 (ArCH), 129.4 (ArCH), 128.6 (ArCH), 128.5 (ArCH), 128.4 (ArCH), 128.4
(ArCH), 128.8 (ArCH), 127.73 (ArCH), 127.69 (ArCH), 127.6 (ArCH), 127.6 (ArCH),
87.7 (C1), 86.4 (C2), 85.1 (C7), 82.5 (C6), 73.3 (OCH2Ph), 71.94 (OCH2Ph), 71.90
(OCH2Ph), 71.7 (C1՛), 71.5 (C7a), 68.7 (C3), 66.5 (C5), 19.3 (C1՛՛).

206:
Rf (1:1 diethyl ether/n-hexane) = 0.38
[α]25
𝐷 +54.7 (c 1.00, CHCl3)
IR max (cm-1): 3369, 3097, 2958, 1608, 1539, 1137, 1023, 699 583 cm–1
LRESIMS m/z 594 (100%) [M+H]+.
1H

NMR (500 MHz, CDCl3) δ 8.04 (2H, d, J = 7.5 Hz, o–Bz), 7.56 (1H, t, J = 7.5 Hz, p–

Bz), 7.43 (2H, t, J = 7.6 Hz, m–Bz), 7.38 – 7.23 (15H, m, ArH), 5.31 (1H, d, J = 4.0 Hz,
H6), 4.62 – 4.51 (3H, m, OCH2Ph), 4.53 – 4.43 (3H, m, OCH2Ph), 4.30 (1H, d, J = 2.6 Hz,
H1), 4.22 (1H, d, J = 2.4 Hz, H2), 4.10 (1H, t, J = 6.1 Hz, H7), 3.98 (1H, dd, J = 4.6, 2.2
Hz, H7a), 3.56 (1H, t, J = 9.0 Hz, H1՛), 3.52 – 3.38 (3H, m, OH, H1՛, H5), 3.30 (1H, ddd,
J = 8.6, 5.9, 2.4 Hz, H3), 1.15 (3H, d, J = 6.5 Hz, H1՛՛).
13C NMR (125 MHz, CDCl

3) δ

165.9 (CO), 138.4 (ArC), 137.9 (ArC), 137.0 (ArC), 133.1

(ArC), 129.8 (ArCH), 128.6 (ArCH), 128.43 (ArCH), 128.36 (ArCH), 128.3 (ArCH),
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128.1 (ArCH), 128.1 (ArCH), 127.8 (ArCH), 127.7 (ArCH), 127.6 (ArCH), 127.5 (ArCH),
84.9 (C2), 83.2 (C6), 82.3 (C1), 75.4 (C7), 73.3 (OCH2Ph), 73.2 (C7a), 72.1 (OCH2Ph),
72.0 (C1՛), 71.7 (OCH2Ph), 69.8 (C3), 62.5 (C5), 16.1 (C1՛՛).

(1S,2S,3R,5R,6R,7R,7aR)-6,7-bis(benzyloxy)-5-((benzyloxy)methyl)-1-hydroxy-3methylhexahydro-1H-pyrrolizin-2-yl benzoate (207) and
(1R,2R,3R,5R,6R,7R,7aS)-6,7-Bis(benzyloxy)-5-((benzyloxy)methyl)-2-hydroxy-3methylhexahydro-1H-pyrrolizin-1-yl benzoate (208)

Compounds 207 and 208 were synthesized from the cyclic sulfate 203 (61 mg, 0.11 mmol)
using the general method for ring opening of cyclic sulfates with benzoate. Purification by
FCC (1:1 EtOAc/n-hexane) gave an inseparable and complex mixture of 207 and 208 (32
mg, 49%). This mixture was subsequently subjected to O–benzoyl hydrolysis (see General
method below) to afford 213 (5 mg, 19%) and 214 (20 mg, 75%) which were separable by
FCC (5:95 MeOH/CH2Cl2).

Rf (1:1 EtOAc/n-hexane) = 0.50
LRESIMS m/z 594 (100%) [M+H]+.
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(1R,2R,3R,5R,6R,7R,7aR)-6,7-Bis(benzyloxy)-5-((benzyloxy)methyl)-1-hydroxy-3methylhexahydro-1H-pyrrolizin-2-yl benzoate (209) and
(1S,2S,3R,5R,6R,7R,7aS)-6,7-bis(benzyloxy)-5-((benzyloxy)methyl)-2-hydroxy-3methylhexahydro-1H-pyrrolizin-1-yl benzoate (210)

Compounds 209 and 210 were synthesized from the cyclic sulfate 204 (45 mg, 0.082
mmol) using the general method for ring opening of cyclic sulfates with benzoate.
Purification by FCC (2:3 EtOAc/n-hexane) gave pure samples of the two title compounds,
209 (11 mg, 23%) and 210 (19 mg, 39%), as clear yellow films.

209:
Rf (2:3 EtOAc/n-hexane) = 0.56
[α]25
𝐷 +13.4 (c 1.00, CHCl3)
IR max (cm-1): 3340, 3063, 2922, 1707, 1496, 1154, 1027, 583 cm–1
LRESIMS m/z 594 (100%) [M+H]+.
HRESIMS found 594.2877, calcd for C37H40NO6, 594.2856 [M+H]+.
1H

NMR (500 MHz, CDCl3) δ 8.04 (2H, d, J = 7.7 Hz, o–Bz), 7.57 (1H, t, J = 7.4 Hz, p–

Bz), 7.44 (2H, t, J = 7.7 Hz, m–Bz), 7.38 – 7.20 (15H, m, ArH), 5.04 (1H, dd, J = 7.3, 4.5
Hz, H6), 4.69 – 4.43 (6H, m, OCH2Ph), 4.30 – 4.19 (2H, m, H1, H7), 4.14 (1H, s, H2),
3.87 (1H, dd, J = 7.1, 2.5 Hz, H7a), 3.55 (1H, d, J = 6.9 Hz, H3), 3.45 (1H, d, J = 9.4 Hz,
H1՛), 3.42 – 3.30 (2H, m, H1՛, H5), 1.32 (3H, d, J = 7.0 Hz, H1՛՛).
13C NMR (125 MHz, CDCl

3) δ

166.7 (CO), 138.3 (ArC), 138.0 (ArC), 137.2 (ArC), 133.2

(ArC), 129.9 (ArCH), 129.8 (ArCH), 128.7 (ArCH), 128.5 (ArCH), 128.4 (ArCH), 128.3
(ArCH), 128.1 (ArCH), 128.0 (ArCH), 127.7 (ArCH), 127.7 (ArCH), 127.6 (ArCH), 86.3
(C6), 85.2 (C2), 82.5 (C1), 77.2 (C7), 73.2 (OCH2Ph), 72.2 (C1՛), 71.8 (OCH2Ph), 71.7
(OCH2Ph), 71.4 (C7a), 62.5 (C3), 58.4 (C5), 15.3 (C1՛՛).

210:
Rf (2:3 EtOAc/n-hexane) = 0.39
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[α]25
𝐷 +9.0 (c 1.00, CHCl3)
IR max (cm-1): 3330, 3112, 2970, 1646, 1453, 1095, 906, 565 cm–1
LRESIMS m/z 594 (100%) [M+H]+.
1H

NMR (500 MHz, CDCl3) δ 8.02 (2H, d, J = 7.8 Hz, o–Bz), 7.57 (1H, t, J = 7.4 Hz, p–

Bz), 7.43 (2H, t, J = 7.6 Hz, m–Bz), 7.37 – 7.22 (15H, m, ArH), 5.16 (1H, d, J = 3.2 Hz,
H7), 4.63 – 4.42 (7H, m, OCH2Ph, H1), 4.14 (1H, s, H2), 4.02 (1H, d, J = 3.7 Hz, H6),
3.84 (1H, t, J = 7.8 Hz, H3), 3.66 (1H, d, J = 3.2 Hz, H7a), 3.58 (1H, dt, J = 10.6, 5.1 Hz,
H5), 3.44 (2H, d, J = 7.8 Hz, H1՛), 1.38 (3H, d, J = 7.0 Hz, H1՛՛).
13C NMR (125 MHz, CDCl

3) δ

166.3 (CO), 138.4 (ArC), 137.9 (ArC), 136.5 (ArC), 133.2

(ArC), 130.0 (ArCH), 129.8 (ArCH), 129.7 (ArCH), 128.6 (ArCH), 128.4 (ArCH), 128.4
(ArCH), 128.3 (ArCH), 128.24 (ArCH), 128.20 (ArCH), 127.7 (ArCH), 127.6 (ArCH),
127.5 (ArCH), 85.6 (C2), 85.3 (C1), 85.1 (C7), 79.5 (C6), 76.4 (C7a), 73.2 (OCH2Ph),
72.7 (C1՛), 72.0 (OCH2Ph), 71.6 (OCH2Ph), 63.5 (C3), 61.2 (C5), 11.4 (C1՛՛).

General method for O-Benzoyl hydrolysis
(1S,2S,3S,5R,6R,7R,7aR)-6,7-Bis(benzyloxy)-5-((benzyloxy)methyl)-3methylhexahydro-1H-pyrrolizine-1,2-diol (211)

To a solution of 205 (23 mg, 0.039 mmol) in MeOH (5 mL) was added solid K2CO3 (8.2
mg, 0.060 mmol). After stirring at 40 oC for 2 h, all volatiles were evaporated and the
residue was dissolved in EtOAc. The solution was washed with water (3 x 5 mL) and brine
(5 mL), dried (MgSO4), filtered and concentrated in vacuo to give a brown oil. The crude
product was purified by FCC (5:95 MeOH/CH2Cl2) to give the product 211 as colourless
crystals (15 mg, 79%).

Rf (5:95 MeOH/CH2Cl2) = 0.28
[α]25
𝐷 +14.6 (c 1.00, CHCl3)
M.P: 115 – 120 oC
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IR max (cm-1): 3370, 3078, 2968, 2930, 1679, 1502, 1467, 1320, 1089, 687 cm–1
LRESIMS m/z 490 [M+H]+.
HRESIMS found 490.2617, calcd for C30H36NO5, 490.2593 [M+H]+.
1H

NMR (500 MHz, CDCl3) δ 7.33 – 7.21 (15H, m, ArH), 4.61 – 4.41 (6H, m, OCH2Ph),

4.10 (1H, t, J = 3.6 Hz, H2), 4.07 (1H, t, J = 3.6 Hz, H1), 3.97 (1H, t, J = 7.5 Hz, H7), 3.68
(1H, t, J = 8.1 Hz, H6), 3.48 – 3.40 (3H, m, H1՛ and H7a), 3.23 (1H, dt, J = 9.8, 4.5 Hz,
H3), 3.06 (2H, s, OH), 2.93 (1H, dq, J = 12.6, 6.4 Hz, H5), 1.17 (3H, d, J = 6.2 Hz, H1՛՛).
13C NMR (125 MHz, CDCl

3) δ 138.3 (ArC), 138.01 (ArC), 138.00 (ArC), 128.42 (ArCH),

128.40 (ArCH), 128.3 (ArCH), 127.8 (ArCH), 127.69 (ArCH), 127.67 (ArCH), 127.5
(ArCH), 87.2 (C1), 86.0 (C2), 83.1 (C6), 80.2 (C7), 73.2 (OCH2Ph), 72.3 (C7a), 71.9
(OCH2Ph), 71.6 (OCH2Ph), 71.3 (C1՛), 69.2 (C3), 65.3 (C5), 19.0 (C1՛՛).

(1R,2R,3S,5R,6R,7R,7aR)-6,7-Bis(benzyloxy)-5-((benzyloxy)methyl)-3methylhexahydro-1H-pyrrolizine-1,2-diol (212)

Compound 212 was synthesized from 206 (8.0 mg, 0.014 mmol) using the general method
for O–benzoyl deprotection. The crude brown oil was purified by FCC (5:95
MeOH/CH2Cl2) to give the product 212 as a clear yellow oil (6.0 mg, 90%.)

Rf (5:95 MeOH/CH2Cl2) = 0.15
[α]25
𝐷 +17.4 (c 1.00, CHCl3)
IR max (cm-1): 3387, 3049, 2922, 1643, 1428, 1354, 1067, 697 cm–1
LRESIMS m/z 490 [M+H]+.
HRESIMS found 490.2613, calcd for C30H36NO5, 490.2593 [M+H]+.
1H

NMR (500 MHz, CDCl3) δ 7.53 – 7.05 (15H, m, ArH), 4.64 – 4.40 (6H, m, OCH2Ph),

4.32 (1H, s, H1), 4.22 – 4.14 (2H, m, H2 and H7), 4.09 (1H, s, H7a), 3.94 (1H, s, H6), 3.61
– 3.55 (2H, m, H1՛), 3.37 – 3.32 (1H, m, H3), 3.29 (1H, bs, H5), 1.23 (3H, d, J = 6.5 Hz,
H1՛՛).
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13C

NMR (125 MHz, CDCl3) δ 138.1 (ArC), 137.7 (ArC), 136.7 (ArC), 128.6 (ArCH),

128.5 (ArCH), 128.4 (ArCH), 128.2 (ArCH), 128.1 (ArCH), 127.9 (ArCH), 127.74
(ArCH), 127.70 (ArCH), 127.66 (ArCH), 84.8 (C2), 81.4 (C1), 81.2 (C6), 76.8 (C7a), 73.3
(OCH2Ph), 72.9 (C7), 72.4 (OCH2Ph), 72.0 (OCH2Ph), 70.6 (C1՛), 69.3 (C3), 64.2 (C5),
14.0 (H1՛՛).

(1R,2R,3R,5R,6R,7R,7aR)-6,7-Bis(benzyloxy)-5-((benzyloxy)methyl)-3methylhexahydro-1H-pyrrolizine-1,2-diol (213)

Compound 213 was synthesized from 209 (11 mg, 0.017 mmol) using the general method
for O–benzoyl deprotection. Purification by FCC (5:95 MeOH/CH2Cl2) returned the
product 213 as a brown film (7.5 mg, 90%).

Rf (5:95 MeOH/CH2Cl2) = 0.20
[α]25
𝐷 –25.4 (c 1.00, CHCl3)
IR max (cm-1): 3360, 3068, 2937, 1640, 1450, 1029, 681 cm–1
LRESIMS m/z 490 (100%) [M+H]+.
HRESIMS found 490.2608, calcd for C30H36NO5, 490.2593 [M+H]+.
1H

NMR (500 MHz, CDCl3) δ 7.43 – 7.10 (15H, m, ArH), 4.67 – 4.36 (6H, m, OCH2Ph),

4.19 (1H, t, J = 2.6 Hz, H1), 4.09 (1H, s, H2), 3.99 (1H, dd, J = 7.5, 4.7 Hz, H7), 3.89 (1H,
dd, J = 7.5, 2.8 Hz, H7a), 3.67 (1H, dd, J = 7.5, 4.6 Hz, H6), 3.53 – 3.40 (3H, m, H3, H1՛),
3.17 (1H, quint, J = 6.5, 6.1 Hz, H5), 2.02 (1H, bs, OH), 1.29 (3H, d, J = 6.9 Hz, H1՛՛).
13C

NMR (125 MHz, CDCl3) δ 138.2 (ArC), 137.9 (ArC), 137.0 (ArC), 128.6 (ArCH),

128.4 (ArCH), 128.4 (ArCH), 128.13 (ArCH), 128.07 (ArCH), 127.8 (ArCH), 127.7
(ArCH), 127.7 (ArCH), 127.7 (ArCH), 85.0 (C2), 84.4 (C6), 82.3 (C1), 79.4 (C7), 73.3
(OCH2Ph), 72.1 (C1՛), 71.9 (OCH2Ph), 71.8 (OCH2Ph), 70.3 (C7a), 62.6 (C3), 60.3 (C5),
14.7 (C1՛՛).
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(1S,2S,3R,5R,6R,7R,7aR)-6,7-Bis(benzyloxy)-5-((benzyloxy)methyl)-3methylhexahydro-1H-pyrrolizine-1,2-diol (214)

Compound 214 was synthesized from benzoate 210 (15 mg, 0.025 mmol) using the general
method for O–benzoyl deprotection, except that the reaction was stirred at rt for 1 h. The
crude brown oil was purified by FCC (5:95 MeOH/CH2Cl2) to give the product 214 as a
clear brown film (10 mg, 83%).

Rf (5:95 MeOH/CH2Cl2) = 0.14
[α]25
𝐷 –1.62 (c 1.00, CHCl3)
IR max (cm-1): 3389, 2890, 1654, 1489, 1054 cm–1
LRESIMS m/z 490 (100%) [M+H]+.
HRESIMS found 490.2615, calcd for C30H36NO5, 490.2593 [M+H]+.
1H

NMR (500 MHz, CDCl3) δ 7.45 – 7.17 (15H, m, ArH), 4.64 – 4.43 (6H, m, OCH2Ph),

4.14 – 4.08 (3H, m, H7, H1, H2), 3.81 (1H, dd, J = 3.8, 1.8 Hz, H6), 3.73 (1H, td, J = 6.9,
3.0 Hz, H3), 3.65 (1H, q, J = 5.2, 4.5 Hz, H5), 3.56 (1H, t, J = 3.1 Hz, H7a), 3.44 (2H, d,
J = 1.6 Hz, H1՛), 1.28 (3H, d, J = 7.0 Hz, H1՛՛).
13C

NMR (125 MHz, CDCl3) δ 138.2 (ArC), 137.8 (ArC), 136.9 (ArC), 128.6 (ArCH),

128.5 (ArCH), 128.3 (ArCH), 128.12 (ArCH), 128.10 (ArCH), 127.8 (ArCH), 127.7
(ArCH), 127.6 (ArCH), 85.8 (C1 or C7 or C2), 85.0 (C1 or C7 or C2), 81.5 (C6), 81.3 (C1
or C7 or C2), 76.8 (C7a), 73.2 (OCH2Ph), 72.3 (OCH2Ph), 71.8 (OCH2Ph), 71.6 (C1՛),
62.5 (C3), 60.1 (C5), 11.4 (C1՛՛).
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(1R,2R,3R,5S,6S,7S,7aR)-3-(hydroxymethyl)-5-methylhexahydro-1H-pyrrolizine1,2,6,7-tetraol [Initially proposed structure of (+)-hyacinthacine C5]

The compound initially proposed to be (+)-hyacinthacine C5117 was synthesized by the
general method of O–benzyl deprotection from 211 (20 mg, 0.04 mmol). The crude
product was filtered through a pad of celite and washed with additional MeOH (6 mL).
The combined filtrates were concentrated in vacuo returning a yellow film. The title
compound was isolated through basic ion–exchange chromatography followed by
concentration in vacuo, as a colourless film (9.0 mg, 99%).
[α]25
𝐷 +9.5 (c 1.00, H2O)
IR max (cm-1): 3302, 2952, 2926, 1603, 1545, 1212, 1079, 694 cm–1
LRESIMS m/z 220 [M+H]+.
HRESIMS found 220.1177, calcd for C9H18NO5, 220.1185 [M+H]+.
1H

NMR (500 MHz, D2O) δ 4.15 (1H, t, J = 7.0 Hz, H1), 4.11 (1H, t, J = 7.1 Hz, H7),

3.96 (1H, t, J = 7.0 Hz, H2), 3.74 – 3.61 (3H, m, H6, H8), 3.05 (1H, t, J = 6.8 Hz, H7a),
2.96 – 2.87 (2H, m, H5, H3), 1.20 (3H, d, J = 6.2 Hz, H9).
13C

NMR (125 MHz, D2O) δ 82.9 (C6), 80.2 (C1), 79.6 (C7), 79.3 (C2), 71.2 (C7a), 71.1

(C5), 66.0 (C3), 62.9 (C8), 17.8 (C9).

(1R,2R,3R,5S,6R,7R,7aR)-3-(Hydroxymethyl)-5-methylhexahydro-1H-pyrrolizine1,2,6,7-tetraol [(+)-5-epi-hyacinthacine C5] (215)
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(+)–6,7-Di-epi-hyacinthacine C5 215 was synthesized by the general method of O–benzyl
deprotection from 212 (6.0 mg, 0.012 mmol). The crude product was filtered through a
pad of celite and washed with additional MeOH (6 mL). The combined filtrates were
concentrated in vacuo returning a yellow film. The title compound 215 was isolated
through basic ion–exchange chromatography followed by concentration in vacuo, as a
white solid (2.0 mg, 78%).
[α]25
𝐷 +10.3 (c 1.00, H2O)
IR max (cm-1): 3298, 2963, 1593, 1546, 1273, 1086, 699 cm–1
LRESIMS m/z 220 (100%) [M+H]+.
HRESIMS found 220.1175, calcd for C9H18NO5, 220.1185 [M+H]+.
1H

NMR (500 MHz, D2O) δ 4.28 (1H, t, J = 7.5 Hz, H1), 4.21 (1H, dd, J = 4.7, 2.4 Hz,

H7), 4.13 (1H, dd, J = 4.2, 2.4 Hz, H6), 3.96 (1H, t, J = 8.4 Hz, H2), 3.78 (1H, dd, J =
12.3, 4.0 Hz, H8), 3.68 (1H, dd, J = 12.0, 4.6 Hz, H8), 3.46 (1H, dd, J = 7.2, 4.6 Hz, H7a),
3.14 (1H, q, J = 6.1, 4.9, 4.3 Hz, H5), 2.78 (1H, dd, J = 9.3, 4.6 Hz, H3), 1.17 (3H, d, J =
6.9 Hz, H9).
13C

NMR (125 MHz, D2O) δ 82.2 (C6), 81.2 (C2), 76.8 (C7), 75.6 (C1), 73.1 (C3), 71.6

(C7a), 65.2 (C5), 64.2 (C8), 16.5 (C9).

(1R,2R,3R,5R,6R,7R,7aR)-3-(Hydroxymethyl)-5-methylhexahydro-1H-pyrrolizine1,2,6,7-tetraol [Corrected structure for (+)-hyacinthacine C5] (216)

The compound for the corrected structure of (+)-hyacinthacine C5 216 was synthesized by
the general method of O–benzyl deprotection from 213 (7.0 mg, 0.014 mmol). The crude
product was filtered through a pad of celite and washed with additional MeOH (6 mL).
The combined filtrates were concentrated in vacuo returning a yellow film. The title
compound 216 was isolated through basic ion–exchange chromatography followed by
concentration in vacuo, as a colourless film (3.0 mg, 95%).
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[α]25
𝐷 +5.25 (c 1.00, H2O)
IR max (cm-1): 3296, 2928, 1602, 1430, 1072 cm–1
LRESIMS m/z 220 (100%) [M+H]+.
HRESIMS found 220.1201, calcd for C9H18NO5, 220.1185 [M+H]+.
1H

NMR (500 MHz, D2O) δ 4.14 (2H, apparent q, J = 7.7 Hz, H7 and H1), 3.94 (1H, t, J

= 7.8 Hz, H2), 3.74 (1H, t, J = 7.7 Hz, H6), 3.66 (2H, dd, J = 9.5, 4.7 Hz, H8), 3.38 (1H,
t, J = 7.6 Hz, H7a), 3.14 (1H, td, J = 9.1, 4.7, 4.0 Hz, H3), 2.95 (1H, dq, J = 6.6, 7.4 Hz,
H5), 1.27 (3H, d, J = 6.7 Hz, H9).
13C

NMR (125 MHz, D2O) δ 78.8 (C6), 78.1 (C2), 75.2 (C1), 74.9 (C7), 66.3 (C7a), 62.8

(C8), 62.1 (C3), 58.4 (C5), 12.8 (C9).

(1R,2R,3R,5R,6S,7S,7aR)-3-(Hydroxymethyl)-5-methylhexahydro-1H-pyrrolizine1,2,6,7-tetraol [(+)-6,7-di-epi-hyacinthacine C5] (217)

(+)–5-Epi-hyacinthacine C5 217 was synthesized by the general method of O–benzyl
deprotection from 214 (10 mg, 0.020 mmol). The crude product was filtered through a pad
of celite and washed with additional MeOH (6 mL). The combined filtrates were
concentrated in vacuo returning a green film. The title compound 217 was isolated through
basic ion–exchange chromatography followed by concentration in vacuo, as a colourless
film (3.4 mg, 75%).
[α]25
𝐷 +6.8 (c 1.00, H2O)
IR max (cm-1): 3290, 2943, 1593, 1375, 1208, 1079 cm–1
LRESIMS m/z 220 (100%) [M+H]+.
HRESIMS found 220.1180, calcd for C9H18NO5, 220.1185 [M+H]+.
1H

NMR (500 MHz, D2O) δ 4.18 (1H, t, J = 4.0 Hz, H7), 4.07 – 3.97 (2H, m, H6, H1),

3.90 (1H, t, J = 8.1 Hz, H2), 3.67 (2H, t, J = 4.0 Hz, H8), 3.41 (1H, dt, J = 11.7, 5.7 Hz,
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H5), 3.33 (1H, dt, J = 9.0, 4.9 Hz, H3), 3.07 (1H, dd, J = 8.1, 3.7 Hz, H7a), 1.24 (3H, d, J
= 7.1 Hz, H9).
13C

NMR (125 MHz, D2O) δ 79.7 (C6 or C7), 78.6 (C6 or C7), 78.0 (C1), 77.9 (C2), 72.1

(C7a), 62.9 (C8), 62.2 (C3), 58.1 (C5), 10.7 (C9).

(1R,2R,3R,5R,6S,7S,7aR)-3-(acetoxymethyl)-5-methylhexahydro-1H-pyrrolizine1,2,6,7-tetrayl tetraacetate (218)

To a solution of 217 (8.0 mg, 0.037 mmol) in pyridine (147 µL, 1.83 mmol) was added
acetic anhydride (173 µL, 1.83 mmol) and a crystal of 4–dimethylaminopyridine. The
mixture was stirred at rt for 24 h, by which time LRESIMS analysis confirmed full
consumption of the starting material. The reaction was quenched through the addition of
sat. NaHCO3 solution (3 mL) and extracted with CH2Cl2 (3 x 5 mL). The combined extracts
were dried (MgSO4), filtered and concentrated in vacuo to give an orange oil. Purification
by FCC (3:97 MeOH/CH2Cl2) gave the pentaacetylated product 218 as a pale–yellow film
(15 mg, 95%).

Rf (3:95 MeOH/CH2Cl2) = 0.35
[α]25
𝐷 +12.9 (c 1.00, CHCl3)
IR max (cm-1): 2934, 1736, 1432, 1368, 1217, 1033, 886, 603 cm–1
LRESIMS m/z 430 (100%) [M+H]+
HRESIMS found 430.1731, calcd for C19H28NO10, 430.1713 [M+H]+.
1H

NMR (500 MHz, CDCl3) δ 5.36 (1H, t, J = 4.8 Hz, H1), 5.24 (1H, t, J = 4.8 Hz, H2),

5.20 (2H, dd, J = 7.6, 3.8 Hz, H6, H7), 4.04 (2H, qd, J = 11.3, 5.8 Hz, H1՛), 3.72 – 3.57
(2H, m, J = 6.1 Hz, H3, H5), 3.41 (1H, t, J = 4.5 Hz, H7a), 2.14 – 2.05 (15H, m, 5 x
AcCH3), 1.25 (3H, d, J = 7.1 Hz, H1՛՛).
13C

NMR (125 MHz, CDCl3) δ 170.8 (CO), 170.2 (CO), 169.9 (CO), 169.7 (CO), 169.6

(CO), 80.4 (C6), 79.5 (C7), 78.6 (C2), 77.6 (C1), 73.1 (C7a), 65.5 (C1՛), 60.4 (C3), 58.6
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(C5), 20.94 (AcCH3), 20.92 (AcCH3), 20.89 (AcCH3), 20.85 (AcCH3), 20.8 (AcCH3), 11.3
(C1՛՛).
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Chapter 5
tert-Butyl

((R,E)-1-((4R,5S,6S)-5-(benzyloxy)-6-((benzyloxy)methyl)-2,2-dioxido-

1,3,2-dioxathian-4-yl)-3-phenylallyl)((R)-but-3-en-2-yl)carbamate (225)

Compound 225 was synthesized from the N–Boc diol 139 (60 mg, 0.10 mmol) by using
the general method for the synthesis of a cyclic sulfate. The resultant crude brown oil 225
(66 mg) was used for the next step without further purification.
LRESIMS m/z 684 (100%) [M+Cl]–.

(4R,5S)-5-((1R,2S)-1,3-bis(benzyloxy)-2-hydroxypropyl)-3-((R)-but-3-en-2-yl)-4((E)-styryl)oxazolidin-2-one (224)

Cyclic sulfate 225 (66 mg, 0.10 mmol) was dissolved in anhydrous MeCN (10 mL) and
heated to 50 oC and stirred for 2 h. After TLC confirmed the consumption of starting
material, the reaction mixture was cooled to rt, followed by the addition of a solution of
THF (4 mL), distilled water (1.5 mL) and conc. H2SO4 (0.5 mL). The reaction mixture was
heated at 50 oC and stirred for 1 h. After TLC confirmed the full consumption of starting
material, the reaction mixture was allowed to cool to rt and neutralized with saturated
NaHCO3 until a pH of 7 was achieved. The solution was extracted with CH2Cl2 (3 x 15
mL), dried (MgSO4), filtered and concentrated in vacuo. Purification by FCC (2:3
EtOAc/n-hexane) returned the oxozolidinone 224 as a pale–yellow oil (20 mg, 39%).
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Rf (1:1 EtOAc/n-hexane) = 0.64
[α]25
𝐷 +20.2 (c 2.00, CHCl3).
IR max (cm-1): 3430, 3028, 2976, 1789, 1214, 1078, 1065, 1083, 951 cm–1
LRESIMS m/z 536 (100%) [M+Na]+.
HRESIMS found 536.2408, calcd for C32H35NO5Na, 536.2413 [M+Na]+.
1H

NMR (500 MHz, CDCl3) δ 7.40 – 7.22 (15H, m, Ar), 6.47 (1H, d, J = 15.8 Hz, H2′′′),

6.02 (1H, dd, J = 15.8, 9.0 Hz, H1′′′), 5.84 (1H, ddd, J = 16.8, 10.7, 5.9 Hz, H2′), 5.15 –
5.09 (2H, m, H3′), 4.77 (1H, d, J = 10.9 Hz, OCH2Ph), 4.64 (1H, d, J = 11.0 Hz, OCH2Ph),
4.53 (1H, dd, J = 8.9, 5.1 Hz, H4), 4.50 – 4.44 (2H, m, OCH2Ph), 4.39 – 4.31 (2H, m H5,
H1′), 3.91 (1H, t, J = 3.8 Hz, H1′′′′), 3.84 (1H, td, J = 5.8, 3.8 Hz, H2′′′′), 3.48 (1H, dd, J
= 9.7, 5.6 Hz, H3′′′′), 3.43 (1H, dd, J = 9.7, 5.6 Hz, H3′′′′), 2.46 (1H, d, J = 6.2 Hz, OH),
1.28 (3H, d, J = 7.0 Hz H1′′).
13C

NMR (125 MHz, CDCl3) δ 156.6 (C2), 137.5 (ArC), 137.4 (ArC), 136.8 (C2′), 135.7

(ArC), 133.9 (C2′′′), 128.7 (ArCH), 128.64 (ArCH), 128.62 (ArCH), 128.5 (ArCH), 128.4
(ArCH), 128.3 (C1′′′), 128.2 (ArCH), 127.9 (ArCH), 126.6 (ArCH), 117.1 (C3′), 79.9 (C5),
78.9 (C1′′′′), 75.7 (OCH2Ph), 73.5 (OCH2Ph), 70.8 (C3′′′′), 69.4 (C2′′′′), 58.2 (C7a), 51.7
(C1′), 18.3 (C1′′).

(1S,5R,7aR)-1-((1R,2S)-1,3-Bis(benzyloxy)-2-hydroxypropyl)-5-methyl-5,7adihydro-1H,3H-pyrrolo[1,2-c]oxazol-3-one (223)

Compound 223 was synthesized from 224 (20 mg, 0.039 mmol), using the general method
for ring–closing metathesis. The crude black oil was purified by FCC (1:1 EtOAc/nhexane) to give 223 as a grey oil (15 mg, 95%).

Rf (1:1 EtOAc/n-hexane) = 0.64
[α]25
𝐷 ‒6.6 (c 1.37, CHCl3).
IR max (cm-1): 3345, 2998, 2885, 1632, 1456, 1279, 1098, 1020, 965 cm–1
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LRESIMS m/z 432 (100%) [M+Na]+.
HRESIMS found 432.1793, calcd for C24H27NO5Na, 432.1787 [M+Na]+.
1H

NMR (500 MHz, CDCl3) δ 7.39 – 7.22 (10H, m, ArH), 5.83 (1H, d, J = 6.1 Hz, H6),

5.76 (1H, d, J = 6.1 Hz, H7), 4.98 (1H, d, J = 8.9 Hz, H7a), 4.83 (1H, d, J = 11.2 Hz,
OCH2Ph), 4.62 (1H, d, J = 11.2 Hz, OCH2Ph), 4.50 – 4.46 (2H, m, OCH2Ph), 4.37 (1H,
dd, J = 9.0, 3.5 Hz, H1), 4.30 (1H, t, J = 6.2 Hz, H5), 3.98 (1H, s, H1′), 3.86 (1H, d, J =
6.9 Hz, H2′), 3.54 (1H, dd, J = 9.4, 6.4 Hz, H3′), 3.44 (1H, dd, J = 9.4, 6.3 Hz, H3′), 2.34
(1H, d, J = 7.2 Hz, OH), 1.55 (3H, d, J = 6.7 Hz, H1′′).
13C

NMR (125 MHz, CDCl3) δ 157.0 (C3), 137.55 (ArC), 137.49 (ArC), 136.4 (C7),

128.53 (ArCH), 128.52 (ArCH), 128.4 (ArCH), 128.2 (ArCH), 128.0 (ArCH), 127.9
(ArCH), 127.3 (C6), 83.1 (C1), 77.0 (C1′), 75.2 (OCH2Ph), 73.5 (OCH2Ph), 70.8 (C3′),
70.3 (C2′), 68.2 (C7a), 60.2 (C5), 17.4 (C1′′).

(1S,5R,6R,7S,7aR)-1-((1R,2S)-1,3-Bis(benzyloxy)-2-hydroxypropyl)-6,7-dihydroxy5-methyltetrahydro-1H,3H-pyrrolo[1,2-c]oxazol-3-one (228)

Compound 228 was synthesized from 223 (15 mg, 0.037 mmol) using the general method
for cis–dihydroxylation. The product was purified by FCC (5:95 MeOH/CH2Cl2) to give
228 as a light brown oil (12 mg, 72%).

Rf (1:1 EtOAc/n-hexane) = 0.64
[α]25
𝐷 +9.1 (c 0.40, CHCl3).
IR max (cm-1): 3443, 2912, 2829, 1758, 1643, 1509, 1265, 1198, 1086 cm–1
LRESIMS m/z 466 (100%) [M+Na]+.
HRESIMS found 466.1834, calcd for C24H29NO7Na, 466.1842 [M+Na]+.
1H

NMR (500 MHz, CDCl3) δ 7.40 – 7.22 (10H, m, ArH), 4.86 – 4.77 (2H, m, OCH2Ph,

H1), 4.59 (1H, d, J = 11.3 Hz, OCH2Ph), 4.49 – 4.32 (2H, m, OCH2Ph), 4.25 – 4.15 (2H,
m, H6, H7a), 4.04 (1H, s, H7), 3.96 (1H, s, H1′), 3.83 (1H, s, H2′), 3.72 – 3.62 (1H, m,
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H5), 3.59 – 3.52 (1H, m, H3′), 3.46 – 3.40 (1H, m, H3′), 3.32 (1H, s, OH), 2.84 (1H, s,
OH), 2.70 (1H, s, OH), 1.46 (3H, d, J = 6.7 Hz, H1′′).
13C

NMR (125 MHz, CDCl3) δ 156.8 (C3), 137.4 (ArC), 137.2 (ArC), 128.7 (ArCH),

128.6 (ArCH), 128.5 (ArCH), 128.29 (ArCH), 128.25 (ArCH), 128.1 (ArCH), 77.9 (C1),
77.0 (C1′), 75.3 (C6), 75.2 (OCH2Ph), 73.7 (OCH2Ph), 70.9 (C3′), 70.8 (C2′), 70.3 (C7),
60.7 (C7a), 55.0 (C5), 11.5 (C1′′).

(3aS,3bR,4S,8R,8aR)-4-((1R,2S)-1,3-Bis(benzyloxy)-2-hydroxypropyl)-2,2,8trimethyltetrahydro-4H,6H-[1,3]dioxolo[4',5':3,4]pyrrolo[1,2-c]oxazol-6-one (221)

Compound 221 was synthesized from 228 (12 mg, 0.027 mmol) by the general method for
acetonide protection of cis–diols. Purification by FCC (7:15) to give 221 as a pale–yellow
oil (13 mg, 95%).

Rf (1:1 EtOAc/n-hexane) = 0.64
[α]25
𝐷 +30.1 (c 0.40, CHCl3).
IR max (cm-1): 2955, 2843, 1798, 1623, 1556, 1190, 1099 cm–1
LRESIMS m/z 484 (100%) [M+H]+.
HRESIMS found 484.2342, calcd for C27H34NO7, 484.2335 [M+H]+.
1H

NMR (500 MHz, CDCl3) δ 7.39 – 7.24 (10H, m, ArH), 4.83 – 4.77 (2H, m, OCH2Ph,

H4), 4.60 (1H, d, J = 11.3 Hz, OCH2Ph), 4.56 (1H, dd, J = 5.5, 4.0 Hz, H8a), 4.53 – 4.46
(3H, m, OCH2Ph, H3a), 4.01 (1H, t, J = 4.4 Hz, H3b), 3.94 – 3.86 (2H, m, H1′, H3′), 3.53
(1H, dd, J = 9.5, 6.3 Hz, H3′), 3.45 – 3.33 (2H, m, H3′, H8), 1.64 (3H, d, J = 7.0 Hz, H1′′),
1.46 (3H, s, C2–CH3), 1.30 (3H, s, C2–CH3).
13C

NMR (125 MHz, CDCl3) δ 157.1 (C4), 137.6 (ArC), 137.6 (ArC), 128.5 (ArCH),

128.4 (ArCH), 128.1 (ArCH), 127.9 (ArCH), 127.9 (ArCH), 112.2 (C2), 83.8 (C8a), 78.8
(C3a), 77.7 (C1′), 75.4 (C4), 75.2 (OCH2Ph), 73.5 (OCH2Ph), 71.0 (C3′), 70.5 (C2′), 62.9
(C3b), 57.2 (C8), 26.1 (C2–CH3), 24.4 (C2–CH3), 10.1 (C1′′).
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General method for Swern oxidation
(3aS,4S,6R,7R,8aR,8bR)-7-(Benzyloxy)-6-((benzyloxy)methyl)-2,2,4trimethylhexahydro-8H-[1,3]dioxolo[4,5-a]pyrrolizin-8-one (231)

To a cooled (–78 oC), stirred solution of DMSO (93 µL, 1.3 mmol) in CH2Cl2 (5 mL) was
added oxalyl chloride (56.0 µL, 0.653 mmol). After stirring for 5 min, a solution of 165
(29 mg, 0.0653 mmol) in CH2Cl2 (2 mL) was added to the mixture followed by the addition
of triethylamine (364 µL, 2.61 mmol). After stirring at –78 oC for 1 h, TLC analysis
confirmed full consumption of the starting material. The reaction mixture was quenched
with the addition of water (5 mL) and extracted with CH2Cl2 (3 x 5 mL). The combined
organic extracts were dried (MgSO4), filtered and concentrated in vacuo. Purification by
FCC (3:7 EtOAc/n-hexane) afforded the ketone 231 as an opaque yellow oil (24 mg, 83%).

Rf (3:7 EtOAc/n-hexane) = 0.25
[α]25
𝐷 +22.7 (c 1.00, CHCl3)
IR max (cm-1): 3030, 2910, 2875, 1716, 1451, 1380, 1227, 1095, 691 cm–1
LRESIMS m/z 438 (100%) [M+H]+.
HRESIMS found 438.2275, calcd for C26H32NO5, 438.2280 [M+H]+.
1H

NMR (500 MHz, CDCl3) δ 7.37 – 7.24 (10H, m, ArH), 5.04 – 4.95 (2H, m, OCH2Ph,

H8b), 4.69 (1H, d, J = 11.8 Hz, OCH2Ph), 4.56 – 4.46 (3H, m, OCH2Ph, H3a), 3.94 (1H,
dd, J = 9.3, 1.3 Hz, H7), 3.89 – 3.83 (2H, m, H8a, H6), 3.79 (1H, q, J = 7.3 Hz, H4), 3.63
(1H, dd, J = 10.2, 2.7 Hz, H1′), 3.45 (1H, dd, J = 10.3, 4.9 Hz, H1′), 1.46 (3H, s, C2–CH3),
1.25 (3H, s, C2–CH3), 1.07 (3H, d, J = 7.3 Hz, H1′′).
13C

NMR (125 MHz, CDCl3) δ 211.0 (C8), 138.1 (ArC), 137.8 (ArC), 128.4 (ArCH),

128.3 (ArCH), 128.1 (ArCH), 127.78 (ArCH), 127.76 (ArCH), 127.68 (ArCH), 112.66
(C2), 88.4 (C3a), 84.1 (C8b), 80.3 (C7), 73.3 (OCH2Ph), 72.6 (OCH2Ph), 70.4 (C1′), 70.2
(C8a), 63.9 (C4), 63.8 (C6), 26.3 (C2–CH3), 23.0 (C2–CH3), 19.3 (C1′′).
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(3aS,4R,6R,7R,8aR,8bR)-7-(Benzyloxy)-6-((benzyloxy)methyl)-2,2,4trimethylhexahydro-8H-[1,3]dioxolo[4,5-a]pyrrolizin-8-one (232)

Compound 232 was synthesized from the tricyclic alcohol 151 (35 mg, 0.080 mmol) by
using the general method for the Swern oxidation. The product was purified by FCC (2:3
EtOAc/n-hexane) to give the target compound 232 as an opaque yellow oil (28 mg, 80%).

Rf (2:3 EtOAc/n-hexane) = 0.25
[α]25
𝐷 +95.2 (c 1.00, CHCl3)
IR max (cm-1): 3379, 2980, 2849, 1716, 1612, 1452, 1363, 1212, 1002, 678 cm–1
LRESIMS m/z 438 (100%) [M+H]+.
HRESIMS found 438.2300, calcd for C26H32NO5, 438.2280 [M+H]+.
1H

NMR (500 MHz, CDCl3) δ 7.36 – 7.21 (10H, m, ArH), 5.03 (1H, d, J = 11.6 Hz,

OCH2Ph), 4.89 (1H, t, J = 5.5 Hz, H8b), 4.59 (1H, d, J = 11.6 Hz, OCH2Ph), 4.54 (1H, dd,
J = 5.8, 4.1 Hz, H3a), 4.46 (2H, s, OCH2Ph), 4.16 (1H, dd, J = 8.5, 1.5 Hz, H7), 3.96 (1H,
ddd, J = 8.6, 3.5, 2.1 Hz, H6), 3.69 (1H, dd, J = 5.2, 1.5 Hz, H8a), 3.65 (1H, dd, J = 10.4,
3.5 Hz, H1′), 3.43 (1H, dd, J = 10.5, 2.1 Hz, H1′), 3.30 (1H, qd, J = 7.2, 4.0 Hz, H4), 1.47
– 1.41 (6H, m, C2–CH3, H1′′), 1.26 (3H, s, C2–CH3).
13C

NMR (125 MHz, CDCl3) δ 211.8 (C8), 138.0 (ArC), 137.9 (ArC), 128.4 (ArCH),

128.2 (ArCH), 128.12 (ArCH), 128.11, 127.8 (ArCH), 127.7 (ArCH), 112.5 (C2), 84.4
(C3a), 83.5 (C8b), 80.9 (C7), 73.4 (OCH2Ph), 73.0 (OCH2Ph), 72.4 (C8a), 69.0 (C1′),
61.01 (C6), 60.97 (C4), 26.2 (C2–CH3), 22.9 (C2–CH3), 12.0 (C1′′).
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(3aR,4R,6R,7R,8aR,8bS)-7-(Benzyloxy)-6-((benzyloxy)methyl)-2,2,4trimethylhexahydro-8H-[1,3]dioxolo[4,5-a]pyrrolizin-8-one (233)

Compound 233 was synthesized from the tricyclic alcohol 149 (71 mg, 0.16 mmol) by
using the general method for the Swern oxidation. The resultant yellow oil 233 (71 mg)
was used for the next step without further purification.
LRESIMS m/z 438 (100%) [M+H]+.

General method for the reduction of a ketone to a secondary alcohol with Lselectride®
(3aS,4S,6R,7R,8S,8aS,8bR)-7-(Benzyloxy)-6-((benzyloxy)methyl)-2,2,4trimethylhexahydro-4H-[1,3]dioxolo[4,5-a]pyrrolizin-8-ol (236)

To a cooled (–78 oC) solution of the cyclic ketone 231 (52 mg, 0.12 mmol) in THF (5 mL)
was added a solution of L–selectride® (1.0 M solution in THF, 476 µL, 0.476 mmol). The
reaction mixture was stirred for 1 h at –78 oC then allowed to warm to room temperature
and stirred for 2 h. By this time, TLC analysis confirmed full consumption of the starting
material, by which time the reaction mixture was quenched with the addition of an NH4Cl
solution (1.0 M, 7 mL). The product was extracted with EtOAc (3 x 10 mL), dried
(MgSO4), filtered and concentrated in vacuo. Purification by FCC (3:97 MeOH/ CH2Cl2)
afforded the title product 236 as an orange oil (50 mg, 96%).

Rf (3:97 MeOH/CH2Cl2) = 0.45
[α]25
𝐷 +25.3 (c 1.00, CHCl3)
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IR max (cm-1): 3398, 3133, 2982, 1620, 1503, 1062, 864, 698 cm–1
LRESIMS m/z 440 (100%) [M+H]+.
HRESIMS found 440.2430, calcd for C26H34NO5, 440.2437 [M+H]+.
1H

NMR (500 MHz, CDCl3) δ 7.37 – 7.23 (10H, m, ArH), 4.86 (1H, t, J = 6.0 Hz, H8b),

4.73 (1H, d, J = 11.7 Hz, OCH2Ph), 4.58 – 4.52 (2H, m, OCH2Ph, H8), 4.50 – 4.45 (2H,
m, OCH2Ph), 4.39 (1H, dd, J = 6.2, 4.9 Hz, H3a), 4.26 (1H, d, J = 4.8 Hz, OH), 3.89 (1H,
dd, J = 7.5, 5.2 Hz, H7), 3.62 (1H, t, J = 5.2 Hz, H8a), 3.54 – 3.49 (1H, m, H1′), 3.49 –
3.42 (2H, m, H1′, H6), 3.34 (1H, dd, J = 6.9, 5.2 Hz, H4), 1.53 (3H, s, C2–CH3), 1.31 (3H,
s, C2–CH3), 1.13 (3H, d, J = 6.7 Hz, H1′′).
13C

NMR (125 MHz, CDCl3) δ 138.4 (ArC), 138.3 (ArC), 128.3 (ArCH), 128.3 (ArCH),

127.8 (ArCH), 127.7 (ArCH), 127.6 (ArCH), 127.5 (ArCH), 113.5 (C2), 88.6 (C3a), 82.2
(C8b), 81.9 (C7), 73.2 (OCH2Ph), 72.4 (OCH2Ph), 71.8 (C1′), 71.2 (C8), 67.1 (C6), 66.3
(C4), 66.3 (C8a), 26.9 (C2–CH3), 24.4 (C2–CH3), 19.1 (C1′′).

(3aS,4R,6R,7R,8S,8aS,8bR)-7-(Benzyloxy)-6-((benzyloxy)methyl)-2,2,4trimethylhexahydro-4H-[1,3]dioxolo[4,5-a]pyrrolizin-8-ol (237)

Compound 237 was synthesized from the tricyclic ketone 232 (28 mg, 0.064 mmol) by
using the general method for the reduction of a ketone to a secondary alcohol with L–
selectride®. The product was purified by FCC (5:95 MeOH/CH2Cl2) to give the target
compound 237 as an orange oil (19 mg, 66%).

Rf (5:95 MeOH/CH2Cl2) = 0.25
[α]25
𝐷 +52.1 (c 1.00, CHCl3)
IR max (cm-1): 3290, 2989, 2926, 2873, 1585, 1484, 1095, 694 cm–1
LRESIMS m/z 440 (100%) [M+H]+.
HRESIMS found 440.2430, calcd for C26H34NO5, 440.2437 [M+H]+.
1H

NMR (500 MHz, CDCl3) δ 7.37 – 7.20 (10H, m, ArH), 4.75 – 4.61 (3H, m, OCH2Ph,

H8b, H8), 4.54 (1H, dd, J = 6.0, 4.4 Hz, H3a), 4.52 – 4.46 (3H, m, OCH2Ph), 3.99 (1H,
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dd, J = 8.1, 4.7 Hz, H7), 3.76 – 3.69 (2H, m, OH, H6), 3.49 (1H, dd, J = 7.3, 4.6 Hz, H8a),
3.42 (1H, dd, J = 9.8, 3.4 Hz, H1′), 3.30 (1H, dd, J = 9.8, 6.3 Hz, H1′), 3.12 (1H, qd, J =
7.0, 4.2 Hz, H4), 1.43 (3H, s, C2–CH3), 1.33 (3H, d, J = 7.1 Hz, H1′′), 1.26 (3H, s, C2–
CH3).
13C

NMR (125 MHz, CDCl3) δ 138.7 (ArC), 138.2 (ArC), 128.3 (ArCH), 128.1 (ArCH),

127.8 (ArCH), 127.7 (ArCH), 127.6 (ArCH), 127.3 (ArCH), 111.8 (C2), 85.4 (C3a), 82.6
(C7), 82.4 (C8), 73.3 (OCH2Ph), 72.8 (OCH2Ph), 72.4 (C1′), 71.3 (C8a), 70.4 (C8b), 63.2
(C6), 58.9 (C4), 25.7 (C2–CH3), 23.3 (C2–CH3), 11.9 (C1′′).

(3aR,4R,6R,7R,8S,8aS,8bS)-7-(Benzyloxy)-6-((benzyloxy)methyl)-2,2,4trimethylhexahydro-4H-[1,3]dioxolo[4,5-a]pyrrolizin-8-ol (238)

Compound 238 was synthesized from the crude tricyclic ketone 233 (71 mg, 0.16 mmol)
by using the general method for the reduction of a ketone to a secondary alcohol with L–
selectride®. The product was purified by FCC (5:95 MeOH/CH2Cl2) to give the target
compound 238 as an orange oil (46 mg, 65%).

Rf (5:95 MeOH/CH2Cl2) = 0.45
[α]25
𝐷 ‒72.0 (c 1.00, CHCl3)
IR max (cm-1): 3340, 2967, 2872, 1516, 1496, 1140, 1066, 866, 635 cm–1.
LRESIMS m/z 440 (100%) [M+H]+.
HRESIMS found 440.2446, calcd for C26H34NO5, 440.2437 [M+H]+.
1H

NMR (500 MHz, CDCl3) δ 7.39 – 7.19 (10H, m, ArH), 4.86 (1H, dd, J = 6.3, 3.2 Hz,

H8b), 4.58 (1H, d, J = 11.7 Hz, OCH2Ph), 4.55 – 4.47 (3H, m, OCH2Ph), 4.23 (1H, t, J =
5.7 Hz, H3a), 4.19 (1H, d, J = 4.7 Hz, H8), 3.87 (1H, t, J = 4.3 Hz, H7), 3.61 (1H, t, J =
4.1 Hz, H8a), 3.47 – 3.36 (2H, m, H1՛, H4), 3.36 – 3.26 (2H, m, H1՛, H6), 1.50 (3H, s, C2–
CH3), 1.32 (3H, s, C2–CH3), 1.21 (3H, d, J = 7.0 Hz, H՛՛).
13C

NMR (125 MHz, CDCl3) δ 138.4 (ArC), 137.5 (ArC), 128.6 (ArCH), 128.4 (ArCH),

128.1 (ArCH), 127.9 (ArCH), 127.59 (ArCH), 127.56 (ArCH), 112.7 (C2), 87.3 (C3a),
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83.4 (C7), 79.0 (C8b), 73.3 (OCH2Ph), 72.8 (C8a), 72.7 (C1՛), 72.3 (OCH2Ph), 69.2 (C8),
62.0 (C4), 60.1 (C6), 27.8 (C2–CH3), 25.7 (C2–CH3), 14.9 (C1՛՛).

(1R,2S,3S,5R,6R,7S,7aR)-6-(Benzyloxy)-5-((benzyloxy)methyl)-3-methylhexahydro1H-pyrrolizine-1,2,7-triol (239)

Compound 239 was synthesized from 236 (50 mg, 0.11 mmol) using the general method
for hydrolysis of an acetonide. The product was purified by FCC (5:95 MeOH/CH2Cl2) to
give the desired product 239 as a pale–yellow oil (36 mg, 79%).

Rf (5:95 MeOH/CH2Cl2) = 0.15
[α]25
𝐷 ‒67.4 (c 1.00, CHCl3)
IR max (cm-1): 3334, 3063, 2925, 2868, 1679, 1512, 1082, 656 cm–1
LRESIMS m/z 400 (100%) [M+H]+.
HRESIMS found 400.2118, calcd for C23H30NO5, 400.2124 [M+H]+.
1H

NMR (500 MHz, CDCl3) δ 7.38 – 7.20 (10H, m, ArH), 4.59 – 4.46 (4H, m, OCH2Ph),

4.34 (1H, t, J = 4.3 Hz, H7), 4.31 (1H, t, J = 5.5 Hz, H1), 4.03 (1H, dd, J = 7.4, 4.0 Hz,
H6), 3.70 – 3.58 (2H, m, H2, H7a), 3.49 (2H, d, J = 4.5 Hz, H1′), 3.13 (1H, dt, J = 8.0, 4.5
Hz, H3), 2.86 (1H, quint, J = 6.3 Hz, H5), 1.19 (3H, d, J = 6.2 Hz, H1′′).
13C

NMR (125 MHz, CDCl3) δ 138.2 (ArC), 136.9 (ArC), 128.7 (ArCH), 128.4 (ArCH),

128.4 (ArCH), 128.1 (ArCH), 127.8 (ArCH), 127.7 (ArCH), 82.6 (C7), 79.4 (C1), 73.4
(C6), 73.1 (C7a), 72.7 (OCH2Ph), 72.2 (OCH2Ph), 71.0 (C1′), 67.4 (C2), 66.7 (C5), 65.7
(C3), 19.4 (C1′′).

(1R,2S,3R,5R,6R,7S,7aR)-6-(Benzyloxy)-5-((benzyloxy)methyl)-3-methylhexahydro1H-pyrrolizine-1,2,7-triol (240)
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Compound 240 was synthesized from 237 (19 mg, 0.042 mmol) using the general method
for hydrolysis of an acetonide. The product was purified by FCC (8:92 MeOH/CH2Cl2) to
give 240 as a yellow oil (15 mg, 87%).

Rf (8:92 MeOH/CH2Cl2) = 0.25
[α]25
𝐷 +12.2 (c 1.00, CHCl3)
IR max (cm-1): 3340, 3119, 2926, 2893, 1568, 1478, 1058, 634 cm–1
LRESIMS m/z 400 (100%) [M+H]+.
HRESIMS found 400.2133, calcd for C23H30NO5, 400.2124 [M+H]+.
1H

NMR (500 MHz, CDCl3) δ 7.39 – 7.22 (10H, m, ArH), 4.60 (1H, d, J = 12.2 Hz,

OCH2Ph), 4.53 – 4.45 (3H, m, OCH2Ph), 4.44 (1H, dd, J = 8.2, 5.0 Hz, H7), 4.18 (1H, t, J
= 3.8 Hz, H1), 4.02 (1H, dd, J = 8.0, 3.4 Hz, H2), 3.81 (1H, t, J = 4.5 Hz, H6), 3.72 (1H,
dd, J = 8.2, 3.4 Hz, H7a), 3.61 (1H, dt, J = 8.1, 4.0 Hz, H3), 3.47 (2H, dd, J = 3.9, 1.6 Hz,
H1′), 3.42 – 3.34 (1H, m, H5), 1.24 (3H, d, J = 7.1 Hz, H1′′).
13C

NMR (125 MHz, CDCl3) δ 138.3 (ArC), 137.1 (ArC), 128.7 (ArCH), 128.4 (ArCH),

128.3 (ArCH), 128.0 (ArCH), 127.8 (ArCH), 127.6 (ArCH), 82.3 (C2), 74.9 (C6), 74.4
(C7), 73.4 (OCH2Ph), 73.1 (OCH2Ph), 71.3 (C1′), 70.8 (C1), 66.8 (C7a), 60.4 (C3), 57.9
(C5), 10.9 (C1′′).

(1S,2R,3R,5R,6R,7S,7aR)-6-(Benzyloxy)-5-((benzyloxy)methyl)-3-methylhexahydro1H-pyrrolizine-1,2,7-triol (241)
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Compound 241 was synthesized from alcohol 238 (40 mg, 0.09 mmol) using the general
method for hydrolysis of an acetonide. The product was purified by FCC (8:92
MeOH/CH2Cl2) to give the desired product 241 as a brown oil (20 mg, 55%).

Rf (5:95 MeOH/CH2Cl2) = 0.30
[α]25
𝐷 +68.2 (c 1.00, CHCl3)
IR max (cm-1): 3387, 3100, 2878, 1657, 1520, 1467, 1075, 696 cm–1
LRESIMS m/z 400 (100%) [M+H]+.
HRESIMS found 400.2127, calcd for C23H30NO5, 400.2124 [M+H]+.
1H

NMR (500 MHz, CDCl3) δ 7.39 – 7.21 (10H, m, ArH), 4.54 – 4.45 (4H, m, OCH2Ph),

4.39 (1H, t, J = 5.1 Hz, H7), 4.13 (1H, t, J = 3.9 Hz, H1), 3.88 (1H, dd, J = 7.9, 3.8 Hz,
H2), 3.80 (1H, t, J = 4.4 Hz, H6), 3.53 – 3.43 (3H, m, H1՛, H7a), 3.40 – 3.30 (2H, m, H5,
H3), 1.10 (3H, d, J = 7.0 Hz, H1՛՛).
13C

NMR (125 MHz, CDCl3) δ 138.3 (ArC), 137.3 (ArC), 128.6 (ArCH), 128.4 (ArCH),

128.2 (ArCH), 128.0 (ArCH), 127.6 (ArCH), 127.5 (ArCH), 83.5 (C2), 79.0 (C6), 73.3
(OCH2Ph), 72.7 (OCH2Ph), 71.9 (C1՛), 71.5 (C7a), 69.1 (C7), 67.5 (C1), 60.7 (C5), 58.8
(C3), 14.3 (C1՛՛).

(1S,2R,3R,5S,6S,7R,7aR)-3-(Hydroxymethyl)-5-methylhexahydro-1H-pyrrolizine1,2,6,7-tetraol [(‒)-5-Epi hyacinthacine C1] (242)
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(‒)-5-epi-hyacinthacine C1 242 was synthesized by the general method for O–benzyl
deprotection from 239 (34 mg, 0.085 mmol). The crude product was filtered through a pad
of celite and washed with additional MeOH (6 mL). The combined filtrates were
concentrated in vacuo returning a clear film. The compound was isolated through basic
ion–exchange chromatography followed by concentration in vacuo providing the title
compound 242 as a colourless film (15 mg, 80%).
[α]25
𝐷 ‒14.1 (c 1.00, H2O)
IR max (cm-1): 3331, 2956, 1590, 1578, 1439, 1067, 812, 732, 643 cm–1
LRESIMS m/z 220 (100%) [M+H]+.
HRESIMS found 220.1177, calcd for C9H18NO5, 220.1185 [M+H]+.
1H

NMR (500 MHz, D2O) δ 4.41 (1H, t, J = 4.9 Hz, H1), 4.37 (1H, t, J = 5.0 Hz, H7),

3.97 (1H, dd, J = 7.3, 4.4 Hz, H2), 3.72 – 3.60 (3H, m, H6, H8), 3.58 (1H, t, J = 5.4 Hz,
H7a), 3.08 – 3.01 (2H, m, H3, H5), 1.21 (3H, d, J = 6.4 Hz, H9).
13C

NMR (125 MHz, D2O) δ 78.4 (C6), 74.5 (C2), 72.6 (C1), 72.0 (C7), 70.6 (C3), 65.1

(C5), 64.3 (C7a), 62.5 (C8), 17.5 (C9).

(1S,2R,3R,5R,6S,7R,7aR)-3-(Hydroxymethyl)-5-methylhexahydro-1H-pyrrolizine1,2,6,7-tetraol [Corrected structure for (+)-hyacinthacine C1] (243)
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The compound for the corrected structure of (+)-hyacinthacine C1 243 was synthesized by
the general method for O–benzyl deprotection from 240 (11 mg, 0.025 mmol). The crude
product was filtered through a pad of celite and washed with additional MeOH (6 mL).
The combined filtrates were concentrated in vacuo returning a clear film. The compound
was isolated through basic ion–exchange chromatography followed by concentration in
vacuo providing the title compound 243 as a colourless film (3.0 mg, 52%).
[α]25
𝐷 +3.0 (c 1.00, H2O)
IR max (cm-1): 3349, 2925, 1598, 1420, 1071, 967, 651 cm–1
LRESIMS m/z 220 (100%) [M+H]+.
HRESIMS found 220.1183, calcd for C9H18NO5, 220.1185 [M+H]+.
1H

NMR (500 MHz, D2O) δ 4.53 (1H, dd, J = 8.6, 4.7 Hz, H7), 4.18 (1H, t, J = 3.8 Hz,

H1), 4.02 (1H, dd, J = 9.2, 3.7 Hz, H2), 3.92 (1H, t, J = 4.4 Hz, H6), 3.68 – 3.62 (3H, m,
H8, H7a), 3.47 (1H, dt, J = 9.2, 4.6 Hz, H3), 3.31 (1H, dt, J = 7.1, 3.9 Hz, H5), 1.29 (3H,
d, J = 7.2 Hz, H9).
13C

NMR (125 MHz, D2O) δ 77.3 (C2), 76.6 (C6), 75.1 (C7), 74.1 (C1), 67.8 (C7a), 65.4

(C8), 64.1 (C3), 59.9 (C5), 12.4 (C9).

(1S,2R,3R,5R,6R,7S,7aR)-3-(Hydroxymethyl)-5-methylhexahydro-1H-pyrrolizine1,2,6,7-tetraol [(+)-6,7-Di-epi hyacinthacine C1] (244)
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(+)-6,7-di-epi-hyacinthacine C1 244 was synthesized by the general method for O–benzyl
deprotection from 241 (18 mg, 0.045 mmol). The crude product was filtered through a pad
of celite and washed with additional MeOH (6 mL). The combined filtrates were
concentrated in vacuo returning a yellow film. The compound was isolated through basic
ion–exchange chromatography followed by concentration in vacuo providing the title
compound 244 as a colourless film (6.0 mg, 61%).
[α]25
𝐷 +13.4 (c 1.00, H2O)
IR max (cm-1): 3302, 2967, 1620, 1578, 1439, 1190, 1056, 687 cm–1
LRESIMS m/z 220 (100%) [M+H]+.
HRESIMS found 220.1197, calcd for C9H18NO5, 220.1185 [M+H]+.
1H

NMR (500 MHz, D2O) δ 4.33 (1H, t, J = 4.7 Hz, H7), 4.17 (1H, t, J = 4.3 Hz, H1),

3.99 (1H, dd, J = 8.1, 4.1 Hz, H2), 3.86 (1H, t, J = 5.4 Hz, H6), 3.66 – 3.57 (2H, m, H8),
3.40 (1H, t, J = 4.6 Hz, H7a), 3.21 (1H, quint, J = 6.7 Hz, H5), 3.14 (1H, dt, J = 8.0, 4.9
Hz, H3), 1.17 (3H, d, J = 7.0 Hz, H9).
13C

NMR (125 MHz, D2O) δ 77.5 (C6), 74.8 (C2), 70.2 (C6), 69.7 (C1), 69.1 (C7), 62.7

(C8), 60.9 (C3), 59.0 (C5), 13.2 (C9).

(3aS,4S,6R,7R,8S,8aS,8bR)-7,8-Bis(benzyloxy)-6-((benzyloxy)methyl)-2,2,4trimethylhexahydro-4H-[1,3]dioxolo[4,5-a]pyrrolizine (245)
300

Compound 245 was synthesized from 236 (46 mg, 0.11 mmol) by the general method for
O–benzylation. The product was purified by FCC (2:3 EtOAc/n-hexane) to give the target
compound 245 as a yellow oil (30 mg, 54%).

Rf (2:3 EtOAc/n-hexane) = 0.55
[α]25
𝐷 +47.6 (c 1.00, CHCl3)
IR max (cm-1): 2328, 1645, 1320, 962, 664 cm–1
LRESIMS m/z 530 (100%) [M+H]+.
HRESIMS found 530.2919, calcd for C33H40NO5, 530.2906 [M+H]+.
1H

NMR (500 MHz, CDCl3) δ 7.45 – 7.12 (15H, m, ArH), 4.80 – 4.72 (2H, m, OCH2Ph,

H8b), 4.71 – 4.64 (1H, m, OCH2Ph), 4.55 – 4.50 (2H, m, OCH2Ph), 4.46 (1H, d, J = 12.2
Hz, OCH2Ph), 4.39 (1H, d, J = 12.0 Hz, OCH2Ph), 4.33 (1H dd, J = 6.4, 4.4 Hz, H3a), 4.13
(1H, t, J = 5.2 Hz, H8), 3.87 (1H, dd, J = 7.4, 5.5 Hz, H7), 3.50 (1H, t, J = 5.2 Hz, H8a),
3.48 – 3.42 (2H, m, H6, H1′), 3.42 – 3.37 (1H, m, H1′), 3.30 (1H, qd, J = 6.7, 4.3 Hz, H4),
1.43 (3H, s, C2–CH3), 1.30 (3H, s, C2–CH3), 1.10 (3H, d, J = 6.7 Hz, H1′′).
13C NMR (125 MHz, CDCl

3) δ 139.0 (ArC), 138.50 (ArC), 138.46 (ArC), 128.24 (ArCH),

128.18 (ArCH), 128.1 (ArCH), 127.82 (ArCH), 127.77 (ArCH), 127.69 (ArCH), 127.44
(ArCH), 127.41 (ArCH), 127.3 (ArCH), 113.3 (C2), 88.7 (C3a), 81.6 (C7), 80.7 (C8b),
76.9 (C8), 73.4 (OCH2Ph), 73.2 (OCH2Ph), 72.5 (OCH2Ph), 71.9 (C1′), 67.6 (C6), 66.7
(C8a), 65.8 (C4), 26.7 (C2–CH3), 24.3 (C2–CH3), 19.4 (C1′′).

(3aR,4R,6R,7R,8S,8aS,8bS)-7,8-Bis(benzyloxy)-6-((benzyloxy)methyl)-2,2,4trimethylhexahydro-4H-[1,3]dioxolo[4,5-a]pyrrolizine (246)
301

Compound 246 was synthesized from 238 (62 mg, 0.14 mmol) by the general method for
O–benzylation. The product was purified by FCC (1:4 EtOAc/n-hexane) to give the target
compound 246 as a yellow oil (39 mg, 52%).

Rf (2:3 EtOAc/n-hexane) = 0.30
[α]25
𝐷 ‒12.9 (c 1.00, CHCl3)
IR max (cm-1): 2978, 1612, 1514, 1254, 1042, 678 cm–1
LRESIMS m/z 530 (100%) [M+H]+.
HRESIMS found 530.2925, calcd for C33H40NO5, 530.2906 [M+H]+.
1H

NMR (500 MHz, CDCl3) δ 7.39 – 7.20 (15H, m, ArH), 5.10 (1H, dd, J = 6.6, 3.0 Hz,

H8b), 4.64 – 4.60 (3H, m, OCH2Ph), 4.56 (1H, d, J = 12.1 Hz, OCH2Ph), 4.47 (2H, s,
OCH2Ph), 4.21 (1H, t, J = 6.8 Hz, H3a), 4.13 (1H, dd, J = 6.3, 4.3 Hz, H8), 3.84 (1H, dd,
J = 4.4, 2.2 Hz, H7), 3.71 (1H, dd, J = 6.5, 3.0 Hz, H8a), 3.37 – 3.23 (3H, m, H6, H4, H1՛),
3.12 (1H, dd, J = 9.5, 7.6 Hz, H1՛), 1.49 (3H, s, C2–CH3), 1.31 (3H, s, C2–CH3), 1.23 (3H,
d, J = 7.0 Hz, H1՛՛).
13C

NMR (125 MHz, CDCl3) δ 138.4 (ArC), 138.3 (ArC), 138.2 (ArC), 128.4 (ArCH),

128.36 (ArCH), 128.35 (ArCH), 127.71 (ArCH), 127.65 (ArCH), 127.6 (ArCH), 113.5
(C2), 86.1 (C3a), 81.0 (C8b), 80.5 (C7), 77.4 (C8), 73.2 (OCH2Ph), 73.1 (C1՛), 72.4
(OCH2Ph), 71.8 (OCH2Ph), 71.1 (C8a), 63.2 (C6), 61.2 (C4), 27.8 (C2–CH3), 25.7 (C2–
CH3), 14.2 (C1՛՛).

(1R,2S,3S,5R,6R,7S,7aR)-6,7-Bis(benzyloxy)-5-((benzyloxy)methyl)-3methylhexahydro-1H-pyrrolizine-1,2-diol (247)
302

Compound 247 was synthesized from 245 (64 mg, 0.12 mmol) using the general method
for hydrolysis of an acetonide. The product was purified by FCC (5:95 MeOH/CH2Cl2) to
give the title compound 247 as a yellow oil (50 mg, 85%).

Rf (5:95 MeOH/CH2Cl2) = 0.25
[α]25
𝐷 +10.5 (c 2.15, CHCl3).
IR max (cm-1): 3347, 3065, 2943, 2889, 1631, 1035, 673 cm–1
LRESIMS m/z 490 (100%) [M+H]+.
HRESIMS found 490.2581, calcd for C30H36NO5, 490.2593 [M+H]+.
1H

NMR (500 MHz, CDCl3) δ 7.39 – 7.22 (15H, m, ArH), 4.89 – 4.78 (1H, m, OCH2Ph),

4.76 (1H, d, J = 11.4 Hz, OCH2Ph), 4.61 (2H, s, OCH2Ph), 4.56 – 4.47 (2H, m, OCH2Ph),
4.33 (1H, dd, J = 6.9, 4.3 Hz, H1), 4.08 (1H, apparent q, J = 4.1 Hz, H7), 4.00 (1H, t, J =
4.5 Hz, H2), 3.73 (1H, t, J = 5.7 Hz, H7a), 3.60 (1H, dd, J = 8.7, 4.1 Hz, H6), 3.43 (1H,
dd, J = 9.8, 4.6 Hz, H1′), 3.34 (1H, dd, J = 9.8, 5.8 Hz, H1′), 3.23 (1H, q, J = 5.1 Hz, H3),
2.90 (1H, quint, J = 6.5 Hz, H5), 1.20 (3H, d, J = 6.3 Hz, H1′′).
13C

NMR (125 MHz, CDCl3) δ 138.1 (ArC), 137.3 (ArC), 137.2 (ArC), 128.6 (ArCH),

128.5 (ArCH), 128.4 (ArCH), 128.10 (ArCH), 128.12 (ArCH), 127.9 (ArCH), 127.8
(ArCH), 127.7 (ArCH), 80.6 (C2), 80.2 (C6), 79.5 (C1), 73.5 (OCH2Ph), 73.4 (OCH2Ph),
72.8 (OCH2Ph), 72.0 (C7), 71.4 (C1′), 68.6 (C3), 66.9 (C5), 65.6 (C7a), 19.1 (C1′′).

(1S,2R,3R,5R,6R,7S,7aR)-6,7-Bis(benzyloxy)-5-((benzyloxy)methyl)-3methylhexahydro-1H-pyrrolizine-1,2-diol (248)
303

Compound 248 was synthesized from 246 (38 mg, 0.072 mmol) using the general method
for hydrolysis of an acetonide. The product was purified by FCC (5:95 MeOH/CH2Cl2) to
give the desired product 248 as a brown oil (30 mg, 85%).

Rf (5:95 MeOH/CH2Cl2) = 0.15
[α]25
𝐷 +18.4 (c 1.00, CHCl3)
IR max (cm-1): 3327, 3099, 2912, 2843, 1589, 1075, 678 cm–1
LRESIMS m/z 490 (100%) [M+H]+.
HRESIMS found 490.2612, calcd for C30H36NO5, 490.2593 [M+H]+.
1H

NMR (500 MHz, CDCl3) δ 7.41 – 7.20 (15H, m, ArH), 4.74 (1H, d, J = 11.6 Hz,

OCH2Ph), 4.63 (1H, d, J = 11.7 Hz, OCH2Ph), 4.59 – 4.39 (5H, m, OCH2Ph, H7), 4.10
(1H, t, J = 4.2 Hz, H1), 3.94 – 3.86 (1H, m, H2), 3.83 (1H, t, J = 4.8 Hz, H6), 3.68 (1H, t,
J = 5.1 Hz, H7a), 3.60 – 3.40 (4H, m, H5, H3, H1՛), 1.96 (1H, s, OH), 1.16 (3H, d, J = 6.9
Hz, C1՛՛).
13C

NMR (125 MHz, CDCl3) δ 138.1 (ArC), 138.0 (ArC), 137.6 (ArC), 128.45 (ArCH),

128.35 (ArCH), 127.9 (ArCH), 127.8 (ArCH), 127.60 (ArCH), 127.58 (ArCH), 82.0 (C2),
78.1 (C6), 75.0 (C1), 73.4 (OCH2Ph), 73.3 (OCH2Ph), 72.6 (OCH2Ph), 71.3 (C7a), 71.1
(C1՛), 69.7 (C7), 61.8 (C5), 59.6 (C3), 14.1 (C1՛՛).

(3aS,4S,6R,7R,8S,8aS,8bR)-7,8-Bis(benzyloxy)-6-((benzyloxy)methyl)-4methylhexahydro-4H-[1,3,2]dioxathiolo[4,5-a]pyrrolizine 2,2-dioxide (249)
304

Compound 249 was synthesized from the diol 247 (43 mg, 0.088 mmol) by using the
general method for the synthesis of a cyclic sulfate. The resultant crude brown oil 249 (48
mg) was used for the next step without further purification.
LRESIMS m/z 586 (100%) [M+Cl]–.

(3aR,4R,6R,7R,8S,8aS,8bS)-7,8-Bis(benzyloxy)-6-((benzyloxy)methyl)-4methylhexahydro-4H-[1,3,2]dioxathiolo[4,5-a]pyrrolizine 2,2-dioxide (250)

Compound 250 was synthesized from the diol 248 (25 mg, 0.051 mmol) by using the
general method for the synthesis of a cyclic sulfate. The resultant crude brown oil 250 (28
mg) was used for the next step without further purification.
LRESIMS m/z 586 (100%) [M+Cl]–.

(1S,2S,3R,5R,6R,7S,7aR)-6,7-Bis(benzyloxy)-5-((benzyloxy)methyl)-1-hydroxy-3methylhexahydro-1H-pyrrolizin-2-yl benzoate (251)
305

Compound 251 was synthesized from the cyclic sulfate 250 (28 mg, 0.051 mmol) using
the general method for ring opening of cyclic sulfates with benzoate. Purification by FCC
(3:2 EtOAc/n-hexane) returned the title compound 251 (13 mg, 42%) as a brown oil.

Rf (3:2 EtOAc/n-hexane) = 0.25
[α]25
𝐷 +8.5 (c 1.00, CHCl3)
IR max (cm-1): 3380, 3093, 1710, 1576, 1104, 1011, 608 cm–1
LRESIMS m/z 594 (100%) [M+H]+.
HRESIMS found 594.2843, calcd for C37H40NO6, 594.2856 [M+H]+.
1H

NMR (500 MHz, CDCl3) δ 8.00 (2H, d, J = 7.7 Hz, o–Bz), 7.54 (1H, dd, J = 7.8 Hz,

p–Bz), 7.39 (2H, t, J = 7.8 Hz, m–Bz), 7.36 – 7.17 (15H, m, ArH), 5.30 (1H, t, J = 5.8 Hz,
H6), 4.77 (1H, dd, J = 6.9, 5.5 Hz, H7), 4.71 (1H, d, J = 12.0 Hz, OCH2Ph), 4.67 (1H, d,
J = 12.0 Hz, OCH2Ph), 4.57 – 4.47 (3H, m, OCH2Ph), 4.42 (1H, d, J = 12.0 Hz, OCH2Ph),
4.13 (1H, t, J = 4.5 Hz, H1), 3.93 – 3.86 (2H, m, H5, H2), 3.69 (1H, q, J = 5.7 Hz, H3),
3.59 (1H, t, J = 5.9 Hz, H7a), 3.44 (2H, d, J = 5.3 Hz, H1՛), 1.25 (3H, d, J = 8.8 Hz, H1՛՛).
13C NMR (125 MHz, CDCl

3) δ

167.2 (CO), 138.4 (ArC), 138.3 (ArC), 137.9 (ArC), 133.2

(ArCH), 129.8 (ArCH), 128.40 (ArCH), 128.37 (ArCH), 128.33 (ArCH), 128.26 (ArCH),
127.7 (ArCH), 127.63 (ArCH), 127.58 (ArCH), 127.5 (ArCH), 84.6 (C6), 81.8 (C2), 75.4
(C1), 74.3 (C7), 73.4 (OCH2Ph), 72.9 (OCH2Ph), 72.3 (OCH2Ph), 72.2 (C1՛), 70.8 (C7a),
60.3 (C3), 57.2 (C5), 11.8 (C1՛՛).

(1S,2S,3R,5R,6R,7S,7aR)-6,7-Bis(benzyloxy)-5-((benzyloxy)methyl)-3methylhexahydro-1H-pyrrolizine-1,2-diol (252)
306

Compound 252 was synthesized from benzoate 251 (11 mg, 0.017 mmol) using the general
method for O–benzoyl deprotection, except that the reaction was stirred at rt for 1 h. The
crude brown oil was purified by FCC (5:95 MeOH/CH2Cl2) to give the product 252 as a
clear brown film (7.0 mg, 87%).

Rf (5:95 MeOH/CH2Cl2) = 0.20
[α]25
𝐷 +29.8 (c 1.00, CHCl3)
IR max (cm-1): 3362, 3101, 2967, 1542, 1489 1027, 872, 696 cm–1
LRESIMS m/z 490 (100%) [M+H]+.
HRESIMS found 490.2597, calcd for C30H36NO5, 490.2593 [M+H]+.
1H

NMR (500 MHz, CDCl3) δ 7.39 – 7.22 (15H, m, ArH), 4.83 (1H, d, J = 11.2 Hz,

OCH2Ph), 4.68 – 4.51 (5H, m, OCH2Ph), 4.40 (1H, t, J = 2.2 Hz, H7), 4.22 (1H, t, J = 4.5
Hz, H1), 4.12 (1H, dd, J = 8.2, 3.7 Hz, H2), 4.09 – 4.01 (1H, m, H7a), 4.01 – 3.92 (2H, m,
H5, H6), 3.76 (1H, dt, J = 8.5, 4.5 Hz, H3), 3.67 (1H, dd, J = 10.4, 5.0 Hz, H1՛), 3.61 (1H,
dd, J = 10.4, 3.9 Hz, H1՛), 1.31 (3H, d, J = 6.7 Hz, H1՛՛).
13C

NMR (125 MHz, CDCl3) δ 137.8 (ArC), 136.9 (ArC), 136.6 (ArC), 128.8 (ArCH),

128.6 (ArCH), 128.5 (ArCH), 128.4 (ArCH), 128.34 (ArCH), 128.30 (ArCH), 128.1
(ArCH), 127.9 (ArCH), 127.8 (ArCH), 127.7 (ArCH), 81.1 (C6), 80.9 (C2), 75.8 (C1),
75.4 (C7), 74.3 (OCH2Ph), 73.7 (OCH2Ph), 73.5 (OCH2Ph), 73.3 (C7a), 68.7 (C1՛), 61.0
(C5), 60.6 (C3), 10.2 (C1՛՛).

(1S,2R,3R,5R,6S,7S,7aR)-3-(Hydroxymethyl)-5-methylhexahydro-1H-pyrrolizine1,2,6,7-tetraol [(+)-7- Epi hyacinthacine C1] (253)
307

(+)-7-epi-hyacinthacine C1 253 was synthesized by the general method of O–benzyl
deprotection from 252 (6.0 mg, 0.012 mmol). The crude product was filtered through a
pad of celite and washed with additional MeOH (6 mL). The combined filtrates were
concentrated in vacuo returning a yellow film. The title compound 253 was isolated
through basic ion–exchange chromatography followed by concentration in vacuo, as a
colourless film (2.0 mg, 75%).
[α]25
𝐷 +6.5 (c 1.00, H2O)
IR max (cm-1): 3303, 2981, 1702, 1570, 1412, 1087, 1078, 656 cm–1
LRESIMS m/z 220 (100%) [M+H]+.
HRESIMS found 220.1181, calcd for C9H18NO5, 220.1185 [M+H]+.
1H

NMR (500 MHz, D2O) δ 4.29 (1H, d, J = 5.8 Hz, H7), 4.15 (1H, t, J = 3.9 Hz, H1),

4.11 (1H, dd, J = 7.4, 6.0 Hz, H6), 3.97 (1H, dd, J = 9.1, 3.9 Hz, H2), 3.74 (1H, dd, J =
11.6, 4.3 Hz, H8), 3.61 (1H, dd, J = 11.7, 6.4 Hz, H8), 3.46 (1H, quint, J = 6.8 Hz, H5),
3.33 – 3.26 (2H, m, H7a, H3), 1.12 (3H, d, J = 7.0 Hz, H9).
13C

NMR (125 MHz, D2O) δ 78.4 (C6), 74.9 (C2), 71.4 (C7), 69.3 (C1), 68.8 (C7a), 63.0

(C8), 60.6 (C3), 57.0 (C5), 10.3 (C9).
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Figure A.1: 1H NMR spectrum (500 MHz, D2O) of 155
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Figure A.2: 13C NMR spectrum (125 MHz, D2O) of 155

323

Figure A.3: gCOSY spectrum (500 MHz, D2O) of 155

Figure A.4: gHSQC spectrum (500 MHz, D2O) of 155
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Figure A.5: NOESY spectrum (500 MHz, D2O) of 155
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Figure A.6: 1H NMR spectrum (500 MHz, D2O) of 156
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Figure A.7: 13C NMR spectrum (125 MHz, D2O) of 156
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Figure A.8: gCOSY spectrum (500 MHz, D2O) of 156

Figure A.9: gHSQC spectrum (500 MHz, D2O) of 156
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Figure A.10: ROESY spectrum (500 MHz, D2O) of 156
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Figure A.11: 1H NMR spectrum (500 MHz, D2O) of 169
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Figure A.12: 13C NMR spectrum (125 MHz, D2O) of 169
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Figure A.13: gCOSY spectrum (500 MHz, D2O) of 169

Figure A.14: gHSQC spectrum (500 MHz, D2O) of 169
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Figure A.15: ROESY spectrum (500 MHz, D2O) of 169
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Figure A.16: 1H NMR spectrum (500 MHz, D2O) of the purported hyacinthacine C5
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Figure A.17: 13C NMR spectrum (125 MHz, D2O) of the purported hyacinthacine C5
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Figure A.18: gCOSY spectrum (500 MHz, D2O) of the purported hyacinthacine C5

Figure A.19: gHSQC spectrum (500 MHz, D2O) of the purported hyacinthacine C5
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Figure A.20: ROESY spectrum (500 MHz, D2O) of the purported hyacinthacine C5
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Figure A.21: 1H NMR spectrum (500 MHz, D2O) of 215
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Figure A.22: 13C NMR spectrum (125 MHz, D2O) of 215
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Figure A.23: gCOSY spectrum (500 MHz, D2O) of 215

Figure A.24: gHSQC spectrum (500 MHz, D2O) of 215

336

Figure A.25: ROESY spectrum (500 MHz, D2O) of 215
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Figure A.26: 1H NMR spectrum (500 MHz, D2O) of 216
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Figure A.27: 13C NMR spectrum (125 MHz, D2O) of 216
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Figure A.28: gCOSY spectrum (500 MHz, D2O) of 216

Figure A.29: gHSQC spectrum (500 MHz, D2O) of 216
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Figure A.30: ROESY spectrum (500 MHz, D2O) of 216
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Figure A.31: 1H NMR spectrum (500 MHz, D2O) of 217
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Figure A.32: 13C NMR spectrum (125 MHz, D2O) of 217
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Figure A.33: gCOSY spectrum (500 MHz, D2O) of 217

Figure A.34: gHSQC spectrum (500 MHz, D2O) of 217
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Figure A.35: 1D-NOE spectrum (500 MHz, D2O) of 217
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Figure A.36: 1H NMR spectrum (500 MHz, CDCl3) of 218

Figure A.37: 13C NMR spectrum (125 MHz, CDCl3) of 218
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Figure A.38: gCOSY spectrum (500 MHz, CDCl3) of 218

Figure A.39: gHSQC spectrum (500 MHz, CDCl3) of 218
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Figure A.40: 1D-NOE spectrum (500 MHz, D2O) of 218
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Figure A.41: 1H NMR spectrum (500 MHz, D2O) of 242
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Figure A.42: 13C NMR spectrum (125 MHz, D2O) of 242

349

Figure A.43: gCOSY spectrum (500 MHz, D2O) of 242

Figure A.44: gHSQC spectrum (500 MHz, D2O) of 242
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Figure A.45: ROESY spectrum (400 MHz, D2O) of 242
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Figure A.46: 1H NMR spectrum (500 MHz, D2O) of 243
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Figure A.47: 13C NMR spectrum (125 MHz, D2O) of 243
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Figure A.48: gCOSY spectrum (500 MHz, D2O) of 243

Figure A.49: gHSQC spectrum (500 MHz, D2O) of 243
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Figure A.50: ROESY spectrum (400 MHz, D2O) of 243
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Figure A.51: 1H NMR spectrum (500 MHz, D2O) of 244
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Figure A.52: 13C NMR spectrum (125 MHz, D2O) of 244
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Figure A.53: gCOSY spectrum (500 MHz, D2O) of 244

Figure A.54: gHSQC spectrum (500 MHz, D2O) of 244
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Figure A.55: 1D-NOE spectrum (500 MHz, D2O) of 244
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Figure A.56: 1H NMR spectrum (500 MHz, D2O) of 253
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Figure A.57: 13C NMR spectrum (125 MHz, D2O) of 253
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Figure A.58: gCOSY spectrum (500 MHz, D2O) of 253

Figure A.59: gHSQC spectrum (500 MHz, D2O) of 253
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Figure A.60: 1D-NOE spectrum (500 MHz, D2O) of 253
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Miscellaneous
Here I have included an unconventional section, highlighting a few moments throughout
the course of this work that deserve to be included in this thesis.
The first of these is the winning of the C&En May “Chemistry in Photos” contest. Below
is the photo I took, along with the small card I received from the C&En office in
Washington, DC, USA. The photo shows ammonia sulfate (white solid) and a copperammonia complex (deep blue). It was the by-product of the acetonide protection of Lxylose. This work up procedure usually involves physically separating the hydrated copper
sulfate (light blue) via vaccum filtration, followed by a separate removal of the precipitated
ammonia sulfate using gravity filtration. Instead of gravity filtering the white precipitate,
I re-used the vaccum filter (containing copper sulfate) and below is what resulted. I was
lucky that the copper sulfate did not re-dissolve into my collecting flask as the copperammonia complex, as this would have defeated the purpose of the initial removal of the
copper. It made for a nice photo though and was printed in C&En captioned “Ice Faux
Floes”. Many thanks to the C&En team, and particularly Dr Reeser for ensuring I received
the $50 cash prize.
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The second mention was prior to the publishing our second body of work in the ACS
Journal of Natural Products. My wife Shenae is extremely talented in arts, graphic and
digital design. She has supported this project in numerous ways including her art. Below
is an art piece that she drew depicting the corrected structure of hyacinthacine C1. We
released ownership of this masterpiece to accompany our manuscript following its
publication in the ACS Journal of Natural Products.
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Towards the end of 2018, I presented at the RACI NSW Natural Products Chemistry
Symposium held at UNSW. I was very fortunate to win the prize for the “Best Student
Oral Presentation”. There were some fantastic speakers on the day and so it was amazing
to win this award.
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The final highlight included in this section was my receiving of the prestigious Larry and
Marilyn Hick award for 2018. This award is presented for the “Best Published Article by
a Postgraduate Student” for that year. The paper that won this award is discussed in
Chapters 2,3 and 4B and was published in the ACS Journal of Organic Chemistry.
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